07 February 2017 George Perry

1

CURRICULUM VITAE

George Perry, Ph.D. Dean and Professor of Biology and Chemistry

Semmes Foundation Distinguished University Chair in Neurobiology, College of Sciences, University of Texas at San Antonio

Personal: Born: 12 April 1953, Point Conception, Lompoc, Santa Barbara County, California, USA Ethnic Origin: Azorean Portuguese http://trees.ancestry.com/tree/38911572/family/familyview Marital Status: Married (21 May 1983), Maria-de-la-Paloma Aguilar-Muñoz Children: Anne Aguilar Perry (14 January 1989), Elizabeth Aguilar Perry (7 September 1991) Languages: English and Spanish Office Address: College of Sciences The University of Texas at San Antonio One UTSA Circle San Antonio, Texas 78249-0661 Telephone: 210-458-4450 / Telefax: 210-458-4445 E-Mail: george.perry@utsa.edu Home Address: 15852 Revello Drive Helotes, Texas 78023-5133 Telephone: 210-241-3400 Email: perry2500@gmail.com Websites:

http://utsa.edu/biology/faculty/GeorgePerry.html

http://en.wikipedia.org/wiki/George_Perry_%28neuroscientist%29

http://my.indexcopernicus.com/gperry

http://orcid.org/0000-0002-6547-0172

http://t1t2.rtrn.net/profilesweb/ProfileDetails.aspx?From=SE&Person=2469&PersonSource=University+of+Texas+at+San+Antonio

Education: 1971 High School, Lompoc Senior High School, Lompoc, California 1973 A.A., Liberal Arts, Allan Hancock College, Santa Maria, California 1974 B.A., High Honors, Zoology, University of California at Santa Barbara 1979 Ph.D., Marine Biology, Scripps Institution of Oceanography, University of California at San Diego (David Epel, Ph.D., Advisor)

http://neurotree.org/neurotree/peopleinfo.php?pid=9501 1982 Postdoctoral Fellow, Department of Cell Biology, Baylor College of Medicine (B.R. Brinkley, Ph.D. and Joseph Bryan, Ph.D., Advisors) 2007 Doctorado Honoris Causa (Hon. D.), Universidad Arturo Prat, Iquique, Chile Professional Training:

1974-1977 Graduate Student, Scripps Institution of Oceanography, University of California at San Diego 1975-1977 Graduate Student, Summer Program, Marine Biological Laboratory, Woods Hole,

Massachusetts

George Perry

2

1977-1979 Graduate Student, Hopkins Marine Station, Department of Biological Sciences, Stanford University, Pacific Grove, California

1979-1982 Postdoctoral Fellow, Department of Cell Biology, Baylor College of Medicine, Houston, Texas

2012 Harvard-Macy Institute, Leading Innovations in Health Care and Education Program, Harvard Medical School, Boston, Massachusetts

2012 Fulbright Senior Specialist, University of Chile, Santiago, Chile Military Service: 1972-1974 Army Reserve Officer Training Corps, University of California at Santa Barbara Friends of the Reserve Officer Training Corps Award, 1973 Faculty Appointments: 1982-1989 Assistant Professor of Pathology, Case Western Reserve University, Cleveland, Ohio 1989-1990 Assistant Professor of Neurosciences, Case Western Reserve University, Cleveland, Ohio 1989 Award of Tenure, Case Western Reserve University, Cleveland, Ohio 1989-1994 Associate Professor of Pathology, Case Western Reserve University, Cleveland, Ohio 1990-1994 Associate Professor of Neurosciences, Case Western Reserve University, Cleveland, Ohio 1994-2005 Professor of Pathology and Neurosciences, Case Western Reserve University, Cleveland,

Ohio 2001-2005 Interim-Chair, Department of Pathology, Case Western Reserve University, Cleveland, Ohio

2006- Affiliate Professor, Department of Chemistry and Biochemistry, University of Alaska, Fairbanks, Alaska, USA

2006- Adjunct Professor of Pathology and Neurosciences, Case Western Reserve University, Cleveland, Ohio

2006- Dean, College of Sciences, The University of Texas at San Antonio, San Antonio, Texas 2006- Professor of Biology, The University of Texas at San Antonio, San Antonio, Texas 2012- Adjoint Professor of Biochemistry, University of Texas Health Science Center, San

Antonio, Texas 2014- Professor of Chemistry, The University of Texas at San Antonio, San Antonio, Texas

Research Support:

1979-1980 National Institutes of Health, Postdoctoral Fellowship Awards, 1979 (declined to accept) and

1980 (declined to accept). 1980-1982 Muscular Dystrophy Association, Postdoctoral Fellow

1982-1988 National Institutes of Health, P01-AG-00795, Co-Investigator, Aging changes in neuronal structure and function. (1985-1989: $399,582) (Raymond Lasek, Program Director, Pierluigi Gambetti, Principal Investigator)

1988-1989 National Institutes of Health, P50-AG-08012, Alzheimer Disease Research Center, Principal Investigator Pilot Project, PHF binding proteins. (1988-1989: $18,929) (Peter Whitehouse, Center Director)

1988-1990 American Health Assistance Foundation, Principal Investigator, Amyloid precursor in Alzheimer disease. (1988-1990: $94,979)

1988-1993 National Institutes of Health, K04-AG00415, Research Career Development Award, Principal Investigator, Amyloid precursor in Alzheimer disease. (1988-1993: $228,584)

1989-1990 Alzheimer's Association Pilot Research Grant, Principal Investigator, Aged or alcoholic rat as experimental model of neurofibrillary pathologies. (1989-1990: $24,886)

1987-1990 Ohio Diagnostic and Treatment Center for Alzheimer's Disease, Principal Investigator, Amyloid precursor in Alzheimer disease. (1987-1990: $147,912) (Peter Whitehouse, Center Director)

1988-1995 National Institutes of Health, R01-AG07552, Principal Investigator, Amyloid precursor in Alzheimer disease. (1988-1991: $165,249; 1991-1994: $296,140)

1989-1994 National Institute of Health, R01-AG08155, MERIT Award, Co-Investigator, Molecular pathology of Alzheimer disease. (1989-1994: $953,475) (Pierluigi Gambetti, Principal Investigator)

George Perry

3

1990-1999 National Institutes of Health, R01-AG09287, Principal Investigator, Neurofibrillary pathology in Alzheimer disease. (1990-1995: $494,125; 1996-2000: $362,669)

1991-1993 National Institute of Health, P35-AG08992, Leadership and Excellence in Alzheimer Disease, Principal Investigator Pilot Project, Aged or alcoholic rat as an experimental model of neurofibrillary pathology. (1991-1993: $49,621) (Pierluigi Gambetti, Primary applicant)

1993-1995 National Institutes of Health, R35-AG08992, Leadership and Excellence in Alzheimer Disease, Principal Investigator Pilot Project, Identify the chemical basis of detergent-insolubility of PHF. (1993-1995 $63,087) (Pierluigi Gambetti, Primary Applicant)

1993-1995 National Institutes of Health, P50-AG08012, Alzheimer‘s Disease Research Center, Co-Investigator, Subproject 1. (1994-1995: $100,566) (Peter Whitehouse, Center Director; Karl Herrup, Principal Investigator)

1994-1998 North Atlantic Treaty Organization, Collaborative Research Grant, CRG 94 0642, Co-Investigator, Soluble amyloid beta protein in brain and cerebral spinal fluid. (1994-1996: 140,000BF; 1996-1998: 147,000BF) (Massimo Tabaton, Principal Investigator)

1994-1999 Belgian National Foundation for Scientific Research, Member of the group, Collaborative Research Group on Alzheimer Disease. (1994-1999: 2,500,000 BF) (Jean-Jacques Martin, Principal Investigator)

1995-1996 Neurogeriatrics Fund, Co-Investigator, Development of imaging agents for amyloid localization in Alzheimer‘s disease and related disorders. (1995-1996: $9,263) (Robert P. Friedland, Principal Investigator)

1995-2005 National Institutes of Health, T32-AG00105, Co-Principal Investigator, 1999-, Cellular and molecular aging. (1995-2000: $901,613; 2000-2005: $1,045,755) (Arnold I. Caplan, Principal Investigator)

1996 Britton Fund, Co-Investigator, Studies in Alzheimer disease. (1996: $25,000) (Pierluigi Gambetti, Principal Investigator)

1996-1999 Neurogeriatrics Fund, Principal Investigator, Noninvasive assessment of oxidative stress in patients with Alzheimer‘s disease. (1996-1999: $50,090)

1997-1999 American Health Assistance Foundation, Principal Investigator, Oxidative damage in Alzheimer disease. (1997-1999: $199,853)

1997-2005 National Institutes of Health, R01-AG14249, Co-Principal Investigator, Cytoskeletal oxidative modifications. (1997-2000: $453,244; Lawrence M. Sayre, Principal Investigator) (2000-2005: $875,000; Vernon Anderson, Principal Investigator)

1998-2001 Alzheimer‘s Association, IIRG98-140, Principal Investigator, Neurofilament proteins are specific targets of oxidative stress. (1998-2001: $163,056)

1999-2002 Alzheimer‘s Association Temple Award, TLL-99-1872, Principal Investigator, Role of metals in oxidative balance in Alzheimer‘s disease. (1999-2001: $226,257)

1999-2002 National Institutes of Health, R01-NS38648, Co-Investigator, Metabolic abnormalities in Alzheimer disease. (1999-2002: $490,448) (Mark A. Smith, Principal Investigator)

2000-2012 Elan Pharmaceuticals Incorporated, Principal Investigator, #1439 Alzheimer Award ($(7,500 annually)

2000-2002 United Mitochondrial Disease Foundation, Principal Investigator, Is oxidative damage a result of metabolic abnormalities in Alzheimer disease? (2000-2002: $16,619)

2000-2003 Alzheimer‘s Association, IIRG-00-2163, Co-Principal Investigator, Modulation of the redox-activity of iron and copper in Alzheimer disease. (2000-2003: $217,815) (Mark A. Smith, Principal Investigator)

2001-2006 National Institutes of Health, R01, Co-Investigator, Anti-apoptotic activity of Alzheimer Aβ. (2001-06: $450,000) (Craig S. Atwood, Principal Investigator)

2002-2003 Fullerton Family Charitable Trust, Co-Principal Investigator, Molecular epidemiology and neurobiology of Aβ-like antibody antigen interactions in Alzheimer‘s disease. (2002-2003: $200,000) (Robert P. Friedland, Principal Investigator)

2002 Case Western Reserve University, Presidential Technology Development Grant Program, Co-Investigator, Labeling of cerebral Aβ deposits in vivo using intranasal administration of serum amyloid P component. (2002: $47,000) (Robert P. Friedland, Principal Investigator)

2003-2005 Philip Morris, USA, Postdoctoral Fellowship (Kazuhiro Honda, M.D., Ph.D.), Sponsor (2003-2005: $80,000)

2004-2007 Philip Morris, USA, Principal Investigator, Sources of reactive oxygen species in Alzheimer disease. (2004-2007: $300,000)

2004-2007 Alzheimer‘s Association, IIRG-04-1272, Principal Investigator, Phosphorylation dependency of protein oxidation. (2004-2007: $218,184)

George Perry

4

2005-2006 Philip Morris, USA, Postdoctoral Fellowship (Gemma Casadesus, Ph.D.), Sponsor (2005-2006: $40,000)

2005-2008 National Institutes of Health, R01-AG026151, Co-Investigator, Amyloid-beta: The Alternate Hypothesis (2005-2008: $492,000) (Mark A. Smith, Principal Investigator)

2006-2009 National Institutes of Health, R01-AG024028, Principal Investigator*, Metal ion is critical in Aβ-Induced JNK activation. (2006-2009: $656,000) (*Principal Investigator changed to Xiongwei Zhu)

2006-2008 University of Texas System, STARS Program (2006-2008; $300,000) 2007-2009 Alzheimer‘s Association Zenith Fellows Award, ZEN-07-59500, Principal Investigator,

Mitochondrial abnormalities in Alzheimer disease. (2007-2009: $250,000) 2007-2008 Autism Research Institute, Co-Investigator, Neuronal oxidative stress in autism. (2007-2008:

$75,000) (Xiongwei Zhu, Principal Investigator) 2010-2013 Alzheimer‘s Association, IIRG-10-173471, Principal Investigator, The role of PGC-1 alpha in

Alzheimer disease. (2010-2013: $200,000) 2011-2014 University of Texas System, Transformation in Medical Education, Member, Facilitated

Acceptance to Medical Education (UTSA-UTHSCSA). (2011-2014: $598,880) 2010-2015 National Institutes of Health, G12-MD007591,Co- Principal Investigator, RCMI Center for

Interdisciplinary Health Research (2010-2015: $12,657,146) 2012-2014 Convocatoria INDICASAT-AIP para proyectos de investigación con fondo SENACYT-BID

(Panama), Co-Investigator, Desarrollo de bioensayos para el cribado de compuestos para el tratamiento de Alzheimer (2012-2014: $60,000) (Patricia Llanes Fernández, Principal Investigator)

2012 National Institutes of Health, G12-MD007591,Principal Investigator, RCMI Center for Interdisciplinary Health Research, Subproject: Protein Biomarkers Core (2010-2015: $1,679,913)

2012 National Institutes of Health, G12-MD007591-1351, Co-Principal Investigator, RCMI Center for Interdisciplinary Health Research Supplement (2012: $171,363)

2012 Fulbright Senior Specialist, University of Chile, Santiago, Chile (2012: $4,820.76) 2013 Hannah Foundation, San Antonio, Texas (2012: $1,000) 2013-2017 Alzheimer‘s Association, IIRG-13-284849, Principal Investigator, PGC-1 alpha as a therapeutic

target for Alzheimer disease (2013-2017: $240,000) 2013-2014 National Institutes of Health, R41AG-046987, Consultant, Inhibition of retinoic acid metabolism for

reversal of cognitive deficits in AD, Fanny Astruc-Diaz, Principal Investigator (2013:$148,691) 2013-2014 National Institutes of Health, G12-MD007591, Co-Principal Investigator, RCMI Center for

Interdisciplinary Health Research Supplement (2013-2014: $191,146) 2014-2016 National Institutes of Health, R44AG044234, Consultant ($5,000), Instrument for single molecule

sequencing of Alzheimer's-relevant genomic oxidation, David E. Wolfe, Principal Investigator (2014-2016: $474,646)

2014-2015 RTRN Pilot Project Program, U54MD008149, Collaborator ($15,000), Frederick Bellinger, Principal Investigator, Selenate and reduction of neurofibrillary tangle formation: role of selenoprotein

2014-2016 National Institutes of Health, G12-MD007591, Principal Investigator, RCMI Center for Interdisciplinary Health Research, Subproject: Biophotonics Core (2014-2016: $338,179)

2014-2015 National Institutes of Health, G12-MD007591, Principal Investigator, RCMI Center for Interdisciplinary Health Research Supplement (2014-2015: $173,219)

2015-2016 RTRN Pilot Project Program, U54MD00919, Collaborator ($4,000), Frederick Bellinger, Principal Investigator, Selenate and reduction of neurofibrillary tangle formation in role of selenoprotein.

2016-2017 San Antonio Life Sciences Institute (SALSI) Cluster in Research Excellence Award, (Principal Investigator changed to Stephen Bach), Utilizing imaging mass spectrometry and electron microscopy to investigate nucleoplasmic reticulum in Alzheimer‘s disease, (2016-2017: $100,000)

2016-2017 National Institutes of Health, G12-MD00814S1, Principal Investigator, RCMI Center for Interdisciplinary Health Research, Supplement (2016-2017: $1,101,680)

Awards and Fellowships:

California Scholarship Federation: Life Member, 1971; One Hundred Percent Member, 1971 Bausch and Lomb Medal, 1971

Alexander—Bee Trust Scholarship, 1974 Kennecott Copper Fellowship, 1974-1975

George Perry

5

National Science Foundation, Research Assistantship, 1974-1979 National Institutes of Health, Postdoctoral Fellowship Awards, 1979 (declined to accept) and 1980 (declined

to accept). Muscular Dystrophy Association, Postdoctoral Fellow, 1980-1982 Canadian Association of Neuropathologists meeting, Mary Tom Award, Best Paper Clinicopathological

Correlation, 1987 National Institutes of Health, Research Career Development Award, 1988-1993 National Institute of Health Leadership and Excellence in Alzheimer Disease, Junior Investigator, 1990

(declined to accept) American Society for Cell Biology Travel Fellowship, Madrid, Spain, 1992 Spectrum of Research on Aging and the Aged, Cleveland, Ohio, First Prize, Biological Sciences, 1995. American Association for the Advancement of Science, Fellow, 1998. Signa XI, 1998 Temple Award, Alzheimer‘s Association, 1999. Distinguished American of Portuguese Ancestry, Portuguese-American Historical and Research Foundation,

Incorporated, 2001. Hall of Fame, Lompoc High School Alumni Association, Lompoc, California, 2003. Mensch Award, Alzheimer Research Forum, 2003. Top 20 Most-Cited Authors in Alzheimer‘s Disease, Essential Science Indicators, 2003. 100 Most-Cited Scientists in Neuroscience and Behavior of the decade, In-cites, 2004,2005,2006,2007 Community Service Award, Cleveland Area Chapter of the Alzheimer‘s Association, 2004. Faculty of 1000 Biology, Member, Neurobiology of Disease and Regeneration section, 2004. Top 25 Lab Heads in free radical research, Free Radical Lab Registry, 2007. Zenith Fellow, Alzheimer‘s Association, 2007.

Doctorado Honoris Causa (Hon. D.), Universidad Arturo Prat, Iquique, Chile, 2007 ISI Highly Cited.com, Neuroscience, 2008, H=107; 45,756 citations

http://highlycited.com/categories/neuroscience/ Denham Harman Research Award, American Aging Association, 2008 Iberoamerican Molecular Biology Organization (IMBO), 2008 Real Academia de Ciencas, Naturales (RAC), Correspondient es extranjeros, (Royal Spanish Academy of

Sciences, Natural Sciences, Foreign corresponding member), Elected 2009, Inducted 2013 Top 100 Alzheimer‘s Disease Investigators, 2009 http://j-alz.com/top100/introduction.html Alzheimer Award / Alzheimer Medal, Journal of Alzheimer‘s Disease, 2010 (Rudy J. Castellani, primary awardee http://www.j-alz.com/award/award_2010.html ) Society for the Advancement of Chicanos and Native American Scientists (SACNAS), Distinguished

Professional Mentor Award, 2010 Royal Society of Medicine, Overseas Fellow, 2010 Academia Mexicana de Ciencias (AMC), Miembro correspondiente (Mexican Academy of Sciences,

Corresponding Member), Elected 2010, Inducted 2012 Dana Alliance for Brain Initiatives, 2010 Linnean Society of London, Fellow (FLS), Elected 2011 Top 20 Alzheimer‘s Disease Authors, 2011 http://sciencewatch.com/ana/st/alz2/authors Royal Society of Chemistry, Fellow (FRSC), Elected 2011 Microscopy Society of America, Fellow (FMSA), Elected 2011 Alzheimer Award / Alzheimer Medal, Journal of Alzheimer‘s Disease, 2011 (Mark A. Smith, primary awardee http://www.j-alz.com/award/award_2011.html ) National Honor Plaque of Panama for exceptional contribution to ―Neuroscience‖, Secretarίa nacional de

Ciencia, Technologίa e Innovación (SENACYT), (National Secretariat for Science, Technology and Innovation), Panama, 2011

Royal Society of Biology (Formerly Society of Biology), Fellow (FRSB), Elected 2011 International College of Geriatric Psychoneuropharmacology (ICGP) Senior Investigator Award, 2011 Royal College of Pathologists, Fellow (RCPath), Elected 2011 Academia de Ciêncas de Lisboa (ACL), Sócio Correspondente Estrangeiro, (Academy of Sciences of

Lisbon, Foreign Corresponding Member), Elected 2011, Inducted 2016 Society of Biology, Chartered Biologist (CBiol), Elected 2011 Fulbright Senior Scholar Specialist Program, 2012 Phi Kappa Phi, Charter and Life Member, 2012 Society of Biology, Chartered Scientist (CSci), Elected 2012

George Perry

6

Royal Society of Chemistry, Chartered Chemist (CChem), Elected 2012 International Conference on Research in Applied Computation Symposium, Association of Computing

Machinery, Outstanding Service Award, 2012 Portuguese Tribune Scientist of the Year, 2012 Governo dos Açores, Notaveis dos Açores (Notable Azoreans), 2012

http://notaveisazores.com/index.php?static=personalidades&action=verPersonalidade&personalidade_id=208

Azorean Spirit, SATA Inflight Magazine, Gente Notável (Notable People), 2012 Semmes Foundation Endowed Chair in Neurobiology, 2013 Martin Goland Award, Sigma Xi, Alamo Chapter, 2013 Leading Expert – Alzheimer Disease, Expertscape, 2013 http://www.expertscape.com/au/alzheimer%20disease/Perry%2C+George Royal Society of the Encouragement of Arts, Manufactures and Commerce, Fellow (FRSA), Elected 2014 UDAAN – Lifetime Achievement Award, International Research Journal of Humanities, Engineering and Pharmaceutical Sciences and Association for Innovation, India, 2014 Semmes Foundation Distinguished Chair in Neurobiology, 2014 Royal Microscopical Society, Fellow (FRMS), Elected 2014 Top 100, Latino Business Leaders, LatinoAmerican Who‘s Who, 2014-2015 Semmes Foundation Distinguished University Chair in Neurobiology, 2015 Distinguished Fellow, International Engineering and Technology Institute, 2015 Fellow, Academy of Biotechnology and Pharmacy (FABAP), India, 2015 Fellow, Texas Academy of Science, 2016 Lifetime Achievement Award, World Automation Congress, 2016 World Academy of Medical Sciences, Fellow (FWAMS), 2017 EU Academy of Sciences, 2017 Committee Appointments: Department of Pathology, Case Western Reserve University: Seminar Committee Member 1984-; Organizer 1984-1994; Chair 1991-1994; Co-Activity Director, Continuing

Medical Education 1985-1994 Committee on Appointment, Promotion and Tenure

Member 1994-2005; Chair 1994-2001 Finance Committee Member 1994-1995

Faculty Equity and Development Committee Member 1996-1999 Departmental Self-Study Committee Sole Elected Member 1998; Chair 1998 Research Committee Ex-Officio Member 2002-2005 Unified Mission Committee Ex-Officio Member 2002-2005 Education Committee Ex-Officio Member 2002-2005 Graduate Committee Ex-Officio Member 2002-2005 Frontier‘s Lecture Committee Ex-Officio Member 2002-2005 75th Anniversary Committee Member 2004-2005 School of Medicine, Case Western Reserve University: Faculty Council

George Perry

7

Member 1992-1996; Steering Committee 1993-1996; Vice-Chair 1993-1994; Chair 1994-1995; Past-Chair 1995-1996

Executive Committee Member 1994-1995, 2001-2002

Committee to Review the Dean‘s Executive Committee Structure and Function Member 2002

Nominating Committee Member 1994-1995; Vice-Chair 1994-1995

Special Committee to Nominate Candidates for the Search Advisory Committee to the President on the Selection of a Dean of the School of Medicine

Member 1995; Chair 1995 Faculty Equity and Development Committee Member 1995-1998 Search Advisory Committee to the Dean on the Selection of a Chair for the Department of Pathology Sole Elected Member 1998-2001 University Memory and Aging Center Oversight Committee for the Laboratory Service Core Member 1999- Basic Science Chairs Member 2001-2005 Council of Clinical Chairs Member 2001-2005 CASE Medicine Chairs Member 2002-2005 Bylaws Committee Member 2003-2006; Chair 2005-2006 CASE Research Strategic Plan Committee Interdisciplinary Member 2003-2004 Committee on Qualifications and Standards for Appointments, Promotions, and Tenure Member and Co-Chair 2003-2004 Graduate Education Steering Committee M.D./M.S. Working Group 2003-2004 Search Advisory Committee for Proteomics Director Member 2004-2005 New Faculty Symposium Planning Committee Member 2005 Committee on Appointments, Promotion and Tenure Member 2005-2008 University, Case Western Reserve University:

Ad Hoc Joint Committee of the Personnel Committee and Faculty Council to deal with the issue of tenure in the School of Medicine

Member 1994-1995 Presidents Advisory Committee to consider the Promotion and Tenure recommendations of the:

Faculty of the College of Arts and Sciences Member 1996

Faculty of the Weatherhead School of Management Member 2002 Fringe Benefits Committee Member 1996-1997 Faculty Senate Member 1996-1997, 2001-2004, 2005-2008 Grievance Committee Witness 1997, 2000 Committee for Inquiry into Possible Scientific Misconduct Member and Chair 1997 University Center on Aging and Health Faculty Associate 1997-2006

George Perry

8

Development Committee 1999-2006 Microscopy Research Center Director 2001-2006 Higher Learning Commission of the North Central Association of Colleges and Schools Interviewee, CASE Accreditation 2005 Committee on Minority Affairs Member 2005-2008 Research ShowCASE Steering Committee, 2005-2006 Civil Lawsuit Witness Deposition, 2005 Neurodegeneration Brain Health Collaborative Advisory Board Member, 2011- University, University of Texas at San Antonio: Center for Advancement of the Life Sciences Director 2006-2007 Electron Microscopy Research Center Advisor 2006- Communication Sciences and Disorders Governing Board Member 2006-2008 Institutional MBRS-SCORE (National Institutes of Health) Advisory Committee Member 2006- Selection Committee Member 2006- Combined Sciences Facility Renovation Building Committee Member 2006- Chair 2006- Center for Research and Training in the Sciences (CRTS) Advisory Committee (formerly Center for the Advancement of the Life Sciences) Member 2006- Chair 2011- Graduate School Orientation Panel Member 2006 Technology Transfer Office Director Search Committee Member 2007, 2009-2010 University Art Commission, Art Project Advisory Committee Member 2007–2010 Team 2016 Member 2007– Medicine and Science (IIMS) Council of Deans Member, 2006- UTSA Architecture, Engineering, Business and Science Student Conference Faculty Advisor 2007, 2008, 2009, 2010, 2011, 2012 Commission on Colleges, Southern Association of Colleges and Schools Reaffirmation Leadership Team Member 2007-2010 Faculty Grievance Defendant 2008 (exonerated), 2009 (exonerated), 2010 Settlements 2007, 2008 Clinical and Translational Science Award – National Institute of Health Member, Council of Deans 2008- UTSA Neuroscience Institute Member 2008- Research Centers in Minority Institutions, (National Institutes of Health) Advisory Board Internal Advisory Committee, Member 2008–, Chair 2012 Co-Principal Investigator 2012 State Employees Charitable Campaign (SECC) Outstanding Dean 2007

George Perry

9

Shining Star 2008 College of Sciences 100% Participation 2007, 2008, 2009, 2010 Department Chair Compensation Task Force Member 2008–2009 Experimental Science Instructional Building Building Committee 2008- Strategic Resource Planning council Member 2009- Institute for Cyber Security Steering Committee for Commercialization 2009-2010 Laboratory Safety Committee Member 2009- College of Sciences Research Conference Judge 2009, 2010, 2011, 2012, 2013, 2015, 2016 Rhodes Scholarship Mock Interviews Interviewer 2009 Minors in Laboratories Committee Member and Chair 2010 Transformation in Medical Education (TIME) (FAME) Executive Committee Member 2010- Alumni Association Associate Life Member 2010- Family Association Member 2010- MARC U* STAR Program Executive Advisory Committee 2010- University of Texas System Transformation in Medical Education (TIME) Steering Committee Member 2010- Reviewer 2011- Competency Framework 2011- Research Advisory Council Member 2011-2012 Chair, Committee on Departmental Research Goals 2012 Civil Lawsuit Mediation 2009 U.S. District Court, Western District of Texas 2010-12 (dismissed) Deposition 2011 Review UTSA Undergraduate Pre-Professional Programs in Preparation for Health Professions or Law School Member 2010-2011 Enrollment Management Member 2011- Academic and Administrative Office Building Program Committee Member 2011- Institute for Integration of Medicine and Science Clinical and Translational Science, Cancer Therapy and Research Center and UTSA Pilot Projects Reviewer 2012 Community Health Advisory Board Member 2015- Grant Reviewer 2015 Graduation Rate Improvement Plan (GRIP) Cross-Campus Team Member 2012 Co-Chair Thematic Team 3: Curricula and Academic Planning 2013 Research Advisory Board Member 2012-2014, 2014-2017 Working Group on Micro Issues Member 2013-2014 Working Group on Multi/Interdisciplinary Research Member 2013-2014

George Perry

10

Corporate Engagement Planning Committee Member 2012-2014 Facilitated Acceptance Medical Education (FAME) Applicant Review Committee 2012, 2013, 2014, 2015, 2016, 2017 Leadership UTSA Mentor 2012, 2013, 2015 Academy of Distinguished Teachers Selection Committee 2013 Dean‘s Council for Research Chair 2012- Strategic Plan Revision 2013 Search Committee for Dean of the College of Engineering Chair 2013-2014 Marshall Scholarship Mock Interviews Interviewer 2013 Neuroscience Cluster Strategic Plan Member 2014 Dean‘s Advisory Council for NSF ADVANCE Grant Member 2014- Open Cloud Institute Executive Committee 2015- UTSA Strategic Planning 2020 Blueprint Recruit Exceptional Scholars Co-Chair 2015 Expand Recruitment and Scholarships Member 2015 Build and Maintain State of the Art Facilities Member 2015 Recognition and Esteem Member 2015- Budget Task Force Member 2016- Science and Engineering Building Advocate 2015- Building Committee 2015- Architect Selection Committee 2016 Contractor Selection Committee 2016 International Education Fund Committee Member 2016 Center for Innovative Drug Discovery Steering Committee 2016- RISE (Research initiative for Scientific Enhancement) Program Advisory Committee 2016- Coordinated & Linked Approach to Student Success (CLASS) Initiative Coordinating Council Member 2016- Leadership & Professional Preparedness Task Force Chair 2016- First to Go and Graduate Faculty Coach 2016- University, University of Texas System: Transformation in Medical Education (TIME) Steering Committee Member 2010- Reviewer 2011- Medical Knowledge and Scholarship Competency/Milestones Task Force 2011- Professional Identity Formation Task Force Chair Search Committee 2011 Medical Knowledge and Scholarship, Co-Chair 2011-

George Perry

11

Neuroscience and the Neurotechnology Institute (formerly Neuroscience Council) Advisory Board 2013- Community: Cuyahoga County Court of Common Pleas Jury Duty 2001 San Antonio Hispanic Chamber of Commerce Member 2006-2008 State of Texas, Bexar County Juror, Criminal 2009 Presiding Juror, Civil 2015 Administrative Accomplishments: President, Microscopy Society of Northeastern Ohio, 1990-1991

Increased membership by 20%.

Balanced budget and assured continued financial strength.

Organized four successful meetings.

Served on local organizing committee for Microscopy and Microanalysis annual national meeting when held in Cleveland.

Chair, Faculty Council, School of Medicine, CWRU, 1994-1995

Primary liaison between Administration of the School of Medicine and Faculty.

Developed and implemented the first ever annual review form for Faculty in the School of Medicine. This system has since served as the model for other schools at CWRU.

Reorganized committee structure to promote Faculty involvement and mentoring of faculty.

Reviewed all promotions for equity.

Initiated and served on a committee to review CWRU tenure policies to strengthen commitment.

Associate Editor, American Journal of Pathology, 1994-2000

Sole editor for Neuropathology handling the review and making decisions on over 100 manuscript per year.

Established the journal as premier site for publications of neuropathology.

Increased impact. Editor-in-Chief, Journal of Alzheimer‘s Disease, 1998-present

Founding Editor.

Developed novel editorial system to promote innovation.

Within 3 years was publishing more articles in Alzheimer disease research than any other journal.

Indexed in Medline, Index Medicus/Medline, BIOSIS Previews, Biological Abstracts, BIOBASE database, CAB Abstracts, CAB Health, Chemical Abstracts, CSA Neurosciences Abstracts, Elsevier BIOBASE/Current Awareness in Biological Sciences, Elsevier GeoAbstracts, EMBASE/Excerpta Medica, e-psyche database. EM Care, Journal Citation Reports/Science Edition, Neuroscience Citation Index, Psyc Info, PubMed, Pubs Hub, Science Citation Index Expanded (Sci Search), Scopus EM Care, Journal Citation, Citation Index, Psyc Info, PubMed, Pubs Hub, Science Citation Index Expanded (Sci Search), Scopus, Index Copernicus.

Established Alzheimer Award and Alzheimer Medal.

Impact Factor 5.1 the highest of any journal focused primarily on Alzheimer disease for 2009

20 issues per year

Index Copernicus Top 100 Journals 2009 (18th), 2010 (24

th), 2011 (23

rd)

President, CWRU chapter of the American Association of University Professors, 1999-2001, 2003-2006

Worked tirelessly over a 9 year period to develop meaningful tenure for all Faculty at CWRU.

Organized meetings where the President, Provost, various Deans, and Chair of the Board of Trustees directly exchanged ideas with faculty.

Increased membership.

George Perry

12

Acted as an independent liaison between the President, Chair of the Board of Trustees, Provost, and Faculty. This function was critical when the President resigned in 2000 and AAUP was the only direct contact with the Board of Trustees.

Assisted Faculty with conflict resolution by guidance in the rules and procedures of the CWRU Faculty Handbook and AAUP policy, mediation with key administration, and assistance in grievance procedures.

Interim-Chair, Pathology, CWRU, 2001-2005

Academically reunited basic science Faculty with clinical Faculty of five different administrative structures.

Education mission enhanced. o Matched 5 top residency candidates at UH in 2002. Best performance of residency programs in

UH in 2002 and of the University Hospitals of Cleveland-Pathology in institutional memory. Continued excellence in succeeding years.

o Appointed committee to provide overview of educational activities to all levels to facilitate integration of Faculty and students into program.

o Enhanced Ph.D. graduate program. Rated 8th in the U.S. by Academic Analytics. Provided

notebook computers and competitive awards and institutional expense accounts for students and Faculty. Lead to over half of incoming Ph.D. students selecting pathology from among 13 competing programs.

Reorganized budget. o Turned a 240K deficit to a 370K surplus in a 2.4M budget. o Did not dismiss any department members. o Provided 12-20% salary increases for staff and 23% for Faculty. o Established individual departmental support accounts for all Faculty and students. o All Faculty now supported primarily by non-departmental sources. o Raised salary of women Faculty to parity with men (increase greater than 33%).

Planned and implemented renovation/restoration of all public and historic regions of the Institute of Pathology by working with facilities administration of the University and the School of Medicine to finance and coordinate goals.

Initiated and supported 75th anniversary celebration.

Developed objective evaluation of academic activities of Faculty as the primary basis for annual salary increase.

Increased salaries to be comparable to peer institutions based on AAMC basic sciences departments (greater than 23%).

Extramural funding increased by 45%.

Increased underrepresented minority groups in our Faculty. Director, Microscopy Research Center, CWRU, 2001-2005

Established Center to perform high quality microscopy services for Cleveland.

Within months, the Center became financially viable.

CLEA Approval in 2002.

College of American Pathologist Approval in 2003. Dean, College of Sciences, University of Texas at San Antonio, 2006 -

Led the first systematic college and departmental strategic plans. Aligned educational excellence goals with excellence in research.

Increased research funding nearly threefold

Organized first recruitment program of graduate and undergraduate students focused on increasing Hispanic representation through outreach in South Texas.

Managed the Texas State Science Fair (sponsored by Exxon Mobil and Texas Work Force Commission) leading to its permanent hosting by UTSA at COS.

Developed the Science Fair into a Science Technology Engineering Math (STEM) center that included the State Science fair and UTeach as a conduit to recruit undergraduate students and engagement with science teachers.

Empowered departments to work more autonomously.

Diversified leadership in our faculty by recruiting leading Hispanic scientists with vision to develop UTSA through building on HSI heritage.

Developed a process to increase salaries to compete with research one unversities.

George Perry

13

Consolidated diversity-related grants under a center increasing effectiveness and creating synergies for program areas success.

Implemented objective criteria for merit review in each department, leading to implementation of realistic measures of performance of our faculty.

Effective use of post-tenure review.

Initiated, researched, and pushed the program to provide health insurance to Ph.D. students.

Initiated and managed a student-run scientific journal: Scope.

Refocused advisory services toward student success.

Developed and implemented the first service core facilities for major equipment managed by the College.

Increased inclusion and communications by adopting a leadership and policy advising body consisting of Associate Deans, Chairs, and Center Directors.

Aligned allocation of fiscal resources to meet priority research and academic needs by revising faculty hiring priorities to meet granting agency requirements and academic needs across the college.

Organized the first meeting of South Texas HSI Deans of Colleges of Science.

Developed joint Ph.Ds. in Biology and Physics with UT Brownsville

Initiated Governor‘s Science and Technology Champions Academy 2008, 2009

Memorandum of Understanding with Universidad Nacional Autonoma de Madrid, Universidad Nacional Autonoma de Mexico, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Universidad de Nuevo León, Universidad de Vericruzana, Ponce School of Medicine and Health Sciences

Initiated and organized the first awards for College faculty and staff

Led College in UTSA‘s Quality Enhancement Plan (QEP) for SACS Commission on College reaffirmation of accreditation

Sigma Xi Chapter Award given to the Alamo Chapter based on their partnership with our Texas State Science Fair

Partnership with Engineering led to UT system award for Graduate Program Initiative, one of only two awarded to a university in the system

Developed a professional teaching track

Developed the first print magazine: Catalyst

Developed the first College of Sciences Research Conference, spanning all of South Texas

Led successful reaccreditation of the College by Southern Association of Colleges

Successfully completed 360 evaluation as Dean in third and sixth years

Advising Center ―Strategies for Academic Success‖ was the 2011 National Academic Advising Association Outstanding Institutional Advising Program Award Winner

Secured two Welch Distinguished University Chairs in Chemistry Total $5M

First Dean to complete Capitol Campaign Fund Goal of $11M and of Second Campaign Fund Goal of $21M and currently over $27M for goal. Raised over $32M total as Dean.

Secured a Kleberg Distinguished Chair in Stem Cell Biology $1.5M

2011, 2012, University Advancement Award

Designated Hispanic-serving Agricultural College and University

Secured a Lutcher Brown Chair in Physics $1M

Secured a Weldon Hammond Professorship in Hydrology $0.5M

[Pages 7-8, UTSA and UT committee leadership listed under Committee Appointments]

Secured a John Feik Distinguished University Chair in Medicinal Chemistry $2M

Secured a Semmes Foundation Distinguished Chair in Neurobiology $1.5M

Increased endowment by over 100% to over $20M

Chaired Council of Deans for Research and led revision of UTSA Strategic Research Plan

Chaired Search for Dean of College of College of Engineering

Secured a Daniel Parman Chair in Applied Mathematics $1M

Nation‘s Top School for Cybersecurity, Computer World Magazine, 2014

Head of Center Research and Training in the Sciences, most well funded center at UTSA

Secured a Voelcker Distinguished Professorship 2014 $0.5M

Served on and led portions of the UTSA Strategic Plan 2020 Blueprint

Secured a Semmes Foundation Chair in Cell Biology 2015 $1M

Secured a Doran Professorship in Neurobiology 2016 $0.5M

George Perry

14

Society Memberships:

1976- American Association for the Advancement of Science Fellow 1998- Council Delegate 2014-2015 Symposium Reviewer 2015, 2016 Southwestern and Rocky Mountain Division of AAAS President 2013-2015 Executive Director (Interim) 2014-2015

1980- American Society for Cell Biology International Affairs Committee, Associate 2009- Ambassador 2010- 1984-2006 Microscopy Society of Northeastern Ohio Treasurer 1986-1988; Trustee 1988-1990; President 1990-1991 Nominating Committee 1997 1984-1995, 2009- Microscopy Society of America Local Arrangement Committee 1997 Fellow 2011 Poster Judge 2012 1985-1990, 1996- American Association of University Professors Case Western Reserve University Chapter, Ohio Conference Executive Committee 1996-2006; Chair, Membership 1996-1998; Vice

President 1998-1999; President 1999-2001, 2003-2006; Court Witness 2005

The University of Texas at San Antonio, Texas Conference Associate Member 2006- 1986- Society for Neuroscience Neuroscientist – Teacher Partner program 2008- 1987- American Association of Neuropathologists Awards Committee 1992-1993, 1995, Chair 2001-2002; International Congress of

Neuropathology, Concilator 1995-2000, 2013-2018; Membership Committee 2002-; Secretary-Treasurer 2003-2008; Newsletter Editor 2003-2008; President-Elect 2007-2008; President 2008-2009; Past President 2009-2010; Nominating Committee 2010-2013 (Chair 2010)

1987- International Society of Neuropathology 1987- American Society for Investigative Pathology BioInfo Net 1996-1997; Program Committee 1998-2001, 2012-; Neuroscience

Theme Committee, Experimental Biology 1999; Intersociety Pathology Council Representative 2005-; Career Development and Diversity (formerly Committee for Career Development, Women and Minorities) 2012-; Summer Research Opportunity Program in Pathology (SROPP) 2012; Abstract Reviewer 2014, 2015, 2016; Pathforward 2016-

1988-1995 Cleveland Society of Pathologists 1992-1997 Serra Club Vice President, Program 1993-1995; President 1995-1997; Vice President,

Membership 1996-1997 1996-1998 American Society for Neurochemistry 1997- Oxygen Club of California 1998- Sigma Xi CASE Chapter 1998-2006 Special Judge, Intel International Science and Engineering Fair, 2003 President, CASE Chapter, 2004-2006 Alamo Chapter 2006- 2008 Advisor, San Antonio Science Café Organizing Committee 2008 Chapter Award Program Winner based on partnership with UTSA 2013 Awards Committee

George Perry

15

Spirit of Innovation Awards, Conrad Foundation Expert 2009 Judge 2013, 2014

Student Research Showcase, Judge 2013 1999- American Institute of Biological Sciences 1999- Mitochondrion Research Society 2000-2006 United States and Canadian Academy of Pathology 2001-2006 Portuguese Ancestry 2001- American-Portuguese Genealogical and Historical Society Member 2001- Life Member 2009- 2001-2005 Association of Pathology Chairs Research Committee 2001-2005 2001-2004 International College of Geriatric Psychoneuropharmacology Senior Investigator Award 2011 2002-2005 University Association for Research and Education in Pathology 2002- Empresarios Argentinos en el Exterior 2005- International Maillard Society Councilor-at-Large 2005-

2005-2010 Portuguese American Leadership Council of the United States Member 2005-2009 Associate Member 2009-2010

2006 Council of Colleges of Arts and Sciences Mentoring Program 2012

2005- Society for Advancement of Chicanos and Native Americans in Science (SACNAS) Member, Awards Committee 2006, 2007, 2009, 2010, 2011, 2012, 2013, 2014 Member, Abstract Review and Selection Committee 2007, 2008, 2009, 2010, 2013, 2014, 2015 Member, MentorNet 2008- Life Member 2009- Distinguished Professional Mentor Award 2010 Friend of the Society 2010- Conversations with Scientists and Engineers 2010, 2011, 2012, 2013, 2014, 2015 2013 SACNAS National Conference Task Force 2012-2013

2006- Texas Association for Science Fairs 2006- Texas Association of Deans of Liberal Arts and Sciences Board Member 2009-

2007-2012 American Society for Biochemistry and Molecular Biology 2007- International Society to Advance Alzheimer‘s Research and Treatment (ISTAART)

Abstract Reviewer AAIC14 2014 2008- Forum Internacional de Investigadores Portugueses 2008- Iberoamerican Molecular Biology Organization (IMBO) 2009- National Organization of Portuguese-Americans Member 2009- Advocate 2010-2013 Advisory Board 2009-2012 Director, Education/Research Initiatives 2012-

Founder‘s Circle 2013- Board of Directors, Chair 2013- 2009- Beta Beta Beta National Biological Honor Society Graduate Lifetime Member, 2009- 2009- Real Academia de Ciencas (RAC)(Royal Spanish Academy of Sciences) Foreign Member, Natural Sciences, Elected 2009 2009- Portuguese American Post-Graduate Society Member 2009- Austin Chapter, Member 2010-2012 Texas Chapter, Leader 2013-2016 2010- Mind Science Foundation Friends of Mind Science 2010-2012

George Perry

16

Research Pioneer 2012-2014 Research Partner 2014- Board of Trustees 2012-2015, 2015-2018 Development Committee 2012- Science Committee 2013-2017 2010-2013 Histochemical Society 2010- Alzheimer‘s Association, Star Chapter Volunteer Recognition 2010 2010- Baylor College of Medicine Alumni Association Executive Committee 2010-2020 Awards Committee 2010-2020 Secretary 2015-2016 Vice President 2016-2017 Bylaws Committee, Chair 2017 President-Elect 2017-2018 President 2018-2019 2010- Texas Society for Microscopy Member 2010- 2010- Royal Society of Medicine Overseas Fellow 2010 2010- Academia Mexicana de Ciencias (AMC), (Mexican Academy of Science), Corresponding Member, Elected 2010, Induction 2012 2010- Dana Alliance for Brain Initiatives 2010- Texas Academy of Science Judge for Poster Presentations 2012, 2013, 2014, 2015, 2016 Judge for Oral Presentations 2012, 2014, 2015, 2016 Neuroscience Section Chair 2014-2016 Academic Director 2014-2017 Abstract Reviewer 2015 Sustaining Member 2015, 2016, 2017 Development Committee 2015- Fellow 2016 Awards Committee 2016- Publications Committee 2016- 2011- Linnean Society of London Fellow, Elected 2011 2011- Royal Society of Chemistry Fellow, Elected 2011 Chartered Chemist 2012 2011- HNE Club 2011- American Aging Association Poster Judge 2012 James Joseph and Mark A Smith Lecture Committee 2012- 2011- UCSD Alumni Association 2011- Royal Society of Biology (Formerly Society of Biology)

Fellow, Elected 2011 Chartered Biologist, 2011, Professional Development Completed 2013, 2014, 2015 Chartered Scientist, 2012

2011- American Chemical Society 2011- European Microscopy Society 2011- American Chemical Society 2011- Royal College of Pathologists

Fellow, Elected 2011 2011- UCSB Alumni Association Life Member 2011- 2011- Academia de Ciêncas de Lisboa (ACL), (Academy of Sciences of Lisbon), Foreign Corresponding Member, Elected 2011 2011- Reproductive Biology and Genetics Society 2012- Phi Kappa Phi (National)

George Perry

17

Life Member 2012 UTSA Charter Member 2012 Life Member (UTSA Chapter) 2014 2012- World Federation of Neurology 2012- Academic Society of Functional Foods and Bioactive Compounds 2012- Capital Area Browns Backers 2012- World Affairs Council of San Antonio 2012- Alpha Epsilon Delta Advisor 2012- 2012- Monarquicos Portugueses – Estados Unidos 2012- Research Centers in Minority Institutions Program Directors Association Nominating Committee 2012- Advocacy Committee 2012- Advocate Selection Committee 2014 2012- Royal Microscopical Society Fellow, Elected 2014 2013- Internet Medical Society Steering Committee Co-chair 2013- Scientific Committee of International Online Medical Conference 2015 2013- Fulbright Association Life Member 2013

2013- Research Centers in Minority Institutions Translational Research Network Steering Committee 2013-2015; 2015-2017 Symposium Committee 2015- 2013- Institute for Systems and Technologies of Information, Control and Communication 2014-2015 Royal Society of the Encouragement of Arts, Manufactures, and Commerce Fellow 2014 2014- Asian Council of Science Editors 2015- UTSA Retired Faculty Association Lifetime Honorary Membership 2015- International Engineering and Technology Institute Senior Member 2015 Distingished Fellow 2015 Executive Committee 2016 Chair, 2016 President 2016 2016- Friend of the Catholic University of Chile 2016- ALZA - Associação Alzheimer Açores Member 2016- 2017- World Academy of Medical Sciences Executive Committee 2017- Scientific Committee 2017- Fellow 2017- Bibliographic Listings:

American Men and Women of Science, 1989-1990; 1992-1993, 1998-1999, 2002-2003; Contemporary Who‘s Who, 2003-2004; Continental Who‘s Who Registry of National Business Leaders, 2005-2006; Dictionary of International Biography, 1996, 1998; International Executive Guild, 2002-; International Who‘s Who in Professionals, 1995, 1998, 2003-2004, 2005-2006; Men of Achievement, 1995; National Register‘s Who‘s Who in Executives and Professionals, 2005-2006; Strathmore‘s Who‘s Who, 1998-1999, 1999-2000, 2003-2004; Who‘s Who in America, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010; 2011, 2012, 2013, 2014, Who‘s Who in American Education, 2004-2005, 2007-2008; Who‘s Who of Executives and Professionals, 2005-2006; Who‘s Who in Finance and Industry, 2004-2005; Who‘s Who in Medicine and Healthcare, 1994-1995; 1997-1998, 2002-2003, 2004-2005 2006-2007, 2009-2010, 2011-2012; ; Who‘s Who in MidWest, 1994-1995, 1996-1997,1998-1999, 2000-2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008; Who‘s Who in Science and Engineering, 1998-1999, 2000-2001, 2010-2011, 2011-2012, 2016-2017; Who‘s Who in Sciences Higher Education, 2006; Who‘s who in the South and Southwest 2013; Who‘s Who in the World, 1996, 2010, 2012, 2013, 2014, 2015; Latino American Who‘s Who

George Perry

18

2014; Latino American Who‘s Who Top 100, 2014; Who‘s Who in this South and Southwest, 2009, 2010, 2011, 2012, 2013, 2014

Review Boards: Granting Agencies: National: Allen Institute for Brain Science Allen Distinguished Investigator Alzheimer‘s Disease Reviewer 2015 Alzheimer‘s Association

Reviewer 1996-2005, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016 Reviewer, Pioneer Grant 1998-1999; Reviewer, Zenith Award 2000, 2012, 2015, 2016 Reviewer, Part the Cloud 2013 Reviewer, Sex and Gender in Alzheimer‘s (SAGA) 2016

Alzheimer Foundation of America Reviewer 2013 Alzheimer‘s Research and Prevention Foundation Reviewer 2013-

American Federation for Aging Research National Advisory Council 2001-2005 American Health Assistance Foundation

External Reviewer 1996-1997 American Institute of Biological Sciences

United States Army, Neurotoxin Exposure Treatment Research Program Reviewer 1998, 2000-2003

Clinical Pilot Research Fund, Kansas University Medical Center Research Institute Reviewer 2004 Kansas Idea Network of Biomedical Excellence Pilot Proposals Reviewer 2010 Kansas Medical Center, Center for Biomedical Research Excellence (COBRE) Reviewer 2014 US Army Telemedicine and Advanced Technology Research Center Reviewer 2012 Alzheimer‘s Drug Discovery Foundation (formerly Institute for the Study of Aging)

Reviewer 2000-2005, Panel Review 2010, 2012 Banner Sun Health Research Institute Arizona Alzheimer‘s Consotrium Research Projects Reviewer 2012 Department of Defense Science, Mathematics and Research for Transformation (SMART) Program Panelist 2017 Kentucky Science and Engineering Foundation

Reviewer 2002, 2005, 2008, 2016 Lifeboat to the Stars Award Reviewer 2013- MacArthur Foundation Fellows Program Reviewer 2010 Mind Science Foundation Reviewer 2013

National Aeronautics and Space Administration (NASA) Life Sciences Radiation Health Program External Reviewer 1999; Regular Member 1999-2004 National Defense Science and Engineering Graduate Fellowship Program Cognitive, Neural and Behavioral Sciences

Reviewer 2015, 2016

George Perry

19

National Institutes of Health (NIH) Brain Disorders and Clinical Neurosciences-1 Study Section Ad Hoc Member 1999; External Reviewer 1999 Brain Disorders and Clinical Neurosciences-2 Study Section Ad Hoc Member 2003, 2004

Brain Disorders and Clinical Neurosciences-3 Study Section Ad Hoc Member 2001, 2003 Center for Scientific Review Stage 1 Reviewer, 2010

Fogarty Foundation Study Section External Reviewer 1992 Immunobiology Study Section Member Ad Hoc Group 1994

Medical Biochemistry Study Section Chair and Member Ad Hoc Group 1994 Molecular, Cellular, and Developmental Neuroscience Study Section

Member Ad Hoc Group 2007 National Institute on Aging

Alzheimer Disease Research Center, University of Kentucky, Lexington, Kentucky Member Site Visit 1985 Alzheimer‘s Disease Research Center Core External Reviewer 1991 Alzheimer Disease Program Project, Chicago, Illinois Member Site Visit 1996 Cell Models for AD: Lipids and Related Signaling Pathways, Program Project, University

of Missouri-Columbia External Reviewer 2005

Leadership and Excellence in Alzheimer‘s Disease Award External Reviewer 1988 Mitochondrial Damage in Alzheimer‘s Disease, Program Project, University of Virginia,

Charlottesville, Virginia Member Site Visit 2001

National Institute of Diabetes and Digestive and Kidney Diseases Special Review Committee External Reviewer 1997 National Institutes Environmental Health Sciences, Research Triangle, North Carolina Special Study Section to review RFA: Role of the Environment in Parkinson‘s Disease Member 2000 Study Section to review RFA: Centers for Neurodegenerative Sciences (CNS) Member 2008

National Institute of Mental Health Board of Scientific Counselors

Ad Hoc Reviewer 1997 National Institute on Neurological Diseases

Special Study Section to Review RFA: Alzheimer‘s Disease and Related Cerebral Degeneration Disorders

Member 1991 National Institute of Neurological Disorder and Stroke Neurological Disorders Program Project Review B Committee Member 1995

Neurological Sciences I Study Section Ad Hoc Member 1988; Member 1989-1993; Chair 1991-1993;

Reviewer Reserve 1993-1997 Neurological Sciences 3 Study Section

Member 1995 Neurology C Study Section Ad Hoc Member 1996 Neurology A Study Section External Reviewer 1988

George Perry

20

Molecular, Cellular and Developmental Neurosciences-2 Study Section External Reviewer 1999 RTRN Collaboration Enhancement Award Program Reviewer 2013, 2014 National Science Foundation External Reviewer 1988,1989,1998 National Science Foundation International Research Fellowship Program External Reviewer 2007 Systems Plus Air Force Summer Faculty Fellowship Program Reviewer 2017 United States Civilian Research and Development Foundation Cooperative Grants Program Reviewer 2001 Veterans Administration External Reviewer 1988,1993,1997,1999-2004 Virginia Center on Aging Reviewer 2003 International: Action Medical Research (United Kingdom) External Reviewer, 2008 Agence Nationale de la Recherche, Programme, Maladie d‘Alzheimer et Maladies Apparentées (France) External Reviewer 2012 Agencia Nacional de Promoción Cientifica y Technologica y de Innovación, Argentina

External Reviewer, 2003,2004,2007,2009 Alzheimer Forschung International e.v.: External Reviewer 1996-2000 Alzheimer Netherland External Reviewer 1999 Alzheimer‘s Research UK External Reviewer 2012, 2014 Alzheimer Society of Canada

External Reviewer 1993 Alzheimer‘s Society (United Kingdom)

External Reviewer 2000,2001,2005,2009,2011, 2017 AFM Telethon (France) Reviewer Trampoline Grant 2015 Reviewer Post Doctoral Fellowship 2016 BBSRC – Biotechnology and Biological Sciences Research Council (United Kingdom) External Reviewer 2015 BUPA Foundation, Alzheimer‘s Society (United Kingdom) External Reviewer 2010

Canadian Alzheimer Association: External Reviewer 1990-1993,1995,2002,2003 Canadian Council for the Arts, Killam Research Fellowship: External Reviewer 1998,1999 Canada Foundation for Innovation External Reviewer 2013

Canadian Institutes of Health Research External Reviewer 2001

Canadian Medical Research Council: External Reviewer 1988,1989,1992-1994,1996,1998-2001 Centres of Excellence in Neurodegenerative Diseases (CoEN) International Review Panel 2015 Chief Scientist Office: External Reviewer 2002

Comisiόn Nacional de Investigaciόn Cientifica y Tecnolόgica (CONICYT), (Chilean Science Foundation) – Fondo Nacional de Desarrollo Cientifico Tecnolόgico (FONDECYT)

George Perry

21

External Reviewer 2013, 2015 Croatian Ministry of Science, Education and Sports External Reviewer 2010 Czech Science Foundation External Reviewer 2012 Dr. Hadwen Trust for Humane Research External Reviewer 2011 Dunhill Medical Trust External Reviewer 2017 Engineering and Physical Sciences Research Council (United Kingdom) External Reviewer 2013 Finland Distingushed Professor Programme (FiDi Pro) External Reviewer 2014 Fondation Plan Alzheimer (France) External Reviewer 2011 Fondazione Italiana Sclerosi Multipla (FISM)

External Reviewer 2006, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016 Fonds zur Forderung de Wissenschaftlichen Forschung (Austrian Science Foundation) External Reviewer 1999 Guangdong-Hong Kong Technology Cooperation Funding Scheme (China) External Reviewer 2005 Health Research Board Research Awards, HRB (Ireland) External Reviewer 2013

Human Frontiers Science Program External Reviewer 1999

Internationale Stichting Alzheimer Onderzolk External Reviewer 1996, 2009, 2011 Israel Ministry of Science, Technology and Space External Reviewer 2015

Israel Science Foundation External Reviewer 1996

Medical Research Council (United Kingdom) External Reviewer 1990-1991, 1999, 2006, 2014 National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) Impact (United Kingdom) External Reviewer 2012 National Health and Medical Research Council (Australia) Assessor 2003 John Cade Fellowship in Mental Health Research Reviewer 2013 National Medical Research Council (Singapore) External Reviewer 2008 National Science Centre (Poland) External Reviewer 2011, 2013, 2014, 2015, 2016 Nazarbayez University (Kazakhstan) External Reviewer 2014, 2015

Netherlands Council for Medical Research GB-MW External Reviewer 1994 Netherlands Organization for Health Research and Development (Zon Mw) External Reviewer 2012, 2015, 2016 Neurological Foundation of New Zealand External Reviewer 1996-2000 Parkinson‘s Disease Society of the United Kingdom External Reviewer 2005, 2007 Portuguese Fundação para a Ciência e a Tecnologia Member National Site Visit Team 1999, 2004 External Reviewer 2012 Maratona da Sáude Reviewer 2016 Portuguese Society for Neuroscience Brain Ageing, Alzheimer‘s Disease and Other Dementias

George Perry

22

External Reviewer 2000,2002,2006 Santa Casa da Misericórdia de Lisboa, Santa Casa Neuroscience Awards Honor Commission 2013, 2014 Jury Panel 2013, 2014 Society for Redox Biology and Medicine Abstract Reviewer 2007, 2009, 2010, 2011, 2013, 2014, 2015 Spanish Ministry of Health and Consumer‘s Affairs

External Reviewer 2006, 2007, 2008 Spanish Ministry of Science and Innovation Reviewer Consolider—Ingenio Program 2010 Spanish National Agency for Scientific Evaluation (ANEP) Severo Ochoa Program Reviewer 2014, 2017 Maria de Maeztu Program Reviewer 2017

Swiss National Science Foundation External Reviewer 2004 Stichting voor Alzheimer Onderzoek (Belgium) External Reviewer 2011

Telethon (Italy) External Reviewer 2000, 2003, 2006, 2014

United States-Israel Binational Science Foundation External Reviewer 1996, 1997, 1999, 2000, 2002, 2004, 2006, 2012 Università degli Studi di Milano External Reviewer 2010, 2011 University of Aberdeen, Scotland Reviewer, Research Excellence Framework 2013 University of Concepción, Chile External Reviewer 2011 Vrije Universiteit External Reviewer 1998

Wellcome Trust External Reviewer 1996, 1997-2000, 2009 External Reviewer Neurodegenerative Diseases Strategic Award 2009 University based: Case Western Reserve University, Cleveland Alzheimer Disease Research Center Pilot Program, Reviewer 1995; Project Reviewer 1998 Geriatrics Care Centers, Pilot Projects Reviewer 1994 Leadership and Excellence in Alzheimer‘s Disease Award, Pilot Program Reviewer 1994 Presidential Research Initiative Grants Reviewer 2000, 2001, 2005 Presidential Technology Development Fund Grants Reviewer 2001 Summer Research Training in Aging for Medical Students Reviewer 2004 Vision Research Core Grant Advisory Committee 2001 City University of New York Center for Translational and Basic Research Reviewer 2014 Collaborative Incentive Research Grant Program (CIRG) 2014, 2015 College of Staten Island, City University of New York Biology Department Site Visit Team 2010 Georgia Research Alliance Collaboration Planning Grants Reviewer 2009 Hunter College Gender Equity Project Mentor 2007 Indiana University, Indianapolis

George Perry

23

Alzheimer‘s Disease Research Center, Pilot Program Reviewer 1996, 2002, 2009 Johns Hopkins University, Baltimore Alzheimer‘s Disease Research Center, Pilot Program Reviewer 2001

Northeastern Ohio University Research Challenge Grant: External Reviewer 1989 Oak Ridge Associated Universities Reviewer 2009, 2010 Ohio University, Athens Baker Fund Awards Reviewer 2002

Ohio University Research Committee External Reviewer 1990 Oregon Health Sciences Center Alzheimer Center Reviewer 2007, 2010 Pennsylvania Performance Review Reviewer 2009, 2010, 2012 Universidad Arturo Prat International Research Advisory Board Member 2008

University of Arizona Alzheimer‘s Disease Research Center Reviewer 2002, 2003 University of California Davis Alzheimer Disease Research Center Pilot Project Reviewer 2013

University of Coimbra, Coimbra, Portugal Center for Neuroscience and Cell Biology Member, Advisory Committee 2002-2015 External Reviewer, Ph.D. Program, 2009 University of Kentucky, Lexington Reviewer 1994; External Reviewer, Veterans Administration 1997 Universitά degli Studi di Milano Reviewer Post doctoral Fellowships 2010 University of Texas, Brownsville

National Institutes of Health – Support of Competitive Research Program (SCORE) External Reviewer 2007, 2009

University of Texas Health Science Center at San Antonio National Institutes of Health – Clinical Science Collaborative (CTSA) Reviewer K-12 Awards 2008, 2010 Council of Deans, 2008- Pilot Project Review, 2010, 2013 Community Health Advisory Board 2015- Grant Reviewer 2015 National Institutes of Health – San Antonio Claude D. Pepper Older Americans

Independence Center Reviewer Pilot and Exploratory Grants 2016 National Institutes of Health – San Antonio Nathan Shock Aging Center Reviewer Pilot Awards 2016

University of Texas at San Antonio – Southwest Research Institute Connect Program Reviewer 2013, 2014, 2015 University of Texas Medical Branch NIEHS Center Pilot Project Reviewer, 2012 UT Health Brain Initiative Reviewer 2014

University of Washington, Seattle

George Perry

24

Alzheimer‘s Disease Research Center External Reviewer 1992 Corporate: Apax Partners and Company: Reviewer 1998 Defined Health Reviewer 2002 Emerging Technology Partners L.L.C. Reviewer 2001 Forest Laboratories Reviewer 2001 Medical Matters Group Reviewer 2007 Novartis Preclinical Expert Panel Member 2002 Philip Morris External Research Program Reviewer 2002, 2004

Research Corporation: External Reviewer 1990 TA Miller Company Reviewer 2003 Takeda – American Scientific Advisory Panel Member 2000 Advisory Boards: 1987, 1990 Ohio Governor‘s Task Force on Alzheimer's Disease, Ad Hoc Member 1988-1990 Scientific Advisory Board, Familial Alzheimer's Disease Research Foundation 1988 Scientific Advisor for Newsletter, Alzheimer Disease and Related Disorders Association,

Cleveland Chapter 1992-1993, 1995-1996 Awards Committee, American Association of Neuropathologists Annual Meetings 1992-1996 Consultant, Molecular Geriatrics, Incorporated 1993-1994 International Scientific Advisory Committee, Fourth International Conference on Alzheimer‘s

Disease and Related Disorders, Minneapolis, Minnesota 1996 Invited Nominator, 1997 Helmut Horten Research Award, Switzerland 1997- Science Advisory Board Steering Committee 2011- 1998-2000 Consultant, Nymox Corporation, Montreal, Canada 1998-2000 Medical Advisory Board, Nymox Corporation, Montreal, Canada 1999- Advisory Council, International Biographical Centre, Cambridge, England 1999-2000 Advisory Panel, International Congress of Neuropathology, Birmingham, England 1999-2000 International Advisory Board, Metals and Brain: From Neurochemistry to

Neurodegeneration, Padova, Italy 2000- Scientific Advisory Board, Institute for the Study of Aging, New York, New York 2000-2002 Scientific Advisory Board, Second International Conference on Metal and the Brain, Fez, Morocco 2000-2003 Scientific Advisory Board, Panacea Pharmaceuticals, Rockville, Maryland 2000- Central Nervous System Panel, BOLT International 2000-2005 Scientific Advisor Board, Alzheimer‘s Foundation of the South 2000- Alzheimer Award and Medal Selection Committee, Journal of Alzheimer‘s Disease, Chair

and Founder 2001 External Advisory Panel, Program Project, University of Southern California 2001- CNS Advisory Board, Takeda Pharmaceuticals 2001-2002 Consultant, Prion Development Laboratories, Buffalo Grove, Illinois 2001-2007 Chair, Scientific Advisory Board, Voyager Pharmaceutical Corporation 2002-2003 Advisory Board, Alzheimer Research Forum

George Perry

25

http://www.alzforum.org/com/res/detail.asp?id=%7BAF7F6C7C-A7F3-4E6D-96BB-6BF5FA53F1AE%7D

2002-2003 Scientific Advisory Board, Third International Congress on Vascular Dementia, Praque, Czech Republic

2002 Vice-Chair, Scientific Advisory Board, World Events Forum, Chicago, Illinois 2002-2004 Scientific Program Committee, 9th International Conference on Alzheimer‘s Disease,

Philadelphia, Pennsylvania 2002- Scientific Committee, The McCusker Foundation for Alzheimer's Disease Research, Perth,

Australia 2002- Scientific Advisory Board, Udall Center for Parkinson‘s Disease, University of Virginia,

Charlottesville, Virginia 2002- International Advisory Board, XI Symposium New Frontiers of Neurochemistry and

Neurophysics on Diagnosis and Treatment of Neurological Diseases, Firenze, Italy 2002-2003 Consulting Group Member, Challenging Views of Alzheimer‘s Disease – Round 2,

Cincinnati, Ohio 2003 Advisory Board, H. Lundbeck A/S and Pharmexa, Denmark 2003-2005 Chair, Scientific Advisory Board, Molecular Cognition Incorporated, Chicago, Illinois 2003- Advisory Board, Council of Healthcare Advisors 2003 Scientific Committee, International Conference in Biomedicine and Biotechnology 2004-2005 International Scientific Committee, Fourth International Congress on Vascular Dementia,

Porto, Portugal 2004 Consultant, Dunn Group, New Jersey 2004-2009 Consultant, Vista‘s Society of Industry Leaders 2004- Member, Faculty of 1000 Biology, Neurobiology of Disease and Regeneration section

http://www.f1000biology.com/about/biography/7956451834408702 2005- Member, Cornerstone Insights 2005-2006 Scientific Advisory Board, Alzheimer: 100 Years and Beyond, Tübingen, Germany 2006-2007 International Scientific Committee, Fifth International Congress on Vascular Dementia,

Budapest, Hungary 2006- Gerson Lehrman Group Educator Program 2009- 2006- Advisor, Scope: Journal of the University of Texas at San Antonio College of Sciences 2007- Advisor, San Antonio-Small Animal Imaging Resource Working Group, The University of

Texas Health Science Center at San Antonio 2007- Scientific Journals International 2007-2008 Commission on Professionals in Science and Technology Nominating Committee 2008- 2007- Community of Science

2007 Abstract Review Committee, Society for Free Radical Biology and Medicine 2007- Blue Chip Expert

2007-2008 Conference Committee, Current Hypothesis on Alzheimer‘s Disease, Viña del Mar, Chile 2007- Anián Advisors, A Reuters Business 2007- Sacoor Medical Group 2007-2008 Member of the Technical Organizing Committee of BioMonterrey 08 2008- McKensey and Company, New York, New York 2008- Neuroinnovation Limited, Santiago, Chile 2008- Mind and Brain Institute, Santiago, Chile 2008- International Center for Biomedicine, Santiago, Chile 2008- Lifeboat Foundation, Minden, Nevada Neuroscience Board 2009- Manager, LinkedIn 2010- Manager, Facebook 2011- Diplomacy Board 2011 Life Extension Board 2011- Lifeboat to the Stars, Judge 2012 2008-2009 Memory XL, Boston, Massachusetts 2008-2009 Sixth International Congress on Vascular Dementia, Barcelona, Spain 2009- Campbell Alliance, Raleigh, North Carolina 2009- Round Table Group, Washington, D.C. 2009- Organizer, First International Meeting, Brain Club International, Smolenice, Slovak

George Perry

26

Republic 2009-2020 Scientific Advisory Board, Alzheimer Research and Prevention Foundation, Tucson, Arizona Chief Science Officer 2016- 2009- Texas Alzheimer‘s Disease State Plan Partnership Strategic Plan 2009-2010 Implementation 2010- Collaborative Research Committee 2013- 2009- National Organization of Portuguese-Americans Advisory Council 2009- Board of Directors Chair, 2013 2009- Institute of Integrative Omics and Applied Biotechnology (IIOAB), India Lifetime Association, Honorary Advisor 2009- Guidepoint Global 2009- InspiredOpinions.com (formerly Schlesinger Associates), Edison, New Jersey 2009- Limelight Technologies, San Antonio, Texas 2009-2010 Program Committee, Microscopy and Microanalysis 2010, Portland, Oregon 2009-2010 BIT‘s 1

st Annual NeuroTalk 2010, Singapore

Scientific Advisory Board 2010-2011 Seventh International Congress on Vascular Dementia, Riga, Latvia 2011 2010- Aria Neurosciences Scientific Advisory Board Member, 2010 Chair, 2011 2010 Program Committee, Biological Data Mining and its Applications in Healthcare, Tenth IEEE International Conference on Data Mining, Sydney, Australia 2010 Advisory Board, Academic Tree 2010 Site Editor, Neuropathology Tree 2010 Site Editor, Alzheimer‘s Tree 2010 Site Editor, Baylor College of Medicine Tree 2010-2011 Program Committee, Microscopy and Microanalysis 2011, Nashville, Tennessee 2010-2013 Carlos III Health Institute, External Scientific Committee, CIBERNED, Networked Cooperative Research Centers, Spain Chair, 2011 2010-2011 Second World Congress on Bioavailability and Bioequivalence: Pharmaceutical R & D Summit, Las Vegas, Nevada 2011 2010-2011 Drug Discovery for Neurodegenerative Diseases: Neurochemical Complexes and Drug Targets, Panama 2011 2010-2011 Ninth International Workshop, Applied Category Theory Graph-Operad-Logic Local Organizing Committee 2011- QS Global Academic Survey Reviewer 2011, 2012, 2013 2011- Biomed SA, Asset Initiative, Neuroscience Committee Chair, Research Subcommittee 2011-2012 Co-Chair, Implementation Plan 2012-2013 2011- United Mitochondrial Disease Foundation, ―Mitochondrial Champion‖ 2011- Webmed Central 2011- Alzheimer‘s Foundation of America, New York, New York Medical Advisory Board 2011 Latino Institute of Care, National Advisory Member 2011 Working Group on AD Scope of Work and Investment 2012- 2011- Integrated Communications Corporation, Parsippany, New Jersey 2011- International Conference and Exhibition on Pharmaceutical Regulatory Affairs, Baltimore, Maryland Organizing Committee 2011 2011 First World Congress of Small RNAs, Shenzhen, China Program Committee

George Perry

27

2011- Workgroup on Novel Conceptual Models of Dementia 2011- ORCID Contributor 2011- Alzheimer‘s Hope for a Cure LLC, Bainbridge, Ohio Board of Advisors 2011 Second Workshop on Biological Data Mining and its Applications in Healthcare, Eleventh IEEE International Conference on Data Mining, Vancouver, Canada 2011 Program Committee 2011- BIT‘s First Annual World Congress of Nano – S&T, Dalian, China 2011 World Congress on Pediatrics and Gynecology, Philadelphia, Pennsylvania 2011 Organizing Committee 2011 ManRos Therapeutics, Roscoff, France Scientific Advisory Board 2011-2012 PECCS 2012, Second International Conference on Pervasive and Embedded Computing andCommunication Systems, Rome, Italy, 2012 2011-2012 Sixth World Congress on Controversies in Neurology (CONy), Vienna, Austria 2012 2011-2012 Third World Congress on Bioavailability and Bioequivalency, Hyberbad, India Organizing Committee 2011-2012 Seventh International Conference on Systems, ICONS 2012, Saint Gilles, Réunion Island 2011- IOS Press Amsterdam, Netherlands Strategic Advisor 2011- Physician Nexus, San Jose, California Board of Advisors 2011- Case Brain Health Collaborative, Cleveland, Ohio Advisory Member 2011-2012 International Conference and Exhibition on Addiction Research and Therapy, Las Vegas, Nevada, 2012 2011-2012 Third International Conference on Neurology, Kos Island, Greece, 2012 2011-2012 International Conference on Tissue Science and Engineering, San Francisco, California 2011- Community of Interest of Global Environmental Standard, Weston, Australia 2011- Portuguese-American Historical and Research Foundation, Inc., Franklin, North Carolina Advisory Council 2011- QS World University Rankings Reviewer 2011, 2012, 2013 2012 Nutricia, U.S. Souvenaid Advisory Board, Rockville, Maryland 2012 International Conference on Clinical Microbiology and Microbial Genomics, San Antonio, Texas, 2012 2012 International Conference and Exhibition on Emerging Therapies, Chicago, Illinois 2012 International Conference and Exhibition on Addiction Research and Therapy, Las Vegas, Nevada, 2012 2012 International Conference on Regenerative and Functional Medicine, San Antonio, Texas, 2012 2012 Second World Congress on Cell Science and Stem Cell Research, San Antonio, Texas, 2012 2012 International Conference and Exhibition on Pharmacovigilance and Clinical Trials, Chicago, Illinois, 2012 2012- Third Workshop on Biological Data Mining and its Applications in Healthcare, Twelfth IEEE International Conference on Data Mining, Brussels, Belgium 2012 2012-2013 Eighth International Congress on Vascular Dementia, Athens, Greece 2013 2012-2013 PECCS 2013, Third International Conference on Pervasive and Embedded Computing and Communication Systems, Barcelona, Spain, 2013 2012 International Conference on Central Nervous System – Drug Effects and Novel Drug Development, Philadelphia, PA 2012 Third World Congress on Biotechnology, Hyderabad, India 2012- Prevention Alzheimer International Foundation 2012 First International Conference on Global Health Challenges, Global Health 2012, Venice, Italy, 2012 2012- Omics Group Membership 2012-2013 Eighth International Conference on Systems, ICONS 2013, Seville, Spain 2012- Functional Food Center, Denton, Texas

George Perry

28

2012-2013 Seventh World Congress on Controversies in Neurology, Istanbul, Turkey, 2013 2012-2013 Second International Conference and Exhibition on Pathology, Chicago, Illinois, 2013 2012-2013 Second International Conference and Exhibition on Biometrics and Biostatistics, Chicago,

Illinois, 2013 2012-2013 Second International Conference and Exhibition on Neurology and Therapeutics, Chicago, Illinois, 2013 2012-2013 Second International Conference and Exhibition on Emerging Cell Therapies, Raleigh,

North Carolina, 2013 2012-2013 International Conference on Psychology, Autism and Alzheimer‘s Disease, San Antonio, Texas, 2013 2012-2013 14

th Research Centers in Minority Institutions International Symposium on Health

Disparities, San Antonio, Texas (cancelled) Executive Council 2012-2013 Chair 2012-2013 Scientific Committee 2012-2013 Community Engagement 2012-2013 Local Host Planning Committee 2013 Second International Conference on Global Health Challenges, Global Health, 2013, Lisbon, Portugal, 2013 2013- Fourth World Congress on Biotechnology, Raleigh, North Carolina, 2013 2013- Second Workshop on Embedded and Ubiquitous, Jeju National University International Center, Jeju Island, Korea 2013 Fourth Workshop on Biological Data Mining and its Applications in Health Care, Thirtieth IEEE International Conference on Data Mining, Dallas, Texas, 2013 2013 USAgainst Alzheimer‘s, Washington, DC, Researcher Network 2013 Exploring the Portuguese Diaspora in Interdisciplinary and Comparative Perspectives: An International Conference, Indianapolis, Indiana Scientific Committee, 2013 2013 NCTA 2013, Fifth International Conference on Neural Computative Theory and Applications, Vilamoura, Portugal, 2013 2013 Neurotechnix 2013, International Congress on Neurotechnology, Electronics and Informatics, Vilamoura, Portugal, 2013 2013 NeuroConf 2013, Neurology and Neurosurgery Conference, Sanya, China, 2013 2013-2014 Eighth World Congress on Controversies in Neurology, Berlin, Germany, 2014 2013-2014 PECCS 2014, Fourth International Conference on Pervasive and Embedded Computing and Communication Systems, Lisbon, Portugal, 2014 2013-2014 International Conference on Women‘s Health, Gynecology and Obstetrics, Chicago, Illinois, 2014 2013-2014 XVIII International Congress of Neuropathology, Rio de Janeiro, Brazil, 2014 2013-2014 Second International Conference on Alzheimer‘s Disease and Dementia, Valencia,

Spain, 2014 2013- Evise Development Community, Elsevier, Amsterdam, Netherlands 2013- Ambassador, ORCID 2013- 2013-2015 Ninth International Congress on Vascular Dementia, Paris, France, 2015 2013- Fourth International Conference on Biochemistry and Medical Chemistry, Paris, France, 2013 2013- ExxonMobil Texas Science and Engineering Fair Advisory Board Member 2013- 2013 International Summit on Clinical Pharmacy and Dispensing, San Antonio, Texas 2013 2013- NeuroBiotech Pharma, Inc., Deerfield Beach, Florida Medical Advisory Committee 2013- 2013-2014 Third International Conference on Global Health Challenges, Global Health 2014, Rome, Italy, 2014 2013-2014 NIMHD (formerly)International Symposium on Minority Health and Health Disparities, Washington DC, 2014 Abstract Reviewer 2014 Program Planning Committee 2014 Moderator, Meet the Expert 2014

George Perry

29

2014- Stop Alzheimer‘s Corporation, Homestead, Florida Founder and Director 2014 Second International Conference on Integrative Biology Summit, Chicago, Illinois, 2014 2014 Second International Conference on Genomics and Pharmacogenomics, Raleigh, North Carolina, 2014 2014 Second International Summit on Clinical Pharmacology, San Francisco, California, 2014 2014 Neurotechnix, 2014, Second International Conference on Neurotechnology, Electronical Informatics, Rome, Italy, 2014 2014 International Program Committee of the 2014 International Conference on Biology and Biomedical Engineering, Venice, Italy, 2014 2014 International Program Committee of the 2014 International Conference on Biology and Biomedicine Prague, Czech Republic, 2014 2014 Fourth International Conference of Ambient Computing, Applications, Services, and Technologies, Ambient 2014, Rome, Italy, 2014 2014- Impactstory 2014 Ninth International Conference on Systems, ICONS 2014, Nice, France 2014 2014 Fifth Workshop on Biological Data Mining and its Applications in Healthcare, ICDM 2014, Shenzhen, China, 2014 2014 Third Embedded and Ubiquitous 2014, Jeju Island, Korea, 2014 2014-2015 PECCS 2015 Fifth International Conference on Pervasive and Embedded Computing and Communication Systems, Loire Valley, France 2015. 2014-2015 ICONS 2015, Tenth International Conference of Systems, Barcelona, Spain, 2015 2014-2015 Ninth World Congress on Controversies in Neurology (CONy), Budapest, Hungary, 2015 2014- ACT-AD, Accelerate Cure/Treatments for Alzheimer‘s Disease Scientific Advisory Board 2014- Seventh Center International Conference on Functional Foods, San Diego, California, 2014- Second International Conference on Genomics and Pharmacogenomics, Raleigh, North Carolina, 2014 2014 Lieberman Research Worldwide, Los Angeles, California 2014 ICBEB2014, Third International Conference on Biomedical Engineering and Biotechnology, Beijing, China, 2014 2014 System Analytic, London, England, Advisor 2014- Asian Council of Science Editors, Deira Dubai, United Arab Emirates 2014-2015 Conference on Advances in Evidence-Based Medicine, Suzhou, China, 2015 2014-2015 International Conference on Biological Information and Engineering CICBIE, 2015 2014-2015 Second International Conference on Gynecology and Obstetrics, San Antonio, Texas, 2015 2014- Nebulab Technologies, Incorporated, San Antonio, Texas 2014-2015 International Congress on Vascular Dementia (ICVD), Ljubljana, Slovenia, 2015 2014-2015 Neurological Disorders Summit, San Francisco, California, 2015 2014-2015 Second International Conference on Health Informatics and Technology, Valencia, Spain, 2015 2014-2015 Neurotechnix 2015, Third International Congress on Neurotechnology, Electronics And Informatics, Lisbon, Portugal, 2015 2015- JoVE Product Advisory Board, Cambridge, Massachusetts 2015 Global Pharma Summit, Philadelphia, Pennsylvania, 2015 2015 CENICS 2015, Eighth International Conference on Advances in Circuits, Electronics And Micro-electronics, Venice, Italy, 2015 2015 Sixth Workshop on Biological Data Mining and its Applications in Healthcare, ICDM 2015,

Atlantic City, New Jersey 2015 2015- Faculty Row 2015-2016 Nanotech 2016, Global Nanotechnology Conference and Expo, Dubai, United Arab

Emirates 2016 2015-2016 ICONS 2016, Eleventh International Conference on Systems, Lisbon, Portugal, 2016 2015-2016 EMBEDDED 2016, International Symposium on Advances in Embedded Systems and

Applications, Lisbon, Portugal 2016 2015-2016 Tenth World Congress on Contraversies in Neurology (CONy), Lisbon, Portugal, 2016 2015- Academic.edu, Editor 2015- Scientific Committee, First International Online Biomedical Conference, 2015

George Perry

30

2015 18th International Conference of Functional Foods Center, Harvard Medical, Boston,

Massachusetts, 2015 2015 First International Workshop on Power Devices and Components, Jeju Island, Korea, 2015 2015 World Bio Summit and Expo, Dubai, United Arab Emirates, 2015 2015 Global Pharma Summit 2015, Philadelphia, Pennysylvania, 2015 2015 Neurological Disorders Summit, United Scientific Group, San Francisco, California, 2015 2015-2016 Fourth Global Experts Meeting on Neuropharmacology, San Antonio, Texas, 2016 2015-2016 SPCS 2016, International Conference on Signal Processing and Communication Systems, Lisbon, Portugal, 2016 2015-2016 Second International Conference and Expo onDrug Discovery and Designing, Istanbul, Turkey, 2016 2015-2016 Ninth International Conference on Advances in Circuits, Electronics and Micro-electronics

(CENICS 2016), Nice, France, 2016 2015-2016 Improving Human Relevance in Alzheimer Research, Physicians Committee For Responsible Medicine, Washington, DC, 2016 2015-2016 Second Neurological Disorders Summit, NDS-2016, Baltimore, Maryland, 2016 2015-2016 Seventh Global Neurologists Annual Meeting on Neurology and Neurosurgery, Vienna, Austria, 2016 2015-2016 Global Congress & Expo on Material Science and Nanoscience, Material Science 2016,

Dubai, UAE 2016 2015-2016 Global Nanotechnology Congress and Expo, Dubai, UAE 2016 2015-2016 World Congress on Nursing & Healthcare, Dubai, UAE 2016 2016 International Engineering and Technology Institute Co-Chair, Executive Committee 2016 Universal Scientific Education and Research Network (USERN) Congress Board, Tehran, Iran 2016 2016 National Research Mentoring Network; Research Resources and Outreach Core External Advisory Board 2016- 2016- Queen Sofia International Award for Research in Neurodegeneration Chair, Selection Committee 2016 Texas FreshAir Neuroscience Meeting, Austin, Texas, 2016 Program Committee 2016- Neuro EM Therapeutics, Phoenix, Arizona Scientific Advisory Board 2016- Academic Leadership Forum 2016- World Congress and Expo on Dementia and Neuroscience, Los Angeles, 2016 2016 JangoBio, LLC, Madison, Wisconsin Advisory Board 2016 First Universal Scientific Education and Research Network (USERN) Prize 2016 International Conference on Bipolar Disorders 2016, Sao Paulo, Brazil, 2016 2016 International Conference of Molecular Evolution, Bangkok, Thailand, 2016 2016 Institute Pasteur International Network Abstract Reviewer 2016 Tenth World Congress on Neurology and Therapeutics, London, England, 2016 2016 International Conference on Aging, Las Vegas, Nevada, 2016 2016 Annual Conference on Bioscience, Berlin, Germany, 2016 2016 International Conference on Novel Approaches in Agriculture and Life Sciences, Tbilisi,

Georgia, 2016 2016 Second World Bio Summit and Expo, Dubai, UAE, 2016 2016 International Conference on Medicine, Public Health and Biological Science, Chair,

Tehran, Iran, 2016 2016 Ninth Global Neuroscience Conference, Melbourne, Australia, 2016 2016 Fourth World Congress on Geriatrics & Gerontology-2016, Bangalore, India 2016 2016 Bioavailability & Bioequivalence, BABE 2016, Atlanta, Georgia, USA 2016 2016- Senior Patient and Family Caregiver Network, Alliance for Aging Research, Washington,

DC 2016- XPRIZE Foundation, Culver City, California Development of prize in Alzheimer disease

George Perry

31

2016-2017 Eleventh World Congress on Controversies in Neurology (CONy), Athens, Greece, 2017 2016-2017 Twenty First International Conference and Expo on Functional Foods, San Diego,

California, 2017 2016-2017 World Congress and Expo on Biotechnology and Bioengineering, Dubai, UAE, 2017 2016-2017 ICONS 2017, Twelfth International Conference of Systems, Venice, Italy, 2017 2016-2017 Eleventh World Congress on Neurology and Therapeutics, Madrid, Spain, 2017 2016-2017 Tenth International Congress on Vascular Dementia, Gdansk, Poland, 2017 2016-2017 Sixth International Conference on Vascular Dementia, Amsterdam, Netherlands, 2017 2016-2017 Eleventh World Congress on Pharmaceutical Sciences and Innovations in Pharma

Industry, Pharmaceutical Sciences 2017, Amsterdam, Netherlands 2017 2016-2017 Eleventh International Conference on Pharmacoepidemiology and Clinical Research,

Kuala Lumpar, Malaysia 2017 2016-2017 Eighth International Conference on Proteomics and Bioinformatics, Proteomics 2017,

Osaka, Japan 2017 2016-2017 Eighteenth European Diabetes Congress, Euro Diabetes 2017, Lisbon, Portugal 2017 2016-2017 Fourth International Conference on Mobile and Wireless Technology, ICMWT2017, Kuala

Lumpur, Malaysia 2017 2016-2017 Fourth International Conference on Neurodegenerative disorders and Stroke, Brain

Stroke 2017, Frankfurt, Germany 2017 2016-2017 International Conference on Diabetes, Nutrition, Metabolism & Medicare, Diabetes

Conference 2017, Vancouver, Canada 2017 2016-2017 Fourth Annual Congress on Drug Discover & Designing, Bangkok, Thailand 2017 2016-2017 International Conference on Neurology and Brain Disorders, Neurology Conference,

Valencia, Spain 2017 Directorates 2008- Board of Directors, Neurotez, Incorporated, Bridgewater, New Jersey 2011- Chief Scientific Officer, Neurotez Incorporated, Bridgewater, New Jersey 2012-2015 Board of Trustees, Mind Science Foundation, San Antonio, Texas Development Committee 2013- Science Committee 2013- 2013- Chair, Board of Directors, National Organization of Portuguese Americans 2014- Board of Directors, Stop Alzheimer‘s Corporation, Homestead, Florida 2016- Chief Science Officer, Alzheimer Research and Prevention Foundation, Tucson, Arizona Award Nominator (Successful) Mark A. Smith 1995, 1996 American Health Assistance Foundation (AHAF), Ruth Salta Junior Investigator

Achievement Award [only two-time awardee] 1995-1997 American Philosophical Society Fellowship 1997 Center for Professional Ethics Fellowship 1997 International Society for Neurochemistry, Young Scientist Lectureship Award 1997 The Gerontological Society of America, Nathan Shock New Investigator Award 2000 American Society for Neurochemistry, Jordi Folch-Pi Award 2002 HNE Society, Hermann-Esterbauer Award 2009 American Association for the Advancement of Science, Fellow 2011 American Society for Investigative Pathology, Outstanding Investigator Award William Fickinger 2003 American Association of University Professors, Ohio Chapter, Kennedy Award Michael E. Lamm

2004 American Society for Investigative Pathology, Gold Headed Cane Award Jesύs Avila

2004 King Juan Carlos and Queen Sofia of Spain, Ramon y Cajal Medal 2014 European Dana Alliance for Brain Initiatives

George Perry

32

Miguel José Yacamán

2008 American Association for the Advancement of Science, Fellow Paula I. Moreira 2008 Medalhas de Honra L‘Oréal Portugal para as Mulheres na Ciência Manuel P. Berriozábal

2009 American Association for Cell Biology, Bruce Alberts Award for Excellence in Science Education

C. Mauli Agrawal 2010 Biomed SA, Julio Palmaz Award 2016 American Association for the Advancement of Science, Fellow A. Claudio Cuello 2010 Order of Canada Pierluigi Gambetti 2011 American Association for the Advancement of Science, Fellow Jerry Silver 2011 American Association for the Advancement of Science, Fellow William Gunning 2011 Microscopy Society of America, Fellow Leroy Hood 2011 Biomed SA, Julio Palmaz Award Andrew Tsin 2011 Presidential Award for Excellence in Science, Mathematics, and Engineering Mentoring (Presented by President Obama) 2011 American Association for the Advancement of Science, Fellow 2012 Royal Society of Biology, Fellow 2014 American Association for the Advancement of Science, Mentor Award Charles Wilson 2012 Dana Foundation for Brain Initiatives BR Brinkley 2014 E.B Wilson Medal, American Society for Cell Biology Francisco Gonzalez-Lima 2014 Texas Academy of Sciences, Distinguished Texas Scientist Bernard P. Arulanandan 2015 America Association for the Advancement of Science, Fellow Jagannatha Rao 2016 Royal Society of Chemistry, Fellow Ronald DePinho 2016 Academia das Ciências de Lisboa Bert W. O‘Malley 2017 Distinguished Texas Scientist External Reviewer for Promotions and Appointments: Academia Sinica (Taiwan); American University of Madaba (Jordan); Brown University; Case Western

Reserve University; Centro de Investigación de Estudios Avenzados de IPN (Mexico); Cleveland Clinic

George Perry

33

Foundation; Cornell Medical College; Dartmouth College; Emory University; Florida Atlantic University. Georgetown University; Houston Methodist Research Institute; Indiana University; Institute for Basic Research in Developmental Disabilities, Johns Hopkins University; Keele University; Kent State University, King‘s College London, Lancaster University; Liberty University; Loyola University Medical Center; Medical College of Georgia;Medical College of South Carolina; Missouri University of Science and Technology; Mount Sinai School of Medicine; National University of Singapore; New York State Institute for Basic Research in Developmental Disability; New York University; National Institutes of Health Study Section; Order of Canada; Oregon Health and Science University; Pennsylvania State Medical School; Stanford University; Texas A&M Health Science Center; University of California, Irvine; University of California, Los Angeles; University of California, San Diego; The Commonwealth Medical College; University of California, Santa Barbara; University of Cambridge, University of Houston, University of Illinois at Chicago, University of Kentucky, Lexington; University of Louisville School of Medicine, Kentucky; University of Maryland, Baltimore; University of North Dakota; University of Pennsylvania; University of Pittsburgh; University of Shayah (United Arab Emirates), University of South Florida; University of Southern California; University of Texas at Brownsville; University of Texas Health Science Center; University of Texas Medical Branch; University of Texas Rio Grande Valley; University of Toronto; University of Washington; University of Western Australia; University of Wisconsin, Madison; Vanderbilt University; Virginia Comonwealth University; Wake Forest University; University of Western Ontario, Yeshiva University (Albert Einstein College of Medicine); Zhejiang University

Editorial Work: Editorships:

1993 Guest Editor for Clinical Neuroscience issue: Alzheimer‘s Disease (Volume 1, issue 4) 1994-1995 Biomedical Journal 1994-2000 Associate Editor (Section editor for Neuropathology), American Journal of Pathology 1998- Editor-in-Chief, Journal of Alzheimer‘s Disease http://www.j-alz.com/about/publications.html#perry 2001-2002 Managing editor for Frontiers in Bioscience (with Mark A. Smith): Alzheimer‘s disease

(Volume 7) 2002 Guest Editor for Free Radicals in Biology and Medicine Forum (with Mark A. Smith and

William A. Pryor): Causes and Consequences of Oxidative Stress in Alzheimer‘s Disease (Volume 32, issue 11)

2002 Guest Editor for Neurosignals (with Mark A. Smith and Xiongwei Zhu): Alzheimer Disease (Volume 11, issue 5)

2002- Senior Associate Editor (Biological Sciences), Microscopy Research and Technique 2003-2006 Assistant Editor, Journal of Pediatric Neurology 2003- Associate Editor, Current Alzheimer Research 2004 Guest Editor for Acta Neurobiologiae Experimentalis (with Mark A. Smith and Xiongwei

Zhu): Alzheimer‘s Disease (Volume 64, issue 1) 2004-2005 Guest Editor for Brain Pathology (with Rudy J. Castellani, Paula I. Moreira, and Mark A.

Smith): Amyloid-β: A Multifaceted Protein, Parts I and II (Volume 14, issue 4, 2004 and Volume 15, issue 1, 2005)

2004- Associate Editor, Journal of Biomedicine and Biotechnology 2005 Guest Editor for International Journal of Experimental Pathology (with Mark A. Smith): Role

of Amyloid-β in Alzheimer Disease (Volume 86, issue 3) 2005 Guest Editor for Microscopy Research & Technique (with Mark A. Smith): Fibril Imaging in

Alzheimer Disease (Volume 67, issue 3-4) 2005 Guest Editor for Current Alzheimer Research (with Mark A. Smith and Jagannatha Rao):

Apoptotic Mechanism in Neurodegenerative Diseases (Volume 3, issue 4) 2006 Guest Editor for Journal of Biomedicine and Biotechnology (with Xiongwei Zhu and Mark

A. Smith): Neurodegenerative Diseases: Mechanisms and Therapies 2007 Guest Associate Editor for American Journal of Biochemistry and Biotechnology: Autism 2008-2010 Editor-in-Chief, Open Neurology Journal 2008- Associate Editor, Therapeutic Advances in Neurological Disorders 2009- Executive Editor, Journal of Bioequivalence and Bioavailability 2009- Associate Editor, Frontiers in Aging Neuroscience 2009- Associate Editor and International Advisory Board, International Journal of Knowledge

Discovery in Bioinformatics

George Perry

34

2009- Co-Editor-in-Chief, Mini-Reviews in Medicinal Chemistry 2009-2016 Associate Editor, Therapeutic Advances in Chronic Diseases 2009- Advisory Board, Atlas Publishing, LP, (formerly KBM Scientific Publishing, Limited) 2010-2011 Co-Editor-in-Chief, The Open Pathology Journal 2006- Founding Editor, Journal of Parkinson‘s Disease 2007- Editor-in-Chief, IIOAB Journal 2010- Editor–in-Chief, Pharmacology and Pharmacy 2010- Editor-in-Chief, Journal of Biophysics 2010-2015 Editor-in-Chief, Advances in Medical Informatics 2010-2016 Associate Editor, International Journal of Drug Discovery 2010-2016 Associate Editor, International Journal of Biotechnology Applications 2010-2015 Associate Editor, Neuroscience Research 2010-2015 Associate Editor, Advances in Medical Information 2010-2015 Associate Editor, International Journal of Parisitology Research 2010-2016 Associate Editor, The Advances in Computational Research 2010- Executive Editor, Journal of Biotechnology and Biomaterials 2010-2016 Associate Editor, The Journal of Biometrics 2010- President Editor (Honorary), Global Journals 2011- Editor-in-Chief, Atlas Journal of Medical and Biological Sciences 2011-2014 Chief Editor, Annual Research and Review in Biology (formerly Annual Review and Research in Biology) 2011- Associate Editor-in-Chief, International Journal of Pharmacology and Medical Sciences 2011- Section Editor, Current and Future Research Profile, Current Medicinal Chemistry 2011- Neurobiology Section Editor, The All Results Journals: Biology 2011- Editor-in-Chief, Webmed Central Plus 2011- Editor-in-Chief, Journal of Pharmaceutical Technology and Drug Research 2012- Editor, Advances in Medicinal Chemistry 2012- Editor-in-Chief, Journal of Biotechnology and Biomaterials 2012- Editor-in-Chief, Journal of Cytology and Histology 2012- Editor-in-Chief, American Journal of Neuroscience 2012- Editor-in-Chief, Journal of Chinese Medicine Research and Development 2012- Editor-in-Chief, Pharmaceutical Regulatory Affair: Open Access 2012- Editor-in-Chief, Analytical and Bioanalytical Techniques 2012- Associate Editor, Journal of Scientific Research and Reports 2012- Editor-in-Chief, Journal of Bioequivalence and Bioavailability 2012- Editor-in-Chief, Journal of Marine Science Research and Development 2012 Editor-in-Chief, Metabolomics: Open Access 2012- Editor-in-Chief, Journal of Molecular Biology 2012- Associate Editor, OA Biochemistry 2012- Deputy Editor, OA Biology 2013- Associate Editor, Ubiquitous Computing and Communication Journal 2013- Executive Editor, Metabolomics: Open Access 2013- Associate Editor, Ubiquitous Computing and Communication Journal 2013- Editor-in-Chief, International Journal of Advance in Medical Science 2014- Editor-in-Chief, Frontiers in Clinical Medicine 2014- Executive Editor, Biological Systems: Open Access 2014- Book Review Editor, Current Medicinal Chemistry 2014 Editor-in-Chief, International Journal of Knowledge Discovery in Bioinformatics 2014- Associate Editor, International Journal of Advanced Biological and Biomedical Research 2014- Section Editor, Pathobiology of Human Disease 2014- Editor-in-Chief, Advances in Life Science and Medicine 2014- Editor-in-Chief, International Journal of Bioorganic Chemistry and Molecular Biology 2015- Editor-in-Chief, Journal of Parkinson‘s disease and Alzheimer‘s disease 2015- Section Editor, Alzheimer‘s, US Neurology 2015- Editor-in-Chief, Gene Therapy and Genetic Syndrome 2015- Section Editor, Alzheimer‘s Disease, US Neurology 2015- Editor-in-Chief, Functional Foods in Health and Disease 2015- Editor-in-Chief, BOAJ Neurology 2015- Editor-in-Chief, Journal of System and Integrative Neuroscience

George Perry

35

2015- Editor-in-Chief, Cardiovascular Pathology: Open Access 2015- Editor-in-Chief, International Journal of Advance in Medical Science 2015- Editor-in-Chief, SDRP Journal of Nanotechnology and Materials Science 2015- Editor-in-Chief, SDRP Journal of Polymer Science and Technology 2016- Editor-in-Chief, International Journal Ecological Bioscience and Biotechnology 2016- Editor-in-Chief, Pharmaceutical Analytical Chemistry: Open Access 2016- Deputy Editor-in-Chief, Remedy: Open Access 2016- Editor-in-Chief, Journal of Trauma and Critical Care 2016- Editor-in-Chief, Letters in Drug Design and Discovery 2016- Editor-in-Chief, Peer Reviewed Academia Sciences 2016- Co-Editor, The Open Medicinal Chemistry Journal 2016- Regional Editor, Current Medicinal Chemistry

Editorial Boards: 1992-2013 American Journal of Pathology 1994- Alzheimer Disease and Associated Disorders

1995-1998 Alzheimer‘s Disease Review 1997-1999 Journal of Neuropathology and Experimental Neurology

1997-1999 Molecular and Chemical Neuropathology 1997- Journal of Alzheimer‘s Disease 1998-2006 Journal of Neural Transmission 1998- Investigational Drugs Journal 1999- Brain Pathology 1999-2001 Journal of Molecular Neuroscience 2000 Research Signpost (Neurochemistry) 2000- Antioxidants and Redox Signaling 2000-2006 Laboratory Investigation 2002- Brain Research 2002- Microscopy Research and Technique 2002- Current Medicinal Chemistry 2003- Journal of Biomedicine and Biotechnology 2003- Neurobiology of Lipids 2003 Pharmaceutical Development and Regulation 2003- Pathology

2003-2006 Journal of Pediatric Neurology 2003-2005 Medicinal Chemistry Reviews - Online 2003- Current Alzheimer Research 2003-2011 NeuroSignals 2003-2016 Disease Markers 2004- Medicinal Chemistry 2004- Neurobiology of Disease 2004- Letters in Drug Design and Discovery

2004- Expert Review of Neurotherapeutics 2005- Mini-Reviews in Medicinal Chemistry

2005- Future Neurology 2005- American Journal of Biochemistry and Biotechnology, Regional Editor (USA) 2005- American Journal of Environmental Sciences, Regional Editor (USA) 2005 American Journal of Immunology, Regional Editor (Neurodegenerative Diseases) 2005- American Journal of Infectious Diseases, Regional Editor (Neurodegenerative Diseases) 2006- Developmental Microbiology and Molecular Biology 2006- Central Nervous System Agents in Medicinal Chemistry

2006-2013 International Journal of Biomedical Science 2006- Brain Research Reviews

2007-2012 Journal of Biological Chemistry 2007- Journal of Clinical Pathology 2007-2015 Molecular Neurodegeneration 2007- The Open Medicinal Chemistry Journal

George Perry

36

2007-2017 Free Radical Biology & Medicine 2007- The Open Neurology Journal 2007-2009 The Open Aging Journal 2007- International Journal of Clinical and Experimental Pathology 2007 International Journal of Biomedical Nanosciences and Nanotechnology 2007- Mitochondrion

2007- Neural Regeneration Research (formerly Chinese Journal of Neural Regeneration Research) International Reviewer

2007- Doping Journal 2007- Neuropsychiatric Disease and Treatment 2007- Clinical Interventions in Aging 2007- Scientific Journals International 2007- Journal of Medical and Biological Sciences 2007- Journal of Agricultural, Food, and Environmental Sciences 2007-2014 The Open Pathology Journal (merged with The Open Medicine Journal in 2014) 2008-2009 Research Letters in Biochemistry 2008-2015 Journal of Biophysics 2008- Journal of Visualized Experiments 2008- British Medical Journal Case Reports 2008-2009 U.S. Neurological Review 2008- Research Journal of Biotechnology 2008-2010 Marine Drugs 2008 - Current Aging Science 2008- Therapeutic Advances in Neurological Disorders 2008-2015 BioMed Research International (formerly Journal of Biomedicine and Biotechnology) 2009-2015 Biochemistry Research International 2009- American Journal of Translational Research 2009- Chemistry Central Journal 2009- Cancer Therapy 2009- Gene Therapy and Molecular Biology 2009- Alzheimer and Dementia 2009- Journal of Bioequivalence and Bioavailability 2009- Frontiers in Aging Neuroscience 2009- The Open Longevity Science Journal 2009-2016 Health

2008- International Journal of Knowledge Discovery in Bioinformatic 2009- BenSci 2009- Journal of Bacteriology Research 2009- U.S. Neurology 2009- Current Trends in Neurology 2009-2016 Therapeutic Advances in Chronic Diseases 2009- Journal of Nucleic Acids Investigation 2009- Neuropsychiatric Disease and Treatment 2009- Eye and Brain 2009- World Journal of Innovations in Medicine 2009-2017 International Journal of Alzheimer‘s Disease 2009- Agriculture and Biology Journal of North America 2009- Journal of Pediatric Biochemistry 2009- Atlas Journal of Biology (formerly KBM Journal of Biology) 2009- Atlas Journal of Chemistry and Biochemistry (formerly KBM Journal of Chemistry and Biochemistry) 2009- Atlas Journal of Medical and Biological Sciences (formerly KBM Journal of Medical and Biological Sciences) 2009- Atlas Journal of Cognitive Science (formerly KBM Journal of Cognitive Science) 2009- Recent Patents on CNS Drug Discovery 2010-2013 Comparative Medicine 2010-2013 Journal of the American Association for Laboratory Animal Science 2010- Frontiers in Dementia 2010- Discussions (CWRU Student Journal)

George Perry

37

2010- International Journal of Clinical and Experimental Medicine 2010- Chinese Medicine 2010- European Journal of Histochemistry 2010- Central European Journal of Medicine 2010- Cellular Oncology 2010-2015 Analytical Cellular Pathology 2010- Current Protein and Peptide Science 2010- Current Drug Targets 2010- Current Vascular Pharmacology 2010 IIOAB Journal 2010 Mendeleev Journal of Chemistry 2010 Neurology International 2010- Clinical Trial Magnifier 2010- Global Journals 2010- Cerebellum 2010-2016 Pharmacology and Pharmacy 2010-2016 Neuroscience and Medicine 2010-2017 Neurosurgery 2010- The Open Geriatric Medicine Journal 2010- Metabolic Brain Disease 2010- Advances in Medical Informatics 2010- Journal of Biophysics

2010- Trends in Cell and Molecular Biology 2010- Therapeutic Delivery 2010- Frontiers in Neuropharmacology 2010- International Journal of Drug Discovery 2010- International Journal of Biometrics and Bioinformatics 2010- Analytical and Bioanalytical Techniques 2010- Journal of Cytology and Histology 2010- Journal of Tissue Science and Engineering 2010-2015 International Journal of Biotechnology Applications 2010-2015 Neuroscience Research 2010-2015 Advances in Medical Informatics 2010-2016 International Journal of Parisitology Research 2010-2016 The Advances in Computational Research 2010-2016 The Journal of Biometrics 2010- Free Radicals and Antioxidants 2010- Journal of Geriatric Cardiology 2010- World Academy of Science, Engineering, and Technology 2010- Journal of Biotechnology and Biomaterials – Open Access 2010- Journal of Genetic Syndrome and Gene Therapy 2011-2019 World Journal of Neurology 2011-2019 World Journal of Pharmacology 2011- Annual Research and Review in Biology (formerly Annual Review and Research in Biology) 2011- Scholarpedia 2011- Journal of Neurology Research 2011-2015 Journal of Alzheimer‘s Disease and Parkinsonism 2011-2015 Neuroscience Research Letters 2011-2019 World Journal of Methodology 2011-2016 Journal of Behavioral and Brain Science 2011- Journal of Natural Science Biology and Medicine 2011- Ubiquitous Computing and Communication Journal 2011- Journal Clinical Medical Research 2011-2012 Open Journal of Psychiatry 2011- Journal of Natural Science, Biology and Medicine 2011- The All Results Journals: Biology 2011- International Journal of Agriscience 2011- Journal of Cardiovascular Research 2011- Atlas Journal of Biotechnology

George Perry

38

2011- Journal of Parkinson‘s Disease 2011- Current Psychopharmacology 2011-2017 Biochemical Pharmacology 2011- Current Angiogenesis 2011- European Journal of Medicinal Plants 2011- Translational Neurodegeneration 2011- Cellular and Molecular Neurobiology 2011- American Journal of Tropical Medicine and Public Health 2011- Online Journal of Biological Sciences 2011- Journal of Cell Science and Therapy 2011- Journal of Pharmaceutical Technology and Drug Research 2011- Open Journal of Pathology 2012-2014 Clinical Practice (formerly Therapy) 2012- Journal of Analytical and Bioanalytical Techniques 2012- Rutherford Journal of Chemistry 2012- Avogadro Journal of Chemistry 2012- Journal of Biotechnology and Biomaterials

2009- De Gruyter Open, Biology (formerly Versita Open, Biology) 2012- Journal of Chinese Medicine Research Development 2012- Cell Bio (formerly Open Journal of Cell Biology) 2012- Journal of Cytology and Histology 2012- Theriogenology Insight 2012- Journal of Marine Biology & Oceanography 2012- American Journal of Neuroscience 2012- International Journal of Cancer Studies and Research 2012- Journal of Huntington‘s Disease 2012- F1000 Research 2012- Journal of Functional Foods in Health and Disease 2012- PeerJ 2012- Advances in Information Mining 2012- Journal of Errology 2012- Advances in Medical Informatics 2012- Word Academic Publishing 2012- Journal of Marine Scince: Research and Development 2012- Journal of Health and Medical Informatics 2012- Metalobomics: Open Access 2012- Pharmaceutical Regulatory Affairs: Open Access 2012- Journal Scientific Research and Reports 2012- Molecular Biology 2012- Analytical and Bioanalytical Techniques 2012- Pharmaceutical Technology and Drug Research 2012- i-Xplore International Research Journal Consortium 2012- Modern Public Health 2012- OA Biochemistry 2012- OA Biology 2012- Health and Medical Informatics 2012- Journal of Bioengineering and Biomedical Sciences 2012- Oceanography – Open Access 2012- Molecular Enzymology and Drug Targets 2012- Biochemical Compounds 2012- Neurology Discovery 2012- International Journal of Advance in Medical Science 2012- Orient Journal of Chemistry 2013- Pathology Discovery 2013- International Journal of Pharmacology and Toxicology 2013- Journal of Neurorestoratology 2013- OA Bone Marrow 2013- Journal of Organ Biology 2013- Journal of Life Medicine

George Perry

39

2013- Ubiquitous Computing and Communication Journal 2013- Cloning and Transgenesis 2013- The Experiment 2013- Journal of Errology 2013- Pathobiology of Human Diseases 2013- Clinical Cardiovascular Drugs 2013- International Research Journal of Bacteriology 2013- Research Journal of Infectious Diseases 2013- Development in Pharmaceutics 2013- Hypoxic Signaling 2013- Research Journal of Infectious Diseases 2013- Pathology Discovery 2013- Advances in Neuroscience Research 2013- Advances in Chemical Engineering 2013- Frontiers in Pharmaceutical Sciences 2013- Pharmaceutical Chemistry Review 2013- Journal of Medical Disorders 2013- Preventive Medicine and Population Health Frontiers 2013- Frontiers in Clinical Medicine 2013- Biological Markers and Guided Therapy 2013- Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanism 2013- Preventive Medicine and Population Health Frontiers 2013- Journal of Biochemical and Pharmacological Research 2013- Applied Scientific Reports 2013- Journal of Neuroinfectious Diseases 2013- Applied Scientific Reports 2013- Journal of Toxicology and Health 2013- European Journal of Health 2013- Journal of Gene Therapy 2013- International Journal of Cancer Studies and Research 2013- Advances in Neuroscience Research 2013- SOJ Pharmacy and Pharmaceutical Sciences 2013- Research Journal of Developmental Biology 2013- Journal of Neurorestoratology 2013- International Journal of Biomedical Engineering and Sciences 2014- Free Radical Research 2014- International Journal of Bioorganic Chemistry and Molecular Biology 2014- Biological Systems: Open Access 2014- Developmental Microbiology and Molecular Biology 2014- Vector Research and Parasitology 2014- International Journal of Clinical Therapeutics and Diagnosis 2014- Journal of Neurology and Psychology 2014- Research Journal of Women‘s Health 2014- Frontiers in Preventive Medicine and Population Health 2014- International Journal of Clinical and Medical Allergy 2014- International Journal of Microbiology and Advanced Immunology 2014- Open Conference Proceedings Journal 2014- Journal of Microbiology and Infections 2014- Scholarena Journal of Neurology 2014- Journal of Pharmacy and Pharmaceutics (Formerly Journal of Pharmaceutical Sciences and Drug Designing) 2014- International Journal of Tropical Disease and Health 2014- Journal of Cytology and Tissue Biology 2014- Wyno Academic Journal of Biological Sciences 2014- Journal of Microbiology and Infections 2014- The Open Medicine Journal 2014- International Journal of Medical Biotechnology and Genetics 2014- Journal of Translational Internal Medicine 2014- World Journal of Medicine and Medical Science

George Perry

40

2014- Journal of Biodiversity and Endangered Species 2014- Journal of Bone Marrow Research 2014- International Journal of BioAnalytical Methods and BioEquivalence Studies 2014- Chronic Diseases-International 2014- UG Reseach Journal (UTSA) 2014- International Journal of Computational and Neural Engineering 2014- Trends in Vector Research and Parasitology 2014- Open Access Library Journal 2014- Chronicles of Science 2014- Journal of Parkinson‘s Disease and Alzheimer‘s Disease 2014- Trends in Life Sciences 2014- Publication Integrity and Ethics Periodical 2014- Journal of Parkinson‘s Diseases and Alzheimer‘s Diseases 2014- International Journal of Vaccines and Research 2014- International Journal of Advanced Biological and Biomedical Research 2014- NanoSciTech Open Library 2014- Austin Alzheimer‘s and Parkinson‘s Disease 2014- Journal of Microbiology and Infections 2014- Journal of AIDS and Immune Research 2014- Advances in Life Science and Medicine 2014- Biology and Medicine 2014- SOJ Psychology 2014- International Journal of Emergency Mental Health and Human Resilience 2014- Austin Journal of Radiology 2014- Neurology: Open Access 2014- Sci Forschen Genetics and Gene Therapy 2014- Journal of Clinical Microbiology and Case Reports 2014- International Journal of Bioorganic Chemistry and Molecular Biology 2015- Journal of Parkinson‘s disease and Alzheimer‘s disease 2015- Internal Medicine: Open Access 2015- Peer J Computer Science 2015- International Archives of Medicine 2015- Advances in Alzheimer‘s Disease 2015- EC Neurology 2015- Bio Accent Neurology 2015- Caribbean Journal of Science and Technology 2015- International Journal of Chronic Diseases and Therapy 2015- Gene Therapy and Genetic Syndrome 2015- Spine, Neurology and Neurophysiology 2015- Neurology Central 2015- Mass Spectrometry: Open Access 2015- Cell and Developmental Biology: Open Access 2015- Oncotarget: Gerotarget 2015- Cardiovascular Pathology: Open Access 2015- Global Hormone Health 2015- JBR—Journal of Translational Diagnostics and Technology 2015- BOAJ Neurology 2015- Pharmaceutical Analytical Chemistry: Open Access 2015- Cell Science and Report 2015- SQT Biosensors, Biomarkers and Diagnostics: Open Access 2015- International Journal of Behavioral Research and Psychology 2015- Global Advanced Research Journal of Pharmacy and Pharmacology 2015- Journal of Systems and Integrative Neuroscience 2015- Clinical Depression 2015- Clinical Pathology Journal 2015- Advances in Antibiotics and Antibodies 2015- International Journal of Medical Biotechnology and Genetics 2015- Cytology and Tissue Biology 2015- HSOA Journal of Spine, Neurology and Neurophysiology

George Perry

41

2015- Source Journal of Genetic Disorders 2015- Cardiovascular and Hematological Agents in Medicinal Chemistry 2015- Medical Reports and Case Studies 2015- International Journal Advances Medical Science 2016- BOAJ Chemistry 2016- EC Bacteriology and Virology Research 2016- Current Opinions in Neurological Science 2016- Journal Herbal Medicine Research 2016- Scientific Pages of Alzheimer‘s Disease and Dementia 2016- Biomedical Research and Clinical Practice 2016- Journal of Ultra Chemistry 2016- SciFed Nanotech Research Letters 2016- Advances inh Biotechnology and Microbiology 2016- Mass Spectrometry and Purification Techniques 2016- OBM Neurobiology 2016- JBR Journal of Translational Biomarkers and Diagnosis 2016- International Journal of Chronic Diseases and Therapy 2016- International Journal of Bone and Rheumatology Research 2016- International Journal of Psychology and Neuroscience 2016- Advances in Biotechnology and Microbiology 2016- Annals of Neurodegenerative Disorders 2016- Clinical Interventions in Aging 2016- Remedy: Open Access 2016- European Journal of Informatics 2016- Journal of Traumatic Stress Disorders and Treatment 2016- Clinics in Oncology 2016- Scholars Report 2016- Journal of Bioorganic Chemistry and Molecular Biology 2016- International Journal of BioAnalytical Methods and BioEquivalence Studies 2016- Clinical Depression 2016- Journal of Pharmaceutical Technology 2016- Research Journal of Women‘s Health 2016- Journal of Medical Disorders 2016- SM Journal of Clinical Pathology 2016- Cardiovascular Pathology 2016- Journal of Systems and Integrative Neuroscience 2016- International Research Journal of Humanities, Engineering and Pharmaceutical Sciences 2016- Medical Reports and Case Studies 2016- Journal of Advances in Molecular Biology 2016- Journal of Oral Health and Dental Science 2016- Herald Scholarly Open Access Journal of Spine, Neurology and Neurophysiology 2016- International Journal of Vaccines and Research 2016- SM Journal of Neurology and Neurosciences 2016- Herald Scholarly Open Access Journal of Alzheimer‘s Disease, Dementia, and Parkinsonism 2016- International Archives of Medicine 2016- International Journal of Behavioral Research and Psychology 2016- Journal of Neurology and Neurosurgery 2016- Journal of Neurology and Neurobiology 2016- Nanomedicine and Biotherapeutic Discovery 2016- Medical Journal Sanamed 2016- Clinical Microbiology and Case Reports 2016- Journal of Biodiversity and Endangered Species 2016- Journal of Genetic Syndromes and Gene Therapy 2016- Sci Fed Journal of Neuroscience 2016- Journal of Trauma and Critical Care 2016- International Journal of Psychology & Behavior Analysis 2016- OBM Geriatrics

2016- Clinical and Diagnostic Pathology

George Perry

42

2016- The Scientific Pages of Translational Medicine 2016- Translational Genetics and Genomics 2016- The Scientific Pages of Brain Disorders 2016- Heliyon 2016- Insight Knowledge 2016- Journal of Oral Care and Dentistry 2016- The Open Access Journal of Science and Technology 2016- 2425 Publishers 2016- Journal of Renal and Nephrology 2016- ournal of Clinical Diabetes and Metabolism 2016- Journal of Biotechnology and Bioengineering 2016- Journal of Cardiology and its Complications 2016- Journal of Medical Case Reports 2016- Journal of Forensic Sciences & Crime 2016- Journal of Gynecology 2016- Journal of Infectious Disease and Immunology 2016- Journal of Nutritional Health Sciences 2016- Journal of Pharmacy and Pharmacology 2016- Journal of Neurology and Neurodisorders 2016- Journal of Cancer Science and Therapy 2016- Journal of Orthopaedics 2016- Journal of Microbiology and Genetics 2016- Journal of Psychiatry and Cognitive Behaviour 2016- Austin Pathology 2016- Journal of Neurology and Neuropsycology 2016- Medical Microbiology Reports 2016- Neuromedicine 2016- Matters 2016- International Journal of Psychology & Behavior Analysis

2016-2017 Neuroimmunology and Neuroinflammation 2017- Biomedical and Pharmacology Journal Journal/Book Reviewer: Academic Press, ACS Chem Neurosci, Acta Neurologica Scandinavica, Acta Neuropathol, Adv Alzheimer‘s

Disease, Adv Med Sci, Addiction Biol, African J Pharmacy Pharmacology, Ageing Res Rev, Aging, Aging Cell, Aging Health, Aging Mechanisms Disease, Aging Res, Alan Liss Publishing Company, Alzheimers Dementia, Alz Dis Assoc Disord, Am J Alzheimer‘s Disease and Other Dementias, Alzheimer‘s Disease and Parkinsonism, Am J Clin Oncol, Am J Env Sci, Am J Human Genetics, Am J Med Genetics, Am J Pathol, Amino Acids, Amyloid, Analyst, Anal Biochem, Ann Human Genet, Ann Neurol, Ann Neurosci Psychol, Ann Rev Res Biol, Antioxid Redox Signal, Appl Biochem Biotech, Arch Biochem Biophys, Arch Gen Psychiatry, Arch Med Res, Arch Neurol, ASN Neuro, Atlas J Med Biol Sci, Austin Alzheimers and Parkinson‘s Disease, Austin Radiology, Autophagy, Behav Brain Res, Bio Accent Neuro, Biochemistry, Biochem J, Biochem Pharm, Biochem Res Inter, Biochem Sciences, Biochimie, Biochim Biophys Acta, Biofactors, Biol Bull, Bio-Medical Material and Engineering, Biol Psychiatry, Biol Res, Biol Systems: Open Access, Biol SystemsBiol Trace Elements Res, Biomarkers, Biomed Res Int, Biomolecular Concepts, Bioorgan Chem, Bioorgan Med Chem, Bioorgan Med Chem Lett, Biotechniques, BMC Chem Biol, BMC Genomics, BMC Neurol, BMC Neurosci, Brain, Brain Pathol, Brain Res, Brain Res Bull, Brain Struct Funct, Braz J Med Biol Res, British J Medicine Medical Research, British J Nutr, British J Pharmacol, British Med J Case Reports, Canadian J Neurol Sci, Cancer Invest, Cancers, Cardiovasc Hematologic Agents in Med Chem, Cardiovasc Psychiatric Neurol, Cardiovasc Toxicol, CellBio, Cell Biochem Biophys, Cell Biol International, Cell Calcium, Cell Chemical Biol, Cell Cycle, Cell Mol Life Sci, Cell Mol Neurobiol, Cell Motil Cytoskeleton, Cent Eur J Biol, Cerebellum, Chem Biol, Chem Central J, ChemMedChem, Chem Res Toxicol, Chem Rev, Chronic Dis Intl, Clin Chem, Clin Chem Lab Med, Clin Microbiol Case Reports, Clin Practice, Clin Psych Rev, CNS Agents Med Chem, CNS Drugs, CNS Neurosci Therapeutics, CNS Spectrums, Columbia University Press, Comp Biochem Physiol, Computational Math Methods in Med, Comp Med, Computational Theoretical Chem, Critical Rev Biochem Mol Biol, Curr Aging Sci, Curr Alzheimer Res, Curr Angiogenesis, Curr Drugs, Curr Drug Targets, Curr Gerontol Geriatric Res, Curr Med Chem, Curr Med Chem - Cent Nerv Syst Agents, Curr Mol Med, Curr Nanosci, Curr Organocatalysis, Curr Pharmaceutical Design, Curr Psychopharmacol, Curr

George Perry

43

Topics Med Chem, Dementia Geriatric Cognitive Dis, Dev Biol, Diabetes, Diabetologia, Discussions (CWRU Student Journal), Disease Markers, Disease Models Mechanisms, DNA Cell Biol, Drug Design Reviews – Online, Elsevier Publishing Company, E-Biomedicine, EMBO J, Environmental Sciences, Environ Res, Environmental Toxicology, Eur J Biochem, Eur J Cell Biol, Eur J Lipid Sci Tech, Eur J Med Chem, Eur J Med Plants, Eur J Med Res, Eur J Neurol, Eur J Neurosci, Eur J Pharmacol, Eur Neurol, Evidence-Based Complementary and Alternative Medicine, Exp Biol Med, Exp Cell Res, Exp Diabetes Res, Exp Gerontol, Exp Neurol, Expert Opinion Drug Delivery, Expert Opinion Emerging Drugs, Expert Opinion Therapeutic Targets, Expert Opin Inv Drug, Expert Rev Biol Therapy, Expert Rev Mol Med, Expert Rev Neurother, Expert Rev Proteomics, F1000 Research, FASEB J, FEBS Lett, FEBSO Open Biol, Flat World Knowledge, Food Chem Toxicol, Food Function, Free Radic Biol Med, Free Radic Res, Frontiers Aging Neurosci, Frontiers Clin Med, Frontiers in Dementia, Frontiers in Neurodegeneration, Frontiers in Neuropharmacology, Future Med, Future Neurol, Gender Med, Geriatrics Gerontology International, Gerontology, Glia, Health, Hippocampus, Human Pathol, Human Mol Genetics, IEEE Health.com, Immunobiol, Immunother, Inorganic Chem, Int Clinical Pathology J, Int J Alzheimer‘s Dis,Int J Advances Med Sci, Int J Animal Sci Husbandry, Int J Biochem, Int J Biochem Cell Biol, Int J Biochem Res Rev, Int J Biol Sci, Int J Biomed Imaging, Int J Biomed Sci, Int J Dev Neurosci, Int J Emergency Mental Health, Int J Exp Pathol, Int J Knowledge Disc Bioinformatics, Int J Mol Genetics Gene Ther, Int J Mol Sci Int J Nanomedicine, Int J Neuropsychopharmacol, Int J Peptides, Int J Vitamin Nutri Res, Invest Drugs, IUBMB Life, John Wiley, J Aging Res, J Agricultural Science and Application, J AIDS HIV Res, J AIDS Immune Res, J Alzheimers Dis, J Amer Chem Soc, J Amer Geriatr Soc, J Amino Acids, J Behav Brain Sci, J Biol Chem, J Biomed Biotech, J Biophys, J Biosciences, J Cell Biochem, J Cell Biol, J Cellular Mol Med; J Cell Physiol, J Cell Sci, J Cerebral Blood Flow Metabol, J Chem Neuroanat, J Chromatography and Separation Techniques, J Clin Diag Path, J Clin Invest, J Clin Med Therapeutics, J Clinical Microbio & Case Reports, J Clin Pathol, J Comp Chem, J Comp Neurol, J Cytol Histol, J Environ Public Health, J Exp Med, J Food Nutritional Disorders, J Gastroenterol Hepatol, J Gerontol: Biol Sci, J Histochem Cytochem, J Histol Histopathol, J Histotechnol, J Infectious Dis, J Inorg Biochem, J Life Medicine, J Lipids, J Marine Biology Oceanography, J Materials Sci Technol, J Med Research Development, J Mod Educ Rev, J Mol Biol, J Mol Endocrinology, J Mol Neurosci, J Neural Transm, J Neurobiol, J Neurochem, Neurodegenerative Disease Management, J Neurodeg Regeneration, J Neuroendocrinol, J Neuroimmunol, J Neuroinflamm, J Neurol Neurosurg Psychiatry, J Neurol Sci, J Neuropathol Exp Neurol, J Neurosci, J Neurosci Behav Health, J Neurosci Meth, J Neurosci Res, J Nutr Biochem, J Nutr Health Aging, J Pediatric Neurol, J Pharm Sci, J Pharm Technol and Drug Res, J Protein Peptide Lett, J Proteome Res, J Steroid Biochem Mol Biol, J Structural Biol, J Theoret Biol, J Toxicol, J Toxicol Health, JAMA Neurol, KB J Biol, Key Opinions, Lab Invest, Lancet, Langmuir, Lett Drug Des Discov, Life Sci, Lipids, Lipids in Health and Disease, Marine Drugs, Mech Ageing Dev, Mediators of Inflam, Med Chem, Med Chem Rev Online, Med Hypotheses, Med Res Rev, Menopause, Metabolic Brain Dis, Metabolism, Metallomics, Methods Find Exp Clin Pharmacol, Microsc Microanalysis, Microsc Res Tech, Mini Rev Med Chem, Mini Rev Org Chem, Mitochondrial DNA, MOJ Cell Sci Rep, Mol Brain, Mol Brain Res, Mol Cell Biochem, Mol Cell Biol, Mol Cell Neurosci, Mol Chem Neuropathol, Mol Med, Mol Neurobiol, Mol Neurodegeneration, Mol Psychiatry, Mutation Res, Nature, Nat Biotechnol, Nat Communications, Nat Clin Prac Cardiovascul Med, Nat Med, Nat Rev Dis Primers, Nat Rev Drug Discovery, Nat Rev Endocrinology, Nat Rev Neurosci, Neural Plasticity, Neural Regener Res, Neurobiol Aging, Neurobiol Dis, Neurochem Int, Neurochem Pathol, Neurodegener Dis, Neurodegener Dis Mgmt, Neurodegeneration, NeuroImage, Neuroimmunomodulation, Neurology, Neurol Res Int, Neuron, Neuropath Appl Neurobiol, Neuropharmacol, Neuropsychiatric Disease Treatment, Neuropsychopharmacology, NeuroReport, Neuroscience, Neurosci Biobehav Rev, Neurosci Lett, Neurosci Disc, Neurosci Med, Neuroscience-net, Neurosignals, Neurosurgery, Neurotherapeutics, Neurotoxicology, Nutr Res, Obstetric Gynecology International, Open Allergy Journal, Open Analytical Chem J, Open Conference Proceedings Journal, Open J Endocrine Metabol Dis, Open Med J, Open Neurol J, Open Neurosci J, Open J Nuclear Med, Open J Pathol, Open J Psychiatry, Open Pathol J, Open Rheumatology J, Parkinson‘s Disease, Oxidative Med Cellular Longevity, Pathol Disc, Pathol Res Int, Pathophysiology, Peer J, Peptides, Pharmaceut Regul Aff: Open Access, Pharmacogenomics, Pharmacol Biochem Behav, Pharm Dev Regul, Pharmacology Pharmacy, Pharmacology Pharmacy, PLoS Biol, PLoS One, Pragmatic and Observational Res, Process Biochem, Primary Health Care Res of Development, Proc Biol Sci, Proc Indian Natl Sci Acad Part B Biol Sci, Proc Natl Acad Sci USA, Prog Neurobiol, Proteomics, Q Rev Biol, Reactome, Reproduction, Reprod Toxicol, Res J Women‘s Health, Retrovirology, Rowman Littlefield Publishers, Royal Soc Chem, Science, Sci Nature, Scientific Pages Alz and Dementia, Scientific Pages Brain Dis, Scientific Reports, Sci Technol, Sci Transl Med, Sci World J, Sensors, Stroke, Synapse, Therapeutic Advances Neurol Disorders, Therapeutic Delivery, Theriogenology Insight, Tox Appl Pharm, Translational Psychiatry, Translational Res; Trends Mol Med, Trends Neurosci, Trends Pharmacol Sci, Tumor Biol, Univ Calif Press,

George Perry

44

Wiley-Blackwell Publishing, World J Clin Cases, World J Hepatol, World J Hypertension, World J Innovations Med, World J Neurol, World J Pharmacol, World J Psychiatry,World J Surgical Proc, Wyno Acad J Biol Sci

Teaching Experience: University Based: University of California at San Diego: Undergraduate: Oceanography, Scripps Institution of Oceanography, Teaching Assistant, 1977 Stanford University: Undergraduate: Developmental Biology, Teaching Assistant, 1978-1979 Graduate: Developmental Biology, Teaching Assistant, 1978 Case Western Reserve University: High School: Shaker Heights High School Independent Study Coordinator, 1992 Minority High School Research Apprentice Program, 1995-1996 Undergraduate:

Pathology 390, Undergraduate Research in Cancer, Immunology or Pathology, 1982-

Health Careers Enhancement Program for Minorities, 1992-2005 Summer Program in Undergraduate Research (SPUR), 1998-1994, 2000 Pre-Medical American Medical Student Association Research Opportunities Fair

1997 (Pathology Representative) Graduate (Doctoral Level): Pathology 410, Aging and the Nervous System, 1985- Pathology 415, Cytoskeleton and Disease, 1987-1994

Pathology 444, Neurodegenerative diseases: pathological, cellular and molecular perspectives, 1998-

Pathology 516, Experimental Pathology, 1985-1993 Graduate Committee, Department of Pathology, Member 1994-1995 Outreach Seminar Program, Basic Scientist Training Program, 1988- Neurodegenerative Disease Mini-Course, 2000- 24th Graduate Student Symposium, Awards Committee, 2001 25th Graduate Student Symposium, Awards Committee, 2002 Research ShowCASE, Graduate Student Poster Judge, 2003 Biological Basis of Disease (I), Histopathology, 2004 Pathology 421, Electron Microscopy in Medicine, 2004-

Medical:

Cytoskeleton Pathology, Flexible program, 1982-1994 Aging and the Nervous System, Flexible program, 1985- Common Neurodegenerative Disease (co-sponsored with Rajesh Kalaria), Flexible

program, 1992-1995 Geriatrics Concentration, Flexible program member, 1984-1987 Tissue Biology, Core Curriculum, Laboratory Instructor, 1984-1986 Nervous System/Mind Committee, Core Curriculum, 1987-1994, 1995

Basic Science Faculty Mentoring Program, 1996 University of Texas at San Antonio:

Minority Biomedical Research Support – Research Initiative in Science Enhancement (MBRS-RISE) Mentor, 2007-2010

BIO 7573.001, Theory and Practice of Electron Microscopy: Application for Tissue and Material Analysis (co-taught with Gjumrakch Aliev), 2007

George Perry

45

BIO 7572.002, Cytoskeleton and Disease, 2008 BIO 7572.003, Aging and the Nervous System, 2008 BIO 1404, Honors Biosciences I (co-taught with David Senseman) 2009 BIO 3433, Neurobiology, Guest Lecture 2008 BIO 3613, Biology of Aging, Guest Lecture 2011

MS Thesis Committees: Robert Schiavone, Pathology, CWRU, 1995; Peggy Richey,

Pathology, CWRU, chair, 1996; Marta Taddeo, Pathology, CWRU, chair, 2003; Tianbing Liu, Pathology, CWRU, 2003; Justin Shenk, Biology, UTSA, Chair, 2008; Taizo Kitahara, Chemistry, UTSA, 2011; Carlos Cardenas, Computer Science (Examination), UTSA, 2013

PhD Thesis Committees: Diane Krill, Biology, CWRU, 1987; Jerrold Turner, Pathology,

CWRU, 1990; Soriba Cisse, Biological Sciences, University of Montreal, Canada, 1991; Ahmet Höke, Neuroscience, CWRU, Chair, 1994; Darja Praprotnik, Pathology, University of Ljubljana, Slovenia, 1994; Michael Pollanen, Neuroscience, University of Toronto, Canada, 1995; David DeWitt, Neuroscience, CWRU, Advisor, 1996; Sic Lung Chan, Microbiology and Immunology, McGill University, 1997; Ganesamoorthy Subbanagounder, Chemistry, CWRU, 1997; I-Mei Siu, Pathology, CWRU, 1998; Mahmoud Rezek Hussein, Pathology, CWRU, 2001; Xiongwei Zhu, Pathology, CWRU, Chair, 2002; Ya Ke, Pathology, CWRU, Gemma Casadesus, Tufts University, 2003; Hasmik Vahradyan, Institute of Biochemistry, Yerevan, 2004; Quan Liu, Pathology, CWRU, Advisor, 2005; Arun K. Raina, Pathology, CWRU, 2005; Hyoung-gon Lee, Pathology, CWRU, 2005; Xie Ling, Surgery, University of Western Australia, 2003; Kate M. Webber, Pathology, CWRU, 2007; Paula Isabel da Silva Moreira, Cellular Neuroscience, University of Coimbra, Portugual (Supervisor), 2007, with honors; Jiawei Chen, Cell Biology, CWRU, 2007; Sandra Isabel Moreira Pinto Vieira Guerra e Paz, Biology, Universidade de Aveiro, Portugal, 2006; Gerald Veunink, Surgery, University of Western Australia, 2009; Anna Barronn, Surgery, University of Western Australia, 2009; Yi Fan, CWRU, 2009; Xinglong Wang, Pathology, CWRU, 2008; Angela M. Boley,Biology, UTSA, 2013; C. Siddhartha Mondragόn-Rodriguez, Centro de Investigaciόn y de Estudios Avanzados del IPN,Mexico, 2009; Hamid Reza Sohrabi, University of Western Australia, 2010; Smt. Jyothi Makka, Acharya Nagarjuna University, India, 2010; Onue Li Min, National University of Singapore, 2011; Olivia Wise-Scira, Chemistry, UTSA, 2014; Kathryn Cimdins, University of Melbourne, Australia, 2012; Sónia Catarina de Sousa Correia, Cellular Neuroscience, University of Coimbra, Portugal, 2012, with honors; Gebremariam Ketema Bezabih, Andhra University, India, 2013; Ong Qi Rui, National University of Singapore, 2013; Tejal Madhukar Shah, University of Western Australia, 2013; Avdesh Avdesh, Edith Cowan University, Australia, 2013; Adam Peter Gunn, University of Melbourne, 2014; Shaun Frost, University of Western Australia, 2013; Balaram Kuinar Kommana, Andhra University, India, 2014; Rhona Creegan, Edith Cowan University, 2014; Pratishtha Chatterjee, University of Western Australia, 2014; Samantha Gardner, Edith Cowan University, Australia, 2014; Andrea Renee Kelley, Chemistry, UTSA, Chair; Nalina Kanta Sahoo, Siksha ‗O‘ Anusandhan University, India 2015; Torbjörn Persson, Karolinska Institutet, 2015; John Kinsey, Environmental Science and Engineering, UTSA; Apsara, Andhra University, India, 2015; Beda Durga Prasad, Andhra University, India, 2016; Bono Naga Sudha, Andhra University, India, 2016; Rafael J. Veraza, Translational Medicine, University of Texas, Nasroallah Moradi Kor, Semnan University.

Undergraduate Students: Case Western Reserve University:

Stacie Colman, Spring and Summer 1983; ―Buzz‖ Barnett, Spring 1983; Brian Taylor, 1984-1985, obtained independent funding from the American Foundation for Aging Research; Dong Hui Kang, 1985-1988; Marlene Miller, Summer 1986; David Pulliam, 1986; Hal Padget, Summer 1987; Madhu Kancherla, Summer 1988; Demaree Inglese, Spring 1988; Janie Yen, Summer 1988; Magdalena Mijares, 1988-1990, LaSalle University, Mexico; Roy Kim, Summer 1989, Brown University; Stephanie Fannin, Summer 1989; Jennifer Vande Weghe, Summer 1990; Michael Stanik, Summer 1990; Patricia Gollin, Summer 1991; Susan Miljkovic, Summer 1991; Kara Kytle, Summer 1992; Jody Barnett, Summer 1992; Lynn Jaskie, 1992-1993; Colleen Dunbar, Summer 1993;

George Perry

46

Kirsten Hassel, 1993; Catherine McCann, 1993; Robert Rifenburg, 1993-1994; Camille Moukwa, Summer 1996 (Minority High School Student); Nicole Mercurio, 1996; Edward Kim, 1997; Dawn Zelasko, 1997-1998; Mayank Kansal, 1997; Kathryn A. Schubert, 1997-1999; Matt Kaminski, 1998-99; Arun Raina, 1998-2000; Damien Carrel, Summer 1999; Adam Cash, 1999-2002; Parag Aggarwal, 2000-2001; Saqib Ali, Summer 2000; Serban Nicolaescu, 2000-2001; Christina Pamies, Summer 2000 (Beaumont High School Student); Meaghan Combs, Summer 2000 (Howard Hughs Fellow); Janicelynn Asamoto, Summer 2001 (High School Student); Ravi Srinivas, 2001-2002; Nick Pesa, 2001-2002; Carl Peterson, 2003-2004; Caleb Rosenberg-Szubski, Summer 2003 (High School Student); Priyesh Mehta, 2003; Walter Sanders, 2003; Iyesha Forna, 2004-2005; Dae Capobianco, 2005

University of Texas at San Antonio: Carina Dudas, 2008; Best Anyama, 2008; Timothy A. Clark, 2009-2010; Abdiel Alvarado (Universidad Autόnoma de Nuevo Leόn), 2010; R. Kilian Schafer, 2011; Jessica Briscoe 2011-2012; Kristie Smith, 2013-2014; David Fields, 2015; Charles Daniel Hammack 2015-2016

Graduate Students: Trained and current positions:

Patrick Cras (Ph.D.), 1992, Professor and Chief of Staff of Neurology, University of Antwerp Darja Praprotnik (Ph.D), M.D., 1995, Clinical Pathology, Blanchard Valley Hospital, Findlay,

Ohio David DeWitt (Ph.D.), 1996, Professor and Chair of Biology and Chemistry and Associate

Director, Center for Creation Studies, Liberty University, Lynchburg, Virginia; Adjunct Graduate Faculty, Institute for Creation Research, Santee, California

Robert Russell (M.A.), 1998-1999, Geriatrics Fellow, St. Louis University, St. Louis, Missouri Marta Taddeo (M.S.), 2001-2003, Instructor, College of Mount St. Vincent, Riverdale, New

York Quan Liu (Ph.D.), 2001-2005, Dental School Student, University of Pennsylvania,

Philadelphia Ya Ke (Ph.D.), 2002-2004 Paula I. Moreira (Ph.D.), 2004-2007, Assistant Professor, Center for Neuroscience and Cell

Biology, University of Coimbra, Portugal Marcela Sjöberg (Ph.D.), 2005, Postdoctoral Fellow, London, England Yi Fan (Ph.D.), 2007- José Jimenez (MA), 2010, Student, University of Chile

Rotation (Graduate Program): Malita Panin, 1990 Tina Dahl, 1993

Susan Barned, 1994 Lori Raetzman, 1994

Elizabeth Valentine, 1995 Yen Li, 1999 John Gomez, 2000 Marta Taddeo, 2001 Quan Liu, 2001 Catherine A. Rottkamp, 2002 Erin Reed, 2003

Xinglong Wang, 2005 Medical Students: Douglas Stewart, 1984-1985 Madelyn Weiss, 1985-1986 Michelle Onorato, 1986-1988 Avi Ben-Meir, 1993-1994 Takafumi Wataya, 1997, Kyoto University Avi Friedlich, 1997-1999, Harvard University

George Perry

47

Fellows trained and current position:

Miguel Pappolla, M.D., 1985-1986, Professor of Neurology and Neuroscience, Louisiana State University Health Science Center, New Orleans, Louisiana.

Pamela Galloway, M.D., 1986-1988, jointly with P. Gambetti, Initially Assistant Professor of Pathology, Case Western Reserve University and subsequently surgeon in private practice.

Valeria Manetto, M.D., 1986-1987, jointly with P. Gambetti, Associate Professor of Pathology, University of Bologna, Italy (deceased, 1995).

Hea-soo Koo, M.D., 1987, jointly with P. Gambetti, Associate Professor of Pathology, Ewha Womans University, Seoul, Korea.

Massimo Tabaton, M.D., 1988, jointly with P. Whitehouse and P. Gambetti, Professor of Neurology, Director of Alzheimer‘s Center, Department of Neurosciences, University of Genoa, Italy.

Mitsuru Kawai, M.D., 1988-1991, Fogarty Fellow, Fulbright Fellow, Professor of Neurology, University of Tokyo, Japan and Vice-Director, Hagashisaitama National Hospital, Saitama, Japan

Patrick Cras, M.D., 1989-1991, Fogarty Fellow, Professor and Chief of Staff of Neurology, University of Antwerp, Belgium.

Mark Smith, Ph.D., 1992 -1994, Daland Fellow (American Philosophical Society), Ruth Salta Junior Achievement Award (American Health Assistance Foundation), Young Scientist Lectureship Award (International Society for Neurochemistry), Nathan Shock New Investigator Award (The Gerontological Society of America), Jordi Folch-Pi Award (American Society of Neurochemistry), Hermann-Esterbauer Award (HNE Society), Denham Harman Research Award (American Aging Association), Professor of Pathology, Case Western Reserve University, Cleveland, Ohio (deceased 2010).

Nancy Tresser, M.D., 1992-1994, jointly with P. Gambetti and A. LeBlanc, Medical Director, Imalux, Cleveland, Ohio.

Darja Praprotnik, M.D., 1993-1994, Pathologist, Diagnostic Cytology Laboratories, Inc, Indianapolis, Indiana.

Rudolph Castellani, M.D., 1994-1995, jointly with P. Gambetti, Professor of Pathology, University of Maryland, Baltimore, Maryland.

Keisuke Hirai, Ph.D., 1997-1998, Leader of CNS Non-Clinical Pharmacology, Takeda Chemical Industries Ltd., Osaka, Japan.

Akihiko Nunomura, M.D., Ph.D., 1997-1999, Associate Professor, Department of Neuropsychiatry, University of Yamanashi, Yamanashi, Japan.

Gjumrakch Aliev, M.D., Ph.D., 1998-1999, Professor of Health Science and Healthcare Administration, University of Atlanta, Georgia.

Jiong Shi, M.D., Ph.D., Director, Cognitive and Behavior Neurology Program, Barrow Neurological Institute, Phoenix, Arizona.

Kazuhiro Honda, M.D., Ph.D., 2003-2005, Physician, Department of Neurology, Kohnodai Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.

Gemma Casadesus, Ph.D., 2003-2006, Associate Professor, Department of Biology, Kent State University, Kent, Ohio.

Gorka Gereñu Lopetegui, Ph.D., 2014, Post Doctoral Fellow, Department of Pathology, Case Western Reserve University, Cleveland, Ohio.

Sabbatical advisees:

Manuel Velasco, M.D., 1992-1993, Associate Professor, Medical College of Ohio, Toledo, Ohio (retired).

Hyoun-Tae Kim, M.D., 1999-2000, Associate Professor, Department of Clinical Pathology, Kangnam Sacred Heart Hospital, Seoul, Korea (deceased, 2000).

Mentorship Program: Gender Equity Program, Hunter College of City University of New York; mentor to Alejandra Alonso, Ph.D., 2007-2008 Mentor Program, University of Texas Health Science Center San Antonio, mentor to Zheny Uqin Mentor Program, Case Western Reserve University, mentor to Xinglong Wang, Ph.D. 2016- NIH K99, University of Texas Health Science Center San Antonio, mentor to Bess Frost, Ph.D. 2016-

George Perry

48

Mentor Program, University of Texas Health Science Center San Antonio, mentor to Miranda Orr, 2016-

Mentor Program, EURAXESS 2016- Mentor Program, National Research Mentor Network 2016- Mentor Program, Association for Academic Minority Physicians 2016-

Training Grants/Programs: 1982-2005 Member, Neuropathology Training Program 1985-1990 Member, Developmental Biology Training Grant 1985-1990 Member, Geriatrics Education Center 1989-2005 Member, Biomedical Sciences Training Program

1993-2005 Member, NIA Cellular and Molecular Aging Training Grant; Co-Principal Investigator and Co-Director, 1999-

2001-2004 Member, Medical Scientist Training Program 2016- Member, European Scientific Diasporas in North America (Euraxess)

Teaching Committees: Pathology Subject Committee Member 2001-2006 Community Based: Ohio Academy of Science, Visiting Scholar, 1990 Science-by-Mail, 1991-1994 Winter Conference on Brain Research, High School Outreach, 1993 Odyssey of the Mind, Judge, 1995-1998 Outstanding OMer Award 1995 American Society for Cell Biology, Inquires from Young People, 1993- Centro Cultural Hispano de Cleveland, Incorporated, Member 1997-1998 Destination Imagination Head Judge 2000, Judge 2001, 2003, 2005 Research ShowCASE Judge 2003 Intel International Science and Engineering Fair Special Judge for Sigma Xi, Cleveland, Ohio, 2003 Lompoc High School Alumni Association Life Member, 2004 Texas Science and Engineering Fair (formerly Exxon-Mobil Texas Science and Engineering Fair), San Antonio, Texas Judge 2006, 2007, 2008, 2010, 2011, 2013, 2014, 2015, 2016 Blue Team Judge 2016 Alamo Junior Academy of Sciences

Keynote Speaker, Awards Ceremony, University of Texas at San Antonio, 2006, 2007, 2008, 2009, 2010

Award of Appreciation, 2006 Certificate of Appreciation, 2007, 2008 National Conference, Society for Advancement of Chicanos and Native Americans in Science Judge 2006-2007, Member 2007-, Reviewer 2007, 2008 International Sustainable World Project Olympiad Advisory Board, 2007-2008 Alamo Regional Science Fair Judge 2008 Awards Presenter 2009 Introductory Speaker 2010 McNair Scholars Program Judge 2008 Texas Science Careers Consortium Member 2006- Texas Math and Science Coaches Association Member 2009-

George Perry

49

Communications Arts High School, Northside Independent School District, San Antonio Volunteer 2009 Expanding Your Horizons Conference Introductory Speaker 2010 National Lab Day Scientist 2010- Alzheimer Association, San Antonio, Texas Panel Discussion, San Antonio Symphony, 2010 Young Portuguese American Leaders Summit, National Organization of Portuguese-Americans Presenter 2011 School of Science and Technology Judge 2011 College and Career Readiness Initiative: Science Faculty Collaborative, San Antonio, Texas 2012 UTSA Pre-Medical Society Presenter 2012 CCRI Faculty Collaborative, San Antonio, Texas Trainee 2013 John Jay High School, Science and Engineering Academy, San Antonio, Texas Science and Engineering Fair Judge 2013 Thomas Edison High School Science Fair, San Antonio, Texas Judge 2014 Communications Arts High School, San Antonio, Texas Mentor, Marisa Williams, 2014-2015 Fourth Annual San Antonio Postdoctoral Research Forum, San Antonio, Texas Judge 2016 International Classes:

Fundación Ramón Areces, Valencia, Spain, 2001 Course Leader

Reminyl Neuroprotection Symposium, Madrid, Spain, 2004 Coordinator of Course Universidad de Concepción, Concepción, Chile 2011 Summer Course Instructor Invited Lectures/Seminars:

1. Gordon Conference, Fertilization and Early Development, New Hampshire, 1977. 2. Department of Biology, Tulane University, New Orleans, Louisiana, 1982. 3. Department of Biochemistry, University of Arkansas Medical Center, Little Rock, Arkansas, 1982. 4. Department of Physiology, Harvard Medical School, Boston, Massachusetts, 1982. 5. Department of Biology, Centenary College, Shreveport, Louisiana, 1982. 6. Department of Biology, Occidental College, Pasadena, California, 1982. 7. Smith Klein Beckman Laboratories, Philadelphia, Pennsylvania, 1982. 8. Department of Pathology, Case Western Reserve University, Cleveland, Ohio, 1982. 9. Department of Biology, Case Western Reserve University, Cleveland, Ohio, 1984. 10. National Neurological Institute, Universidad Nacional Autonoma de Mexico, Mexico, 1984. 11. XIII International Congress of Gerontology, New York, New York, 1985. 12. Department of Pathology, Case Western Reserve University, Cleveland, Ohio, 1985. 13. Lakewood Hospital, Lakewood, Ohio, 1986. 14. Mini Symposium, American Society for Cell Biology, Washington, D.C., 1986. 15. Xth International Congress of Neuropathology, Stockholm, Sweden, 1986. 16. Alzheimer Disease and Related Disorders Association, Erie Chapter, Erie, Pennsylvania, 1987. 17. Department of Neurology, Case Western Reserve University, Cleveland, Ohio, 1987. 18. First Symposium on Familial Alzheimer's Disease, Tulsa, Oklahoma, 1987. 19. Upjohn Company, Kalamazoo, Michigan, 1987. 20. Electron Microscope Society of Northeastern Ohio, Cleveland, Ohio, 1988.

George Perry

50

21. Born-Bunge Foundation, University of Antwerp, Antwerp, Belguim, 1988. 22. Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, 1988. 23. First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada,

1988. 24. Ohio University College of Osteopathic Medicine, Athens, Ohio, 1988. 25. Department of Anatomy, Northeastern Ohio University College of Medicine, Rootstown, Ohio, 1989. 26. Second Symposium on Familial Alzheimer's Disease, Seattle, Washington, 1989. 27. Alzheimer Center, University of Cincinnati Medical School, Cincinnati, Ohio, 1990. 28. Department of Biology, Dickinson College, Carlisle, Pennsylvania, 1990. 29. Second International Conference on Alzheimer's Disease and Related Disorders, Toronto, Canada,

1990. 30. Neuroscience of Alzheimer Disease Conference, Gliatech, Cleveland, Ohio, 1990. 31. Alzheimer's Disease and Related Disorders Association, Canton Chapter, Canton, Ohio 1990. 32. Department of Environmental Health Sciences, Case Western Reserve University, Cleveland, Ohio,

1990. 33. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 1991. 34. Developmental Biology Retreat, Gwinn Estate, Cleveland, Ohio, 1991. 35. Department of Biology, Hope College, Holland, Michigan, 1991. 36. Cell Biology Retreat, Gwinn Estate, Cleveland, Ohio, 1991. 37. Department of Biology and Biochemistry, University of Montreal, Montreal, Canada, 1991. 38. French Foundation for Alzheimer's Research workshop, Brain amyloid and blood and spinal fluid tests

for Alzheimer disease, Los Angeles, California, 1992. 39. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 1992. 40. Department of Biology, Heidelberg College, Tiffin, Ohio, 1992. 41. Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, 1992. 42. Department of Pathology, Case Western Reserve University, Cleveland, Ohio, 1992. 43. Fifth International Congress of Cell Biology, Madrid, Spain, 1992. 44. Neurological Institute, Universidad Nacional Autonoma de Mexico, Mexico, 1992. 45. Fourth All Ohio Alzheimer Symposium, Toledo, Ohio, 1992. 46. Cell Biology Retreat, Cleveland Museum of Natural History, Cleveland, Ohio, 1992. 47. Department of Biology, Muskingum College, New Concord, Ohio, 1992. 48. Tanz Center for Neuroscience, University of Toronto, Canada, 1992. 49. Louisville Chapter Society for Neuroscience, University of Louisville Medical Center, Louisville,

Kentucky, 1992. 50. Department of Biology, Wilburforce University, Wilburforce, Ohio, 1992. 51. Workshop: Potential animal and cellular models of Alzheimer's, Winter Conference on Brain Research,

Whistler, British Columbia, Canada, 1993. 52. Panel: β-amyloid peptides: deposition, aggregation, neurotoxicity, biological effects. Winter Conference

on Brain Research, Whistler, British Columbia, Canada, 1993. 53. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 1993. 54. FASEB Mini Symposium on Alzheimer's Disease, New Orleans, Louisiana, 1993. 55. Histology Society of Ohio, Annual Meeting, Cleveland, Ohio, 1993. 56. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio 1993. 57. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio 1993. 58. Neuroscience Program, Michigan State University, East Lansing, Michigan, 1994. 59. Department of Neurology, Sparrow Hospital, Lansing, Michigan, 1994. 60. Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 1994. 61. Neuroscience Program, Ohio State University, Columbus, Ohio, 1994. 62. Dementia in Parkinson's Disease International Symposium, Jerusalem, Israel, 1994. 63. Superoxide Dismutase and Free Radicals in ALS and Neurodegeneration, Lake Bluff, Illinois, 1994. 64. Satellite Symposium on Normal and Pathological Brain Iron, Twelvth International Congress of

Neuropathology, Niagara Falls, New York, 1994. 65. Society of Neuroscientists of Africa First International Neuroscience Meeting, Marrakech, Morocco,

1995.

George Perry

51

66. Tanz Center for Neuroscience, University of Toronto, Canada, 1995. 67. Alzheimer‘s Disease International Symposium, Born Bunge Foundation, University of Antwerp, Antwerp,

Belgium, 1995. 68. Second Tel Aviv University Alzheimer‘s Disease Conference, Tel Aviv, Israel, 1995. 69. Department of Neurosciences, Cleveland Clinic Research Institute, Cleveland, Ohio, 1995. 70. Amyotrophic Lateral Sclerosis Foundation, San Francisco, California, 1995. 71. Alzheimer Association, Mansfield Chapter, Mansfield, Ohio, 1995. 72. Department of Pathology, Henry Ford Hospital, Detroit, Michigan, 1995. 73. Institute of Pathology, Technical University of Dresden, Dresden, Germany, 1995. 74. Ernst Schering Foundation Workshop, Alzheimer‘s Disease: Etiological mechanisms and therapeutic

possibilities, Berlin, Germany, 1995. 75. Great Lakes Regional Microscopy Affilliates Meeting, Toledo, Ohio, 1995. 76. Cell Biology Retreat, Crawford Hall, Cleveland, Ohio, 1995. 77. American Society for Neurochemistry, Philadelphia, Pennsylvania, 1996. 78. Cephalon Incorporated, West Chester, Pennsylvania, 1996. 79. Department of Neuroscience, Centro de Investigacion y de Estudios Avanzados del Institute de

Polytechnicos Nacional, Mexico, 1996. 80. Department of Anatomy, University of Kentucky, Lexington, Kentucky, 1996. 81. Department of Biology, Gannon University, Sharon, Pennsylvania, 1996. 82. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 1996. 83. Fourth International Congress of Movement Disorders, Vienna, Austria, 1996. 84. Gordon Research Conference, Intermediate Filaments, Holdness School, New Hampshire, 1996. 85. Fifth International Conference on Alzheimer‘s Disease and Related Disorders, Osaka, Japan, 1996. 86. Department of Biochemistry, Osaka University Medical School, Osaka, Japan, 1996. 87. Sumitomo Pharmaceuticals Company, Ltd., Osaka, Japan, 1996. 88. Takeda Chemical Industries, Ltd., Osaka, Japan, 1996. 89. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 1996. 90. Fourth Conference on Neurodegenerative Disorders: Common Molecular Mechanisms, Ochos Rios,

Jamaica, 1997. 91. FASEB Course: Neurobiology of CNS Disease, New Orleans, Louisiana, 1997. 92. Gerontology Research Center, National Institute on Aging, National Institutes of Health, Bethesda,

Maryland, 1997. 93. Department of Pathology, University of Maryland, Baltimore, Maryland, 1997. 94. Molecular Geriatrics Corporation, Vernon Hills, Illinois 1997. 95. Microscopy and Microanalysis ‘97, Cleveland, Ohio 1997. 96. Symposium on the Neuroscience of Alzheimer‘s Disease, Cleveland, Ohio, 1997. 97. Rammelkamp Center, MetroHealth Medical Center, Cleveland, Ohio, 1997. 98. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 1997. 99. Biological Basis of a Rational Approach to Therapy for Alzheimer Disease, Pamplona, Spain, 1997. 100. Centro de Biologia Molecular ‗Severo Ochoa‘, Universidad Autonoma de Madrid, Spain, 1997. 101. Alzheimer Disease, Belgian Society of Neurology, Antwerp, Belgium, 1997. 102. Protein Aging Group of Cleveland, Cleveland, Ohio, 1997. 103. World Congress, Oxidants and Antioxidants in Biology, Oxygen Club of California, Santa Barbara,

California, 1998. 104. Gordon Research Conference, Oxygen Radicals in Biology, Ventura, California, 1998. 105. Manhattan Alzheimer Meeting, New York, New York, 1998. 106. University Center on Aging and Health, Case Western Reserve University, Cleveland, Ohio 1998. 107. Gordon Research Conference, Intermediate Filaments, Holderness School, New Hampshire, 1998. 108. Metabolism and Alzheimer‘s Hallmarks, Sixth International Conference on Alzheimer‘s Disease and

Related Disorders, Amsterdam, Netherlands, 1998. 109. Protein Aging Group of Cleveland, Cleveland, Ohio, 1998. 110. Molecular and Genomic Effects of Tissue Oxygen Deprivation in Sleep Apnea, National Heart, Lung,

and Blood Institute, Bethesda, Maryland, 1998. 111. Fourth Hungarian Conference on Alzheimer‘s Disease and Related Disorders, Szeged, Hungary, 1998. 112. Neurology Grand Rounds, Rush-Presbyterian-St. Luke‘s Medical Center, Chicago, Illinois, 1999. 113. Program in Neuroscience, University of Massachusetts, Worchester, Massachusetts, 1999.

George Perry

52

114. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland, Ohio, 1999.

115. Oxygen Club of California, Santa Barbara, California, 1999. 116. Apoptosis in Alzheimer Disease, Alzheimer Research Forum, http://www.alzforum.org/res/for/ journal/apoptosis/default.asp, 1999. 117. Experimental Biology ‘99, FASEB, Washington, D.C., 1999. 118. National Institutes of Neurological Diseases and Stroke, Bethesda, Maryland, 1999. 119. Neuroscience Program, Louisiana State University Medical Center, Shreveport, Louisiana, 1999. 120. International Society of Neurochemistry, Satellite Symposium on Neuronal Apoptosis, Tübingen,

Germany, 1999. 121. Gordon Research Conference, Oxidative Stress and Disease, Waterville Valley, New Hampshire, 1999. 122. Institute of Cellular and Molecular Biology, University of Oporto, Oporto, Portugal, 1999. 123. Portugese Society for Neuroscience, Lisbon, Portugal, 1999. 124. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 1999. 125. Neuroimaging and Biological Markers for Alzheimer‘s disease, National Institute on Aging, Bethesda,

Maryland, 1999. 126. Alzheimer Disease: Models and Mechanisms, Thomas Jefferson University, Philadelphia, Pennsylvania,

1999. 127. American College of Neuropsychopharmacology, Acapulco, Mexico, 1999. 128. Fourth International Symposium on Medicinal Chemistry in Neurodegenerative Diseases, Cancun,

Mexico, 2000. 129. Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, 2000. 130. Neurobiology and Clinical Management of Alzheimer‘s Disease and Related Disorders, Cleveland,

Ohio, 2000. 131. Mitochondrial Pathology in Aging and Neurodegeneration, Experimental Biology 2000, San Diego,

California, 2000. 132. Pathobiology for Basic Scientists; Cell Injury/Cell Death, Experimental Biology 2000, San Diego,

California, 2000. 133. Transgenic Models in the Nervous System, Experimental Biology 2000, San Diego, California, 2000. 134. Mitokor Corporation, San Diego, California, 2000. 135. Basic Science Research Conference, Alzheimer Center, Case Western Reserve University, Cleveland,

Ohio, 2000. 136. Linus Pauling Institute, Oregon State University, Corvalis, Oregon, 2000. 137. World Alzheimer Congress 2000, Washington, D.C., 2000. 138. XIVth International Congress of Neuropathology, Birmingham, England 2000. 139. Neuromuscular Disorders of Aging, Marseille, France, 2000. 140. Centro de Biologia Molecular ‗Severo Ochoa‘, Universidad Autonoma de Madrid, Spain, 2000. 141. Metals and Brain: From Neurochemistry to Neurodegeneration, Padova, Italy, 2000. 142. Takeda Chemical Industries, Ltd., Osaka, Japan, 2000. 143. Department of Neurology, Kyoto University, Japan, 2000. 144. Tenth Biennial Meeting of the International Society for Free Radical Research, Kyoto, Japan, 2000. 145. Department of Biochemistry, Osaka University Medical School, Osaka, Japan, 2000. 146. Sumitomo Pharmaceutical Company, Osaka, Japan 2000. 147. Eisai Pharmaceutical Company, Asahikawa, Japan, 2000. 148. Asahikawa Medical College, Asahikawa, Japan, 2000. 149. Can Alzheimer‘s Disease be Prevented?, University of Western Australia, Perth, Australia, 2000. 150. Cell Biology Department, Cleveland Clinic Foundation, Cleveland, Ohio 2000. 151. First Annual Summit, Panacea Pharmaceuticals, Rockville, Maryland, 2001. 152. Department of Biomedical Sciences, Iowa State University, Ames, Iowa 2001. 153. Clinical Pathology Conference, University Hospitals of Cleveland, Cleveland, Ohio 2001. 154. Fundación Ramón Areces, Valencia, Spain, 2001. 155. Gordon Research Conference, Oxidative Stress and Disease, Ventura, California, 2001.

156. -Synclein Biology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, 2001. 157. Neuroscience Research Institute, Department of Molecular, Cellular, Developmental Biology, University

of California, Santa Barbara, California, 2001. 158. Annual Summit, Panacea Pharmaceuticals, Rockville, Maryland 2001. 159. New Insights in Neurodegenerative Disease, Philadelphia, Pennsylvania, 2001.

George Perry

53

160. Seventeenth Annual Alzheimer‘s Disease Symposium, Alzheimer‘s Association, Eastern Tennessee Chapter, Gatlinburg, Tennessee, 2001.

161. Biology of Synucleins, National Institute on Aging, Bethesda, Maryland 2001. 162. Department of Neurology, Ohio State University, Columbus, Ohio 2001. 163. International Society for Neurochemistry, Buenos Aires, Argentina, 2001. 164. Ethics Seminar, Case Western Reserve University, Cleveland, Ohio, 2001. 165. Ageing and Dementia 2001, University of Graz, Graz, Austria, 2001. 166. International Workshop on Comparative Aspects of Oxidative Stress in Biological Systems, La Paz,

Baja California Sur, Mexico, 2001. 167. Keynote Address, Second International Workshop on Iron and Copper Homeostasis, Pucon, Chile,

2001. 168. Mind and Brain, 56th Congress of the Chilean Neurological, Psychiatric and Neurosurgical Societies,

Pucon, Chile, 2001. 169. Controversies in Alzheimer Disease: Etiopathology and Therapeutics, 56th Congress of the Chilean

Neurological, Psychiatric and Neurosurgical Societies, Pucon, Chile, 2001. 170. Plenary Lecture, 56th Congress of the Chilean Neurological, Psychiatric and Neurosurgical Societies,

Pucon, Chile, 2001. 171. University Memory and Aging Center, Case Western Reserve University, Cleveland, Ohio 2001. 172. Hemochromatosis as a Factor in AD, Alzheimer Research Forum, http://www.alzforum.org/res/for/ journal/milward/default.asp, 2002. 173. Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, 2002. 174. Clinical Pathology Conference, Department of Pathology, Case Western Reserve University,

Cleveland, Ohio, 2002. 175. Neuroscience Program, University of Rochester, Rochester, New York, 2002. 176. Second Annual Summit, Panacea Pharmaceuticals, Inc., Rockville, Maryland, 2002. 177. Plenary Lecture, 8th International Conference on Alzheimer‘s Disease, Stockholm, Sweden, 2002. 178. Discussant, Enabling Technologies for Alzheimer‘s Disease II, Alzheimer Research Forum, Bar

Harbor, Maine, 2002. 179. Cell and Molecular Biology of Alzheimer‘s Disease, Hamburg, Germany, 2002. 180. CNS Research Department, Boehringer Ingelheim, Ingelheim am Rhein, Germany, 2002. 181. Opening Plenary Lecture and Closing Roundtable, Second International Conference on Metals and the

Brain, Fez, Morocco, 2002. 182. The Regulation of Cell Hydration in Norm and Pathology, UNESCO-USA-Caucasus Workshop, Yerven,

Armenia, 2002. 183. 11th Annual Puerto Rico Neuroscience Conference, San Juan, Puerto Rico, 2002. 184. Protein Aging Group of Cleveland, Cleveland, Ohio, 2003. 185. Magnetic Resource Imaging Division, General Electric Global Research, Schenectady, New York, 2003. 186. Department of Neurology, Albany Medical College, Albany, New York, 2003. 187. Oxidative Stress in Brain Aging and Neurodegenerative Diseases: From Biology to Therapy,

Perugia, Italy, 2003. 188. Bioiron 2003: World Congress on Iron Metabolism, National Institutes of Health, Bethesda,

Maryland, 2003. 189. 6th International Conference on on Alzheimer‘s and Parkinson‘s Disease, Seville, Spain, 2003. 190. Mitochondria 2003, San Diego, California, 2003. 191. Voyager Pharmaceuticals, Atlanta, Georgia and Naples, Florida, 2003. 192. Summer Program in Undergraduate Research, Case Western Reserve University, Cleveland, Ohio,

2003. 193. Cancer Center/Blood Club Seminar, Case Western Reserve University, Cleveland, Ohio, 2003. 194. Endocrine Grant Rounds, Case Western Reserve University, Cleveland, Ohio, 2003. 195. Reminyl Neuroprotection Symposium, Madrid, Spain, 2004. 196. Minority Views and Professional Responsibilities—Scientists Air Their Views, Alzheimer Research

Forum, http://www.alzforum.org/res/for/journal/perry/default.asp, 2004. 197. Protein Aging Group, Cleveland, Ohio, 2004. 198. XII Meeting of the Society for Free Radical Research International, Buenos Aires, Argentina, 2004. 199. Special Lecture in memory of Carlos Garcia, 18th Annual Meeting of the Group for the Study of Brain

Diseases and Dementia, Obidos, Portugal, 2004. 200. Alzheimer‘s Disease: The Current State, 18th Annual Meeting of the Group for the Study of Brain

Diseases and Dementia, Obidos, Portugal, 2004. 201. Cell Biology Retreat, Sawmill Creek Resort, Huron, Ohio, 2004.

George Perry

54

202. Challenging Views of Alzheimer‘s Disease – 2004, Roundtable ―What is Aging, What Is its Role in Alzheimer's Disease and What Can We Do About It?‖, Philadelphia, Pennsylvania, 2004.

203. Science Enrichment and Opportunity Program, Case Western Reserve University, Cleveland, Ohio, 2004.

204. American Society for Neurochemistry, New York, New York, 2004. 205. 8th International Symposium on the Maillard Reaction, Charleston, South Carolina, 2004. 206. New Therapeutic Approaches to Alzheimer Disease, Project of Queen Sofia of Spain, Madrid, Spain,

2004. 207. Michigan State University, Lansing, Michigan, 2004. 208. Korean Conference on Innovative Science and Technology, Gyeongju, Korea, 2004. 209. Department of Microbiology and Immunology, Hallym University College of Medicine, Kangwo-Do,

Korea, 2004. 210. Third International Workshop on Iron and Copper Homeostasis, Viña del Mar City, Chile, 2004. 211. International Conference on Inclusion-Body Myositis (s-IBM): Frontiers of Research Potentially Relevant

to Treatment, Los Angeles, California, 2005. 212. Hopkins Marine Station, Department of Biological Sciences, Stanford University, 2005. 213. Prion Development Laboratories, Buffalo Grove, Illinois, 2005. 214. 7th International Conference on Alzheimer‘s and Parkinson‘s Disease, Sorrento, Italy, 2005. 215. Masamichi Memorial Symposium, Case Western Reserve University, Cleveland, Ohio, 2005. 216. Experimental Biology, San Diego, California, 2005. 217. Panel: Alzheimers and Other Neural Degenerative Diseases of Aging: Unraveling the Mystery,

Research ShowCASE, Cleveland, Ohio, 2005. 218. International Symposium on Aging and Neurodegeneration, Seoul, Korea, 2005. 219. Hallym University, Chuncheon-si, Gangwon-do, Korea, 2005. 220. IPSEN Symposium: Alzheimer‘s disease: From repair to prevention, Brugges, Belgium, 2005. 221. Oxidative Stress in Autism Symposium, New York, New York, 2005. 222. 4th International Congress on Vascular Dementia, Porto, Portugal, 2005. 223. Centro de Biologia Cellular, University of Aveiro, Aveiro, Portugal, 2005. 224. Protein Oxidation, Misfolding and Dysfunction in Neurodegenerative Diseases, Santiago, Chile, 2005. 225. Cell & Molecular Biology Seminar Series, University of Texas at San Antonio, San Antonio, Texas,

2006. 226. Sigma Xi Presentation, Trinity University, San Antonio, Texas, 2006. 227. Pathology Research Conference, The University of Texas Health Science Center at San Antonio, San

Antonio, Texas, 2006. 228. 10th International Conference on Alzheimer‘s Disease and Related Disorders, Madrid, Spain, 2006. 229. Lo major de la Universidad de Texas - San Antonio en Mexico, El Colegio Nacional, Mexico, D.F.,

Mexico, 2006. 230. XVI International Congress of Neuropathology, San Francisco, California, 2006. 231. Molecular Medicine Seminar Series, University of Texas Health Science Center at San Antonio, San

Antonio, Texas, 2006. 232. Reflecting on 100 Years of Alzheimer‘s, Cleveland, Ohio, 2006. 233. Department of Biology, University of Texas at Brownsville, Brownsville, Texas, 2006. 234. The Minority Access to Research Careers/Minority Biomedical Research Support Programs Spring

Seminar Series, University of Texas at San Antonio, San Antonio, Texas, 2007. 235. 8th International Conference on Alzheimer‘s and Parkinson‘s Disease, Salzburg, Austria, 2007. 236. Pathology Seminar Series, University of Wisconsin - Madison, Madison, Wisconsin, 2007. 237. Department of Psychology, University of Texas at Austin, Austin, Texas, 2007. 238. Department of Molecular Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands,

2007. 239. 6th Dutch Endo-Neuro-Psycho Meeting, Doorwerth, The Netherlands, 2007.

240. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 2007. 240. American College of Veterinary Pathology Annual Meeting, Savannah, George, 2007. 241. Autism Spectrum Disorders, Twenty-fourth International Neurotoxicology Conference, San Antonio, Texas, 2007. 242. 5

th International Congress on Vascular Dementia, Budapest, Hungary, 2007.

243. 1st International Conference on Current Hypotheses of Alzheimer‘s Disease, Viña del Mar, Chile, 2007. 244. Philip Morris External Research Symposium, Washington DC, 2007. 245. 1

st International Conference on Drug Design and Discovery, Dubai, United Arab Emirates, 2008.

George Perry

55

246. Medicine Research Seminar Series, The University Health Science Center at San Antonio, San Antonio, Texas, 2008.

247. Symposium/Roundtable, 54th Brazilian Congress of Genetics, Salvador, Bahia, Brazil, 2008.

248. Conference, 54th Brazilian Congress of Genetics, Salvador, Bahia, Brazil, 2008.

249. Special Keynote Lecture, BioMonterrey 08, Monterrey, Mexico, 2008. 250. Keynote Plenary Lecture, XVIth National Congress of Biochemistry, Portuguese Biochemical Society,

University of the Açores, Ponta Delgada, São Miguel Island, Açores, Portugal, 2008. 251. 13

th International Meeting on Trace Elements in Man and Animals. Pucón, Chile, 2008.

252. Faculty of Medicine, University of Chile, Santiago, Chile, 2008. 253. VI Encontro do Fόrum Internacional de Investigadores Portuguese – FIIP, Institute de Medicina

Molecular, Universidade de Lisboa, Portugal, 2008. 254. Department of Chemistry, University of Texas at Dallas, Dallas, Texas, 2009. 255. 9

th International Conference on Alzheimer‘s and Parkinson‘s Diseases, Prague, Czech Republic, 2009.

256. Science Café, Sigma XI, San Antonio, Texas, 2009. 257. Fred E. Samson Memorial Lecture, Department of Molecular and Integrative Physiology, University of

Kansas Medical Center, Kansas City, Kansas, 2009 258. Special Course, American Association of Neuropathologists Annual Meeting, San Antonio, Texas, 2009. 259. Presidential Address, American Association of Neuropathologists, San Antonio, Texas, 2009. 260. Department of Pathology, University of Texas at Houston Health Science Center, Houston, Texas,

2009. 261. VI Symposium ―Advances in Alzheimer‘s Disease‖, Project of Queen Sofia of Spain, Madrid, Spain,

2009. 262. Brainstorming Session On the Cause of Alzheimer‘s Disease Present and Future. Project of Queen

Sofia of Spain, Madrid, Spain, 2009. 263. Hill Country Symposium, Alzheimer‘s Association, Star Chapter, Boerne, Texas, 2009. 264. Plenary Lecture, XV Congreso Latinoamericano de Nutriciόn, Sociedad Latinoamericana de Nutriciόn,

Santiago, Chile, 2009. 265. Centro Internacional de Biomedicina, Universidad de Chile, Santiago, Chile, 2009. 266. Symposium, XV Congreso Latinoamericano de Nutriciόn, Sociedad Latinoamericana de Nutriciόn,

Santiago, Chile, 2009. 267. International Course on Molecular Biology of Development, Neurodegeneration and Genomic Medicine,

University of Guadalajara, Guadalajara, Mexico, 2009. 268. Mitchell Center, University of Texas Medical Branch, Galveston, Texas, 2010. 269. Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San

Antonio, Texas, 2010. 270. Neuroscience and Experimental Therapeutics Seminar, Texas A&M Health Science Center, College

Station, Texas, 2010. 271. Geriatrics, Gerontology and Palliative Care Grand Rounds,South Texas Veterans Health Center

Services, San Antonio, Texas, 2010. 272. Texas State Plan for Alzheimer Disease, Austin, Texas, 2010. 273. Keynote speaker, 4

th Annual UTSA Architecture, Business, Engineering and Science Students

Conference 2010, University of Texas at San Antonio, San Antonio Texas, 2010. 274. Institute of Basic Research in Developmental Disabilities, Staten Island, New York, 2010 275. San Antonio Council for the Cooperation of Engineering and Scientific Societies (SACCESS), San

Antonio, Texas, 2010 276. Healthcare Professional Conference, Alzheimer‘s Association, Star Chapter, San Antonio, Texas, 2010 277. Microscopy and Microanalysis 2010, Portland, Oregon, 2010 278. Symposium, 17

th International Congress of Neuropathology, Salzburg, Austria, 2010

279. Mitochondrial Advisory Group, Eisai Company, London, England, 2010 280. Department of Biology, University of Massachusetts, Dartmouth, 2010 281. TEDx Alamo, San Antonio, Texas, 2010 http://www.youtube.com/watch?v=6tBSFEzkk0A 282. Eulogy for Mark Anthony Smith, Church of the Holy Angels, Bainbridge Township, Ohio, 2010 283. Progress in Neurological Disorders: Basic and Tanslational Research, Universidad de Concepción,

Concepción, Chile, 2011 284. Memorial Service for Mark A. Smith, Case Western Reserve University, Cleveland, Ohio, 2011

http://www.youtube.com/watch?v=oS8fBhUM09Y&feature=player_embedded 285. Strategy Days, IOS Press, Amsterdam, Netherlands, 2011 286. Plenary lecture, Associazione Autonoma per le Demenzeadesente alla Sin (SINDEM), Milan, Italy, 2011 287. Beta Beta Beta UTSA Chapter, San Antonio, Texas, 2011

George Perry

56

288. Mark A. Smith, Posthumous Outstanding Investigator Acceptance, American Society for Investigative Pathology, Washington DC, 2011

289. 2011 PhysTEC Conference Panel, Austin, Texas, 2011 290. Jim Flood Memorial Alzheimer‘s Disease Distinguished Lectureship, 22

nd Annual Saint Louis University

Geriatric Institute, Saint Louis University, Saint Louis, Missouri, 2011 291. International Conference on New Discoveries of the Brain, Panama, 2011 292. Age Pioneers: A Tribute to Jim Joseph and Mark A. Smith, American Aging Association, Raleigh, North

Carolina, 2011 293. Young Portuguese-American Leaders Summit, National Organization of Portuguese-Americans,

Washington, DC, 2011 294. Neurosurgery Center for Research, Training and Education, Loma Linda University, California, 2011 295. Microscopy and Microanalysis 2011, Nashville, Tennessee, 2011 296. International Alzheimer‘s Research Year, Fundacion Reina Sofia and Fundacion Pasqual Mangall,

Madrid, Spain, 2011 http://www.alzheimerinternacional2011.org/diferido.php?ver=u06&idioma=en&i=1

297. UTB/TSC Alzheimer‘s Research Symposium, Brownsville, Texas, 2011 http://media.utb.edu/2011_Alzheimer/Perry.html

298. Junior Investigator Day, International College of Geriatric Psychoneuropharmacology, Irvine, California, 2011

299. Senior Investigator Award Lecture, International College of Geriatric Psychoneuropharmacology, Irvine, California, 2011

300. Case Brain Health Collaborative, Beachwood, Ohio, 2012 301. Abbott Laboratories, Chicago, Illinois, 2012 302. Induction Ceremony, Academia Mexicana de Ciencas, Centro de Investigación y Estudias Avanzados

del IPN, Mexico, DF, 2012 303. Texas Academy of Sciences, Alpine, Texas, 2012 304. MBRS-RISE Seminar, University of Texas at San Antonio, San Antonio, Texas, 2012 305. Twenty-Fifth Anniversary, IOS Press, Amsterdam, Netherlands, 2012 306. MSTP Distinguished Lecture, Medical Scientist Training Program, University of Virginia, Charlottesville,

Virginia, 2012 307. Plenary Speaker, 1

st International Symposium on Prion Chemical Biology and Emerging Technologies:

Toward a cure for Alzheimer‘s diseases. UK Prion Chemical Biology Network, Sheffield, England, 2012

308. Distinguished Speaker Series, Mind Science Foundation, San Antonio, Texas, 2012 309. Alzheimer‘s Centers of Excellence, Tampa, Florida, 2012 310. RTRN Webinar, RCMI Network, 2012 http://rtrn.adobeconnect.com/p2hd5uls9kh/ 311. Geriatric Research, Education and Clinical Center, University of Washington, Seattle, Washington, 2012 312. Plenary Speaker, VI Ibero-American Alzheimer‘s Congress, Santiago, Chile, 2012 313. Panelist, The Power of Diversity and Community Engagement, 13

th RCMI International Symposium on

Health Disparities, San Juan, Puerto Rico, 2012 http://genecenter.org/rcmi/2012/dec-12/GS4 314. State of the State Plan Alzheimer Disease Partnership Meeting, Austin, 315. Spring 2013 Seminar Series, Health Science Center, University of North Texas, Fort Worth, Texas,

2013 316. Keynote Speaker, Vascular Mechanisms in Alzheimer‘s Disease and Neurodegeneration Disorders

Symposium, University of Texas Southwestern Medical Center, Dallas, Texas, 2013 http://www.utsouthwestern.edu/education/medical-school/departments/neurology/programs/alzheimers-disease-center/adc-symposium-2013-lectures.html#Perry

317. Minority Access to Research Careers, New Mexico State University, Las Cruces, New Mexico, 2013 318. MBRS-RISE, Minority Biomedical Research Support – Research Initiative for Scientific Enhancement,

University of Texas at San Antonio, Texas, 2013 319. Keynote Speaker, First International Conference on Advances in Research and Therapeutics in

Alzheimer Disease, Benemérita Universidad Autónoma de Puebla, Mexico, 2013 320. XIV Portuguese-American Postgraduate Society (PAPS) Forum, Massachusetts Institute of Technology,

Boston, Massachusetts, 2013 321. American Association of Pathologist Assistants, San Antonio, Texas, 2013 322. Induction Ceremony, Spanish Royal Academy of Sciences, Madrid, Spain, 2013 323. Opening Lecture, Excellence in Neurodegeneration Seminar Series, CIBERNED, Madrid, Spain, 2013 324. Summer Institute on Aging, 2013 (SIA 2013), Veterans Administration, San Antonio, Texas, 2013

George Perry

57

325. Cardiovascular Research Seminar Series, Morehouse School of Medicine, Atlanta, Georgia, 2013 326. Diplomacy and Politics; Exploring the Portuguese Diaspora in Interdisciplinary and Comparative

Perspectives: An International Conference, Indianapolis, Indiana, 2013 327. Interdisciplinary dialogues; Exploring the Portuguese Diaspora in Interdisciplinary and Comparative

Perspectives: An International Conference, Indianapolis, Indiana, 2013 328. Martin Goland Lecture, Sigma Xi Alamo Chapter, San Antonio, Texas, 2013 329. Keynote Presentation, International Conference on Psychology, Autism and Alzheimer‘s Disease, San

Antonio, Texas, 2013 330. Track 4 Scientific Presentation, International Conference on Psychology, Autism and Alzheimer‘s

Disease, San Antonio, Texas, 2013 331. From Neurodegeneration to Brain Health: An Integrated Approach, Case Brain Health Collaborative,

Cleveland, Ohio, 2013 332. Cantoblanco Workshop on tau, Madrid, Spain, 2013 333. Oxidative Stress and the Next Generation of Discovery, BU-Pfizer Symposium on Translational

Sciences, Boston University, Boston, Massachusetts, 2013 334. 2013 Alzheimer‘s Educational, Alzheimer‘s Association for San Antonio and South Texas Chapter, San

Antonio, Texas, 2013 335. Keynote Presentation, International Summit on Clinical Pharmacy and Dispensing, San Antonio, Texas,

2013. 336. Track 3 Scientific Presentation, International Summit on Clinical Pharmacy and Dispensing, San

Antonio, Texas, 2013. 337. American Society for Nanomedicine Spring Conference, University of Maryland at Shady Grove,

Rockville, Maryland, 2014 338. National Hispanic Medical Association, Washington, DC, 2014 339. Department of Neurology Resident Conference, University of Maryland, Baltimore, Maryland, 2014 340. Department of Pathology Resident Conference, University of Maryland, Baltimore, Maryland, 2014 341. Southwest Fulbright Symposium: Transcending Borders, Fulbright Association, San Antonio Chapter,

San Antonio, Texas, 2014 342. Keynote Presentation, Arctic Science Conference, Arctic Chapter, AAAS, University of Alaska,

Fairbanks, Alaska, 2014 343. International Symposium on Minority Health and Health Disparities, Washington DC, 2014 344. Roundtable on Alzheimer Disease Research, Physicians‘ Committee for Responsible Medicine,

Washington, DC, 2015 345. Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, 2015 346. Webinar: Targets for the Next Generation of Alzheimer‘s Disease Treatment, ACT-AD, Washington DC,

2015 http://act-ad.org/activities/webinars/ 347. Department of Psychology, Ponce Health Sciences University, Ponce, Puerto Rico, 2015 348. Research Seminar Series, Ponce Health Sciences University, Ponce, Puerto Rico, 2015 349. Journal of Alzheimer‘s Disease Editorial Meeting, Alzheimer‘s Association International Conference on

Alzheimer‘s Disease, Washington, D.C. 2015 350. Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, California,

2015 351. Distinguished Seminar Series, Loma Linda, 2015. University School of Medicine, Loma Linda, California 352. Expert Presentation, Eighth Annual Meeting, Accelerating Cures/Treatments for Alzheimer‘s Disease,

ACT-AD, Washington, DC, 2015 353. Panel Of Experts, Accelerating Cures/Treatments for Alzheimer‘s Disease, Washington, DC, 2015 354. Inaugural Session, International Online Biomedical Conference, 2015,

https://www.youtube.com/watch?v=_0KyBQylytA&list=PLA90trmgVPCymG9o2FWVQ_jKESaoffsMz 355. Keynote Lecture, Second Border Biomedical Research Center Symposium on Health Disparities: From

Molecules to Disease, University of Texas at El Paso, Texas, 2015 356. Cell Biology Symposium, Argentine Society for Biochemistry and Molecular Biology Congress 2015,

Mar del Plata, Argentina, 2015 357. Local Keynote Speaker, First National Hispanic Alzheimer‘s Conference, Fuerza Contra Alzheimer‘s,

San Antonio, Texas, 2015 358. Azorean Alzheimer Association, Ponta Delgada, Azores., Portugal 2016 359. International Congress on Integrative Medicine and Health, Las Vegas, Nevada 2016 360. Scientific Lecture, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden, 2015 361. Opponent Ph.D. Thesis, Karolinska Institutet, Stockholm, Sweden, 2015 362. Scientific Lecture, International Conference on Recent Advances in Biosciences and Applications of

George Perry

58

Engineering in Production of Biopharmaceuticals & 9th Convention of Association of Biotechnology

and Pharmacy, Special Satellite Meeting on ―Molecular Neurochemical Networking Complexes in Alzheimer‘s disease‖, KL University, Andhra Pradesh India, 2015

363. Public Lecture, International Society of Neurochemistry Sponsored Public Awareness Program of Alzheimer‘s and Parkinson Diseases, Hotel Regency, Guntur, Andhra Pradesh, India, 2015

364. Department of Chemistry and Biochemistry, Baylor University, Waco, Texas, 2016 365. Department of Neurobiology and Anatomy, Drexel University, Colege of Medicine, Philadelphia,

Pennsylvania 2016 366. Second San Antonio Conference on Stem Cell Research & Regenerative Medicine, San Antonio,

Texas, 2016 367. Induction Ceremony, Academy of Sciences Lisbon, Portugal 2016 368. Debate: Does Chronic Traumatic Encephalopathy Exist? Controversies in Neurology (CONY), Lisbon,

Portugal, 2016 http://cdn.simul-europe.com/cony2016/1640_Discussion_fri_C.mp4 http://cdn.simul-europe.com/cony2016/1625_Perry_fri_C.mp4

369. Debate Host: Prion-like Spreading is a Relevant Theory for Neurodegenerative Disease, Controversies in Neurology (CONY), Lisbon, Portugal 2016

370. Beyond the Horizon in Dementia, Controversies in Neurology (CONY), Lisbon, Portugal 2016 http://cdn.simul-europe.com/cony2016/1030_Perry_sun_A.mp4

371. Institute for Integration of Medicine and Science (IIMS), Community Health Advisory Board Meeting, University of Texas Health Science Center San Antonio, San Antonio, Texas 2016

372. International Congress on Integrative Medicine and Health, Las Vegas, Nevada 2016 373. 2016 San Antonio Drug Discovery Symposium, San Antonio, Texas 2016 374. Prediction and Prevention of Dementia: New Hope, Milan, Italy 2016 375. World Automation Congress, Puerto Rico 2016 376. Center for Collaborative Research in Health Disparities, University of Puerto Rico Medical Sciences

Campus, San Juan, Puerto Rico, 2016 377. 2016 Center for Genome Research and Biocomputing (CGRB), Fall Conference, Oregon State

University, Corvallis,Oregon 2016 378. Sixteenth Portuguese American Postgraduate Society Forum, Memorial Sloan-Kettering Cancer Center,

New York City, New York, 2016 379. Grand Challenges in Neuroscience: Texas FreshAir 2016 Annual Conference, Austin, Texas 2016 380. Three separate talks, Tenth Anniversary, Associação Alzheimer Açores –ALZA, Conference on

Dementia, Ponta Delgada, Azores, Portugal, 2016. 381. Keynote Seminar, Annual Meeting Arkansas Chapter of the Society for Neuroscience, Little Rock,

Arkansas 2016 382. Second National Hispanic Alzheimer‘s Conference, Fuerza Contra Alzheimer‘s, New York City, New

York 2016 383. MD Anderson Hospital, Houston, 2017 384. Roundtable, Alzheimer Foundation of America, Washington DC, 2017 385. Controversies in Neurology, Plenary Session, American Academy of Neurology Annual Meeting,

Boston, Massachusetts, 2017 386. International Congress ―State of the Art in Non-Clinical Models of Neurodegenerative Diseases‖,

Varadero, Cuba, 2017. Community Lectures

1. UTSA Development Board, San Antonio, Texas, 2006 2. Exxon-Mobil Texas Science and Engineering Fair, San Antonio Texas, 2006, 2007, 2009, 2010, 2011, 2013 3. Seventh Annual UTSA Great Conversation!, University of Texas at San Antonio Honors College, San Antonio, Texas, 2007, 2008 4. Closing Day Assembly, Prefreshman Engineering Program, San Antonio, Texas, 2007 5. Graduate Student Orientation, University of Texas at San Antonio, San Antonio, Texas, 2007, 2008 6. Teacher Open House, University of Texas at San Antonio, San Antonio, Texas, 2008 7. Pre concert Talk, ―Alzheimer‘s Stories‖, San Antonio and Fredericksburg, Texas, 2009 8. Teaching Assistant Orientation, San Antonio, Texas, 2011, 2012, 2013, 2014, 2015 9. Rotary Club of Boerne, Texas, 2011 10. Conversations, KLRN, San Antonio, Texas, 2011 http://video.klrn.org/video/2202477810 11. Table Topic, UTSA Development Board, San Antonio, Texas, 2012

George Perry

59

12. Rotary Club of Alamo Heights, Texas, 2012 13. Cappy‘s First Wednesday Breakfast Club, San Antonio, Texas, 2012 14. Career Development, College of Architecture, University of Texas at San Antonio, Texas, 2012 15. Asset Initiative Proposal, Neuroscience Subcommittee, Biomed SA, San Antonio, Texas, 2013 16. The Source, Radio Call-in Show, Texas Public Radio, San Antonio, Texas, 2013 http://tpr.org/post/source-measuring-economic-impact-eagle-ford-shale 17. Psychology and Sociology Class, Brunswick High School, Brunswick, Ohio, 2013 18. Business and Social Division, Lone Star College – Montgomery, Conroe, Texas, 2013 19. Open Compute Project Engineering Workshop, University of Texas at San Antonio, Texas, 2013 20. 12

th Annual Candlelight Remembrance Service, Alzheimer Association of San Antonio and South

Texas, Chapel of the Incarnate Word, San Antonio, Texas, 2013 21. Civic Club, San Antonio, Texas, 2014 22. PREP IV Scholars Symposium, San Antonio, Texas, 2014 23. CIMA Project Undergraduate Research Program, University of Texas at San Antonio, 2014 24. Ninth International Workshop on Disordered System, San Antonio, Texas, 2014 25. Academic Excellence Council, University of Texas at San Antonio, 2014 26. mmLearn.org, Morningside Ministry, San Antonio Texas, 2015

http://msm.mediasite.com/mediasite/Play/07c1f5414cfe42cfbd4687faf4b1be5a1d?catalog=f861ae94-be61-450a-a964-814b6edd1176

27. Top Tier Scientists, San Antonio Country Club, San Antonio, Texas, 2015 28. Understanding Impact Factors, Faculty Center, University of Texas at San Antonio, Texas, 2015 29. UTSA Retired Faculty Association, University of Texas at San Antonio, 2015 30. Pre Concert Talk, ―Alzheimer Stories‖, UTSA Recital Hall, San Antonio, Texas, 2015 31. Planned Giving Council and Sombrilla Society, University of Texas at San Antonio, San Antonio, Texas, 2015 32. Downtown Rotary, San Antonio, Texas, 2015 33. Blood and Tissue Center Foundation, San Antonio, Texas 2015 34. Understanding Impact Factors, Faculty, University of Texas at San Antonio, 2015 35. San Antonio Medical Foundation Board, San Antonio, Texas, 2015 36. ―The Doctor Is In‖, Children‘s Hospital of San Antonio, San Antonio, Texas, 2015 37. Sombrilla Society, University of Texas at San Antonio, San Antonio, Texas, 2016 38. UTSA Alumni Reception, Houston, Texas 2016 39. UTSA Alumni Reception, Dallas, Texas 2016 40. Sloan Program, University of Texas at San Antonio, San Antonio, Texas 2016 41. MEDTalk Conference, University of Texas at San Antonio, San Antonio, Texas 2016 42. City of San Antonio Economic and Human Development Committee, City of San Antonio Council, San Antonio, Texas, Texas 2016 43. Alzheimer‘s with MacKenzie Rogers and George Perry, Ph.D., Health Stories that Matter, 790 KSPD, Boise, Idaho 2016 http://790kspd.com/alzheimers-with-mackenzie-rogers-and-george-perry-ph-d/ 44. Monster in the Mind, 2016 45. Oakes Club, Plaza Club, San Antonio, Texas 2016 46. Conopus Club, San Antonio Country Club, San Antonio, Texas 2016 47. UTSA Alumni Reception, Corpus Christi, Texas 2017 48. Think Science, Texas Public Radio, San Antonio, Texas 2017

Commencement Speaker 1. Pathologists‘ Assistant Program, University of Maryland, Baltimore, Maryland, 2014

Meeting Session Chairs:

1. American Association of Neuropathologists Annual Meeting, Minneapolis, Minnesota, 1986. 2. American Society for Cell Biology Mini Symposium, Organizer, Washington D.C., 1986. 3. American Association of Neuropathologists Annual Meeting, Charleston, South Carolina, 1987. 4. American Association of Neuropathologists Annual Meeting, Dallas, Texas, 1987. 5. American Association of Neuropathologists Annual Meeting, San Diego, California, 1989. 6. Second International Conference on Alzheimer Disease, Toronto, Canada, 1990. 7. Third International Conference on Alzheimer Disease, Padua, Italy, 1992.

George Perry

60

8. Fourth All Ohio Alzheimer Symposium, Toledo, Ohio, 1992. 9. American Association of Neuropathologists Annual Meeting, Salt Lake City, Utah, 1993. 10. Dementia in Parkinson's Disease International Symposium, Jerusalem, Israel, 1994. 11. Satellite Symposium on Normal and Pathological Brain Iron, Twelfth International Congress of

Neuropathology, Niagara Falls, New York, 1994. 12. Twelfth International Congress of Neuropathology, Toronto, Canada, 1994. 13. Society of Neuroscientists of Africa Symposium Organizer, International Neuroscience Meeting,

Marrakech, Morocco, 1995. 14. Alzheimer‘s Disease International Symposium, Born Bunge Foundation, University of Antwerp,

Antwerp, Belgium, 1995. 15. Second Tel Aviv University Alzheimer‘s Disease Conference, Tel Aviv, Israel, 1995. 16. Fifth International Conference on Alzheimer‘s Disease and Related Disorders, Osaka, Japan, 1996. 17. Microscopy and Microanalysis ‘97, Cleveland, Ohio, 1997. 18. American Association of Neuropathologists Annual Meeting, Pittsburgh, Pennsylvania, 1997. 19. Society for Neuroscience Annual Meeting, New Orleans, Louisiana, 1997. 20. Fourth Hungarian Conference on Alzheimer‘s Disease and Related Disorders, Szeged, Hungary,

1998. 21. American Association of Neuropathologists Annual Meeting Portland, Oregon, 1999. 22. Experimental Biology 2000, San Diego, California, 2000. 23. American Association of Neuropathologists Annual Meeting, Atlanta, Georgia, 2000. 24. World Alzheimer Congress 2000, Washington, D.C., 2000. 25. Fourteenth International Congress of Neuropathology, Birmingham, England, 2000. 26. Metals and the Brain, Padova, Italy, 2000. 27. Tenth Biennial Meeting of the International Society for Free Radical Research, Kyoto, Japan,

2000. 28. Can Alzheimer‘s Disease be Prevented?, University of Western Australia, Perth, Austrialia, 2000. 29. Gordon Research Conference, Oxidative Stress and Disease, Ventura, California, 2001. 30. American Association of Neuropathologists Annual Meeting, Chicago, Illinois, 2001. 31. Hemochromatosis as a Factor in AD, Alzheimer Research Forum,

http://www.alzforum.org/res/for/journal/milward/default.asp, 2002. 32. Stress-Induced Pathogenic Mechanisms, Eighth International Conference on Alzheimer Disease,

Stockholm, Sweden, 2002. 33. Inflammation/Oxidation, Eighth International Conference on Alzheimer Disease, Stockholm,

Sweden, 2002. 34. Second International Conference on Metals in the Brain, Fez, Morocco, 2002. 35. Society for Neuroscience Annual Meeting, Anaheim, California, 2002. 36. Bioiron 2003: World Congress on Iron Metabolism, Bethesda, Maryland, 2003. 37. 6th International Conference on Alzheimer‘s and Parkinson‘s Disease, Seville, Spain, 2003. 38. American Association of Neuropathologists Annual Meeting, Orlando, Florida, 2003. 39. Society for Neuroscience Annual Meeting, New Orleans, Louisiana, 2003. 40. Annual Education Retreat: Moving Medical Education Forward, Cleveland, Ohio, 2004. 41. Regulation of Nuclear Functions, Cleveland, Ohio, 2004. 42. XII Meeting of the Society for Free Radical Research International, Buenos Aires, Argentina, 2004. 43. Minority Views and Professional Responsibilities—Scientists Air Their Views, Alzheimer Research

Forum, http://www.alzforum.org/res/for/journal/perry/default.asp, 2004. 44. 9th International Conference on Alzheimer‘s Disease and Related Disorders, Philadelphia,

Pennsylvania, 2004. 45. 8th International Symposium on the Maillard Reaction, Charleston, South Carolina, 2004. 46. Third International Workshop on Iron and Copper Homeostasis, Viña del Mar, Chile, 2004. 47. International Conference on Inclusion-Body Myositis (s-IBM), Frontiers of Research Relevant to

Treatment. Los Angeles, California, 2005. 48. Masamichi Aikawa Memorial Symposium, Case Western Reserve University, Cleveland, Ohio,

2005. 49. New Faculty Symposium, CASE School of Medicine, Cleveland, Ohio, 2005. 50. 4th International Congress on Vascular Dementia, Porto, Portugal, 2005. 51. 10th International Conference on Alzheimer‘s Disease and Related Disorders, Madrid, Spain,

2006. 52. National Conference, Society for Advancement of Chicanos and Native Americans in Science,

Tampa, Florida, 2006.

George Perry

61

53. Reflecting on 100 Years of Alzheimer‘s, Cleveland, Ohio, 2006. 54. 5

th International Congress on Vascular Dementia, Budapest, Hungary, 2007.

55. 1st International Conference on Current Hypothesis of Alzheimer Disease, Viña del Mar, Chile

2007. 56. American Association of Neuropathologists Annual Meeting, Experimental Biology 2008, San

Diego, California, 2008. 57. Special Course, American Association of Neuropathologists Annual Meeting, San Antonio, Texas,

2009. 58. Presidential Symposium, American Association of Neuropathologists Annual Meeting, San

Antonio, Texas, 2009. 59. Microscopy and Microanalysis 2010, Portland, Oregon, 2010. 60. Microscopy and Microanalysis 2011, Nashville, Tennessee, 2011. 61. Global Alzheimer‘s Research Summit, Madrid, Spain, 2011 62. Case Brain Health Collaborative Retreat, Hunting Valley, Ohio, 2012 63. VI Congreso Iberoamericano de Alzheimer, Santiago, Chile, 2012 64. 13

th Annual Career Development Program, Experimental Biology 2013, Boston, Massachusetts,

2013 65. Exploring the Portuguese Diaspora in Interdisciplinary and Comparative Perspectives: An

International Conference, Indianapolis, Indiana, 2013 66. International Conference on Psychology, Autism and Alzheimer‘s Disease, San Antonio, Texas

2013 67. Cantoblanco Workshop on Tau, Madrid, Spain, 2013 68. International Symposium on Minority Health and Health Disparities, Washington, DC, 2014 69. World Stem Cell Summit, San Antonio, Texas, 2014 70. Texas Academy of Science, San Antonio, Texas, 2015 71. Argentinean Society of Biochemistry and Molecular Biology, Argentina, 2015 72. Neuroscience Oral Session, Texas Academy of Science, Junction, Texas, 2016 73. Neuroscience Poster Session, Texas Academy of Science, Junction, Texas, 2016 74. Controversies in Neurology (CONY), Lisbon, Portugal, 2016 75. Texas FreshAir, Neuroscience Meeting, Austin, Texas, 2016 76. Tenth Health Disparities Conference, Xavier University, New Orleans, Louisiana 2017

Philanthropy: Alzheimer‘s Association Walk to End Alzheimer Disease, Cleveland, Ohio, 2009, 2011 Walk to End Alzheimer Disease, San Antonio, Texas, 2009, 2010 Alzheimer Research and Prevention Foundation Mark Smith Memorial 2011 Baylor College of Medicine Jaworski Society 2014 Case Western Reserve University Mark Smith Memorial Fund for the Scientific Enrichment and Opportunity Program 2011 Satcher/Pamies Scholarship Fund 2011 Mark A. Smith Endowed Lectureship Drs. Smith and Sayre Alzheimer Research Fund Dean‘s Society (Clifford J. Vogt Level) Fundación Ibero Meneses Texas Public Radio Member 2012- Professional Member 2013- University of Massachusetts Dartmouth

George Perry

62

Chancellors Circle 2011 Ferreira-Mendes Portuguese-American Archive 2010 University of Texas at San Antonio Alicia Romo Memorial Scholarship 2010 Alumni Association Life Membership 2009- (Four) COS Dean‘s Fund for Excellence 2009 Paseo Society 2009- President‘s Associates 2006- Paul Rodriguez Scholarship 2011 Bring Rowdy Home 2013 Fill the Fountain 2013 Sombrilla Society 2014- Chancelor‘s Circle 2014- Romo Challenge 2014 Collaborative Study Area 2014 Roadrunner Memorial Garden 2016 National Organization of Portuguese-Americans Bronze Sponsor, Portuguese-American Postgraduate Society Forum 2013, 2014 Rivard Report Advocate 2016- Music and Memory 2017 References: Nathan A. Berger, M.D. Past Dean and Director Center for Science, Health and Society Health Sciences Library, 1st floor CASE School of Medicine 10900 Euclid Avenue Cleveland, Ohio 44106-4971 216-368-4084 216-368-3244 (fax) nab@case.edu

William R. Brinkley, Ph.D. Professor of Cell Biology Emeritus Senior Vice President of Graduate Studies Baylor College of Medicine One Baylor Plaza Houston, Texas 77030 713-798-5262 713-798-6325 (fax) brinkley@bcm.tmc.edu

Pierluigi Gambetti, M.D. Professor and Director Division of Neuropathology Institute of Pathology 2085 Adelbert Road Cleveland, Ohio 44106 216-844-1808 216-844-3627 (fax) pierluigi.gambetti@case.edu

David Epel, Ph.D. Jane and Marshall Steel Jr. Professor of Marine Sciences and Emeritus Professor of Biological Sciences Stanford University Biological Sciences Hopkins Marine Station Pacific Grove, California 93950 408-373-0302 408-375-0793 (fax) depel@stanford.edu

Colin Masters, M.D. Professor and Chair Department of Pathology University of Melbourne Parkville, Victoria 3052 Australia 011-61-3-344-5867 011-61-3-344-4004 (fax)

Jerold S. Goldberg, M.D. (Previous Interim Provost and Interim Dean of Medicine, Case Western Reserve University) Professor and Dean School of Dental Medicine, Dean‘s Office Case Western Reserve University 10900 Euclid Avenue Cleveland, Ohio 44106

George Perry

63

c.masters@pathology.unimelb.edu.au 216-368-3266 jerold.goldberg@case.edu

John Frederick, Ph.D. Provost and Vice President of Academic Affairs University of Texas at San Antonio One UTSA Circle San Antonio, Texas, 78249 210-458-4110 john.frederick@utsa.edu

Publications: http://www.researcherid.com/rid/A-8611-2009 http://highlycited.com/categories/neuroscience/ ISI citations = 45,788 H-Factor = 107 Publications = 1057 http://scholar.google.com/citations?user=ySklo5EAAAAJ&hl=en Google citations = 70,852 H-Factor = 132 Publications = 1309 http://www.researchgate.net/profile/George_Perry/ Citations = 57,673 H Factor = 120 Publications = 1171 https://utsa.influuent.utsystem.edu/en/persons/george-perry Citations = 49,485 H Factor = 110 Publications = 772 Thesis: Perry G. Studies on calcium-stimulated oxidations in the sea urchin egg, Ph.D. Thesis. University of California, San Diego, pp 124, 1979.(9)

Books and Editorships:

1. Perry G, Ed. Advances in Behavioral Biology 34: Alterations in the Neuronal Cytoskeleton in Alzheimer Disease. Plenum Press, New York, pp 229, 1987.(13)

2. Perry G, Ed. Alzheimer's disease. Clin Neurosci 1(4):163-224, 1993.

3. Perry G, Smith MA, Eds. Alzheimer disease. Part of: Frontiers in Bioscience 7, 2002 http://www.bioscience.org/current/special/perry.htm.

4. Smith MA, Perry G, Pryor WA, Eds. Causes and consequences of oxidative stress in Alzheimer‘s disease. Free Radic Biol Med 32(11):1049-1083, 2002; 32(12):1264-1282, 2002; 33(1):45-51, 2002; 33(2):173-191; 33(5):620-626; and 33(9):1194-1199, 2002.

5. Smith MA, Zhu X, Perry G, Eds. Signal transduction in Alzheimer‘s disease. Neurosignals 11(5):235-298, 2002.

6. Smith MA, Perry G, Zhu X, Eds. Alzheimer‘s disease. Acta Neurobiol Exp 64(1):1-118, 2004.

7. Smith MA, Moreira PI, Castellani RJ, Perry G, Eds. Amyloid-β: A multifaceted protein, Parts I and II. Brain Pathol 14(4):425-452, 2004 and 15(1):66-87, 2005.

8. Smith MA, Perry G, Eds. Role of amyloid-β in Alzheimer disease. Int J Exp Pathol 86(3):131-185, 2005.

9. Perry G, Smith MA, Eds. Imaging in Alzheimer disease. Microsc Res Tech 67(3-4):113-217, 2005.

10. Perry G, Avila J, Kinoshita J, Smith MA, Eds. Alzheimer‘s Disease: A Century of Scientific and Clinical Research. IOS Press, Amsterdam, pp. 456, 2006, and J Alzheimer‘s Dis 9(Suppl):1-456, 2006.

11. Smith MA, Rao KSJ, Perry G, Eds. Apoptotic mechanism in neurodegenerative diseases. Curr Alzheimer Res 3(4):267-408, 2006.

George Perry

64

12. Smith MA, Perry G, Zhu X, Haoudi A, Eds. Neurodegenerative diseases: mechanisms and therapies [18 articles]. J Biomed Biotechnol, 2006 http://www.hindawi.com/journals/jbb/volume-2006/si.2.html

13. Zhu X, Perry, G, Smith MA, Eds. Forum Reviews: Neurodegeneration. Antioxidants and Redox Signaling 9(10):1591-1690, 2007.

14. Chauhan A, Ed., Chauhan V, Perry G, Associate Eds. Autism spectrum disorders American J Biochem Biotech, 4(2):61-225, 2008 http://www.scipub.org/scipub/detail_issue.php?V_No=173&j_id=ajbb

15. Avila J, Perry G, Smith MA, Eds. Is tau aggregation toxic or protective? J Alzheimer‘s Dis 14(4):363-457, 2008.

16. Maccioni R, Perry G, Eds. Current Hypotheses and Research Milestones in Alzheimer‘s Disease. Springer Press, pp. 247, 2009.

17. Zhu X, Beal MF, Wang X, Perry G, Smith MA, Eds. Mitochondria and Neurodegenerative Diseases. J Alzheimer‘s Dis 20(suppl 2): S253-S643, 2010.

18. Casadesus G, Ed.; Perry G, Smith MA, Series Eds. Advances in Alzheimer‘s Disease 1: Handbook of Animal Models in Alzheimer‘s Disease. IOS Press, Amsterdam, pp. 340, 2011.

19. Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M, Eds.; Perry G, Smith MA, Series Eds. Advances in Alzheimer‘s Disease 2: Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam, pp. 808, 2011.

20. Britton G, Smith MA, Perry G, Sambamurti K, Jagannatha Rao KS, Eds. Drug Discovery for Neurodegenerative Diseases: Challenges and Novel Biochemical Targets. J Alzheimer‘s Dis 24(Suppl 2): pp.1-232, 2011.

21. Perry G, Castellani RJ, Zhu X, Eds. Alzheimer‘s disease. Therapy 8(5):457-504, 2011. 22. Miklossy J, Donta S, Mueller K, Nolte O, Perry G, Eds. Chronic or Late Lyme Neuroborreliosis: Present

and Future. Open J Neurol 6(Suppl 1): 78-178, 2012. 23. Morelli L, Perry G, Tagliavini F, Eds. The Contribution of the Amyloid Hypothesis to the Understanding of

Alzheimer‘s Disease: A Critical Overview. International J Alzheimer‘s Dis 2012: pp. 56, 2012, http://www.hindawi.com/journals/ijad/si/975419/

24. Lee H-g, Perry G, Zhu X, Eds. Mark Smith: Pioneer of Alzheimer Disease Research. Neurotox Res 22(3): 181-248, 2012.

25. Castellani RJ, Perry G; Perry G, Castellani, Series Eds. Molecular Pathology of Alzheimer disease. Morgan & Claypool Life Sciences, San Rafael, California, pp 83, 2013.

26. Perry G, Zhu X, Smith MA, Sorensen A, Avila J, Eds.; Perry G, Smith MA, Series Eds. Advances in Alzheimer‘s Disease 3: Alzheimer‘s Disease: Advances for a New Century. IOS Press, Amsterdam, pp. 474. J Alzheimer‘s Dis 33(Suppl1):S1-S469, 2013.

27. Castellani R, Perry G, Eds. Alzheimer‘s Disease – Amyloid, Tau and Beyond Biochemical Pharmacology 88(4):423-682, 2014.

28. Atta-ur-Rahman, Choudhary MI, Perry G. Recent Advances in Medicinal Chemistry, Volume 1. Bentham Science Publisher, Sharjah, United Arab Emirates, pp. 469, 2014.

29. Perry G, Ed. Marine Compounds and Their Application in Neurological Disorders, Marine Drugs 13(9):5750-5766, 2015; 13(10):6117-6137, 6407-6424, 2015; 13(11):6636-6664, 6665-6686, 2015; 14(1):5, 2016; 14(3):55, 2016; 14(5):102, 2016, 2015.

30. Smith G, Ed. Perry G, Ashford JW, Series Eds. Advances in Alzheimer‘s Disease 4: Handbook of Depression in Alzheimer‘s Disease. IOS Press, Amsterdam, pp. 381, 2015.

31. Miklossy J, Perry G, Ashford JW, Series Eds. Advances in Alzheimer‘s Disease 5: Handbook of Infection and Alzheimer‘s Disease. IOS Press, Amsterdam, pp. 426, 2017.

32. Atta-ur-Rahman, Choudhary MI, Perry G. Recent Advances in Medicinal Chemistry, Volume2. Bentham Science Publisher, Sharjah, United Arab Emirates (in preparation).

33. Perry G, et al. Mark A. Smith: A Life Remembered. IOS Press (in preparation). 34. Perry G, Ed. Alzheimer Disease. Scholarpedia (in preparation). 35. Castellani, RJ, Perry G. Chronic Effects of Mild Trauma (in preparation). 36. Perry G, Carper J. Prevent Alzheimer‘s NOW! Everything You need to Know and Do (in preparation) 37. Atta-ur-Rahman, Perry G. Frontiers in Clinical Drug Research – Alzheimer Disorders Vol. 6 (in

preparation). 38. Rao, KSJ, Perry G, ZHU YZ, Hegde M, von Zglinicki T, Perez-Pinzon M, Eds. Molecular Pathways in

Aging and Neurodegeneration: Mechanisms and Therapeutics. J Alzheimer‘s Dis (in preparation) 39. Perry G, Ashford W, Series Ed. Cognitive-mobility interactions in Alzheimer‘s disease and cognitively

impaired populations. J Alzheimer‘s Dis (in preparation) 40. Perry G, Farías G, López O, Eds. Biomarkers of Neurodegenerative Diseases. BioMed Research

International (in preparation).

George Perry

65

41. Sena C, Seiça R, Perry G. Oxidative stress revisited—major role in non-communicable diseases. In: Frontiers in Physiology (in preparation)

Patents: 1. Perry G, Smith MA, Ghanbari H. (20020016284) Olfactory neuron cultures and methods of making and

using the same. Filed U.S. Patent Office, 9 July 2001.

2. Perry G, Smith MA, Ghanbari H. (60/217,087US) Oxidative stress model and method of using thereof. Filed U.S. Patent Office, 10 July 2001.

3. Friedland RP, Perry G, Shi J. (20030175278) Amyloid deposit imaging. Filed U.S. Patent Office, October 2000.

4. Monteiro MJ, Man AL, Perry G, Smith MA. Ubiquilin, a presenilin interactor and methods of using same. Filed U.S. Patent Office, 3 November 2002.

Peer Reviewed Journal Articles:

1. Byrd W, Perry G. Cytochalasin B blocks sperm incorporation but allows activation of the sea urchin egg. Exp Cell Res 126:333-342, 1980.(28)

2. Perry G, Epel D. Ca2+

-stimulated production of H2O2 from naphthoquinone oxidation in Arbacia eggs. Exp Cell Res 134:65-72, 1981.(15)

3. Pardue RL, Brady RC, Perry GW [sic], Dedman JR. Production of monoclonal antibodies against calmodulin by in vitro immunization of spleen cells. J Cell Biol 96:1149-1154, 1983. (75)

4. Gambetti P, Autilio-Gambetti L, Perry G, Shecket G, Crane RC. Antibodies to neurofibrillary tangles of Alzheimer's disease raised from human and animal neurofilament fractions. Lab Invest 49:430-435, 1983.(50)

5. Anderson DC, Hughes BJ, Wible LJ, Perry GJ [sic], Smith CW, Brinkley BR. Impaired motility of neonatal PMN leukocytes: relationship to abnormalities of cell orientation and assembly of microtubules in chemotactic gradients. J Leukoc Biol 36:1-15, 1984.(50)

6. Perry G, Epel D. Characterization of a Ca2+

-stimulated lipid peroxidizing system in the sea urchin egg. Dev Biol 107:47-57, 1985.(31)

7. Perry G, Epel D. Fertilization stimulates lipid peroxidation in the sea urchin egg. Dev Biol 107:58-65, 1985.(34)

8. Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc Natl Acad Sci USA 82:3916-3920, 1985.(215)

9. Perry G, Selkoe DJ, Block BR, Stewart D, Autilio-Gambetti L, Gambetti P. Electron microscopic localization of Alzheimer neurofibrillary tangle components recognized by an antiserum to paired helical filaments. J Neuropathol Exp Neurol 45:161-168, 1986.(28)

10. Perry G, Wible L, Brinkley BR. Microtubules are not altered in the dystrophic chicken. Exp Cell Res 163:266-272, 1986.(3)

11. Kasper M, Goertchen R, Stosiek P, Perry G, Karsten U. Coexistence of cytokeratin, vimentin and neurofilament protein in human choroid plexus: an immunohistochemical study of intermediate filaments in neuroepithelial tissues. Virchows Archiv A 410:173-177, 1986.(45)

12. Galloway PG, Perry G, Kosik KS, Gambetti P. Hirano bodies contain tau protein. Brain Res 403:337-340, 1987.(66)

13. Galloway PG, Perry G, Gambetti P. Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol 46:185-199, 1987.(88)

14. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 84:3033-3036, 1987.(483)

15. Perry G, Stewart D, Friedman R, Manetto V, Autilio-Gambetti L, Gambetti P. Filaments of Pick's bodies contain altered cytoskeletal elements. Am J Pathol 127:559-568, 1987.(65)

16. Perry G, Friedman R, Kang DH, Manetto V, Autilio-Gambetti L, Gambetti P. Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. Brain Res 420:233-242, 1987.(25)

17. Perry G, Mulvihill P, Manetto V, Autilio-Gambetti L, Gambetti P. Immunocytochemical properties of Alzheimer straight filaments. J Neurosci 7:3736-3738, 1987.(62)

George Perry

66

18. Matsumoto Y, Perry G, Scheibel LW, Aikawa M. Role of calmodulin in Plasmodium falciparum: Implications for erythrocyte invasion by the merozoite. Eur J Cell Biol 45:36-43, 1987.(65)

19. Atkinson CT, Aikawa M, Perry G, Fujino T, Bennett V, Davidson EA, Howard RJ. Ultrastructural localization of erythrocyte cytoskeletal and integral membrane proteins in Plasmodium falciparum-infected erythrocytes. Eur J Cell Biol 45:192-199, 1988.(25)

20. Matsumoto Y, Perry G, Levine RJC, Blanton R, Mahmoud AAF, Aikawa M. Paramyosin and actin in schistosomal teguments. Nature 333:76-78, 1988.(125)

21. Tabaton M, Perry G, Autilio-Gambetti L, Manetto V, Gambetti P. Influence of neuronal location on antigenic properties of neurofibrillary tangles. Ann Neurol 23:604-610, 1988.(41)

22. Manetto V, Perry G, Tabaton M, Mulvihill P, Fried VA, Smith HT, Gambetti P, Autilio-Gambetti L. Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci USA 85:4501-4505, 1988.(205)

23. Perry G, Lambert C. Arachidonic acid metabolism in Ascidia ceratodes eggs: Role of lipid peroxidation. Comp Biochem Physiol 90B:785-789, 1988.(4)

24. Tabaton M, Whitehouse PJ, Perry G, Davies P, Autilio-Gambetti L, Gambetti P. Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Ann Neurol 24:407-413, 1988.(71)

25. Perry G, Lipphardt S, Mulvihill P, Kancherla M, Mijares M, Gambetti P, Sharma S, Maggiora L, Cornette J, Lobl T, Greenberg B. Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet ii 746, 1988.(77)

26. Manetto V, Sternberger NH, Perry G, Sternberger LA, Gambetti P. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 47:642-653, 1988.(168)

27. Galloway PG, Grundke-Iqbal I, Iqbal K, Perry G. Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles. J Neuropathol Exp Neurol 47:654-663, 1988.(99)

28. Ohta M, Marceau N, Perry G, Manetto V, Gambetti P, Autilio-Gambetti L, Metuzals J, Kawahara H, Cadrin M, French SW. Ubiquitin is present on the cytokeratin intermediate filaments and Mallory bodies of hepatocytes. Lab Invest 59:848-856, 1988.(101)

29. Autilio-Gambetti L, Morandi A, Tabaton M, Schaetzle B, Kovacs D, Perry G, Greenberg B, Gambetti P. The amyloid precursor protein of Alzheimer disease is expressed as a 130 kDa polypeptide in various cultured cell types. FEBS Lett 241:94-98, 1988.(36)

30. Kalaria RN, Gravina SA, Schmidley JW, Perry G, Harik SI. The glucose transporter of the human brain and blood-brain barrier. Ann Neurol 24:757-764, 1988.(131)

31. Manetto V, Abdul-Karim FW, Perry G, Tabaton M, Autilio-Gambetti L, Gambetti P. Selective presence of ubiquitin in intracellular inclusions. Am J Pathol 134:505-513, 1989.(90)

32. Lew EO, Rozdilsky B, Munoz DG, Perry G. A new type of neuronal cytoplasmic inclusion: Histological, ultrastructural, and immunocytochemical studies. Acta Neuropathol 77:599-604, 1989.(3)

33. Mulvihill P, Perry G. Immunoaffinity demonstration that paired helical filaments of Alzheimer disease share epitopes with neurofilaments, MAP2 and tau. Brain Res 484:150-156, 1989.(29)

34. Perry G, Mulvihill P, Fried VA, Smith HT, Grundke-Iqbal I, Iqbal K. Immunochemical properties of ubiquitin conjugates in the paired helical filaments of Alzheimer disease. J Neurochem 52:1523-1528, 1989.(61)

35. Galloway PG, Bergeron C, Perry G. The presence of tau distinguishes Lewy bodies of diffuse Lewy body disease from those of idiopathic Parkinson disease. Neurosci Lett 100:6-10, 1989.(47)

36. Tabaton M, Cammarata S, Manetto V, Perry G, Mancardi G. Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neurosci Lett 103:259-262, 1989.(9)

37. Palmert MR, Siedlak SL, Podlisny MB, Greenberg B, Shelton ER, Chan HW, Usiak M, Selkoe DJ, Perry G, Younkin SG. Soluble derivatives of the β amyloid protein precursor of Alzheimer's disease are labeled by antisera to the β amyloid protein. Biochem Biophys Res Commun 165:182-188, 1989.(83)

38. Tabaton M, Mandybur TI, Perry G, Onorato M, Autilio-Gambetti L, Gambetti P. The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Ann Neurol 26:771-778, 1989.(82)

39. Galloway PG, Likavec MJ, Perry G. Tropomyosin isoform expression in normal and neoplastic astrocytes. Lab Invest 62:163-170, 1990.(15)

40. Kawahara H, Cadrin M, Perry G, Autilio-Gambetti L, Swierenga SHH, Metuzals J, Marceau N, French SW. Role of cytokeratin intermediate filaments in transhepatic transport and canalicular secretion. Hepatology 11:435-448, 1990.(35)

George Perry

67

41. Kasper M, Terpe HJ, Perry G. Age-dependent pattern of intermediate filament protein expression in the human pineal gland. J Hirnforsch 31:215-221, 1990.(10)

42. Galloway PG, Likavec MJ, Perry G. Immunohistochemical recognition of ethylnitrosourea induced rat brain microtumors by anti-Leu 7 monoclonal antibody. Cancer Lett 49:243-248, 1990.(4)

43. Harik SI, Kalaria RN, Whitney PM, Andersson L, Lundahl P, Ledbetter SR, Perry G. Glucose transporters are abundant in cells with "occluding" junctions at the blood-eye barriers. Proc Natl Acad Sci USA 87:4261-4264, 1990.(105)

44. Cras P, Kawai M, Siedlak S, Mulvihill P, Gambetti P, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Neuronal and microglial involvement in β-amyloid protein deposition in Alzheimer's disease. Am J Pathol 137:241-246, 1990.(164)

45. Galloway PG, Mulvihill P, Siedlak S, Mijares M, Kawai M, Padget H, Kim R, Perry G. Immunochemical demonstration of tropomyosin in the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 137:291-300, 1990.(21)

46. Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 137:1435-1446, 1990.(119)

47. Harik SI, Kalaria RN, Andersson L, Lundahl P, Perry G. Immunocytochemical localization of the erythroid glucose transporter: Abundance in tissues with barrier functions. J Neurosci 10:3862-3872, 1990.(162)

48. Murphy GM, Eng LF, Ellis WG, Perry G, Meissner LC, Tinklenberg JR. Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's Syndrome: a comparison with Alzheimer's disease. Brain Res 537:102-108, 1990.(41)

49. Kasper M, Perry G, Stosiek P. Cytokeratin expression in human spinal meninges and ependymal cells. J Hirnforsch 32:19-25, 1991.(17)

50. Galloway PG, Perry G. Tropomyosin distinguishes Lewy bodies of Parkinson disease from other neurofibrillary pathology. Brain Res 541:347-349, 1991.(23)

51. 51. Tabaton M, Cammarata S, Mancardi GL, Cordone G, Perry G, Loeb C. Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer's disease. Neurology 41:391-394, 1991.(41)

52. Tabaton M, Cammarata S, Mancardi G, Manetto V, Autilio-Gambetti L, Perry G, Gambetti P. Ultrastructural

localization of β-amyloid, and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci USA 88:2098-2102, 1991.(82)

53. Kalaria RN, Galloway PG, Perry G. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol Appl Neurobiol 17:189-201, 1991.(77)

54. Perry G, Kawai M, Tabaton M, Onorato M, Mulvihill P, Richey P, Morandi A, Connolly JA, Gambetti P. Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. J Neurosci 11:1748-1755, 1991.(117)

55. Siedlak SL, Cras P, Kawai M, Richey P, Perry G. Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. J Histochem Cytochem 39:899-904, 1991.(52)

56. Gheuens J, Cras P, Perry G, Boons J, Ceuterick-de Groote C, Lubke U, Mercken M, Tabaton M, Gambetti P, Vandermeeren M, Mulvihill P, Siedlak S, Van Heuverswijn H, Martin J-J. Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases. Brain Res 558:43-52, 1991.(14)

57. Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci USA 88:7552-7556, 1991.(157)

58. Cras P, Kawai M, Siedlak S, Perry G. Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease. Brain Res 558:312-314, 1991.(61)

59. Vande Weghe J, Cras P, Kawai M, Siedlak SL, Tabaton M, Greenberg B, Perry G. Dystrophic neurites infiltrate extracellular neurofibrillary tangles in Alzheimer disease. Brain Res 560:303-305, 1991.(11)

60. Perry G, Siedlak SL, Richey P, Kawai M, Cras P, Kalaria RN, Galloway PG, Miriam Scardina J, Cordell B, Greenberg BD, Ledbetter SR, Gambetti P. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. J Neurosci 11:3679-3683, 1991.(114)

61. Perry G, Cras P, Siedlak SL, Tabaton M, Kawai M. β protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol 140:283-290, 1992.(71)

George Perry

68

62. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. 1-Antitrypsin and 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3:201-203, 1992.(62)

63. Candy JM, McArthur FK, Oakley AE, Taylor GA, Chen CPL-H, Mountfort SA, Thompson JE, Chalker PR, Bishop HE, Beyreuther K, Perry G, Ward MK, Martyn CN, Edwardson JA. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci 107:210-218, 1992.(64)

64. Hirose S, Mohney RP, Mutka SC, Ravi L, Singleton DR, Perry G, Tartakoff AM, Medof ME. Derivation and characterization of glycoinositol-phospholipid anchor-defective human K562 cell clones. J Biol Chem 267:5272-5278, 1992.(64)

65. Aikawa M, Brown A, Smith CD, Tegoshi T, Howard RJ, Hasler TH, Ito Y, Perry G, Collins WE, Webster K. A primate model for human cerebral malaria: Plasmodium coatneyi-infected rhesus monkeys. Am J Trop Med Hyg 46:391-397, 1992.(63)

66. Kawai M, Cras P, Richey P, Tabaton M, Lowery DE, Gonzalez-DeWhitt PA, Greenberg BD, Gambetti P, Perry G. Subcellular localization of amyloid precursor protein in senile plaques of Alzheimer's disease. Am J Pathol 140:947-958, 1992.(37)

67. Galloway PG, Mulvihill P, Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 140:809-822, 1992.(83)

68. Perry G, Richey P, Siedlak SL, Galloway P, Kawai M, Cras P. Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res 579:350-352, 1992.(25)

69. Kawai M, Cras P, Perry G. Serial reconstruction of β-protein amyloid plaques: relationship to microvessels and size distribution. Brain Res 592:278-282, 1992.(33)

70. Tabaton M, Cammarata S, Mandybur T, Richey P, Kawai M, Perry G, Gambetti P. Senile plaques in cerebral amyloid angiopathy show accumulation of amyloid precursor protein without cytoskeletal abnormalities. Brain Res 593: 299-303, 1992.(12)

71. Kalaria RN, Kroon SN, Grahovac I, Perry G. Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease. Neuroscience 51:177-184, 1992.(36)

72. Kalaria RN, Bhatti SU, Palatinsky EA, Pennington DH, Shelton ER, Chan HW, Perry G, Lust WD. Accumulation of the β amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 4:211-214, 1993.(128)

73. Villanova M, Kawai M, Lübke U, Oh SJ, Perry G, Six J, Ceuterick C, Martin J-J, Cras P. Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. Brain Res 603:343-347, 1993.(35)

74. Cissé S, Perry G, Lacoste-Royal G, Cabana T, Gauvreau D. Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol 85:233-240, 1993.(48)

75. Harik SI, Hall AK, Richey P, Andersson L, Lundahl P, Perry G. Ontogeny of the erythroid/HepG2-type glucose transporter (GLUT-1) in the rat nervous system. Dev Brain Res 72:41-49, 1993.(31)

76. Perry G. Neuritic plaques in Alzheimer disease originate from neurofibrillary tangles. Med Hypotheses 40:257-258, 1993.(25)

77. DeWitt DA, Silver J, Canning DR, Perry G. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 121:149-152, 1993.(119)

78. Smith MA, Kalaria RN, Perry G. 1-Trypsin immunoreactivity in Alzheimer disease. Biochem Biophys Res Commun 193:579-584, 1993.(23)

79. Sisodia SS, Koo EH, Hoffman PN, Perry G, Price DL. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J Neurosci 13:3136-3142, 1993.(206)

80. Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am J Pathol 143:886-893, 1993.(40)

81. Kawai M, Kalaria RN, Cras P, Siedlak SL, Velasco ME, Shelton ER, Chan HW, Greenberg BD, Perry G. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res 623:142-146, 1993.(138)

82. Shimohama S, Perry G, Richey P, Takenawa T, Whitehouse PJ, Miyoshi K, Suenaga T, Matsumoto S,

Nishimura M, Kimura J. Abnormal accumulation of phospholipase C- in filamentous inclusions of human neurodegenerative diseases. Neurosci Lett 162:183-186, 1993.(21)

George Perry

69

83. Canning DR, McKeon RJ, DeWitt DA, Perry G, Wujek JR, Frederickson RCA, Silver J. β-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp Neurol 124:289-298, 1993.(125)

84. Perry G, Richey PL, Siedlak SL, Smith MA, Mulvihill P, DeWitt DA, Barnett J, Greenberg BD, Kalaria RN. Immunocytochemical evidence that the β-protein precursor is an integral component of neurofibrillary tangles of Alzheimer's disease. Am J Pathol 143:1586-1593, 1993.(37)

85. Holash JA, Harik SI, Perry G, Stewart PA. Barrier properties of testis microvessels. Proc Natl Acad Sci USA 90:11069-11073, 1993.(104)

86. Kalaria RN, Perry G. Amyloid P component and other acute-phase proteins associated with cerebellar A-deposits in Alzheimer's disease. Brain Res 631:151-155, 1993.(34)

87. Smith MA, Perry G. Alzheimer disease: an imbalance of proteolytic regulation? Med Hypotheses 42:277-279, 1994.(23)

88. Smith MA, Taneda S, Richey PL, Miyata S, Yan S-D, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91:5710-5714, 1994. Erratum in: Proc Natl Acad Sci USA 92:2016, 1995.(589)

89. Smith MA, Kutty RK, Richey PL, Yan S-D, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer‘s disease. Am J Pathol 145:42-47, 1994.(327)

90. Yan S-D, Chen X, Schmidt A-M, Brett J, Godman G, Zou Y-S, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen S-H, Stern D. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91:7787-7791, 1994.(447)

91. DeWitt DA, Richey PL, Praprotnik D, Silver J, Perry G. Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases. Brain Res 656:205-209, 1994.(38)

92. Shimohama S, Perry G, Richey P, Praprotnik D, Takenawa T, Fukami K, Whitehouse PJ, Kimura J.

Characterization of the association of phospholipase C- with Alzheimer neurofibrillary tangles. Brain Res 669:217-224, 1995.(19)

93. Richey PL, Siedlak SL, Smith MA, Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem Biophys Res Commun 208:657-663, 1995.(41)

94. Smith MA, Siedlak SL, Richey PL, Mulvihill P, Ghiso J, Frangione B, Tagliavini F, Giaccone G, Bugiani O, Praprotnik D, Kalaria RN, Perry G. Tau protein directly interacts with the amyloid β-protein precursor: implications for Alzheimer‘s disease. Nat Med 1:365-369, 1995.(41)

95. Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 89:291-295, 1995.(110)

96. Shimohama S, Fujimoto S, Matsushima H, Takenawa T, Taniguchi T, Perry G, Whitehouse PJ, Kimura J.

Alteration of phospholipase C- protein level and specific activity in Alzheimer‘s disease. J Neurochem 64:2629-2634, 1995.(27)

97. Smith MA, Rudnicka-Nawrot M, Richey PL, Praprotnik D, Mulvihill P, Miller CA, Sayre LM, Perry G. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer‘s disease. J Neurochem 64:2660-2666, 1995.(120)

98. Rifenburg RP, Perry G. Dystrophic neurites define diffuse as well as core-containing senile plaques in Alzheimer‘s disease. Neurodegeneration 4:235-237, 1995.(9)

99. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier JL, Stern D. Non-enzymatically glycated tau in Alzheimer‘s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat Med 1:693-699, 1995.(210)

100. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer‘s disease. J Neurochem 65:1399-1402, 1995.(153)

101. Tabaton M, Rolleri M, Masturzo P, Cammarata S, Angelini G, Hansen LA, Saitoh T, Petersen RB, Perry G,

Richey P, Gambetti P, Bertolini S. Apolipoprotein E 4 allele frequency is not increased in progressive supranuclear palsy. Neurology 45:1764-1765, 1995.(36)

George Perry

70

102. Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P, Perry G. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 696:268-271, 1995.(48)

103. Kindy MS, King AR, Perry G, deBeer MC, deBeer FC. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab Invest 73:469-475, 1995.(34)

104. Shimohama S, Fujimoto S, Chachin M, Taniguchi T, Perry G, Whitehouse PJ, Kimura J. Alterations of low molecular weight acid phosphatase protein level in Alzheimer‘s disease. Brain Res 699:125-129, 1995.(11)

105. Giaccone G, Pedrotti B, Migheli A, Verga L, Perez J, Racagni G, Smith MA, Perry G, De Gioia L, Selvaggini C, Salmona M, Ghiso J, Frangione B, Islam K, Bugiani O, Tagliavini F. βPP and tau interaction: a possible link between amyloid and neurofibrillary tangles in Alzheimer‘s disease. Am J Pathol 148:79-87, 1996.(31)

106. Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G. Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer‘s disease: an index of oxidative stress. Acta Neuropathol 91:1-5, 1996.(48)

107. Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer‘s disease. Acta Neuropathol 91:226-235, 1996.(75)

108. Smith MA, Dunbar CE, Miller EJ, Perry G. Trypsin interaction with the senile plaques of Alzheimer disease is mediated by β-protein precursor. Mol Chem Neuropathol 27:145-154, 1996.(6)

109. Smith MA, Siedlak SL, Richey PL, Nagaraj RH, Elhammer A, Perry G. Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res 717:99-108, 1996.(50)

110. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer‘s. Nature 382:120-121, 1996.(690)

111. Xiao J, Perry G, Troncoso J, Monteiro MJ. -Calcium-calmodulin-dependent kinase II is associated with paired helical filaments of Alzheimer‘s disease. J Neuropathol Exp Neurol 55:954-963, 1996.(27)

112. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737:195-200, 1996.(196)

113. Tabaton M, Perry G, Smith M, Vitek M, Angelini G, Dapino D, Garibaldi S, Zaccheo D, Odetti P. Is amyloid β-protein glycated in Alzheimer‘s disease? Neuroreport 8:907-909, 1997.(12)

114. Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer‘s disease. J Neurosci 17:2653-2657, 1997.(912)

115. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer‘s disease. J Neurochem 68:2092-2097, 1997.(728)

116. Salomon RG, Subbanagounder G, O‘Neil J, Kaur K, Smith MA, Hoff HF, Perry G, Monnier VM. Levuglandin E2-protein adducts in human plasma and vasculature. Chem Res Toxicol 10:536-545, 1997.(45)

117. Smith MA, Nagaraj RH, Perry G. Protocol for quantitative analysis of paired helical filament solubilization: a method applicable to insoluble amyloids and inclusion bodies. Brain Res Protocols 1:247-252, 1997.(4)

118. Castellani RJ, Perry G, Harris PLR, Monnier VM, Cohen ML, Smith MA. Advanced glycation modification of Rosenthal fibers in patients with Alexander disease. Neurosci Lett 231:79-82, 1997.(18)

119. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866-9868, 1997.(744)

120. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer‘s disease. Brain Res 780:260-269, 1998.(174)

121. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, Piombo G, Perry G, Smith M, Traverso N, Tabaton M. Early glycoxidation damage in brains from Down‘s syndrome. Biochem Biophys Res Commun 243:849-851, 1998.(89)

122. DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer‘s disease. Exp Neurol 149:329-340, 1998.(142)

123. Castellani RJ, Perry G, Harris PLR, Cohen ML, Sayre LM, Salomon RG, Smith MA. Advanced lipid peroxidation end-products in Alexander‘s disease. Brain Res 787:15-18, 1998.(19)

124. Smith MA, Wehr K, Harris PLR, Siedlak SL, Connor JR, Perry G. Abnormal localization of iron regulatory protein in Alzheimer‘s disease. Brain Res 788:232-236, 1998.(128)

George Perry

71

125. Pappolla MA, Chyan Y-J, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer‘s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871-877, 1998.(192)

126. Perry G, Smith MA, McCann CE, Siedlak SL, Jones PK, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer‘s disease. Brain Res 791:63-66, 1998.(47)

127. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlak SL, Tabaton M, Perry G. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70:2212-2215, 1998.(400)

128. Smith MA, Sayre LM, Anderson VE, Harris PLR, Beal MF, Kowall N, Perry G. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 46:731-735, 1998.(173)

129. Hattori N, Kitagawa K, Higashida T, Yagyu K, Shimohama S, Wataya T, Perry G, Smith MA, Inagaki C. Cl- -

ATPase and Na+/K

+-ATPase activities in Alzheimer‘s disease brains. Neurosci Lett 254:141-144, 1998.(72)

130. Guevara J, Espinosa B, Zenteno E, Vázquez L, Luna J, Perry G, Mena R. Altered glycosylation pattern of proteins in Alzheimer disease. J Neuropathol Exp Neurol 57:905-914, 1998.(19)

131. Smith MA, Vašák M, Knipp M, Castellani RJ, Perry G. Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic Biol Med 25:898-902, 1998.(36)

132. Velasco ME, Smith MA, Siedlak SL, Nunomura A, Perry G. Striation is the characteristic neuritic abnormality in Alzheimer disease. Brain Res 813:329-333, 1998.(17)

133. Chen X, Eswaran D, Smith MA, Perry G, Anderson VE. Universal isolation of cross-linked peptides: application to neurofibrillary tangles. Bioconjug Chem 10:112-118, 1999.(5)

134. Morgan TE, Xie Z, Goldsmith S, Yoshida T, Lanzrein A-S, Stone D, Rozovsky I, Perry G, Smith MA, Finch CE. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 89:687-699, 1999.(114)

135. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer‘s disease. J Neurosci 19:1959-1964, 1999.(469)

136. Raina AK, Templeton DJ, Deak JC, Perry G, Smith MA. Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer‘s disease. Redox Rep 4:23-27, 1999.(50)

137. Raina AK, Takeda A, Nunomura A, Perry G, Smith MA. Genetic evidence for oxidative stress in Alzheimer‘s disease. Neuroreport 10:1355-1357, 1999.(8)

138. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ. Parkinson‘s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154:1423-1429, 1999.(328)

139. Castellani RJ, Smith MA, Nunomura A, Harris PLR, Perry G. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 26:1508-1512, 1999.(61)

140. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PLR, Smith MA. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10:2411-2415, 1999.(197)

141. Aliev G, Ragazzi E, Smith MA, Mironov A, Perry G. Morphological features of regeneration of rabbit aortic endothelium after cryoinduced vascular damage. J Submicrosc Cytol Pathol 31:495-502, 1999.(3)

142. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 370:236-239, 1999.(74)

143. Shi J, Perry G, Aliev G, Smith MA, Ashe KH, Friedland RP. Serum amyloid P is not present in amyloid β deposits of a transgenic animal model. Neuroreport 10:3229-3232, 1999.(18)

144. Capellari S, Zaidi SIA, Urig CB, Perry G, Smith MA, Petersen RB. Prion protein glycosylation is sensitive to redox change. J Biol Chem 274:34846-34850, 1999.(49)

145. Sayre LM, Perry G, Harris PLR, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer‘s disease: a central role for bound transition metals. J Neurochem 74:270-279, 2000.(189)

146. Takeda A, Perry G, Abraham NG, Dwyer BE, Kutty RK, Laitinen JT, Petersen RB, Smith MA. Overexpression of heme oxygenase in neuronal cells, the possible interaction with tau. J Biol Chem 275:5395-5399, 2000.(130)

George Perry

72

147. Castellani RJ, Harris PLR, Lecroisey A, Izadi-Pruneyre N, Wandersman C, Perry G, Smith MA. Evidence for a novel heme-binding protein, HasAh, in Alzheimer disease. Antioxid Redox Signal 2:137-142, 2000.(20)

148. Odetti P, Garibaldi S, Norese R, Angelini G, Marinelli L, Valentini S, Menini S, Traverso N, Zaccheo D, Siedlak S, Perry G, Smith MA, Tabaton M. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 59:393-397, 2000.(57)

149. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S. Activation of NADPH oxidase in Alzheimer‘s disease brains. Biochem Biophys Res Commun 273:5-9, 2000.(158)

150. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI. Evidence that the β-amyloid plaques of Alzheimer‘s disease represent the redox-silencing and entombment of Aβ by zinc. J Biol Chem 275:19439-19442, 2000.(271)

151. Castellani RJ, Siedlak SL, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson‘s disease. Acta Neuropathol 100:111-114, 2000.(114)

152. Takeda A, Smith MA, Avilá J, Nunomura A, Siedlak SL, Zhu X, Perry G, Sayre LM. In Alzheimer‘s disease,

heme oxygenase is coincident with Alz50, an epitope of induced by 4-hydroxy-2-nonenal modification. J Neurochem 75:1234-1241, 2000.(114)

153. Aliev G, Shi J, Perry G, Friedland RP, LaManna JC. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. Anat Rec 260:16-25, 2000.(14)

154. Kim HT, Russell RL, Raina AK, Harris PLR, Siedlak SL, Zhu X, Petersen RB, Shimohama S, Smith MA, Perry G. Protein disulfide isomerase in Alzheimer disease. Antioxid Redox Signal 2:485-489, 2000.(11)

155. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59:880-888, 2000.(208)

156. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J Neuropathol Exp Neurol 59:1011-1017, 2000.(218)

157. Mah AL, Perry G, Smith MA, Monteiro MJ. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. J Cell Biol 151:847-862, 2000.(135)

158. Pérez M, Cuadros R, Smith MA, Perry G, Avila J. Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett 486:270-274, 2000.(83)

159. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer‘s disease. J Neurochem 76:435-441, 2001.(251)

160. Wong B-S, Liu T, Li R, Pan T, Petersen RB, Smith MA, Gambetti P, Perry G, Manson JC, Brown DR, Sy M-S. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. J Neurochem 76:565-572, 2001.(119)

161. Aliev G, Seyidova D, Neal ML, Shi J, Vigano T, Hernandez A, Folco G, Soas AH, Zimina TV, Smith MA, Perry G, LaManna JC, Friedland RP. The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cell in vitro. J Submicrosc Cytol Pathol 33:141-149, 2001.(1)

162. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA. Redox-active iron mediates amyloid-β toxicity. Free Radic Biol Med 30:447-450, 2001.(245)

163. Clapp-Lilly KL, Smith MA, Perry G, Duffy LK. Melatonin reduces interleukin secretion in amyloid-β stressed mouse brain slices. Chem Biol Interact 134:101-107, 2001.(17)

164. Alicigüzel Y, Özdem SN, Özdem SS, Karayalçin Ü, Siedlak SL, Perry G, Smith MA. Erythrocyte, plasma, and serum antioxidant activities in untreated toxic multinodular goiter patients. Free Radic Biol Med 30:665-670, 2001.(22)

165. Wong B-S, Liu T, Paisley D, Li R, Pan T, Chen SG, Perry G, Petersen RB, Smith MA, Melton DW, Gambetti P, Brown DR, Sy M-S. Induction of HO-1 and NOS in Doppel-expressing mice devoid of PrP: implications for Doppel function. Mol Cell Neurosci 17:768-775, 2001.(53)

166. Raina AK, Hochman A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, Boux H, Castellani RJ, Perry G, Smith MA. Abortive apoptosis in Alzheimer‘s disease. Acta Neuropathol 101:305-310, 2001.(115)

George Perry

73

167. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PLR, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer‘s disease. J Neurosci 21:3017-3023, 2001.(671)

168. Clapp-Lilly KL, Smith MA, Perry G, Harris PL, Zhu X, Duffy LK. Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer‘s disease. Neuroreport 12:1277-1280, 2001.(14)

169. Aliev G, Samedov SK, Seyidova DY, Mironov A, Burnstock G, LaManna JC, Smith MA, Perry G, Gasimov EK. The morphological features of the development of atherosclerosis in Watanabe heritable hyperlipidemic rabbits (WHHL) (Russian). Vita Medical Journal 1-2:11-16, 2001.

170. Alicigüzel Y, Özdem S, Demir AY, Ünal F, Kumbul D, Özdem SS, Perry G, Smith MA. Effect of the herbicide 4-CPA on human erythrocyte antioxidant enzymes in vitro. Redox Rep 6:153-154, 2001.(4)

171. Zhou F, Zhu X, Castellani RJ, Stimmelmayr R, Perry G, Smith MA, Drew KL. Hibernation, a model of neuroprotection. Am J Pathol 158:2145-2151, 2001.(83)

172. Pappolla MA, Omar RA, Chyan Y-J, Ghiso J, Hsiao K, Bozner P, Perry G, Smith MA, Cruz-Sanchez F. Induction of NADPH cytochrome P450 reductase by the Alzheimer β-protein. Amyloid as a ―foreign body‖. J Neurochem 78:121-128, 2001.(11)

173. Castellani RJ, Harris PLR, Sayre LM, Fujii J, Taniguchi N, Vitek MP, Founds H, Atwood CS, Perry G, Smith

MA. Active glycation in neurofibrillary pathology of Alzheimer disease: N-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 31:175-180, 2001.(115)

174. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759-767, 2001.(965)

175. Aliev G, Smith MA, Turmaine M, Neal ML, Zimina TV, Friedland RP, Perry G, LaManna JC, Burnstock G. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Exp Mol Pathol 71:40-54, 2001.(21)

176. Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA. Activation of MKK6, an upstream activator of p38, in Alzheimer‘s disease. J Neurochem 79:311-318, 2001.(93)

177. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ―two hit‖ hypothesis. Mech Ageing Dev 123:39-46, 2001.(197)

178. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt A-M, Stern DM, Häring H-U, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription

factor nuclear factor-B. Diabetes 50:2792-2808, 2001.(224)

179. Aliev G, Smith MA, Seyidova D, Neal ML, Shi J, Loizidou M, Turmaine M, Friedland RP, Taylor I, Burnstock G, Perry G, LaManna JC. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. J Submicrosc Cytol Pathol 34:37-50, 2002.(8)

180. Zhang J, Montine TJ, Smith MA, Siedlak SL, Gu G, Robertson D, Perry G. The mitochondrial common deletion in Parkinson‘s disease and related movement disorders. Parkinsonism Relat Disord 8:165-170, 2002.(21)

181. Clapp-Lilly KL, Smith MA, Perry G, Harris PL, Zhu X, Drew KL, Duffy LK. Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. Int J Circumpolar Health 61:32-40, 2002.(5)

182. Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J, Montine T, Sayre LM, Smith MA. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 319:25-28, 2002.(78)

183. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PLR, Shimohama S, Szweda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 277:4644-4648, 2002.(90)

184. Kakimura J-I, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Microglial activation and amyloid-β clearance induced by exogenous heat-shock proteins. FASEB J 10.1096/fj.01-0530fje, 2002. Summary published in FASEB J 16:601-603, 2002.(160)

George Perry

74

185. Borghi R, Giliberto L, Assini A, Delacourte A, Perry G, Smith MA, Strocchi P, Zaccheo D, Tabaton M. Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology 58:589-592, 2002.(20)

186. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y. Systemic increase of oxidative nucleic acid damage in Parkinson‘s disease and multiple system atrophy. Neurobiol Dis 9:244-248, 2002.(141)

187. Pérez M, Hernández F, Gómez-Ramos A, Smith M, Perry G, Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem 269:1484-1489, 2002.(82)

188. Guentchev M, Siedlak SL, Jarius C, Tagliavini F, Castellani RJ, Perry G, Smith MA, Budka H. Oxidative damage to nucleic acids in human prion disease. Neurobiol Dis 9:275-281, 2002.(59)

189. Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan Y-J, Poeggeler B, Dubocovich M, Bick R, Perry G, Cruz-Sanchez F, Smith MA. The neuroprotective activities of melatonin against the Alzheimer β-protein are not mediated by melatonin membrane receptors. J Pineal Res 32:135-142, 2002.(62)

190. Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, LaManna JC, Friedland RP. Labeling of cerebral amyloid β deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 43:1044-1051, 2002. Erratum in: J Nucl Med 43:1506, 2002.(28)

191. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10:279-288, 2002.(219)

192. Hartzler AW, Zhu X, Siedlak SL, Castellani RJ, Avilá J, Perry G, Smith MA. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol Aging 23:855-859, 2002.(31)

193. Bowen RL, Smith MA, Harris PLR, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer‘s disease pathology. J Neurosci Res 70:514-518, 2002.(77)

194. Nunomura A, Chiba S, Kosaka K, Takeda A, Castellani RJ, Smith MA, Perry G. Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. Neuroreport 13:2035-2039, 2002. Erratum in: Neuroreport 14:293, 2003.(42)

195. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Vinters HV, Head E, Perry G, LaManna JC, Friedland RP, Cotman CW. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann NY Acad Sci 977:45-64, 2002.(56)

196. Takata K, Kitamura Y, Kakimura J-i, Shibagaki K, Tsuchiya D, Taniguchi T, Smith MA, Perry G, Shimohama S. Role of high mobility group protein-1 (HMG1) in amyloid-β homeostasis. Biochem Biophys Res Commun 301:699-703, 2003.(33)

197. Gómez-Ramos A, Díaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 71:863-870, 2003.(74)

198. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR. Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42:2768-2773, 2003.(333)

199. Zhu X, Ogawa O, Wang Y, Perry G, Smith MA. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer‘s disease. J Neurochem 85:87-93, 2003.(45)

200. Ogawa O, Lee H-g, Zhu X, Raina A, Harris PLR, Castellani RJ, Perry G, Smith MA. Increased p27, an essential component of cell cycle control, in Alzheimer‘s disease. Aging Cell 2:105-110, 2003.(58)

201. Veurink G, Liu D, Taddei K, Perry G, Smith MA, Robertson TA, Hone E, Groth DM, Atwood CS, Martins RN. Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radic Biol Med 34:1070-1077, 2003.(26)

202. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton M, Johnson AB, Paula-Barbosa M, Avíla J, Jones PK, Castellani RJ, Smith MA, Perry G. Microtubule reduction in Alzheimer‘s disease and aging is independent of τ filament formation. Am J Pathol 162:1623-1627, 2003.(162)

203. Ogawa O, Zhu X, Lee H-G, Raina A, Obrenovich ME, Bowser R, Ghanbari HA, Castellani RJ, Perry G, Smith MA. Ectopic localization of phosphorylated histone H3 in Alzheimer‘s disease: a mitotic catastrophe? Acta Neuropathol 105:524-528, 2003.(90)

George Perry

75

204. Bruckner SR, Perry G, Estus S. 4-Hydroxynonenal contributes to NGF withdrawal-induced neuronal apoptosis. J Neurochem 85:999-1005, 2003.(16)

205. Zhu X, Sun Z, Lee H-g, Siedlak SL, Perry G, Smith MA. Distribution, levels, and activation of MEK1 in Alzheimer‘s disease. J Neurochem 86:136-142, 2003.(41)

206. Tateyama M, Takeda A, Onodera Y, Matsuzaki M, Hasegawa T, Nunomura A, Hirai K, Perry G, Smith MA, Itoyama Y. Oxidative stress and predominant Aβ42(43) deposition in myopathies with rimmed vacuoles. Acta Neuropathol 105:581-585, 2003.(25)

207. Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol Endocrinol 17:1344-1355, 2003.(40)

208. Aliev G, Obrenovich ME, Seyidova D, Rzayev NM, Aliyev AS, Raina AK, LaManna JC, Smith MA, Perry G. X-ray contrast media induce aortic endothelial damage, which can be prevented with prior heparin treatment. J Submicrosc Cytol Pathol 35:253-266, 2003.

209. Kitamura Y, Tsuchiya D, Takata K, Shibagaki K, Taniguchi T, Smith MA, Perry G, Miki H, Takenawa T, Shimohama S. Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer‘s disease. Neurosci Lett 346:149-152, 2003.(9)

210. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G. Mitochondria and vascular lesions as a central target for the development of Alzheimer‘s disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 25:665-674, 2003.(67)

211. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan Y-J, Smith MA, Perry G (Chain DG, Neria E), Shoji M, Abe K, Leone A, Grundke-Ikbal I [sic], Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer‘s disease. J Neurochem 85:1101-1108, 2003. Erratum in: J Neurochem 86:1312, 2003.(157)

212. Perry G, Castellani RJ, Smith MA, Harris PLR, Kubat Z, Ghanbari K, Jones PK, Cordone G, Tabaton M, Wolozin B, Ghanbari H. Oxidative damage in the olfactory system in Alzheimer‘s disease. Acta Neuropathol 106:552-556, 2003.(57)

213. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling K-Q, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI. Copper mediates dityrosine cross-linking of Alzheimer‘s amyloid-β. Biochemistry 43:560-568, 2004.(211)

214. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS. Amyloid-β-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88:554-563, 2004.(60)

215. Ghanbari HA, Ghanbari K, Harris PLR, Jones PK, Kubat Z, Castellani RJ, Wolozin BL, Smith MA, Perry G. Oxidative damage in cultured human olfactory neurons from Alzheimer‘s disease patients. Aging Cell 3:41-44, 2004.(59)

216. Zhu X, McShea A, Harris PLR, Raina AK, Castellani RJ, Funk JO, Shah S, Atwood C, Bowen R, Bowser R, Morelli L, Perry G, Smith MA. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer‘s disease. J Neurosci Res 75:698-703, 2004.(46)

217. Lee H-g, Ogawa O, Zhu X, O‘Neill MJ, Petersen RB, Castellani RJ, Ghanbari H, Perry G, Smith MA. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer‘s disease. Acta Neuropathol 107:365-371, 2004.(30)

218. Kang S-C, Brown DR, Whiteman M, Li R, Pan T, Perry G, Wisniewski T, Sy M-S, Wong B-S. Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol 203:603-608, 2004.(30)

219. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-β precursor protein and amyloid-β deposition. J Biol Chem 279:20539-20545, 2004.(110)

220. Dozza B, Smith MA, Perry G, Tabaton M, Strocchi P. Regulation of glycogen synthase kinase-3β by products of lipid peroxidation in human neuroblastoma cells. J Neurochem 89:1224-1232, 2004.(24)

221. Zhu X, Wang Y, Ogawa O, Lee H-g, Raina AK, Siedlak SL, Harris PLR, Fujioka H, Shimohama S, Tabaton M, Atwood CS, Petersen RB, Perry G, Smith MA. Neuroprotective properties of Bcl-w in Alzheimer disease. J Neurochem 89:1233-1240, 2004.(30)

George Perry

76

222. Dwyer BE, Raina AK, Perry G, Smith MA. Homocysteine and Alzheimer‘s disease: a modifiable risk? Free Radic Biol Med 36:1471-1475, 2004.(32)

223. Hasegawa T, Matsuzaki M, Takeda A, Kikuchi A, Akita H, Perry G, Smith MA, Itoyama Y. Accelerated α-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res 1013:51-59, 2004.(38)

224. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G. Neuronal RNA oxidation is a prominent feature of familial Alzheimer‘s disease. Neurobiol Dis 17:108-113, 2004.(105)

225. Yuan J, Kinter M, McGeehan J, Perry G, Kneale G, Gambetti P, Zou W-Q. Concealment of epitope by reduction and alkylation in prion protein. Biochem Biophys Res Commun 326:652-659, 2005.(10)

226. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, Perry G, Tabaton M. β-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92:628-636, 2005.(175)

227. Webber KM, Smith MA, Lee H-g, Harris PL, Moreira P, Perry G, Zhu X. Mitogen- and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer‘s disease. J Neurosci Res 79:554-560, 2005.(19)

228. Liu Q, Smith MA, Avilá J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PLR, Sayre LM, Perry G. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 38:746-754, 2005.(66)

229. Aliyev A, Chen SG, Seyidova D, Smith MA, Perry G, de la Torre J, Aliev G. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer‘s disease. J Neurol Sci 229-230:285-292, 2005.(43)

230. Rajendran R, Ren M, Casadesus G, Smith MA, Perry G, Huang E, Ong WY, Halliwell B, Watt F. Nuclear microscopy of diffuse plaques in the brains of transgenic mice. Nucl Instrum Methods Phys Res B 231:326-332, 2005.(5)

231. Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 280:20978-20986, 2005.(46)

232. Santa-María I, Smith MA, Perry G, Hernández F, Avila J, Moreno FJ. Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochim Biophys Acta 1740:472-480, 2005.(25)

233. Sahin M, Karaüzüm SB, Perry G, Smith MA, Alicigüzel Y. Retinoic acid isomers protect hippocampal neurons from amyloid-β induced neurodegeneration. Neurotox Res 7:243-250, 2005.(22)

234. Zhu X, Smith MA, Perry G, Wang Y, Ross AP, Zhao HW, LaManna JC, Drew KL. MAPKs are differentially modulated in arctic ground squirrels during hibernation. J Neurosci Res 80:862-868, 2005.(20)

235. Zhu X, Mei M, Lee H-g, Wang Y, Han J, Perry G, Smith MA. p38 activation mediates amyloid-β cytotoxicity. Neurochem Res 30:791-796, 2005.(30)

236. Lin D, Lee H-g, Liu Q, Perry G, Smith MA, Sayre LM. 4-oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol 18:1219-1231, 2005.(91)

237. Baykal A, Sarigül F, Süleymanlar G, Moreira PI, Perry G, Smith MA, Alicigüzel Y. Ciprofloxacin does not exert nephrotoxicity in rats. Am J Infect Dis 1:145-148, 2005.(9)

238. Petersen RB, Siedlak SL, Lee H-g, Kim Y-S, Nunomura A, Tagliavini F, Ghetti B, Cras P, Moreira PI, Castellani RJ, Guentchev M, Budka H, Ironside JW, Gambetti P, Smith MA, Perry G. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol 110:232-238, 2005.(40)

239. Castellani RJ, Siedlak SL, Fortino AE, Perry G, Ghetti B, Smith MA. Chitin-like polysaccharides in Alzheimer‘s disease brains. Curr Alzheimer Res 2:419-423, 2005.(3)

240. Santa-María I, Hernández F, Smith MA, Perry G, Avila J, Moreno FJ. Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Mol Cell Biochem 278:203-212, 2005.(17)

241. Aliev G, Samedov SKH, Obrenovich ME, Mirinov AA, Burnstock G, LaManna JC, Smith MA, Perry G, Gasimov EK. Molecular features of the development of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. The Proceedings of the National Academy of Sciences of the Azerbaijan Republic (Azerbaijani and Russian) 62:57-66, 2006.(257)

George Perry

77

242. Smith MA, Zhu X, Lee H-g, Harris PLR, Fortino AE, Perry G, Castellani RJ. Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy. AGE 28:85-91, 2006.(1)

243. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA. Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762:447-452, 2006.(82)

244. Hasegawa T, Matsuzaki-Kobayashi M, Takeda A, Sugeno N, Kikuchi A, Furukawa K, Perry G, Smith MA, Itoyama Y. α-Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson‘s disease. FEBS Lett 580:2147-2152, 2006.(31)

245. Aliev G, Miller JP, Leifer DW, Obrenovich ME, Shenk JC, Smith MA, LaManna JC, Perry G, Lust DW, Cohen AR. Ultrastructural analysis of a murine model of congenital hydrocephalus produced by overexpression of transforming growth factor-β1 in the central nervous system. J Submicrosc Cytol Pathol 38:85-91, 2006.

246. Franco S, Blasco MA, Siedlak SL, Harris PLR, Moreira PI, Perry G, Smith MA. Telomeres and telomerase in Alzheimer‘s disease: epiphenomena or a new focus for therapeutic strategy? Alzheimers Dement 2:164-168, 2006.(1)

247. Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, Smith MA, Sharma A, Derosa S, Ziolkowski C, Stankovic G. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging 10:247-254, 2006.(59)

248. Obrenovich ME, Smith MA, Siedlak SL, Chen SG, de la Torre JC, Perry G, Aliev G. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res 10:43-56, 2006.(34)

249. Webber KM, Stocco DM, Casadesus G, Bowen RL, Atwood CS, Previll LA, Harris PLR, Zhu X, Perry G, Smith MA. Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. Mol Neurodegener 1:8 pages, doi:10.1186/1750-1326-1-14, 2006.(19)

250. Liu G, Men P, Harris PLR, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406:189-193, 2006.(78)

251. Strocchi P, Smith MA, Perry G, Tamagno E, Danni O, Pession A, Gaiba A, Dozza B. Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells. Neurobiol Aging 27:1588-1594, 2006.(16)

252. Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG. LRRK2 protein is a component of Lewy bodies. Ann Neurol 60:617-618, 2006.(37)

253. Zhu X, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG. LRRK2 in Parkinson‘s disease and dementia with Lewy bodies. Mol Neurodegener 1:9 pages, doi:10.1186/1750-1326-1-17, 2006.(21)

254. Lee H-g, Ueda M, Zhu X, Perry G, Smith MA. Ectopic expression of phospho-Smad2 in Alzheimer‘s disease: uncoupling of the transforming growth factor-β pathway? J Neurosci Res 84:1856-1861, 2006.(40)

255. Lee H-g, Ueda M, Miyamoto Y, Yoneda Y, Perry G, Smith MA, Zhu X. Aberrant localization of importin α1 in hippocampal neurons in Alzheimer disease. Brain Res 1124:1-4, 2006.(15)

256. Casadesus G, Smith MA, Basu S, Hua J, Capobianco DE, Siedlak SL, Zhu X, Perry G. Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener 2:8 pages, doi:10.1186/1750-1326-2-2, 2007.(36)

257. Wung JK, Perry G, Kowalski A, Harris PLR, Bishop GM, Trivedi MA, Johnson SC, Smith MA, Denhardt DT, Atwood CS. Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer‘s disease brain. Curr Alzheimer Res 4:67-72, 2007.(20)

258. Previll LA, Crosby ME, Castellani RJ, Bowser R, Perry G, Smith MA, Zhu X. Increased expression of p130 in Alzheimer disease. Neurochem Res 32:639-644, 2007.(13)

259. Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Perry G, Keri RA, Smith MA. Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol 269:107-111, 2007.(42)

260. Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee H-g, Zhu X, Perry G, Smith MA. BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease. Int J Med Sci 4:140-145, 2007.(2)

261. Gonzalez-Cuyar LF, Hunter B, Harris PLR, Perry G, Smith MA, Castellani RJ. Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Report 12:119-124, 2007.(5)

George Perry

78

262. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol 66:525-532, 2007. Erratum in: J Neuropathol Exp Neurol 66:674, 2007.(85)

263. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X. c-Jun phosphorylation in Alzheimer disease. J Neurosci Res 85:1668-1673, 2007.(45)

264. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 12:195-206, 2007.(92)

265. Liu Q, Ju W-K, Crowston JG, Xie F, Perry G, Smith MA, Lindsey JD, Weinreb RN. Oxidative stress is an early event in hydrostatic pressure-induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci 48:4580-4589, 2007.(76)

266. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama K, Hayashi T. Three histidine residues of amyloid-β peptide control the redox activity of copper and iron. Biochem 46:12737-12743, 2007.(97)

267. Bishop GM, Smith MA, LaManna JC, Wilson AC, Perry G, Atwood CS. Iron homeostasis is maintained in the brain, but not the liver, following mild hypoxia. Redox Report 12:257-266, 2007.(6)

268. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura M. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-β peptide. Free Rad Biol Med 43:1552-1559, 2007.(59)

269. Chan HW, Liu T, Verdile G, Bishop G, Haasl RJ, Smith MA, Perry G, Martins RN, Atwood CS. Copper induces apoptosis of neuroblastoma cells via post-translational regulation of the expression of Bcl-2-family proteins and the tx

J mouse is a better model of hepatic than brain Cu toxicity. Int J Clin Exp Med 1:76-88,

2008.(10)

270. Thakur A, Siedlak SL, James SL, Bonda DJ, Rao A, Webber KM, Camins A, Pallàs M, Casadesus G, Lee H-g, Bowser R, Raina AK, Perry G, Smith MA, Zhu X. Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. Int J Clin Exp Pathol 1:134-146, 2008.(218)

271. Mondragón-Rodríguez S, Mena R, Binder LI, Smith MA, Perry G, García-Sierra F. Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology. Neuropathol Appl Neurobiol 34:62-75, 2008.(15)

272. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo D-G, Mattson MP, Tabaton M. Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J Neurochem 104:683-695, 2008.(61)

273. Evans TA, Siedlak SL, Lu L, Fu X, Wang Z, McGinnis WR, Fakhoury E, Castellani RJ, Hazen SL, Walsh WJ, Lewis AT, Salomon RG, Smith MA, Perry G, Zhu X. The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical-induced lipid oxidation. Am J Biotech Biochem 4:61-72, 2008.

274. Mondragón-Rodríguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, Smith MA, Perry G, García-Sierra F. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer‘s disease. Int J Exp Pathol 89:81-90, 2008.(44)

275. Collingwood JF, Chong RKK, Kasama T, Cervera-Gontard L, Dunin-Borkowski RE, Perry G, Pósfai M, Siedlak SL, Simpson ET, Smith MA, Dobson J. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer‘s plaque core material. J Alzheimers Dis 14:235-245, 2008.(62)

276. Su B, Wang X, Drew KL, Perry G, Smith MA, Zhu X. Physiological regulation of tau phosphorylation during hibernation. J Neurochem 105:2098-2108, 2008.(21)

277. Gustaw KA, Garrett MR, Lee H-g, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem 106:1350-1356, 2008.(29)

278. Zhu X, Siedlak SL, Wang Y, Perry G, Castellani RJ, Cohen ML, Smith MA. Neuronal binucleation in Alzheimer disease hippocampus. Neuropath Appl Neurobiol 34:457-465, 2008.(35)

279. Friedland RP, Tedesco JM, Wilson AC, Atwood CS, Smith MA, Perry G, Zagorski MG. Antibodies to potato virus Y bind the amyloid β peptide: immunohistochemical and NMR studies. J Biol Chem 283:22550-22556, 2008.(10)

George Perry

79

280. Bryan KJ, Zhu X, Harris PL, Perry G, Castellani RJ, Smith MA, Casadesus G. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer‘s disease. Mol Neurodegener 3:5 pages, doi:10.1186/1750-1326-3-13, 2008.(23)

281. Gonzalez-Cuyar LF, Perry G, Miyajima H, Atwood CS, Riveros-Angel M, Lyons PF, Siedlak SL, Smith MA, Castellani RJ. Redox active iron accumulation in aceruloplasminemia. Neuropathology 28:466-471, 2008.(18)

282. Gelfand SL, Vento M, Sastre J, Lust WD, Smith MA, Perry G, Walsh M, Martin R. A new model of oxidative stress in rat pups. Neonatology 94:293-299, 2008.(3)

283. Myung N-H, Zhu X, Kruman II, Castellani RJ, Petersen RB, Siedlak SL, Perry G, Smith MA, Lee H-g. Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. AGE 30:209-215, 2008.(35)

284. Lee H-g, Zhu X, Casadesus G, Pallàs M, Camins A, O‘Neill MJ, Nakanishi S, Perry G, Smith MA. The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res 1249:244-250, 2009.(12)

285. Aliev G, Liu J, Shenk JC, Fischbach K, Pacheco GJ, Chen SG, Obrenovich ME, Ward WF, Richardson AG, Smith MA, Gasimov E, Perry G, Ames BN. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 13:320-333, 2009.(54)

286. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, Danni O, Parola M, Smith MA, Perry G, Tamagno E, Tabaton M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1α. J Neurochem 108:1045-1056, 2009.(102)

287. Ramiro-Puig E, Casadesύs G, Lee H-g, Zhu X, McShea A, Perry G, Pérez-Cano FJ, Smith MA, Castell M. Neuroprotective effect of cocoa flavonids [sic] on in vitro oxidative stress. Eur J Nutr 48:54-61, 2009.(4)

288. Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA, Perry G. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer‘s disease. Free Rad Res 43:156-164, 2009.(32)

289. Lee H-g, Casadesus G, Nunomura A, Zhu X, Castellani RJ, Richardson SL, Perry G, Felsher DW, Petersen RB, Smith MA. The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am J Pathol 174:891-897, 2009.(32)

290. Lee H-P, Zhu X, Zhu X, Skidmore SC, Perry G, Sayre LM, Smith MA, Lee H-g. The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells. J Neurochem 108:1434-1441, 2009.(10)

291. Bonda DJ, Evans TA, Santocanale C, Llosá JC, Viña J, Bajic VP, Castellani RJ, Siedlak SL, Perry G, Smith MA, Lee H-g. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging 1:382-388, 2009.(31)

292. Rajendran R, Minqin R, Ynsa MD, Casadesus G, Smith MA, Perry G, Halliwell B, Watt F. A novel approach to the identification and quantitative elemental analysis of amyloid deposits–insights into the pathology of Alzheimer‘s disease. Biochem Biophys Res Comm 382:91-95, 2009.(13)

293. Stone JG, Rolston RK, Ueda M, Lee H-G, Richardson SL, Castellani RJ, Perry G, Smith MA. Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain. Int J Clin Exp Pathol 2:267-274, 2009.(6)

294. Dwyer BE, Zacharski LR, Balestra DJ, Lerner AJ, Perry G, Zhu X, Smith MA. Getting the iron out: phlebotomy for Alzheimer‘s disease? Med Hypotheses 72:504-509, 2009.(6)

295. Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 455:187-190, 2009. (56)

296. Perez M, Santa-Maria I, Gomez de Barreda E, Zhu X, Cuadros R, Cabrero JR, Sanchez-Madrid F, Dawson HN, Vitek MP, Perry G, Smith MA, Avila J. Tau - an inhibitor of deacetylase HDAC6 function. J Neurochem 109:1756-1766, 2009.(75)

297. Wang X, Su B, Lee H-g, Li X, Perry G, Smith MA, Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer‘s disease. J Neurosci 29:9090-9103, 2009. (54)

298. Su B, Liu H, Wang X, Chen SG, Siedlak SL, Kondo E, Choi R, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee H-g. Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson‘s disease. Mol Neurodegener 4:5 pages, doi:10.1186/1750-1326-4-32, 2009.(15)

299. Dwyer BE, Smith MA, Richardson SL, Perry G, Zhu X. Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer‘s disease. Neurosci Lett 460:180-184, 2009.(2)

George Perry

80

300. Dwyer BE, Stone ML, Gorman N, Sinclair PR, Perry G, Smith MA, Zhu X. Heme-α, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer‘s disease. Neurosci Lett 461:302-305, 2009.(3)

301. Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA. Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer‘s disease: a population-based study. Exp Gerontol 45:47-52, 2010.(11)

302. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19:363-372, 2010.(140)

303. Su B, Wang X, Lee H-g, Tabaton M, Perry G, Smith MA, Zhu X. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett 468:267-271, 2010. (34)

304. Wang X, Perry G, Smith MA, Zhu X. Amyloid-β-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons. Neurodegener Dis 7:56-59, 2010.(45)

305. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, Yamaguchi H, Shimohama S, Lee H-g, Zhu X, Smith MA, Perry G. Intraneuronal amyloid β accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 37:731-737, 2010.(42)

306. Nair NG, Perry G, Smith MA, Reddy VP. NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion complexing site of amyloid-β peptide. J Alzheimers Dis 20:57-66, 2010.(20)

307. Poeggeler B, Sambamurti K, Siedlak SL, Perry G, Smith MA, Pappolla MA. A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan. PLoS ONE 5:8 pages, doi:10.1371/journal.pone.0010206, 2010.(8)

308. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Akutsu H, Hayashi T. Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid. Free Radic Res 44:734-741, 2010.(3)

309. Storace D, Cammarata S, Borghi R, Sanguineti R, Giliberto L, Piccini A, Pollero V, Novello C, Caltagirone C, Smith MA, Bossù P, Perry G, Odetti P, Tabaton M. Elevation of β-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol 67:867-872, 2010.(17)

310. Moh CF, Siedlak SL, Tabaton M, Perry G, Castellani RJ, Smith MA. Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease. J Neurosci Meth 190:244-247, 2010.(1)

311. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Staniszewska M, Castellani RJ, Siedlak SL, Zhu X, Lee H-g, Perry G, Nagaraj RH, Smith MA. Indoleamine 2, 3-dioxygenase and 3-hydroxy-kynurenine modifications are found in the neuropathology of Alzheimer‘s disease. Redox Report 15:161-168, 2010.(27)

312. Valdez CM, Smith MA, Perry G, Phelix CF, Santamaria F. Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus 20:902-905, 2010.(15)

313. Zou W-Q, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld JPM, Castellani R, Notari S, Crain B, Schmidt RE, Geschwind M, DeArmond SJ, Cairns NJ, Dickson D, Honig L, Torres JM, Mastrianni J, Capellari S, Giaccone G, Belay ED, Schonberger LB, Cohen M, Perry G, Kong Q, Parchi P, Tagliavini F, Gambetti P. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 68:162-172, 2010.(65)

314. Borghi R, Piccini A, Barini E, Cirmena G, Guglielmotto M, Tamagno E, Fornaro M, Perry G, Smith MA, Garuti A, Tabaton M. Upregulation of presenilin 1 in brains of sporadic, late-onset Alzheimer‘s disease. J Alzheimers Dis 22:771-775, 2010.(7)

315. Buxton GA, Siedlak SL, Perry G, Smith MA. Mathematical modeling of microtubule dynamics: insights into physiology and disease. Prog Neurobiol 92:478-483, 2010.

316. Heath JE, Siedlak SL, Zhu X, Lee H-g, Thakur A, Yan R, Perry G, Smith MA, Castellani RJ. Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology 30:574-579, 2010.(4)

317. Castellani RJ, Nugent SL, Morrison AL, Zhu X, Lee H-g, Harris PLR, Bajić V, Sharma HS, Chen SG, Oettgen P, Perry G, Smith MA. CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson‘s disease. J Neural Transm 118:23-26, 2011.(3)

318. Phelix CF, LeBaron RG, Roberson DJ, Villanueva RE, Villareal G, Rahimi OB, Siedlak S, Zhu X, Perry G. Transcriptome-to-metabolome

TM biosimulation reveals human hippocampal hypometabolism with age and

Alzheimer‘s disease. Int J Knowl Discov Bioinforma 2:1-18, 2011.

319. Valdez CM, Phelix CF, Smith MA, Perry G, Santamaria F. Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Mol Biosyst 7:1891-1901, 2011.

George Perry

81

320. Stone JG, Siedlak SL, Tabaton M, Hirano A, Castellani RJ, Santocanale C, Perry G, Smith MA, Zhu X, Lee H-g. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol 70:578-587, 2011.(16)

321. Wang X, Su B, Liu W, He X, Gao Y, Castellani RJ, Perry G, Smith MA, Zhu X. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson‘s disease. Aging Cell 10:807-823, 2011.(28)

322. Wise-Scira O, Xu L, Kitahara T, Perry G, Coskuner O. Amyloid-β peptide structure in aqueous solution varies with fragment size. J Chem Phys 135:13 pages, doi:10.1063/1.3662490, 2011.(14)

323. Castellani RJ, Gupta Y, Sheng B, Siedlak SL, Harris PLR, Coller JM, Perry G, Lee H-g, Tabaton M, Smith MA, Wang X, Zhu X. A novel origin for granulovacuolar degeneration in aging and Alzheimer‘s disease: parallels to stress granules. Lab Invest 91:1777-1786, 2011.(19)

324. Colom LV, Castaneda MT, Hernandez S, Perry G, Jaime S, Touhami A. Intrahippocampal amyloid-β (1-40) injections injure medial septal neurons in rats. Curr Alzheimer Res 8:832-840, 2011.(9)

325. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 33:196e.13-196.e27, 2012.(7)

326. Calderón-Garcidueñas L, Kavanaugh M, Block M, D‘Angiulli A, Delgado-Chávez R, Torres-Jardón R, González-Maciel A, Reynoso-Robles R, Osnaya N, Villarreal-Calderon R, Guo R, Hua Z, Zhu H, Perry G, Diaz P. Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. J Alzheimers Dis 28:93-107, 2012.(36)

327. Sheng B, Wang X, Su B, Lee H-g, Casadesus G, Perry G, Zhu X. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer‘s disease. J Neurochem 120:419-429, 2012.

328. Zhu X, Castellani RJ, Moreira PI, Aliev G, Shenk JC, Siedlak SL, Harris PLR, Fujioka H, Sayre LM, Szweda PA, Szweda LI, Smith MA, Perry G. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radic Biol Med 52:699-704, 2012.(15)

329. Nunomura A, Tamaoki T, Motohashi N, Nakamura M, McKeel DW Jr, Tabaton M, Lee H-g, Smith MA, Perry G, Zhu X. The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. J Neuropathol Exp Neurol 71:233-241, 2012.(29)

330. Kudo W, Lee H-P, Zou W-Q, Wang X, Perry G, Zhu X, Smith MA, Petersen RB, Lee H-g. Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum Mol Genet 21:1138-1144, 2012.(48)

331. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, Zhu X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21:1931-1944, 2012.

332. Wise-Scira O, Xu L, Perry G, Coskuner O. Structures and free energy landscapes of aqueous zinc(II)-bound amyloid-β(1–40) and zinc(II)-bound amyloid-β(1–42) with dynamics. J Biol Inorg Chem 17:927-938, 2012.(16)

333. Piccini A, Borghi R, Guglielmotto M, Tamagno E, Cirmena G, Garuti A, Pollero V, Cammarata S, Fornaro M, Messa M, Colombo L, Salmona M, Perry G, Tabaton M. β-amyloid 1-42 induces physiological transcriptional regulation of BACE1. J Neurochem 122:1023-1031, 2012.

334. Greco SJ, Hamzelou A, Johnston JM, Richardson S, Smith MA, Perry G, Ashford JW, Tezapsidis N. Isotyping the human TOMM40 variable-length polymorphism by gene amplification and restriction digest. Curr Alzheimer Res 9:1168-1173, 2012.

335. Coskuner O, Wise-Scira O, Perry G, Kitahara T. The structures of the E22∆ mutant-type amyloid-β alloforms and the impact of E22∆ mutation on the structures of the wild-type amyloid-β alloforms. ACS Chem Neurosci 4:310-320, 2013.(10)

336. Greco SJ, Perry G, Ashford JW, Hamzelou A, Johnston JM, Tezapsidis N. Leptin rescues neurons from alzheimer‘s [sic] disease-related pathways triggered by lipid burden. Adv Alzheimer‘s Dis 2:31-39, 2013.

337. Correia SC, Santos RX, Santos MS, Casadesus G, LaManna JC, Perry G, Smith MA, Moreira PI. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer‘s disease. Curr Alzheimer Res 10:406-419, 2013.(6)

338. Perry EA, Castellani RJ, Moreira PI, Nunomura A, Lui Q, Harris PLR, Sayre LM, Szweda PA, Szweda LI, Zhu X, Smith MA, Perry G. Neurofilaments are the major neuronal target of hydroxynonenal-mediated protein cross-links. Free Radic Res 47:507-510, 2013.(9)

George Perry

82

339. Durán-González J, Michi ED, Elorza B, Perez-Córdova MG, Pacheco-Otalora LF, Touhami A, Paulson P, Perry G, Murray IV, Colom LV. Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiol Aging 34:2071-2076, 2013

340. Hou L, Lee H-g, Han F, Tedesco JM, Perry G, Smith MA, Zagorski MG. Modification of amyloid-β1-42 fibril structure by methionine-35 oxidation. J Alzheimers Dis 37:9-18, 2013.

341. Živković L, Spremo-Potparević B, Siedlak SL, Perry G, Plećaš-Solarović B, Milićević Z, Bajić VP. DNA damage in Alzheimer disease lymphocytes and its relation to premature centromere division. Neurodegener Dis 12:156-163, 2013.(3)

342. Williams WM, Torres S, Siedlak SL, Castellani RJ, Perry G, Smith MA, Zhu X. Antimicrobial peptide β-defensin-1 expression is upregulated in Alzheimer‘s brain. J Neuroinflammation 10:11 pages, doi:10.1186/1742-2094-10-127, 2013.

343. Fujioka H, Phelix CF, Friedland RP, Zhu X, Perry EA, Castellani RJ, Perry G. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer‘s disease. J Health Care Poor Underserved 24:70-78, 2013.(37)

344. Haldar S, Beveridge AJ, Wong J, Singh A, Galimberti D, Borroni B, Zhu X, Blevins J, Greenlee J, Perry G, Mukhopadhyay CK, Schmotzer C, Singh N. A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. Antioxid Redox Signal 19:1662-1675, 2013.

345. Paley EL, Perry G. Sokolova O. Tryptamine induces axonopathy and mitochondriopathy mimicking neurodegenerative diseases via tryptophanyl-tRNA deficiency. Curr Alzheimer Res 10:987-1004, 2013.(3)

346. Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G. Oxidative stress in blood in Alzheimer‘s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 59:100-110, 2013.

347. Jarero-Basulto JJ, Luna-Muñoz J, Mena R, Kristofikova Z, Ripova D, Perry G, Binder LI, Garcia-Sierra F. Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease. J Neuropathol Exp Neurol 72:1145-1161, 2013.

348. Bonda DJ, Stone JG, Torres SL, Siedlak SL, Perry G, Kryscio R, Jicha G, Casadesus G, Smith MA, Zhu X, Lee H-g. Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. J Neurochem 128:162-172, 2014.(19)

349. Mohorovic L, Lavezzi AM, Stifter S, Perry G, Malatestinic D, Micovic V, Materljan E, Haller H, Petrovic O. Methemoglobinemia—a biomarker and a link to ferric iron accumulation in Alzheimer‘s disease. Adv Biosci Biotechnol 5:12-18, http://dx.doi.org/10.4236/abb.2014.51003, 2014.

350. Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 11:165-174, 2014.(15)

351. Mondragón-Rodríguez S, Perry G, Luna-Muñoz J, Acevedo-Aquino MC, Williams S. Phosphorylation of tau protein at sites Ser

396-404 is one of the earliest events in Alzheimer‘s disease and Down syndrome.

Neuropathol Appl Neurobiol 40:121-135, 2014.

352. Blair JA, Siedlak SL, Wolfram JA, Nunomura A, Castellani RJ, Ferreira ST, Klein WL, Wang Y, Casadesus G, Smith MA, Perry G, Zhu X, Lee H-g. Accumulation of intraneuronal amyloid-β is common in normal brain. Curr Alzheimer Res 11:317-324, 2014.(4)

353. Xia J, Rocke DM, Perry G, Ray M. Differential network analyses of Alzheimer‘s disease identify early events in Alzheimer‘s disease pathology. Int J Alzheimer‘s Dis 2014:18 pages, doi:10.1155/2014/721453, 2014.

354. Ruegner CN, Benton M, Dunsmore N, Perry G, Castellani RJ. Colonic adenocarcinoma of a neovagina in a patient with mullerian agenesis. Reprod Syst Sex Disord 3: 3 pages, doi: 10.4172/2161-038X.1000138, 2014.

355. Phelix CF, Villareal G, LeBaron RG, Perry G, Roberson DJ. Precision medicine using individualized biosimulations of drug dosing: Alzheimer‘s disease, 2014 Health Innovations and Point-of-Care Technologies Conferenc, pp.292-295, 2014.

356. Fawver JN, Ghiwot Y, Koola C, Carrera W, Rodriguez-Rivera J, Hernandez C, Dineley KT, Kong Y, Li J, Jhamandas J, Perry G, Murray IVJ. Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer‘s disease, Curr Alzheimer Res 11:928-940, 2014.(4)

357. Fornicola W, Pelcovits A, Li B-X, Heath J, Perry G, Castellani RJ. Alzheimer disease pathology in middle age reveals a spatial-temporal disconnect between amyloid-β and phosphorylated tau, Open Neurol J 8:22-26, 2014.

George Perry

83

358. Hammack C, Perry G, LeBaron R, Villareal G, Phelix C. Low dose Pioglitazone attenuates oxidative damage in early Alzheimer‘s disease by binding mitoNEET: transcriptome-to-reactome

TM biosimulation of neurons.

Intl J Knowledge Discovery Bioinformatics 5:24-46, 2015.

359. Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of Lupron depot in the treatment of women with Alzheimer‘s disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose Lupron over 48 weeks. J Alzheimers Dis 44:549-560, 2015.(1)

360. Calderón-Garcidueñas L, Gónzalez-Maciel A, Vojdani A, Franco-Lira M, Reynoso-Robles R, Montesinos-Correa H, Pérez-Guillé B, Sarathi-Mukherjee P, Torres-Jardón R, Calderón-Garcidueñas A, Perry G. The intestinal barrier in air pollution-associated neural involvement in Mexico City residents: mind the gut, the evolution of a changing paradigm relevant to Parkinson disease risk. J Alzheimer‘s Dis Parkinsonism 5: http://dx.doi.org/10.4172/2161-0460.1000179, 2015.

361. Pelcovits A, Marriotti R, Heath J, Perry G, Castellani RJ. Simultaneous onset of Alzheimer‘s disease in a husband and wife in their mid- fifties: what do we really know about environmental factors? Open Neurol J 9:1-3, 2015.

362. Zhang F, Su B, Wang C, Siedlak SL, Mondragon-Rodriguez S, Lee H-g, Wang X, Perry G, Zhu X. Posttranslational modifications of α-tubulin in Alzheimer disease Translational Neurodegen 4:1-9, 2015.

363. Calderón-Garcidueñas L, Chao C-k, Thompson C, Rodríguez-Díaz J, Franco-Lira M, Mukherjee PS, Perry G. CSF biomarkers: low Amyloid-β 1-42 and BDNF and high IFN γ differentiate children exposed to Mexico City high air pollution V controls. Alzheimer‘s disease uncertainties. J Alzheimer‘s Dis Parkinsonism 5: http://dx.doi.org/10.4172/2161-0460.1000189, 2015.

364. Zhang F, Wang W, Siedlak SL, Liu Y, Liu J, Jiang K, Perry G, Zhu X, Wang X. Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in Aging Neurosci 7:8 pages, doi: 10.3389/fnagi.2015.00100, 2015.

365. Calderón-Garcidueñas L, Franco-Lira M, D‘Angiulli A, Rodríguez-Díaz J, Blaurock-Busch E, Busch Y, Chao C-k, Thompson C, Mukherjee PS, Torres-Jardón R, Perry G. Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. Environmental Res 140:579-592, 2015. (1)

366. Rodriguez AR, Plascencia-Villa G, Witt CM, Yu J-J, José-Yacamán J, Chambers JP, Perry G, Guentzel MN, Arulanandam BP. Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Cell Immunol 295:83-91, 2015.

367. Gerenu G, Liu K, Chojnacki JE, Saathoff J, Martinez-Martin P, Perry G, Zhu X Lee H-g, Zhang S. Curcumin/melatonin hybrid, 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide, ameliorates AD-like pathology in the APP/PS1 mouse model. ACS Chem Neurosci 8:1393-1399, 2015,

368. Spremo-Potparevic B, Bajic V, Perry G, L Zivkovic. Alterations of the X chromosome in lymphocytes of Alzheimer‘s disease patients. Curr Alz Res 12:990-996, 2015.

369. Sharoar MG, Shi Q, Ge Y, He W, Hu X, Perry G, Zhu X, Yan R. Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer‘s disease. Molecular Psychiatry 21:1263-1271, 2016.

370. Pérez-Ibave DC, Rodríguez-Sánchez IR, Garza-Rodríguez MdL, Pérez-Maya AA, Luna M, Arámburo C, Cun L, Tsin A, Perry G, Mohamed-Noriega K, Mohamed-Noriega J, Adame HC, Hamsho JM, Barrera-Saldaña HA. Expression of growth hormone and prolactin in the baboon eye. (submitted).

371. Cornejo A, Sandoval FA, Caballero L, Caballero J, Perry G, Serrano C, Areche C, Melo F. rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to β sheet formation as evaluated by Raman spectroscopy. (in preparation)

372. Verdile G, Liu T, Smith MA, Perry G, Atwood CS, Martins RN. Amyloid-β generation from the amyloid-β precursor protein is a late event in the life cycle of a neuron, and is not a response to oxidative stress (in preparation).

373. Villanueva-Vedia RE, Ibarra V, LeBaron RG, Wayner MJ, Rogers J, McCarey J, Martinez JL Jr, Perry G, Smith MA, Levi M, Phelix CF. Cholesterogenic markers, SREBP-2 and HMG CoA reductase, are decreased in the hippocampus of perimenopausal compared with young reproductive age female baboons (in preparation).

374. Chen LY, Perry G, Rodriguez RA, Hung C-Y, Yu L. In vitro evidence for the inhibition of water permeation through aquaglyceroporins by erythritol and xylitol from osmotic lysis assays of human erythrocytes. (in preparation)

George Perry

84

375. Calderón-Garcidueñas L, Reynoso-Robles R, Vargas-Martínez J, Gómez-Maqueo-Chew A, Pérez-Guillé B, Mukherjee PS, Torres-Jardón R, Perry G, Gónzalez-Maciel A. Prefrontal white matter pathology in air pollution exposed Mexico City young urbanites and their potential impact on neurovascular unit dysfunction and the development of Alzheimer‘s disease. Environmental Res 146:404-417, 2016.

376. Matsuzaki-Kobayashi M, Hasegawa T, Takeda A, Kikuchi A, Smith MA, Perry G, Itoyama Y. α-Synuclein aggregate induced by iron protects cells from apoptotis (in preparation).

377. Guentzel N, Chaganty B, Murthy A, Arulanandam B, Perry G. Study of the antimicrobial activity of Amyloid beta (in preparation)

378. Plascencia-Villa G, Ponce A, Collingwood JR, Arellano-Jiménez MJ, Zhu X, Rogers JT, Betancourt I, José-Yacaman M, Perry G. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer‘s disease. Scientific Reports 6: doi:1010.1038/srep24873, 2016.

379. Mondragón-Rodríguez S, Su B, Salas-Benito JS, Mena R, Binder LI, Perry G, Smith MA, García-Sierra F. Phosphorylation and cleavage of tau protein follows the appearance of P70 S6 kinase (in preparation).

380. Ochoa C, Perry G, Barea-Rodriguez E. Methylene blue and aging (in preparation).

381. Nunomura A, Perry G. Relationship of oxidative damage to mitochondria (in preparation).

382. Kelley A, Colley M, Perry G, Bach SBH. The role of metal salts in the analysis of Amyloid-beta and ɑ-Synuclein via matrix . (in preparation)

383. Beaird H, Bowen RL, Perry G, Smith MA, Koroukian SM, Diaz M, Rimm AA. Gonadotropin therapy in dementia supported by Medicare data (submitted).

384. Henderson LE, Abdelmegeed M, Moon K-H, Rhee SG, Zhu X, Perry G, Song B-J. Increased phosphorylation and mitochondrial association of bax in the brains of Alzheimer‘s disease individuals (submitted).

385. Aryan N, Betts-Obregon BS, Perry G, Tsin AT.Oxidative stress induces senescence in cultured RPE cells. Open Neurol J 10:83-87, 2016..

386. Cash AD, Harris PLR, Siedlak SL, Smith MA, Perry G. Defining the mechanism for nitrotyrosine formation in Alzheimer disease (in preparation).

387. Smith MA, Yuan Z, Rimm A, Koprowski H, Perry G. Protective effects of gout on Alzheimer disease (in preparation).

388. Cash AD, Perry G. Synaptic vesicle analysis (in preparation)

389. Kelley AR, Perry G, Bethea C, Castellani RJ, Bach SBH. Molecular mapping Alzheimer‘s disease: MALDI imaging of formalin-fixed, paraffin-embedded human hippocampal tissue. Open Neurol J 10:88-98, 2016.

390. Wang C, Wang W, Shen K, Rao AS, Siedlek SL, Phelix CF, Perry G, Shen L, Tang B, Yan R, Zhu X. The sterol regulatory element-binding protein 2 is dysregulated in Alzheimer disease. (submitted).

391. Manassero G, Guglielmotto M, Borghi R, Perry G, Tamagno E, Tabaton M. Beta amyloid 1-42 monomers produce PHF-like conformation of Tau protein. Aging Cell 15:914-923, 2016.

392. Barh D, García-Solano ME, Jain N, Bhattacharya A, García-Solano J, Torres-Moreno D, Tiwari S, Farri B, Gupta KK, Kamapantula B, Nalluri J, Silva A, Azevedo V, Ghosh P, Conesa-Zamora P, Blum K. BARHL1 is downregulated in Alzheimer‘s disease and may regulate cognitive functions through ESR1 and multiple pathways (submitted).

393. Yu L, Rodriguez RA, Chen LL, Chen LY, Perry G. McHardy SF, Yeh C-k. 1,3-Propanediol binds deep inside the channel to inhibit water permeation through aquaporins. Protein Science 2016:433-441, 2015.

394. Rueli RHLH, Torres DJ, Dewing AST, Kiyohara AC, Bellinger MT, Uyehara-Lock JH, White LR, Moreira PI, Berry MJ, Perry G, Bellinger FP. Selenoprotein S reduces ER stress-induced phosphorylation of Tau: potential role in selenite mitigation of Tau pathology. J Alzheimer‘s Dis 55:749-762, 2017.

395. Ontiveros-Torres MA, Labra-Barrios ML, Díaz-Cintra S, Aguilar-Vázquez RA, Moreno-Campuzano S, Flores-Rodríguez P, Luna-Herrera C, Mena R, Perry G, Florán-Garduño B, Luna-Muñoz J, Luna-Arias JP. Fibrillar Amyloid-beta accumulation triggers an inflammatory mechanism leading to hyperphosphorylation of the carboxyl-terminal end of tau polypeptide in the hippocampal formation of the 3xTg-AD transgenic mouse. J Alzheimer‘s Dis 52:243-269, 2016.

396. Everett J, Collingwood J, Tjendana-Tjhin V, Plascencia-Villa G, Hands-Portman I, Dobson J, Tyliszczak T, Perry G, Telling ND. Identification of ferrous iron and calcium loading in Alzheimer‘s disease amyloid plaque cores. (submitted)

397. Cook D, Zhu X, Perry G. Brain Injury. (in preparation)

George Perry

85

398. Kelley AR, Perry G, Castellani RJ, Bach SBH. Laser-induced in-source decay applied to the determination of Amyloid-Beta in Alzheimer‘s brains. ACS Chemical Neurosci 7:261-268, 2016.

399. Reynald J, Montgomery EL, Upson S, Bass B, Gonnella R, Tautiva N, Badiya M, Perry G, Murray IVJ. Effect of oxidative stress on metabolism and synaptic activity in Alzheimer‘s disease – a review (in preparation).

400. Wang C, Zhang F, Jiang S, Siedlak SL, Shen L, Perry G, Wang X, Tang B, Zhu X. Estrogen receptor-α is localized to neurofibrillary tangles in Alzheimer‘s disease. Sci Reports 6: doi:10.1038/srep20352, 2016.

401. Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Perry G. Telomere length in Parkinson‘s Disease: a meta-analysis. Experimental Gerontology 75:53-55, 2016.

402. Castellani RJ, Perry G, Mojica G. The role of the iron stain in assessing intracranial hemorrhage. Open Neurol J 10:136-142, 2016.

403. Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Perry G. Meta-analysis of telomere length in Alzheimer‘s disease. Journals of Gerontology: Medical Sciences 71:1069-1073, 2016.

404. Gore E, Appleby BS, Cohen ML, DeBrosse SD, Leverenz JB, Miller BL, Perry G, Siedlak SL, Zhu X, Lerner AJ. Neuropathology characteristics of late onset mitochondrial membrane protein-associated neurogdegeneration (MPAN) (in preparation).

405. Herrera L, Stephens DE, Avila AD, George KG, Arman H, Zhang Y, Perry G, Lleonart R, Larionov OV, Fernández. Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles. Organic & Biomolecular Chem 14:7053-7060, 2016.

406. Kelley AR, Perry G, Bach SBH. The role of metal salts in the analysis of amyloid-beta and ɑ-synuclein via matrix-assisted laser desorption/ionization mass spectrometry (in preparation).

407. Martín-Maestro P, Gargini R, Perry G, Ávila J, García-Escudero V. PARK2 is able to compensate mitophagy alterations found in sporadic Alzheimer‘s disease. Human Molecular Genetics 25:792-806, 2016.

408. Zhu X, Perry G, Wang X. PS1 deficiency causes abnormal mitochondrial dynamics and dysfunction. (submitted).

409. Doens D, Valiente PA, Mfuh AM, Vo AXT, Tristan A, Carreño L, Quijada M, Nguyen VT, Perry G, Larionov OV, Lleonart R, Fernández PL. Identification of inhibitors of CD36-Amyloid beta binding as potential agents for Alzheimer‘s disease. ACS Chem Neurosci (in print), 2017.

410. Forero DA, Prada CF, Perry G. Functional and genomic features of human genes mutated in neuropsychiatric disorders. Open Neurol J 10:143-148, 2016.

411. Rodriguez RA, Chen LY, Perry G. conformational and entropic barrier in the formation pathway of Aβ42 fibril—computing the elongation affinity from all-atom simulations with chemical accuracy. (in preparation)

412. Wang L, Gao J, Siedlak SL, Torres S, Jiang Y, Xie F, Liang J, Fujioka H, Nosek T, Perry G, Li H, Wang X. Mitofusion 2 is a calpastatin-dependent checkpoint for neuromuscular synapse maintenance. (in preparation)

413. Phelix CF, Dugan JL, Villareal G, Chen LY, Renthal RD, McHardy SF, Perry G. Human mitochondrial pyruvate carrier (MPC) 1 and 2 heterodimer models of wild type and mutant MPC1 sequences, L361, L79H, and R97W: protein homology, protein, pyruvate, and inhibitor docking, and dynamic modeling.

Book Chapters/Invited Papers/Letters to Editor/Book Reviews:

1. Epel D, Nishioka D, Perry G. The role of Ca2+

in triggering development at fertilization. Biol Cellulaire 32:135-140, 1978.(5)

2. Perry G, Brinkley BR, Bryan J. Interaction of calcium-calmodulin in microtubule assembly in vitro. In: Muscle and Cell Motility, Dowben RM and Shay JW, Eds, Vol. 2, Plenum Press, New York, 1982, pp 73-84.(8)

3. Epel D, Perry G, Schmidt T. Intracellular calcium and fertilization: Role of the cation and regulation of intracellular calcium levels. In: Membranes in Growth and Development, Gerisch G and Hofman J, Eds, Alan R. Liss, New York, 1982, pp 171-183.(12)

4. Gambetti P, Perry G, Autilio-Gambetti L. Alzheimer's paired helical filaments contain insoluble cytoskeletal elements. In: Proc Elec Microscopy Soc Amer, Bailey GW, Ed, Vol. 43, San Francisco Press, San Francisco, 1985, pp 748-751.(2)

5. Gambetti P, Perry G, Autilio-Gambetti L. Alzheimer paired helical filaments contain insoluble cytoskeletal elements. In: Electron Microscopy and Alzheimer's Disease, Metuzals J, Ed, San Francisco Press, San Francisco, 1986, pp 50-52.(2)

George Perry

86

6. Perry G, Gambetti P. Conclusions, discussions and outlook. The helix clock model of the neurofilamentous network. In: Electron Microscopy and Alzheimer's Disease, Metuzals J, Ed, San Francisco Press, San Francisco, 1986, pp 67-68.

7. Gambetti P, Perry G, Autilio-Gambetti L. Paired helical filaments: do they contain neurofilament epitopes? (Commentary) Neurobiol Aging 7:451-452, 1986.(7)

8. Perry G. Immunocytochemical study of the neuronal cytoskeleton in dementia: Alzheimer, Pick and Parkinson diseases. ICN Quality Line 2:6-7, 1987.

9. Perry G, Weiss M. Antibodies to the neuronal cytoskeleton: tools for studying dementia. Biomakor Newsletter, Autumn 1987, pp 4-6.

10. Gambetti P, Autilio-Gambetti L, Manetto V, Perry G. Composition of paired helical filaments of Alzheimer's disease as determined by specific probes. In: Banbury Report 27, Molecular Neuropathology of Aging, Davies P and Finch CE, Eds, Cold Spring Harbor, New York, 1987, pp 309-320.(10)

11. Perry G, Manetto V, Mulvihill P. Ubiquitin in Alzheimer and other neurodegenerative diseases. In: Advances in Behavioral Biology 34: Alterations in the Neuronal Cytoskeleton in Alzheimer Disease, Perry G, Ed, Plenum Press, New York, 1987, pp 53-59.(15)

12. Perry G, Manetto V, Onorato M, Weiss M, Mulvihill P, Galloway P, Tabaton M, Autilio-Gambetti L, Gambetti P. Alteration of the neurofilament-microtubule network in Alzheimer disease and other neurodegenerative disorders. In: Advances in Behavioral Biology 34: Alterations in the Neuronal Cytoskeleton in Alzheimer Disease, Perry G, Ed, Plenum Press, New York, 1987, pp 137-149.(14)

13. Galloway PG, Perry G. Microfilament involvement in Hirano body formation. In: Advances in Behavioral Biology 34: Alterations in the Neuronal Cytoskeleton in Alzheimer Disease, Perry G, Ed, Plenum Press, New York, 1987, pp 199-21.(2)

14. Gambetti P, Manetto V, Tabaton M, Mulvihill P, Fried VA, Smith HT, Autilio-Gambetti L, Perry G. A new protein in Alzheimer and other neurodegenerative diseases ubiquitin. In: Fidia Research Series 15: New Trends in Aging Research. Pepeu G, Tomlinson B, Wischik CM, Eds, Liviana Press, Padova, 1988, pp 153-164.

15. Whitehouse PJ, Gambetti P, Harik SI, Kalaria RN, Perry G, Younkin SI, Tabaton M, Unnerstall JR. Neurochemistry of dementia: establishing the links. In: Progress in Clinical and Biological Research 317: Alzheimer's Disease and Related Disorders, Iqbal K, Wisniewski HM, Winblad B, Eds, Alan R. Liss Inc., New York, 1989, pp 131-142.(1)

16. Onorato M, Mulvihill P, Connolly J, Galloway P, Whitehouse P, Perry G. Alteration of neuritic cytoarchitecture in Alzheimer disease. In: Progress in Clinical and Biological Research 317: Alzheimer's Disease and Related Disorders, Iqbal K, Wisniewski HM, Winblad B, Eds, Alan R. Liss Inc., New York, 1989, pp 781-789.(26)

17. Autilio-Gambetti L, Morandi A, Kovacs DM, Tabaton M, Schaetzle B, Hauer C, Groger RK, Tykocinski ML, Perry G, Greenberg BD, Satish S, Cornette J, Gambetti P. Amyloid precursor protein in cell cultures: a 130 kDa polypetide. In: Progress in Clinical and Biological Research 317: Alzheimer's Disease and Related Disorders, Iqbal K, Wisniewski HM, Winblad B, Eds, Alan R. Liss Inc., New York, 1989, pp 985-990.

18. Perry G, Siedlak S, Mulvihill P, Kancherla M, Mijares M, Kawai M, Gambetti P, Sharma S, Maggiora L, Cornette J, Lobl T, Greenberg B. Immunolocalization of the amyloid precursor protein within the senile plaque. In: Progress in Clinical and Biological Research 317: Alzheimer's Disease and Related Disorders, Iqbal K, Wisniewski HM, Winblad B, Eds, Alan R. Liss Inc., New York, 1989, pp 1021-1025.(10)

19. Gambetti P, Tabaton M, Cammarata S, Morandi A, Schaetzle B, Wicker N, Perry G, Autilio-Gambetti L. Neurofibrillary tangles, neuropil threads and neuritic plaques in Alzheimer disease: are these lesions interrelated? In: International Congress Series 884: Molecular Biology and Genetics of Alzheimer's Disease, Miyatake T, Selkoe DJ, Ihara Y, Eds, Elsevier Publishing, Amsterdam, 1990, pp 57-66.(1)

20. Golde TE, Palmert MR, Estus S, Usiak M, Siedlak SL, Perry G, Younkin LH, Younkin SG. The β amyloid protein precursor: analysis of mRNAs in AD and control brains and of soluble derivatives in human cerebrospinal fluid. In: International Congress Series 884: Molecular Biology and Genetics of Alzheimer's Disease, Miyatake T, Selkoe DJ, Ihara Y, Eds, Elsevier Publishing, Amsterdam, 1990, pp 137-147.

21. Perry G, Cras P, Kawai M, Mulvihill P, Tabaton M. Transformation of neurofibrillary tangles in the extracellular space. Bull Clin Neurosci 56:107-119, 1991.(16)

22. Perry G. The relationship between senile plaques and neurofibrillary tangles. Alzheimer's Association Cleveland Chapter, Issues in Focus, November 1991, p. 11.

23. Cras P, Perry G. Dementia with argyrophilic grains. Ann Neurol 30:853, 1991.(18)

George Perry

87

24. Perry G. Alzheimer's disease. In: Neuroscience Year, Smith B and Adelman G, Eds, Birkhauser, Boston, 1992, pp 5-8.(5)

25. Perry G. The Neuronal Cytoskeleton by Burgoyne RD (Book Review). Neurol 42:1130, 1992.

26. Perry G, Kawai M, Kalaria RN, Tabaton M, Cras P. Origin of neuritic plaques in Alzheimer disease. In: Advances in the Biosciences 87: Alzheimer's Disease and Related Disorders, Nicolini M, Zatta PF, Corain B, Eds, Pergamon Press, Oxford, 1993, pp 153-154.(2)

27. Villanova M, Lübke U, Vandermeeren M, Mercken M, Guazzi GC, Martin J-J, Perry G, Cras P. Rimmed vacuoles in oculopharyngeal muscular dystrophy contain amyloid precursor protein. In: Advances in the Biosciences 87: Alzheimer's Disease and Related Disorders, Nicolini M, Zatta PF, Corain B, Eds, Pergamon Press, Oxford, 1993, pp 157-158.(2)

28. Kalaria RN, Kroon SN, Perry G. Serum proteins and the blood-brain barrier in the pathogenesis of Alzheimer's disease. In: Advances in the Biosciences 87: Alzheimer's Disease and Related Disorders., Nicolini M, Zatta PF, Corain B, Eds, Pergamon Press, Oxford, 1993, pp 281-282.(7)

29. Shimohama S, Fujimoto S, Tresser N, Perry G, Homma Y, Takenawa T, Taniguchi T, Suenaga T, Kimura J. Aberrant phosphoinositide metabolism in Alzheimer's disease. In: Proc 7th Meeting Intern Study Group Pharmacology Memory Disorders Associated with Aging; Alzheimer's Disease: Amyloid Precursor Proteins, Signal Transduction, and Neuronal Transplantation, Nitsch RM, Growden JH, Corkin S, Wurtman RJ, Eds, 1993, pp 225-229.(8)

30. Kalaria RN, Bhatti SU, Perry G, Lust WD. The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion. In: Proc 7th Meeting Intern Study Group Pharmacology Memory Disorders Associated with Aging; Alzheimer's Disease: Amyloid Precursor Proteins, Signal Transduction, and Neuronal Transplantation, Nitsch RM, Growden JH, Corkin S, Wurtman RJ, Eds, 1993, pp 291-294.(1)

31. Greenberg BD, Ali SM, Howland D, Gonzalez-DeWhitt PA, Altman RA, Siedlak S, Cras P, Scott R, Perry G. Transgenic mouse studies of Alzheimer amyloid precursor. In: Amyloid and Amyloidosis, Kisilevsky R, Benson M, Frangione B, Gauldie J, Muckle TJ, Young ID, Eds, Parthenon Press, New York, 1993, pp 328-331.(3)

32. Smith MA, Kalaria RN, Perry G. Proteolytic anomalies in Alzheimer disease. In: Amyloid and Amyloidosis, Kisilevsky R, Benson M, Frangione B, Gauldie J, Muckle TJ, Young ID, Eds, Parthenon Press, New York, 1993, pp 335-337.(2)

33. DeWitt DA, Silver J, Canning DR, Perry G. Chondroitin sulfate proteoglycan and the regenerative failure model of Alzheimer's disease. In: Amyloid and Amyloidosis, Kisilevsky R, Benson M, Frangione B, Gauldie J, Muckle TJ, Young ID, Eds, Parthenon Press, New York, 1993, pp 347-349.

34. Smith MA, Richey PL, Miller CA, Nawrot MT, Perry G. Carbonyl-crosslinking in Alzheimer disease: pathogenic considerations. In: Amyloid and Amyloidosis, Kisilevsky R, Benson M, Frangione B, Gauldie J, Muckle TJ, Young ID, Eds, Parthenon Press, New York, 1993, pp 371-373.

35. Perry G, Smith MA, Mulvihill P, Siedlak SL, Richey PL, DeWitt DA, Kalaria RN. Alzheimer disease: concurrent amyloidoses. In: Amyloid and Amyloidosis, Kisilevsky R, Benson M, Frangione B, Gauldie J, Muckle TJ, Young ID, Eds, Parthenon Press, New York, 1993, pp 374-376.(1)

36. Shimohama S, Fujimoto S, Tresser N, Richey P, Perry G, Whitehouse PJ, Homma Y, Takenawa T, Taniguchi T, Suenaga T, Kimura J. Aberrant phosphoinositide metabolism in Alzheimer's disease. Ann NY Acad Sci 695:46-49, 1993.(6)

37. Kalaria RN, Bhatti SU, Lust WD, Perry G. The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion. Ann NY Acad Sci 695:190-193, 1993.(52)

38. Perry G, Smith MA. Senile plaques and neurofibrillary tangles: what role do they play in Alzheimer‘s disease? Perry G, Ed. Clin Neurosci 1:199-203, 1993.(30)

39. Smith MA, Perry G. Is a Lewy body always a Lewy body? In: Dementia in Parkinson's Disease, Korczyn AD, Ed, Monduzzi Editore, Bologna, Italy, 1994, pp 187-193.(9)

40. Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end

products, free radicals, and protein oxidation in Alzheimer‘s disease. In: The Neurobiology of NO and OH, Chuieh CC, Gilbert DL, Colton CA, Eds. Ann NY Acad Sci 738:447-454, 1994.(106)

41. Gambetti P, Perry G. Alzheimer‘s disease and prion proteins: a meeting made in muscle. Am J Pathol 145:1261-1264, 1994.(5)

42. Smith MA, Sayre LM, Vitek MP, Monnier VM, Perry G. Early AGEing and Alzheimer‘s. Nature 374:316, 1995.(37)

George Perry

88

43. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer‘s disease. Trends Neurosci 18:172-176, 1995.(325)

44. Smith MA, Richey PL, Kutty RK, Wiggert B, Perry G. Ultrastructural localization of heme oxygenase-1 to the neurofibrillary pathology of Alzheimer disease. Mol Chem Neuropathol 24:227-230, 1995.(12)

45. Smith MA, DeWitt DA, Praprotnik D, Perry G. Senile plaques and neurofibrillary tangles: the concurrent lesions of Alzheimer‘s disease. Neurobiol Aging 16:343-344, 1995.(1)

46. DeWitt DA, Canning DR, Silver J, Perry G. Glial cell extracellular matrix in Alzheimer‘s disease. In: Non-Neuronal Cells in Alzheimer‘s Disease, Zatta P, Nicolini M, Eds, World Scientific Publishing Company, London, 1995, pp 158-170.

47. Smith MA, Monnier VM, Sayre LM, Perry G. Glycation in neuropathies - Reply. Trends Neurosci 18:342, 1995.

48. Smith MA, Monnier VM, Sayre LM, Perry G. Amyloidosis, advanced glycation end products and Alzheimer disease. Neuroreport 6:1595, 1995.(16)

49. Smith MA, Perry G. Free radical damage, iron, and Alzheimer‘s disease. J Neurol Sci 134 (Suppl):92-94, 1995.(88)

50. Savage MJ, Howland DS, Ali SM, Siedlak S, Perry G, Siman R, Scott RW, Greenberg BD. APP transgenesis: approaches towards the development of animal models for Alzheimer‘s disease neuropathology. In: Neurobiology of Alzheimer‘s Disease, Dawbarn D, Allen S, Eds, BIOS Scientific Publishers Ltd., Oxford, 1996, pp 149-192.(2)

51. Smith MA, Perry G. Diseases of the aging brain - the role of oxidative stress. The Physician‘s Newsletter 1:3-4, 1996.

52. Smith MA, Sayre LM, Perry G. Diabetes mellitus and Alzheimer‘s disease: glycation as a biochemical link. Diabetologia 39:247, 1996.(24)

53. Greenberg BD, Savage MJ, Howland DS, Ali SM, Siedlak SL, Perry G, Siman R, Scott RW. APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol Aging 17:153-171, 1996.(35)

54. Ali SM, Siedlak SL, Gonzalez-DeWhitt PA, Altman RA, Glendening JM, Lowery DE, Savage MJ, Polites HG, Perry G, Greenberg BD. Artifactual strain-specific signs of incipient brain amyloidosis in APP transgenic mice. Neurobiol Aging 17:223-234, 1996.(8)

55. Smith MA, Perry G. Protein modifications and interactions in Alzheimer‘s disease. In: Alzheimer‘s Disease: Etiological Mechanisms and Therapeutic Possibilities, Turner JD, Beyreuther K, Theuring F, Eds, Springer-Verlag, Berlin, 1996, pp 169-182.(3)

56. Smith MA, Sayre LM, Monnier VM, Perry G. Oxidative posttranslational modifications in Alzheimer disease: a possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol Chem Neuropathol 28:41-48, 1996.(52)

57. Smith MA, Richey PL, Kalaria RN, Perry G. Elastase is associated with the neurofibrillary pathology of Alzheimer disease: a putative link between proteolytic imbalance and oxidative stress. Restorative Neurol Neurosci 9:213-217, 1996.(4)

58. Smith MA, Sayre L, Perry G. Is Alzheimer‘s a disease of oxidative stress? Alzheimer‘s Disease Review (http://www.mc.uky.edu/ADReview/Vol2/Smith/smith.pdf) 1:63-67, 1996.(39)

59. Smith MA, Perry G. Oxidative stress and protein modification in neurodegenerative disease. In: Free Radicals in Brain Physiology and Disorders, Packer L, Hiramatsu M, Yoshikawa T, Eds, Academic Press, San Diego, 1996, pp 287-292.(4)

60. Smith MA, Tabaton M, Perry G. Early contribution of oxidative glycation in Alzheimer disease. Neurosci Lett 217:210-211, 1996.(18)

61. Smith MA, Perry G. Alzheimer disease: protein-protein interaction and oxidative stress. Boletín de Estudios Médicos y Biológicos 44:5-10, 1996.(8)

62. Smith MA, Sayre LM, Perry G. A primary role for redox imbalance and oxidative damage in neurodegenerative diseases. Redox Regulation of Cell Signaling and its Clinical Application. 3rd Internet World Congress on Biomedical Sciences at the Virtual Conference Hall, 1996. (http://www.3iwc.riken.go.jp/CONGRESS/SYMPO/SBF0206/AP0116/TIT.HTM).

63. Smith MA, Perry G. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis (Letter to the Editor). J Neuropathol Exp Neurol 56:217, 1997.(8)

George Perry

89

64. Sayre LM, Zagorski MG, Surewicz WK, Krafft GA, Perry G. Mechanisms of neurotoxicity associated with amyloid β deposition and the role of free radicals in the pathogenesis of Alzheimer‘s disease: a critical appraisal. Chem Res Toxicol 10:518-526, 1997.(88)

65. Smith MA, Sayre LM, Perry G. Oxidative damage in Alzheimer‘s disease. In: Neurogerontology and Neurogeriatrics 2: Inflammation and Neuroimmunotrophic Activity in Alzheimer‘s Disease, Cacabelos R, Winblad B, Eikelenboom P, Eds, Prous Science Publishers, Barcelona, 1997, pp 57-62.

66. Smith MA, Sayre LM, Perry G. Morphological aspects of oxidative damage in Alzheimer‘s disease. In: Mitochondria and Free Radicals in Neurodegenerative Diseases, Beal MF, Howell N, Bodis-Wollner I, Eds, Wiley-Liss, Inc., New York, 1997, pp 335-342.(6)

67. Smith MA, Perry G. Microscopic evaluation of oxidative damage in Alzheimer disease. Microscopy and Microanalysis 3 (Suppl 2):41-42, 1997.

68. Perry G, Zelasko DA, Sayre LM, Smith MA. Oxidative damage to axonal cytoskeletal proteins. Microscopy and Microanalysis 3 (Suppl 2):43-44, 1997.

69. Perry G, Smith MA. A central role for oxidative damage in the pathogenesis and therapeutics of Alzheimer‘s disease. Investigational Drugs Research Alert 2:319-324, 1997.(7)

70. Smith MA, Petot GJ, Perry G. Commentary: Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer‘s disease. Alzheimer‘s Disease Review (http://www.mc.uky.edu/ADReview/PDF/smith-comment.pdf) 2:58-60, 1997.(14)

71. Smith MA, Perry G, Sayre LM. Protein oxidation and glycation in neurodegenerative diseases. In: Oxidative Stress in Cancer, AIDS, and Neurodegenerative Diseases, Montagnier L, Olivier R, Pasquier C, Eds, Marcel Dekker, Inc., New York, 1998, pp 485-496.(1)

72. Perry G, Smith MA. Neuronal oxidative stress is a common feature of Alzheimer‘s and Parkinson‘s diseases. In: Advances in Behavioral Biology 49:Progress in Alzheimer‘s and Parkinson‘s Diseases, Fisher A, Hanin I, Yoshida M, Eds, Plenum Press, New York, 1998, pp 77-80.(1)

73. Perry G, Smith MA. Oxidative damage: an early and central event in the pathogenesis of Alzheimer disease. In: Progress in HPLC-HPCE 7:Neurochemical Markers of Degenerative Nervous Diseases and Drug Addiction, Qureshi GA, Parvez H, Caudy P, Parvez S, Eds, VSP Press, Amsterdam, 1998, pp 93-110.

74. Smith MA, Perry G. The role of oxidative stress in the pathological sequelae of Alzheimer disease. In: Free Radicals, Oxidative Stress, and Antioxidants: Pathological and Physiological Significance, Özben T, Ed, Plenum Press, New York, 1998, pp 195-204.(4)

75. Perry G, Smith MA. Alzheimer‘s disease. In: Encyclopedia of Neuroscience, 2nd Edition, Adelman G, Smith BH, Eds, Elsevier Science BV, Amsterdam, 1998, article 00000709.

76. Perry G, Castellani RJ, Hirai K, Smith MA. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1:45-55, 1998.(67)

77. Perry G. Alzheimer‘s Disease, 7-8 November 1997, Ter Elst, Antwerp, Belgium. Investigational Drugs Weekly Highlights, (March) Week 10:16-17, 1998.

78. Perry G. Conferencia Nacional Alzheimer, 6-9 November 1997, Pamplona, Spain. Investigational Drugs Weekly Highlights, (March) Week 12:18-19, 1998.

79. Perry G. Oxidants and Antioxidants in Biology: Oxygen Club of California 1998 World Congress, 5-8 February 1998, Santa Barbara, California, USA. Investigational Drugs Weekly Highlights, (April) Week 13:32-34, 1998.

80. Perry G. Alzheimer‘s Disease 1998 Manhattan Conference, 16-17 March 1998, New York, USA. Investigational Drugs Weekly Highlights, (April) Week 15:17-20, 1998.

81. Smith MA, Petot GJ, Perry G. Commentary: Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer‘s disease. Townsend Letter for Doctors and Patients, p. 73, 1998.

82. Perry G, Smith MA. The case for vascular abnormalities in Alzheimer‘s disease. Current Research in Alzheimer‘s Disease 3:181-186, 1998.(4)

83. Perry G. Alzheimer‘s Disease 1998 Manhattan Conference, 16-17 March 1998, New York, USA. Current Research in Alzheimer‘s Disease 3:250-253, 1998.

84. Perry G, Smith MA. Is oxidative damage central to the pathogenesis of Alzheimer disease? Acta Neurol Belg 98:175-179, 1998.(20)

George Perry

90

85. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P. Alzheimer‘s disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439-461, 1998.(175)

86. Perry G, Nunomura A, Smith MA. A suicide note from Alzheimer disease neurons? (News and Views). Nature Med 4:897-898, 1998.(85)

87. Perry G. American Association of Neuropathologists 74th Annual Meeting, 18-21 June 1998, Minneapolis, Minnesota, USA. Investigational Drugs Weekly Highlights, (August) Week 33:24-25, 1998.

88. Perry G. Satellite Symposium on AD7c-NTP and Roundtable C: Metabolism and Alzheimer‘s. News from the Sixth International Conference on Alzheimer‘s Disease and Related Disorders. 18-23 July, 1998, Amsterdam. Alzheimer Research Forum, http://www.alzforum.org/res/for/vir/amsterdam/news/satellite.asp and http://www.alzforum.org/res/for/vir/amsterdam/news/metabolism.asp, 1998.

89. Perry G. Alzheimer‘s Disease and Other Related Disorders – Sixth International Conference (Part V), 18-23 July 1998, Amsterdam, Investigational Drugs Weekly Highlights, (August) Week 34:40-43, 1998.

90. Perry G. Molecular and Genomic Effect of Tissue Oxygen Deprivation in Sleep Apnea, 24-25 September 1998, National Institutes of Health, Bethesda, MD, USA. Investigational Drugs Weekly Highlights, (October) Week 41:34-36, 1998.

91. Perry G, Nunomura A, Lucassen P, Lassmann H, Smith MA. Apoptosis and Alzheimer‘s disease (Letter). Science 282:1268-1269, 1998.(86)

92. Perry G. Alzheimer‘s Disease and Related Disorders - Fourth Hungarian Conference, 7-9 October 1998, Szeged, Hungary. Investigational Drugs Weekly Highlights, (November) Week 45:28-32, 1998 (also http://www.alzforum.org/new/detail.asp?id=532).

93. Smith MA, Perry G. What are the facts and artifacts of the pathogenensis [sic] and etiology of Alzheimer disease? J Chem Neuroanat 16:35-41, 1998.(22)

94. Smith MA, Hirai K, Nunomura A, Perry G. Mitochondrial abnormalities: a primary basis for oxidative damage in Alzheimer‘s disease. Drug Dev Res 46:26-33, 1999.(15)

95. Perry G, Hirai K, Nunomura A, Raina A, Smith MA. Neuronal oxidative damage in Alzheimer disease may be brought about by a fundamental shift in redox balance and oxidative metabolism. Recent Res Devel Neurochem 2:277-285, 1999.

96. Perry G, Smith MA. ¿Es la lesión producida por oxidación una parte central en la patogenia de la enfermedad de Alzheimer? (Spanish) Neurología 14:78-84, 1999.(2)

97. Perry G, Smith MA. Alzheimer‘s disease. In: Encyclopedia of Neuroscience, 2nd Edition, Adelman G, Smith BH, Eds, Elsevier Science BV, Amsterdam, 1999, pp 59-61.

98. Smith MA, Sayre LM, Perry G. Primary involvement of oxidative damage and redox imbalance in Alzheimer and other neurodegenerative diseases. In: Redox Regulation of Cell Signaling and Its Clinical Application, Packer L, Yodoi J, Eds, Marcel Dekker, Inc., New York, 1999, pp 115-126.(1)

99. Sayre LM, Perry G, Smith MA. Redox metals and neurodegenerative disease. Curr Opin Chem Biol 3:220-225, 1999.(168)

100. Coleman P, Cotman C, Smith M, Perry G, Mattson M. Transcript of Live Apoptosis Panel Discussion. Alzheimer Research Forum, 1999, http://www.alzforum.org/res/for/journal/apoptosis/default.asp.

101. Perry G. Experimental Biology ‘99 (Part III), 17-21 April 1999, Washington DC, USA. Investigational Drugs Weekly Highlights, (May) Week 19:46-47, 1999.

102. Perry G, Nunomura A, Smith MA. Antioxidant reversal of oxidative stress-induced memory deficits. Neuroreport 10, i, 1999.(1)

103. Perry G. Oxidants and Antioxidants in Biology (Part II), 3-6 March 1999, Santa Barbara, CA, USA. Investigational Drugs Weekly Highlights, (June) Week 22:43-49, 1999.

104. Perry G. Annual Meeting of the American Association of Neuropathologists, 17-20 June 1999, Portland, OR, USA. Investigational Drugs Weekly Highlights, (June) Week 26:17-18, 1999.

105. Gerst JL, Siedlak SL, Nunomura A, Castellani R, Perry G, Smith MA. Role of oxidative stress in frontotemporal dementia. Dement Geriatr Cogn Disord 10 (Suppl 1):85-87, 1999.(12)

106. Smith MA, Nunomura A, Takeda A, Perry G. Asking the right questions. Science 285:665, 1999.

107. Perry G. Neuronal Apoptosis – ISN Satellite Symposium, 5-7 August 1999, Tübingen, Germany. Investigational Drugs Weekly Highlights, (August) Week 34:22-25, 1999.

George Perry

91

108. Castellani RJ, Perry G, Brenner DS, Smith MA. Alexander disease: Alzheimer disease of the developing brain? Alzheimer Dis Assoc Disord 13:232-235, 1999.(4)

109. Sayre LM, Perry G, Smith MA. In situ methods for detection and localization of markers of oxidative stress: application in neurodegenerative disorders. In: Methods of Enzymology, Vol. 309, Wetzel R, Ed, Academic Press, San Diego, 1999, pp 133-152.(41)

110. Perry G. European Federation of Neurological Societies – Fourth Congress, 7-8 September 1999, Lisbon, Portugal. Investigational Drugs Weekly Highlights, (October) Week 41:30-31, 1999.

111. Perry G. Imaging and Biological Markers for Diagnosis and Progression of Alzheimer‘s Disease, 27-28 September 1999, Bethesda, MD, USA. Investigational Drugs Weekly Highlights, (October) Week 41:63-65, 1999.

112. Perry G. Neuronal Apoptosis – ISN Satellite Symposium, 5-7 August 1999, Tübingen, Germany. IDrugs 2:992-994, 1999.

113. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA. Neuronal RNA oxidation in Alzheimer‘s disease and Down's syndrome. Ann NY Acad Sci 893:362-364, 1999.(73)

114. Smith MA, Petot GJ, Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer‘s disease. J Alzheimers Dis 1:203-206, 1999.(17)

115. Nunomura A, Perry G, Zhang J, Montine TJ, Takeda A, Chiba S, Smith MA. RNA oxidation in Alzheimer and Parkinson diseases. J Anti-Aging Medicine 2:227-230, 1999.(7)

116. Perry G, Smith MA. Neurodegeneration Methods and Protocols, Methods in Molecular Medicine, Volume 22, Harry J, Tilson HA, Eds, Humana Press, Totowa, New Jersey, 1999 (Book Review). Q Rev Biol 74:510, 1999.

117. Perry G. Alzheimer‘s Disease: Models and Mechanisms, 11 November 1999, Philadelphia, PA, USA. Investigational Drugs Weekly Highlights, (December) Week 49:55-57, 1999.

118. Perry G. American College of Neuropsychopharmacology 38th Annual Meeting, 12-17 December 1999, Acapulco, Mexico. Investigational Drugs Weekly Highlights, (December) Week 52:12-14, 1999.

119. Smith MA, Perry G. Molecular and cellular aspects of oxidative damage in Alzheimer‘s disease. In: Free Radicals in Brain Pathophysiology, Poli G, Cadenas E, Packer L, Eds, Marcel Dekker, Inc., New York, 2000, pp 313-321.(6)

120. Pappolla MA, Chyan Y-J, Sos M, Perry G, Smith MA, Cruz-Sanchez F. Role of transgenic models for the study of oxidative neurotoxicity in Alzheimer‘s disease. In: Free Radicals in Brain Pathophysiology, Poli G, Cadenas E, Packer L, Eds, Marcel Dekker, Inc., New York, 2000, pp 359-381.(2)

121. Castellani RJ, Perry G, Smith MA. Oxidative protein modifications in Rosenthal fibers: implications for Alexander‘s disease pathogenesis. In: Free Radicals in Brain Pathophysiology, Poli G, Cadenas E, Packer L, Eds, Marcel Dekker, Inc., New York, 2000, pp 383-392.

122. Perry G, Nunomura A, Smith MA. Amylose dans la maladie d‘Alzheimer (French). In: Les Amyloses, Grateau G, Benson MD, Delpech M, Eds, Médecine-Sciences Flammarion, Paris, 2000, pp 513-518.

123. Perry G, Nunomura A, Friedlich AL, Boswell MV, Brazdil L, Jones PK, Rottkamp CA, Zhu X, Raina AK, Hirai K, Friedland RP, Shi J, Aliev G, Cash A, Russell RL, Wataya T, Shimohama S, Atwood CS, Smith MA. Factors controlling oxidative damage in Alzheimer disease: metals and mitochondria. In: Free Radicals in Chemistry, Biology and Medicine, Yoshikawa T, Toyokuni S, Yamamoto Y, Naito Y, Eds, OICA International (UK) Limited, London, UK, 2000, pp 417-423.(2)

124. Perry G, Nunomura A, Smith MA. Homeostatic control of oxidant balance in Alzheimer disease. Recent Res Devel Neurochem 3:157-159, 2000.

125. Perry G. Medicinal Chemistry of Neurodegenerative Diseases - Fourth International Symposium, 30 January – 2 February, 2000, Cancun, Mexico. Investigational Drugs Weekly Highlights, (February) Week 8:27-32, 2000.

126. Raina AK, Perry G, Nunomura A, Sayre LM, Smith MA. Histochemical and immunocytochemical approaches to the study of oxidative stress. Clin Chem Lab Med 38:93-97, 2000.(10)

127. Perry G, Nunomura A, Raina AK, Smith MA. Amyloid-β junkies. Lancet 355:757, 2000.(70)

128. Perry G, Raina AK, Nunomura A, Wataya T, Sayre LM, Smith MA. How important is oxidative damage? Lessons from Alzheimer‘s disease. Free Radic Biol Med 28:831-834, 2000.(133)

129. Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer‘s disease. Neurobiol Aging 21:357-361, 2000.(73)

George Perry

92

130. Perry G, Smith MA. Promise and pitfalls of therapeutics to modify oxidant balance in chronic disease. IDrugs 3:371-372, 2000.(1)

131. Friedland RP, Shi J, LaManna JC, Smith MA, Perry G. Prospects for noninvasive imaging of brain amyloid β in Alzheimer‘s disease. Ann NY Acad Sci 903:123-128, 2000.(17)

132. Nunomura A, Chiba S, Smith MA, Perry G. RNA oxidation and Alzheimer‘s disease (Japanese). Dementia Japan 14:39-45, 2000.

133. Rottkamp CA, Nunomura A, Raina AK, Sayre LM, Perry G, Smith MA. Oxidative stress, antioxidants, and Alzheimer disease. Alzheimer Dis Assoc Disord 14 (Suppl 1):S62-S66, 2000.(48)

134. Perry G. Medicinal Chemistry of Neurodegenerative Diseases - Fourth International Symposium, 30 January - 2 February 2000, Cancun, Mexico. IDrugs 3:485-489, 2000.

135. Perry G. Experimental Biology 2000 (Part III), 15-18 April 2000, San Diego, CA, USA. Investigational Drugs Weekly Highlights, (May) Week 19:41-44, 2000.

136. Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell Mol Biol 46:731-741, 2000.(85)

137. Perry G, Smith MA. Methods in Molecular Medicine, Vol. 32, Alzheimer‘s Disease: Methods and Protocols, Hooper NM, Ed, Humana Press, Totowa, New Jersey, 2000 (Book Review). J Mol Neurosci 14:205, 2000.

138. Perry G. American Association of Neuropathologists – 76th Annual Meeting, 8-11 June 2000, Atlanta, GA, USA. Investigational Drugs Weekly Highlights, (June) Week 26:25-26, 2000.

139. Aliev G, Samedov SKH, Seyidova D, LaManna JC, Smith MA, Perry G, Gasimov EK. The pathogenesis of cerebrovascular lesions in Alzheimer‘s disease (Russian). Reports of the Academy of Sciences of Azerbaijan 56:236-242, 2000.

140. Perry G, Kaminski MA, Nunomura A, Raina AK, Smith MA. What oxidative stress tells us about therapeutic targets for Alzheimer‘s disease. Current Opinion in CPNS Investigational Drugs 2:423-426, 2000.(1)

141. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer‘s disease. Biochim Biophys Acta 1502:139-144, 2000.(432)

142. Rottkamp CA, Nunomura A, Hirai K, Sayre LM, Perry G, Smith MA. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? Mech Ageing Dev 116:169-179, 2000.(26)

143. Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA. Oxidative damage in Alzheimer‘s disease: the metabolic dimension. Int J Devl Neurosci 18:417-421, 2000.(63)

144. Perry G. World Alzheimer Congress 2000, 9-18 July 2000, Washington DC, USA. Investigational Drugs Weekly Highlights, (August) Week 32:51-53, 2000.

145. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2:413-420, 2000.(66)

146. Perry G, Nunomura A, Jones PK, Rottkamp CA, Zhu X, Aliev G, Cash AD, Smith MA. Oxidative imbalance is a major feature of Alzheimer disease. Curr Topics Biochem Res 3:151-156, 2000.

147. Perry G. Neuromuscular Disorders and Aging: Basic and Clinical Aspects, 14-15 September 2000, Marseille, France. Investigational Drugs Weekly Highlights, (October) Week 42:79-81, 2000.

148. Perry G. Metals and the Brain - First International Conference, 20-23 September 2000, Padova, Italy. Investigational Drugs Weekly Highlights, (October) Week 42:86-88, 2000.

149. Perry G. International Society for Free Radical Research Tenth Biennial Meeting, 16-20 October 2000, Kyoto, Japan. Investigational Drugs Weekly Highlights, (November) Week 48:44-47, 2000.

150. Smith MA, Joseph JA, Perry G. Arson: tracking the culprit in Alzheimer‘s disease. Ann NY Acad Sci 924:35-38, 2000.(43)

151. Atwood CS, Huang X, Moir RD, Smith MA, Tanzi RE, Roher AE, Bush AI, Perry G. Neuroinflammatory responses in the Alzheimer‘s disease brain promote the oxidative post-translational modification of amyloid deposits. In: Alzheimer‘s Disease: Advances in Etiology, Pathogenesis and Therapeutics, Iqbal K, Sisodia SS, Winblad B, Eds, John Wiley & Sons, Ltd., Chichester, UK, 2001, pp 341-361.(22)

152. Perry G, Nunomura A, Avila J, Perez M, Rottkamp CA, Atwood CS, Zhu X, Aliev G, Cash AD, Smith MA. Oxidative damage and antioxidant responses in Alzheimer‘s disease. In: Alzheimer‘s Disease: Advances in Etiology, Pathogenesis and Therapeutics, Iqbal K, Sisodia SS, Winblad B, Eds, John Wiley & Sons, Ltd., Chichester, UK, 2001, pp 371-378.(1)

George Perry

93

153. Avila J, Lucas JJ, Lim F, Pérez M, Hernández F, Arrasate M, Armas Portela R, Champion E, Perry G, Smith MA, Díaz Nido J. Phosphorylation, microtubule binding and aggregation of tau protein in Alzheimer‘s disease. In: Alzheimer‘s Disease: Advances in Etiology, Pathogenesis and Therapeutics, Iqbal K, Sisodia SS, Winblad B, Eds, John Wiley & Sons, Ltd., Chichester, UK, 2001, pp 601-607.

154. Perry G, Zhu X, Smith MA. Commentary: Do neurons have a choice in death? Am J Pathol 158:1-2, 2001.(26)

155. Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA. Copernicus revisited: amyloid beta in Alzheimer‘s disease. Neurobiol Aging 22:131-146, 2001.(128)

156. Joseph JA, Perry G, Shukitt-Hale B, Denisova NA, Martin A, Smith MA. A diet at amyloid beta? Neurobiol Aging 22:161-163, 2001(4)

157. Perry G. Research evaluation (Letter). The Scientist 15(1):6, 8 January 2001.(2)

158. Perry G, Avila J, Espey MG, Wink DA, Atwood CS, Smith MA. Biochemistry of neurodegeneration (Letter) Science 291:595-596, 2001.(11)

159. Perry G. We will miss you Henryk. J Alzheimers Dis 3:1, 2001.

160. Aliev G, Smith MA, Perry G, Samedov SKH, Seyidova D, Friedland RP, LaManna JC, Gasimov EK. The experimental model of Alzheimer‘s disease and its seiective [sic] pharmacological treatments. Reports of the Academy of Sciences of Azerbaijan 57:112-118, 2001.

161. Smith MA, Perry G. Comment: Pathogenic versus pathology. Alzheimer Research Forum, 2001, http://www.alzforum.org/pap/annotation.asp?powID=14724.

162. Campbell A, Smith MA, Sayre LM, Bondy SC, Perry G. Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Res Bull 55:125-132, 2001.(72)

163. Perry G, Smith M. Comment: Oxidative abnormalities as the earliest changes in amyloid-β disease. Alzheimer Research Forum, 2001, http://www.alzforum.org/pap/annotation.asp?powID=15164.

164. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8:721-738, 2001.(201)

165. Perry G, Smith MA. Comment: Is oxidative damage specific? Alzheimer Research Forum, 2001, http://www.alzforum.org/pap/annotation.asp?powID=14824.

166. Masters C, Stanculescu N, Bowen R, Bishop G, Morgan JP, Smith M, Perry G, Teplow D, Kim SH, DeKosky S, Chen M, Atwood C, Kinoshita J. Transcript of Live Discussion: Nomenclature Discussion. Alzheimer Research Forum, 2001, http://www.alzforum.org/res/for/journal/nomenclature/nom_transcript.asp.

167. Perry G, Nunomura A, Siedlak SL, Harris PLR, Zhu X, Castellani RJ, Aliev G, Smith MA. Oxidant and antioxidant responses in Alzheimer disease. Recent Res Devel Biophys Biochem 1:35-41, 2001.(3)

168. Smith MA, Perry G, Castellani R. FTD and ADHD: pathology versus pathophysiology. Neurol Psychiatr BR 9:137-138, 2001.

169. Perry G, Kumar BS, Smith MA. Journal of Alzheimer‘s Disease established as a leading journal. J Alzheimers Dis 3:521-523, 2001.

170. Perry G, Smith MA. Neurodegenerative disease: role of free radical damage. In: Research and Practice in Alzheimer‘s Disease, Vol. 6, Vellas B, Fitten LJ, Winblad B, Feldman H, Grundman M, Giacobini E, Kurz A, Eds, Serdi Publisher, Paris, France, 2002, pp 287-290.

171. Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA. Reactive oxygen: its sources and significance in Alzheimer disease. J Neural Transm Suppl 62:69-75, 2002.(27)

172. Castellani RJ, Atwood CS, Perry G, Petersen RB, Smith MA. Prion and Alzheimer diseases: the road to pathogenesis is paved with copper. In: Prion Diseases and Copper Metabolism: BSE, Scrapie and CJD Research, Brown DR, Ed, Horwood Publishing, Chichester, United Kingdom, 2002, pp 96-101 and 195-250.(1)

173. Aliev G, Smith MA, Seyidova D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 12:21-35, 2002.(113)

174. Smith MA, Perry G, Casadesus G, Joseph JA. Comment: Homeostatic control: relevance to Alzheimer disease. Alzheimer Research Forum, 2002, http://www.alzforum.org/new/detail.asp?id=349.

George Perry

94

175. Raina AK, Sayre LM, Atwood CS, Rottkamp CA, Hochman A, Zhu X, Obrenovich ME, Shimohama S, Nunomura A, Takeda A, Perry G, Smith MA. Apoptotic and oxidative indicators in Alzheimer‘s disease. In: Neuromethods, Vol. 37, Apoptosis Techniques and Protocols, 2nd Edition, LeBlanc AC, Ed, Humana Press, Inc., Totowa, New Jersey, 2002, pp 225-246.(1)

176. Smith MA, Raina AK, Perry G. The six degrees of Medline (Letter). The Scientist 16(3):12, 4 February 2002.

177. Smith MA, Perry G. Comment: Will anti-inflammatories fulfill their promise? Alzheimer Research Forum, 2002, http://www.alzforum.org/new/detail.asp?id=363.

178. Atwood CS, Bishop GM, Perry G, Smith MA. Comment: Vaccine disrupting ―scab‖? Aβ as a vascular sealant that protects against hemorrhage. Alzheimer Research Forum, 2002, http://www.alzforum.org/res/for/journal/vaccine/#comments.

179. Ogawa O, Perry G, Smith MA. The ―Down‘s‖ side of mitochondria. Dev Cell 2:255-256, 2002.(8)

180. Perry G, Smith M. Comment: Mitochondria, amyloid-β, and metabolism. Alzheimer Research Forum, 2002, http://www.alzforum.org/pap/annotation.asp?powID=15319.

181. Raina AK, Rottkamp CA, Zhu X, Ogawa O, Hochman A, Shimohama S, Takeda A, Nunomura A, Perry G, Smith MA. Neuronal survival and death in Alzheimer disease. In: Advances in Behavioral Biology 51: Mapping the Progress of Alzheimer‘s and Parkinson‘s Disease, Mizuno Y, Fisher A, Hanin I, Eds, Kluwer Academic/Plenum Publishers, New York, New York, 2002, pp 49-57.

182. Perry G, Smith MA. Comment: Alcohol and dementia: an antioxidant mechanism? Alzheimer Research Forum, 2002, http://www.alzforum.org/pap/annotation.asp?powID=11992.

183. Reddy VP, Obrenovich ME, Atwood CS, Perry G, Smith MA. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 4:191-209, 2002.(29)

184. Bishop GM, Robinson SR, Smith MA, Perry G, Atwood CS. Call for Elan to publish Alzheimer‘s trial details (Letter). Nature 416:677, 2002.(18)

185. Perry G, Sayre LM, Atwood CS, Castellani RJ, Cash AD, Rottkamp CA, Smith MA. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16:339-352, 2002.(87)

186. Smith MA, Drew KL, Nunomura A, Takeda A, Hirai K, Zhu X, Atwood CS, Raina AK, Rottkamp CA, Sayre LM, Friedland RP, Perry G. Amyloid-β, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 40:527-531, 2002.(32)

187. Perry G, Smith MA. Comment: Stalling the ravages of aging (and Alzheimer‘s?) with antioxidants. Alzheimer Research Forum, 2002, http://www.alzforum.org/pap/annotation.asp?powID=13518.

188. Smith MA, Atwood CS, Joseph JA, Perry G. Predicting the failure of amyloid-β vaccine. The Lancet 359:1864-1865, 2002.(37)

189. Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 24:184-187, 2002.(93)

190. Smith MA, Perry G, Pryor WA. Serial Review: Causes and consequences of oxidative stress in Alzheimer‘s disease. Free Radic Biol Med 32:1049, 2002.(33)

191. Koudinov AR, Smith MA, Perry G, Koudinova NV. Alzheimer‘s amyloid dogma. A time for change (Letter). BMJ, 2002, http://bmj.com/cgi/eletters/324/7352/1467#23197.(4)

192. Koudinov AR, Smith MA, Perry G, Koudinova NV. Alzheimer‘s disease and amyloid beta protein (Letter). Science, 2002, http://www.sciencemag.org/cgi/eletters/296/5575/1991#469.

193. Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA. The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease. Peptides 23:1333-1341, 2002.(67)

194. Atwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins. Peptides 23:1343-1350, 2002.(65)

195. Smith MA, Joseph JA, Atwood CS, Perry G. Dangers of the amyloid-β vaccination (Letter). Acta Neuropathol 104:110, 2002.(7)

196. Perry G, Cash AD, Srinivas R, Smith MA. Metals and oxidative homeostasis in Alzheimer‘s disease. Drug Dev Res 56:293-299, 2002.(13)

197. Perry G, Casadesus G, Joseph JA, Smith MA. Comment: What is the promise of antioxidants in Alzheimer disease? Alzheimer Research Forum, 2002, http://www.alzforum.org/new/detail.asp?id=600.

George Perry

95

198. Pappolla MA, Smith MA, Bryant-Thomas T, Bazan N, Petanceska S, Perry G, Thal LJ, Sano M, Refolo LM. Cholesterol, oxidative stress, and Alzheimer‘s disease: expanding the horizons of pathogenesis. Free Radic Biol Med 33:173-181, 2002.(49)

199. Takeda A, Itoyama Y, Kimpara T, Kutty RK, Abraham NG, Dwyer BE, Petersen RB, Perry G, Smith MA. Role of heme catabolism in neurodegenerative diseases. In: Heme Oxygenase in Biology and Medicine, Abraham NG, Ed, and Alam J, Nath K, Assoc Eds, Kluwer Academic/Plenum Publishers, New York, New York, 2002, pp 135-143.(1)

200. Smith MA, Atwood CS, Joseph JA, Perry G. Ill-fated amyloid-β vaccine (Letter). J Neurosci Res 69:285, 2002.(8)

201. Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2:120-123, 2002.(57)

202. Cash AD, Perry G, Smith MA. Therapeutic potential in Alzheimer disease. Curr Med Chem 9:1605-1610, 2002.(20)

203. Smith MA, Zhu X, Perry G. Signal transduction in Alzheimer‘s disease (Editorial). Neurosignals 11:235, 2002.

204. Zhu X, Lee H-g, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer‘s disease. Neurosignals 11:270-281, 2002.(174)

205. Lee H-g, Zhu X, Ghanbari HA, Ogawa O, Raina AK, O‘Neill MJ, Perry G, Smith MA. Differential regulation of glutamate receptors in Alzheimer‘s disease. Neurosignals 11:282-292, 2002.(22)

206. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA. Is Alzheimer‘s disease a mitochondrial disorder? Neuroscientist 8:489-496, 2002.(29)

207. Raina AK, Perry G, Zhu X, Smith MA. Comment: Harlequin and Alzheimer disease: remarkable parallels. Alzheimer Research Forum, 2002, http://www.alzforum.org/pap/annotation.asp?powID=20695.

208. Perry G, Smith MA. Comment: Eat less, live more - but why? Alzheimer Research Forum, 2002, http://www.alzforum.org/pap/annotation.asp?powID=19971.

209. Robinson S, Bishop G, Smith M, Perry G, Atwood C. Comment: The Alzheimer‘s vaccination story, continued. Alzheimer Research Forum, 2002, http://www.alzforum.org/new/detail.asp?id=679#robinson.

210. Ogawa O, Zhu X, Perry G, Smith MA. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease. Science‘s SAGE KE, 2002, http://sageke.sciencemag.org/cgi/content/full/sageke;2002/41/pe16.(3)

211. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-β and τ serve antioxidant functions in the aging and

Alzheimer brain. Free Radic Biol Med 33:1194-1199, 2002.(121)

212. Atwood CS, Bishop GM, Perry G, Smith MA. Commentary: Amyloid-β: a vascular sealant that protects against hemorrhage? J Neurosci Res 70:356, 2002.(26)

213. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G, Smith MA. Perspective: Role of mitochondrial dysfunction in Alzheimer‘s disease. J Neurosci Res 70:357-360, 2002.(155)

214. Perry G, Smith MA. Comment: New Parkinson‘s gene: DJ mutations make neurons change their tune. Alzheimer Research Forum, 2002, http://www.alzforum.org/new/detail.asp?id=713.

215. Obrenovich ME, Joseph JA, Atwood CS, Perry G, Smith MA. Commentary: Amyloid-β: a (life) preserver for the brain. Neurobiol Aging 23:1097-1099, 2002.(24)

216. Perry G, Nunomura A, Hirai K, Zhu X, Pérez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, Smith MA. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer‘s and other neurodegenerative diseases? Free Radic Biol Med 33:1475-1479, 2002.(183)

217. Drew KL, Tøien Ø, Rivera PM, Smith MA, Perry G, Rice ME. Role of the antioxidant ascorbate in hibernation and warming from hibernation. Comp Biochem Physiol C Toxicol Pharmacol 133:483-492, 2002.(46)

218. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, Shimohama S, Avila J, Castellani RJ, Smith MA. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 133:507-513, 2002.(42)

219. Kakimura J, Kitamura Y, Takata K, Tsuchiya D, Taniguchi T, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Possible involvement of ER chaperone Grp78 on reduced formation of amyloid-β deposits. Ann NY Acad Sci 977:327-332, 2002.(9)

George Perry

96

220. Takata K, Kitamura Y, Kakimura J, Shibagaki K, Taniguchi T, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Possible protective mechanisms of heme oxygenase-1 in the brain. Ann NY Acad Sci 977:501-506, 2002.(9)

221. Zhu X, Perry G, Smith MA. Oxidative stress and cell signaling in Alzheimer disease. In: XI Biennial Meeting of the Society for Free Radical Research International, Pasquier C, Ed, Monduzzi Editore, Bologna, Italy, 2002, pp 333-341.

222. Perry G, Srinivas R, Nunomura A, Smith MA. The role of oxidative mechanisms in neurodegenerative diseases. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Dickson DC, Ed, ISN Neuropath Press, Basel, Switzerland, 2003, pp 8-10.(3)

223. Perry G, Raina AK, Nunomura A, Lee H-G, Zhu X, Ogawa O, Liu Q, Perez M, Cash AD, Avila J, Castellani RJ, Atwood CS, Aliev G, Takeda A, Smith MA. Oxidative stress and the pathogenic mechanism of Alzheimer disease. In: Alzheimer‘s Disease and Related Disorders: Research Advances, Iqbal K, Winblad B, Eds, Ana Aslan International Academy of Aging, Bucharest, Hungary, 2003, pp 425-432.

224. Aliev G, Smith MA, De La Torre J, Perry G. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. In: Third International Congress on Vascular Dementia, Korczyn AD, Ed, Monduzzi Editore, Bologna, Italy, 2003, pp 9-20.

225. Atwood CS, Smith MA, Martins RN, Tanzi RE, Roher AE, Bush AI, Perry G. Neuroinflammatory environments promote amyloid-β deposition and posttranslational modification. In: Neuroinflammation: Mechanisms and Management, 2nd edition, Wood PL, Ed, Humana Press Inc., Totowa, New Jersey, 2003, pp 249-266.(2)

226. Perry G, Smith MA. Vejez y olvido (Spanish). La Vanguardia, 5 January 2003, p. 23, 2003.

227. Atwood CS, Perry G, Smith MA. Cerebral hemorrhage and amyloid-β (Letter). Science 299:1014, 2003.(18)

228. Aliev G, Perry G, Smith MA. Comment: Focus on the mitochondrion in neurodegenerative disease. Alzheimer Research Forum, 2003, http://www.alzforum.org/new/detail.asp?id=760.

229. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PLR, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals 16:77-81, 2003.(64)

230. Smith MA, Perry G, Atwood CS, Bowen RL. Estrogen replacement and risk of Alzheimer disease (Letter). JAMA 289:1100, 2003.(16)

231. Aliev G, Seyidova D, Raina AK, Obrenovich ME, Neal ML, Siedlak SL, Lamb BT, Vinters H, LaManna JC, Smith MA, Perry G. Vascular hypoperfusion, mitochondria failure and oxidative stress in Alzheimer disease. Proc Indian Natl Sci Acad B Biol Sci 69:209-238, 2003.(8)

232. Chao M, Zhu X, Raina AK, Aliev G, Takeda A, Petersen RB, Nunomura A, Tabaton M, Perry G, Smith MA. Sources contributing to the initiation and propagation of oxidative stress in Alzheimer disease. Proc Indian Natl Sci Acad B Biol Sci 69:251-260, 2003.(1)

233. Raina AK, Hochman A, Ickes II H, Zhu X, Ogawa O, Cash AD, Shimohama S, Perry G, Smith MA. Apoptotic promoters and inhibitors in Alzheimer‘s disease: who wins out? Prog Neuropsychopharmacol Biol Psychiatry 27:251-254, 2003.(34)

234. Atwood C, Bishop G, Perry G, Smith MA. Comment: Chelation, metals and Parkinson‘s disease. Alzheimer Research Forum, 2003, http://www.alzforum.org/new/detail.asp?id=786.(1)

235. Atwood C, Perry G, Smith MA, Webber K. Comment: Chelation as a therapeutic for neurodegenerative diseases. Alzheimer Research Forum, 2003, http://www.alzforum.org/new/detail.asp?id=786.

236. Perry G, Raina A, Smith MA, Zhu X. Comment: Oncogenic processes in Alzheimer‘s disease: a common link? Alzheimer Research Forum, 2003, http://www.alzforum.org/pap/annotation.asp?powID=26238.

237. Lee H-g, Zhu X, Webber KM, Raina AK, Perry G, Smith MA. Comment: Are two hits required for AD? Oxidative stress and cell cycle reentry. Alzheimer Research Forum, 2003, http://www.alzforum.org/pap/annotation.asp?powID=26367.

238. Raina AK, Zhu X, Perry G, Smith MA. Comment: How to die? Alzheimer Research Forum, 2003, http://www.alzforum.org/pap/annotation.asp?powID=26548.

239. Zhu X, Perry G, Smith MA. Amyotrophic lateral sclerosis: a novel hypothesis involving a gained ‗loss of function‘ in the JNK/SAPK pathway. Redox Rep 8:129-133, 2003.(2)

George Perry

97

240. Casadesus G, Smith MA, Perry G. Comment: Dietary antioxidants and Alzheimer disease. Alzheimer Research Forum, 2003, http://www.alzforum.org/new/detail.asp?id=840.

241. Aliev G, Obrenovich ME, Smith MA, Perry G. Hypoperfusion, mitochondria failure, oxidative stress, and Alzheimer disease. J Biomed Biotechnol 2003:162-163, 2003.(10)

242. Liu Q, Raina AK, Smith MA, Sayre LM, Perry G. Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Mol Aspects Med 24:305-313, 2003.(33)

243. Cash AD, Srinivas R, Rottkamp CA, Zhu X, Taddeo MA, Aliev G, Fujioka H, Atwood CS, Sayre LM, Castellani RJ, Smith MA, Perry G, Nunomura A. Metal homeostasis and its relation to oxidative stress in Alzheimer‘s disease. In: Redox-Genome Interactions in Health and Disease, Fuchs J, Podda M, Packer L, Eds, Marcel Dekker, Inc., New York, New York, 2003, pp 425-437.

244. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN. Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Brain Res Rev 43:1-16, 2003.(173)

245. Atwood CS, Bowen RL, Smith MA, Perry G. Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Brain Res Rev 43:164-178, 2003.(19)

246. Atwood C, Casadesus G, Perry G, Smith MA. Comment: Coping with copper—minute amount of metal plagues rabbit brain. Alzheimer Research Forum, 2003, http://www.alzforum.org/new/detail.asp?id=861.

247. Atwood C, Casadesus G, Perry G, Smith MA. Comment: Copper: a role in AD? Alzheimer Research Forum, 2003, http://www.alzforum.org/new/detail.asp?id=861.

248. Perry G, Nunomura A, Raina AK, Aliev G, Siedlak SL, Harris PLR, Casadesus G, Petersen RB, Bligh-Glover W, Balraj E, Petot GJ, Smith MA. A metabolic basis for Alzheimer disease. Neurochem Res 28:1549-1552, 2003.(34)

249. Zhu X, Raina AK, Lee H-G, Chao M, Nunomura A, Tabaton M, Petersen RB, Perry G, Smith MA. Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal 5:571-576, 2003.(45)

250. Lee H-g, Zhu X, Petersen RB, Perry G, Smith MA. Amyloids, aggregates and neuronal inclusions: good or bad news for neurons? Curr Med Chem – Immun Endoc Metab Agents 3:293-298, 2003.(1)

251. Lee H-g, Petersen RB, Zhu X, Honda K, Aliev G, Smith MA, Perry G. Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol 13:630-638, 2003.(19)

252. Perry G, Ávila J, Casadesus G, Nunomura A, Tabaton M, Cash A, Aliev G, Wataya T, Shimohama S, Drew K, Atwood C, Smith M. La función del estrés oxidativo en la patogénesis de la enfermedad de Alzheimer (Spanish). Rev Chil Neuro-Psiquiat 41 (Suppl 2);47-52, 2003.

253. Raina AK, Zhu X, Shimohama S, Perry G, Smith MA. Tipping the apoptotic balance in Alzheimer‘s disease: the abortosis concept. Cell Biochem Biophys 39:249-255, 2003.(15)

254. Nunomura A, Chiba S, Smith MA, Perry G. Oxidative damage and amyloid β deposition in the brains of Alzheimer‘s disease (Japanese). Proceedings of the Annual Meeting of the Japanese Research Group on Senile Dementia 13:43-45, 2003.

255. Nunomura A, Chiba S, Smith MA, Perry G. Alzheimer‘s disease and oxidative stress (Japanese). Proceedings of the Annual Meeting of the Japanese Research Group on Senile Dementia 13:83-85, 2003.

256. Taddeo MA, Smith MA, Liu Q, Atwood CS, Sayre LM, Perry G. Metal-catalyzed redox activity in neurodegenerative disease. In: Metal Ions and Neurodegenerative Disorders, Zatta P, Ed, World Scientific Publishing Co., Singapore, 2003, pp 1-14.

257. Aliev G, Smith MA, Obrenovich ME, De La Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotox Res 5:491-504, 2003.(78)

258. Moreira PI, Nunomura A, Honda K, Liu Q, Aliev G, Oliveira CR, Santos MS, Zhu X, Smith MA, Perry G. Stress and homeostatic regulation of oxidative damage in neurodegenerative disease. In: XII Biennial Meeting of the Society for Free Radical Research International, Puntarulo S, Boveris A, Eds, Medimond S.r.l., Bologna, Italy, 2004, pp 219-224.

259. Honda K, Perry G, Smith MA. Comment: Ceramide, cholesterol, and oxidative stress. Alzheimer Research Forum, 2004, http://www.alzforum.org/new/detail.asp?id=967.

George Perry

98

260. Perry G, Raina A, Smith MA. Comment: DNA damage mediated cell cycle reentry in AD. Alzheimer Research Forum, 2004, http://www.alzforum.org/new/detail.asp?id=968.

261. Zhu X, Perry G, Smith MA. Foreword: Alzheimer‘s disease. Acta Neurobiol Exp 64(1):i, 2004.

262. Castellani RJ, Perry G, Smith MA. Prion disease and Alzheimer‘s disease: pathogenic overlap. Acta Neurobiol Exp 64:11-17, 2004.(21)

263. Gómez-Ramos A, Smith MA, Perry G, Avila J. Tau phosphorylation and assembly. Acta Neurobiol Exp 64:33-39, 2004.(13)

264. Marlatt M, Lee H-g, Perry G, Smith MA, Zhu X. Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer‘s disease. Acta Neurobiol Exp 64:81-87, 2004.(28)

265. Lee H-g, Zhu X, O‘Neill MJ, Webber K, Casadesus G, Marlatt M, Raina AK, Perry G, Smith MA. The role of metabotropic glutamate receptors in Alzheimer‘s disease. Acta Neurobiol Exp 64:89-98, 2004.(24)

266. Webber KM, Bowen R, Casadesus G, Perry G, Atwood CS, Smith MA. Gonadotropins and Alzheimer‘s disease: the link between estrogen replacement therapy and neuroprotection. Acta Neurobiol Exp 64:113-118, 2004.(20)

267. Cash AD, Smith MA, Perry G. Oxidative stress mechanisms and potential therapeutic modalities in Alzheimer disease. Med Chem Rev Online 1:19-23, 2004.(4)

268. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer‘s disease. Ann NY Acad Sci 1012:179-182, 2004.(114)

269. Honda K, Liu Q, Perry G, Smith MA. Comment: Is redox regulation of development in Caenorhabditis elegans a critical issue? Alzheimer Research Forum, 2004, http://www.alzforum.org/new/detail.asp?id=923.

270. Zhu X, Raina AK, Lee H-g, Casadesus G, Smith MA, Perry G. Oxidative stress signalling in Alzheimer‘s disease. Brain Res 1000:32-39, 2004.(248)

271. Casadesus G, Perry G, Joseph JA, Smith MA. Eat less, eat better, and live longer: does it work and is it worth it? The role of diet in aging and disease. In: The Fountain of Youth: Cultural, Scientific, and Ethical Perspectives on a Biomedical Goal, Post SG, Binstock RH, Eds, Oxford University Press, New York, New York, 2004, pp 201-227.

272. Nunomura A, Chiba S, Takeda A, Smith MA, Perry G. Oxidative stress in Alzheimer disease: the earliest cytological and biochemical feature. In: Molecular Neurobiology of Alzheimer Disease and Related Disorders, Takeda M, Tanaka T, Cacabelos R, Eds, Karger, Basel, Switzerland, 2004, pp 164-171.(178)

273. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer‘s disease: the two-hit hypothesis. Lancet Neurol 3:219-226, 2004.(252)

274. Lee H-g, Casadesus G, Zhu X, Joseph JA, Perry G, Smith MA. Perspectives on the amyloid-β cascade hypothesis. J Alzheimers Dis 6:137-145, 2004.(34)

275. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, Perry G. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 6:165-169, 2004.(59)

276. Honda K, Perry G, Smith MA. Metal Ions and Neurodegenerative Diseases, Zatta P, Ed, World Scientific Publishing Co. Pte. Ltd., Singapore, 2004 (Book Review). Aging Cell 3:85, 2004.

277. Perry G, Smith MA. Comment: Amyloid-β: a stress-related protein. Alzheimer Research Forum, 2004, http://www.alzforum.org/com/pol/polldetail.asp?PollID=31.

278. Smith MA, Perry G. Leave the good amyloid β alone (Letter). The Scientist 18(8):10, 26 April 2004.

279. Honda K, Liu Q, Moreira P, Perry G, Smith MA, Zhu X. Comment: Parkin and mitochondria: are they allies in the war against Parkinson‘s disease? Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=35242.

280. Honda K, Shimohama S, Smith MA, Perry G. Comment: Role of redox-active iron in Alzheimer‘s disease. Curr Med Lit-Neurol 20:25-30, 2004.

281. Avila J, Pérez M, Lucas JJ, Gómez-Ramos A, Santa María I, Moreno F, Smith M, Perry G, Hernández F. Assembly in vitro of tau protein and its implications in Alzheimer‘s disease. Curr Alzheimer Res 1:97-101, 2004.(16)

282. Atwood C, Bowen R, Casadesus G, Perry G, Smith MA, Webber K. Comment: Sex, aging and Alzheimer‘s disease. Alzheimer Research Forum, 2004, http://www.alzforum.org/com/pol/polldetail.asp?PollID=32.

George Perry

99

283. Honda K, Liu Q, Moreira P, Perry G, Smith MA. Comment: Embalming amyloid-β: the role for aldehyde stress in Alzheimer‘s disease. Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=35429.

284. Aliev G, Moreira P, Oliveira C, Perry G, Santos M, Smith MA. Comment: ABAD – The new/old good/bad guy in Alzheimer‘s disease. Alzheimer Research Forum, 2004, http://www.alzforum.org/new/detail.asp?id=1000.

285. Atwood C, Perry G, Smith MA. Comment: When all that shines is not golden: metals in Alzheimer disease. Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=35663.

286. Martin A, Smith MA, Perry G, Joseph J. Nutritional antioxidants, vitamins, cognition, and neurodegenerative disease. In: Principles of Gender-Specific Medicine, Legato ML, Ed, Elsevier Academic Press, San Diego, California, 2004, pp 813-823.

287. Bowen R, Atwood CS, Perry G, Smith MA. Mechanisms involved in gender differences in Alzheimer‘s disease: the role of leuteinizing [sic] and follicle stimulating hormones. In: Principles of Gender-Specific Medicine, Legato ML, Ed, Elsevier Academic Press, San Diego, California, 2004, pp 1234-1237.

288. Perry G, Smith M. Professional grant writers (Letter). The Scientist 18(10):11, 24 May 2004.

289. Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer‘s disease pathogenesis. Neurobiol Aging 25:599-602, 2004.(11)

290. Seyidova D, Aliyev A, Rzayev N, Obrenovich M, Lamb BT, Smith MA, De La Torre JC, Perry G, Aliev G. The role of nitric oxide in the pathogenesis of brain lesions during the development of Alzheimer‘s disease. In Vivo 18:325-334, 2004.(17)

291. Sayre LM, Harris PLR, Perry G, Smith MA. In situ localization of nonenzymatic peroxidase-like activity of tissue-bound transition metals. In: Current Protocols in Toxicology, Maines MD, Costa LG, Hodgson E, Reed DJ, Sipes IG, Eds, John Wiley & Sons, Inc., Hoboken, New Jersey, 2004, pp 17.4.1-17.4.8.(1)

292. Lee H-G, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-β as protective adaptations to Alzheimer disease. Ann NY Acad Sci 1019:1-4, 2004.(88)

293. Zhu X, Webber KM, Casadesus G, Raina AK, Lee H-g, Marlatt M, Hartzler A, Atwood CS, Bowen R, Perry G, Smith MA. Mitotic and gender parallels in Alzheimer disease: therapeutic opportunities. Curr Drug Targets 5:559-563, 2004.(5)

294. Moreira PI, Oliveira C, Santos MS, Smith MA, Perry G. Comment: Brain aging and age-related neurodegenerative diseases: are vitamin and trace-element supplementation the ―miraculous‖ solution? Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=593.

295. Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G, Smith MA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 3:319-326, 2004.(57)

296. Aliyev A, Seyidova D, Rzayev N, Obrenovich ME, Lamb BT, Chen SG, Smith MA, Perry G, de la Torre JC, Aliev G. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer‘s disease? Neurol Res 26:547-553, 2004.(22)

297. Aliev G, Castellani RJ, Petersen RB, Burnstock G, Perry G, Smith MA. Pathobiology of familial hypercholesterolemic atherosclerosis. J Submicrosc Cytol Pathol 36:225-240, 2004.

298. Casadesus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen RL, Smith MA. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer‘s disease. Curr Drug Targets CNS Neurol Disord 3:281-285, 2004.(11)

299. Casadesus G, Perry G, Smith MA. Comment: Neurogenesis in AD: good, bad or ugly? Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=37525.

300. Honda K, Liu Q, Moreira P, Perry G, Smith MA, Zhu X. Comment: Mitochondria and Alzheimer‘s disease: a complex interrelationship. Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=38453.

301. Perry G, Raina A, Smith MA. Comment: Caspase activation but not apoptosis. Alzheimer Research Forum, 2004, http://www.alzforum.org/pap/annotation.asp?powID=38344.

302. Moreira PI, Perry G. Mitochondria and Alzheimer‘s disease: a powerful link. United Mitochondrial Disease Foundation: Mitochondrial News 9(3):1, 8 & 15, 2004.

303. Aliev G, Smith MA, de la Torre JC, Perry G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer‘s disease. Mitochondrion 4:649-663, 2004.(49)

George Perry

100

304. Perry G, Smith MA. Alzheimer‘s disease. In: Encyclopedia of Neuroscience, 3rd Edition, Adelman G, Smith BH, Eds, Elsevier Science BV, Amsterdam, 2004, article 00000709.

305. Takeda A, Itoyama Y, Kimpara T, Zhu X, Avila J, Dwyer BE, Perry G, Smith MA. Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid Redox Signal 6:888-894, 2004.(25)

306. Smith MA, Moreira PI, Castellani RJ, Perry G. Symposium: Amyloid-β: a multifaceted protein. Brain Pathol 14:425, 2004.

307. Zhu X, Perry G, Smith MA. Hypothesis: Two hits and you‘re out? A novel mechanistic hypothesis of Alzheimer disease. Alzheimer Research Forum, 2004, http://www.alzforum.org/res/adh/cur/zhu/default.asp.

308. de la Torre J, Aliev G, Perry G. Drug therapy in Alzheimer's disease. N Engl J Med 351:1911, 2004.(3)

309. Smith MA, Perry G. Pathology is not necessarily pathogenic. Sci Aging Knowl Environ (Bulletin Board, 29 October 2004), http://sageke.sciencemag.org/cgi/forum-display/short/sageke_el;276.

310. Moreira PI, Smith MA, Zhu X, Santos MS, Oliveira CR, Perry G. Therapeutic potential of oxidant mechanisms in Alzheimer‘s disease. Expert Rev Neurother 4:995-1004, 2004.

311. Lee H-g, Moreira PI, Zhu X, Smith MA, Perry G. Commentary: Staying connected: synapses in Alzheimer disease. Am J Pathol 165:1461-1464, 2004.(13)

312. Moreira PI, Oliveira CR, Santos MS, Honda K, Liu Q, Smith MA, Zhu X, Perry G. Alzheimer disease: oxidative stress and homeostatic regulation. Dedicated to the memory of Professor Carlos Garcia. Rev Fac Med Lisboa 9:455-460, 2004.

313. Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures in Alzheimer‘s disease. Am J Alzheimers Dis Other Demen 19:345-352, 2004.(27)

314. Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua [sic] X, Smith MA, Perry G. Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057-3075, 2004.(71)

315. Perry G, Raina AK, Cohen ML, Smith MA. When hypotheses dominate: established ideas can strangle the assessment of valid alternatives (Opinion). The Scientist 18(23):6, 6 December 2004.(5)

316. Garrett M, Perry G, Smith MA. Comment: Leaping on leptin: what‘s the skinny? Alzheimer Research Forum, 2004, http://www.alzforum.org/new/detail.asp?id=1121.

317. Zhu X, Casadesus G, Lee H-g, Perry G, Smith MA. Mitogen-activated protein kinase pathways in nervous system and Alzheimer disease. In: Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects, Clinical Perspectives and New Insights, Özben T, Chevion M, Eds, IOS Press, Amsterdam, The Netherlands, 2004, pp 189-199.

318. Zhu X, Casadesus G, Raina AK, Perry G, Smith MA. Neuronal cell cycle re-entry: a doomed journey in Alzheimer disease? In: Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects, Clinical Perspectives and New Insights, Özben T, Chevion M, Eds, IOS Press, Amsterdam, The Netherlands, 2004, pp 200-206.

319. Perry G, Friedland RP, Petot GJ, Nunomura A, Castellani RJ, Kubat Z, Smith MA. Alzheimer as a disease of metabolic demand: benefits of physical and brain exercise. In: Exercise and Diseases: Prevention Through Training, Radak Z, Ed, Meyer & Meyer Sport (UK) Ltd., Oxford, United Kingdom, 2005, pp 7-16.

320. Moreira PI, Nunomura A, Petot GJ, Aliev G, Smith MA, Perry G. Brain metabolic alterations are early signs in Alzheimer disease pathophysiology. In: Research and Practice in Alzheimer‘s Disease, Special Issue on Nutrition, Cognitive Decline and Aging, Vellas B, Fitten LJ, Eds, Serdi, Paris, France, 2005, pp 61-65.

321. Moreira PI, Zhu X, Nunomura A, Honda K, Lee H-g, Aliev G, Smith MA, Perry G. Oxidative stress in Alzheimer disease: an overview. In: Perspectives in Neurosciences, Baloyannis SJ, Ed, Greece Society for Amelioration of the Quality of Life for Chronic Neurologic Patients, Thessalonikh, Greece, 2005, pp 419-433.

322. Liu Q, Lee H-g, Honda K, Siedlak SL, Harris PLR, Cash AD, Zhu X, Avila J, Nunomura A, Takeda A, Smith MA, Perry G. Tau modifiers as therapeutic targets for Alzheimer‘s disease. Biochim Biophys Acta 1739:211-215, 2005.(8)

323. Moreira PI, Smith MA, Zhu X, Honda K, Lee H-g, Aliev G, Perry G. Oxidative damage and Alzheimer‘s disease: are antioxidant therapies useful? Drug News Perspect 18:13-19, 2005.(20)

324. Garrett M, Perry G, Smith MA. Comment: Mitochondria in Alzheimer disease: pulling the plug on the synapse. Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1124.

325. Webber K, Smith MA, Zhu X, Perry G. Comment: Peripheral diagnosis of signaling intermediates in Alzheimer disease. Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1117.

George Perry

101

326. Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, Perry G, Bowen RL, Smith MA. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci 62:293-298, 2005.(38)

327. Zhu X, Lee H-g, Casadesus G, Avila J, Drew K, Perry G, Smith MA. Oxidative imbalance in Alzheimer‘s disease. Mol Neurobiol 31:205-217, 2005.(76)

328. Zhu X, Perry G, Smith MA. Alzheimer disease: mitotic and oxidative stressors. The two hit hypothesis. In: Proceedings of the 9th International Conference on Alzheimer‘s Disease and Related Disorders [CD-ROM], Iqbal K, Winblad B, Thies WH, Eds, Alzheimer‘s Association, Chicago, Illinois, 2005, pp 178-189.

329. Moreira PI, Honda K, Liu Q, Aliev G, Oliveira CR, Santos MS, Zhu X, Smith MA, Perry G. Alzheimer‘s disease and oxidative stress: the old problem remains unsolved. Curr Med Chem Cent Nerv Syst Agents 5:51-62, 2005.

330. Perry G. Obituary: Masamichi Aikawa. Reminiscences of Masamichi Aikawa, Matsumura A, Ito Y, Aikawa H, Eds. (Hirakawa-kogyosha Co. Ltd.), Tokyo, Japan, 2005, p.123.

331. Zhu X, Perry G, Smith MA. Commentary: Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J Alzheimers Dis 7:81-84, 2005.(26)

332. Perry G, Smith MA. Oxidative stress and inflammation in neurodegenerative diseases. In: Topics in Neurodegeneration, Michaelson DM, Hartmann T, Eds, 2005, http://www.ipa-online.org/neurosite/PPT/perry_Oxstress.ppt.

333. Aliev G, Moreira P, Obrenovich ME, Oliveira C, Perry G, Smith MA. Comment: Mitochondria: another dimension in protein misfolding. Alzheimer Research Forum, 2005, http://www.alzforum.org/pap/annotation.asp?powID=43769.

334. Moreira PI, Oliveira CR, Santos MS, Nunomura A, Honda K, Zhu X, Smith MA, Perry G. A second look into the oxidant mechanisms in Alzheimer‘s disease. Curr Neurovasc Res 2:179-184, 2005.(7)

335. Lee H-g, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer‘s disease: pathogen or protector? Trends Mol Med 11:164-169, 2005.(138)

336. Castellani RJ, DeWitt DA, Perry G, Smith MA. Involvement of complex carbohydrate chemistry in Alzheimer disease. Med Hypotheses Res 2:393-400, 2005.

337. Webber KM, Casadesus G, Perry G, Atwood CS, Bowen R, Smith MA. Gender differences in Alzheimer disease: the role of luteinizing hormone in disease pathogenesis. Alzheimer Dis Assoc Disord 19:95-99, 2005.(18)

338. Smith MA, Nunomura A, Lee H-g, Zhu X, Moreira PI, Avila J, Perry G. Commentary: Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging 26:579-580, 2005.(14)

339. Marlatt MW, Webber KM, Moreira PI, Lee H-g, Casadesus G, Honda K, Zhu X, Perry G, Smith MA. Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 12:1137-1147, 2005.(36)

340. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowl Environ 18:pe12, 2005 (http://sageke.sciencemag.org/cgi/content/full/2005/18/pe12).

341. Barbeito L, Chun J, Binder LI, Neto VM, Perry G, Scazzochio C, Violini G. The end of a Chilean institute (Letter). Science 308:792-793, 2005.

342. Lee H-g, Smith MA, Dwyer B, Nunomura A, Perry G, Zhu X. Comment: Homocysteine and AD: more than meets the eye. Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1201.

343. Sayre LM, Moreira PI, Smith MA, Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanità 41:143-164, 2005.

344. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, Smith MA, Perry G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 112:921-932, 2005.(42)

345. Moreira PI, Smith MA, Zhu X, Nunomura A, Castellani RJ, Perry G. Oxidative stress and neurodegeneration. Ann NY Acad Sci 1043:545-552, 2005.(53)

346. Webber KM, Casadesus G, Marlatt MW, Perry G, Hamlin CR, Atwood CS, Bowen RL, Smith MA. Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann NY Acad Sci 1052:201-209, 2005.(23)

347. Smith MA, Perry G. Introduction: Role of amyloid-β in Alzheimer‘s disease. Int J Exp Pathol 86:131, 2005.

348. Lee H-G, Castellani RJ, Zhu X, Perry G, Smith MA. Amyloid-β in Alzheimer‘s disease: the horse or the cart? Pathogenic or protective? Int J Exp Pathol 86:133-138, 2005.(33)

George Perry

102

349. Ashford JW, Atwood CS, Blass JP, Bowen RL, Finch CE, Iqbal K, Joseph JA, Perry G. What is aging? What is its role in Alzheimer‘s disease? What can we do about it? J Alzheimers Dis 7:247-253, 2005.(14)

350. Casadesus G, Lee H-g, Perry G, Smith MA, Webber K, Zhu X. Comment: The wheel of death: neuronal cell cycle and Alzheimer disease. Alzheimer Research Forum, 2005, http://www.alzforum.org/pap/annotation.asp?powID=45758.

351. Casadesus G, Perry G, Smith MA. Comment: Cortico-cortical connectivity: a key aspect to neurodegeneration. Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1191.

352. Dwyer BE, Takeda A, Zhu X, Perry G, Smith MA. Ferric cycle activity and Alzheimer disease. Curr Neurovasc Res 2:261-267, 2005.(9)

353. Casadesus G, Smith MA, Perry G. Commentary: ―Ceramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer‘s disease. Just hypotheses or molecular pathways to be identified?‖ by Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli. Alzheimers Dementia 1:51-52, 2005.

354. Perry G, Smith MA. Introduction: Imaging in Alzheimer‘s disease. Microsc Res Tech 67:113, 2005.

355. Casadesus G, Perry G, Smith MA. Comment: DNA fragmentation mechanism involving oxidative stress:

relevance to Alzheimer disease. Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1215.

356. Casadesus G, Lee H-g, Moreira P, Nunomura A, Perry G, Smith MA, Zhu X. Comment: Neurofibrillary tangles: villain or merely vilified? What‘s next? TADDLs/TAuDDLs! Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1227.

357. Lee H-g, Zhu X, Perry G, Smith M. Comment: Another disconnect between amyloid and cognition. Alzheimer Research Forum, 2005, http://www.alzforum.org/new/detail.asp?id=1231.

358. Perry G. Portuguese-Americans: the lost Hispanics. Portuguese-American Historical & Research Foundation, 2005, http://www.portuguesefoundation.org/gp_portuguese_americans.htm.

359. Honda K, Moreira PI, Liu Q, Siedlak SL, Zhu X, Smith MA, Perry G. Redox active iron at the center of oxidative stress in Alzheimer disease. Lett Drug Des Discov 2:479-482, 2005.(3)

360. Zhu X, Moreira PI, Smith MA, Perry G. Alzheimer‘s disease: an intracellular movement disorder? Trends Mol Med 11:391-393, 2005.(12)

361. Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 1741:246-252, 2005.(75)

362. Webber KM, Raina AK, Marlatt MW, Zhu X, Prat MI, Morelli L, Casadesus G, Perry G, Smith MA. The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech Ageing Dev 126:1019-1025, 2005.(45)

363. Moreira PI, Honda K, Liu Q, Santos MS, Oliveira CR, Aliev G, Nunomura A, Zhu X, Smith MA, Perry G. Oxidative stress: the old enemy in Alzheimer‘s disease pathophysiology. Curr Alzheimer Res 2:403-408, 2005.(23)

364. Casadesus G, Perry G, Smith MA. Comment: In search of ―absolute‖ truth: has the lab bench replaced the ―burning at the stake‖? Alzheimer Research Forum, 2005, http://www.alzforum.org/pap/annotation.asp?powID=51392.

365. Guevara J, Espinosa B, Vázquez L, Luna J, Zenteno E, Perry G, Mena R. Confocal analysis of abnormal posttranslational protein procesing [sic] in Alzheimer‘s disease. In: Electron Microscopy 1998, Vol. 1, Calderón Benavides HA, José Yacamán M, Eds, Institute of Physics Publishing: Bristol and Philadelphia, Philadelphia, Pennsylvania, 1998, pp 819-820.(6)

366. Zhou F, Zhu X, Smith MA, Castellani RJ, Stimmelmayr R, Perry G, Drew KL. Hibernation, a model of neuroprotection. TheScientificWorld 1(S3):2 pages, doi:10.1100/TSW.2001.132, 2001.

367. Perry G. Inflammation and oxidative mechanisms in Alzheimer‘s disease – novel therapeutic windows to treatment. In: XIV Symposium: Current Themes in Biological Research: New Approaches in Alzheimer‘s Disease Therapy, Edicionades Mayo, S.A., Barcelona, Spain, 2005, pp 65-84.

368. Gustaw KA, Casadesus G, Friedland RP, Perry G, Smith MA. Cell cycle activation and the amyloid-β protein in Alzheimer‘s disease. In: The Cell Cycle in the Central Nervous System, Janigro D, Ed, Humana Press Inc., Totowa, New Jersey, 2006, pp 299-308.

369. Casadesus G, Zhu X, Lee H-g, Marlatt MW, Friedland RP, Gustaw KA, Perry G, Smith MA. Neurogenesis in Alzheimer‘s disease: compensation, crisis, or chaos? In: The Cell Cycle in the Central Nervous System, Janigro D, Ed, Humana Press Inc., Totowa, New Jersey, 2006, pp 359-370.

George Perry

103

370. Castellani RJ, Nunomura A, Lee H-g, Zhu X, Perry G, Smith MA. Amyloid-β and ԏ in Alzheimer‘s disease: what is the neuropathology trying to tell us? In: Oxidative Stress and Age-Related Neurodegeneration, Luo Y, Packer L, Eds, Taylor & Francis Group, Boca Raton, Florida, 2006, pp 121-129.

371. Moreira PI, Zhu X, Smith MA, Perry G, Nunomura A. Antioxidant therapies in the prevention and treatment of Alzheimer disease. In: Oxidative Stress and Age-Related Neurodegeneration, Luo Y, Packer L, Eds, Taylor & Francis Group, Boca Raton, Florida, 2006, pp 131-145.

372. Nunomura A, Tabata K, Chiba S, Smith MA, Perry G. Temporal primacy of oxidative stress in the pathological cascade of Alzheimer disease. In: Oxidative Stress and Age-Related Neurodegeneration, Luo Y, Packer L, Eds, Taylor & Francis Group, Boca Raton, Florida, 2006, pp 365-372.

373. Lee H-g, Zhu X, Drew KL, Joseph JA, Nunomura A, Hirai K, Takeda A, Perry G, Smith MA. Oxidative adaptation in aging and Alzheimer‘s disease: the roles of amyloid and tau. In: Molecular Interventions in Lifestyle-Related Diseases, Hiramatsu M, Yoshikawa T, Packer L, Eds, Taylor & Francis Group, Boca Raton, Florida, 2006, pp 117-125.

374. Nunomura A, Zhu X, Moreira PI, Smith MA, Perry G. Involvement of oxidative stress in the early-stage of Alzheimer‘s disease: implications for therapeutics. In: Trends in Alzheimer‘s Disease Research, Welsh EM, Ed, Nova Science Publishers, Inc., Hauppauge, New York, 2006, pp 161-183.

375. Reddy VP, Perry G, Cooke MS, Sayre LM, Smith MA. Mechanisms of DNA damage and repair in Alzheimer disease. In: DNA Repair and Human Disease, Balajee AS, Ed, Landes Bioscience and Springer Science+Business Media, Austin, Texas, Philadelphia, Pennsylvania, 2006, pp 98-113.

376. Smith MA, Perry G. The changing landscape of Alzheimer‘s disease: from insoluble to soluble and from pathogen to protector. In: Alzheimer: 100 Years and Beyond, Jucker M, Beyreuther K, Haass C, Nitsch RM, Christen Y, Eds, Springer-Verlag, Berlin, Heidelberg, Germany, 2006, pp 367-369 and pp 467-538.

377. Moreira PI, Zhu X, Lee H-g, Nunomura A, Smith MA, Perry G. Therapeutic potential of oxidative stress reduction in Alzheimer‘s disease. Future Neurol 1:1-4, 2006.

378. Moreira PI, Zhu X, Liu Q, Honda K, Siedlak SL, Harris PL, Smith MA, Perry G. Compensatory responses induced by oxidative stress in Alzheimer disease. Biol Res 39:7-13, 2006.(24)

379. Moreira PI, Honda K, Zhu X, Nunomura A, Casadesus G, Smith MA, Perry G. Brain and brawn: parallels in oxidative strength. Neurology 66 (Suppl 1):S97-S101, 2006.(27)

380. Lee H-g, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 3:75-80, 2006.(11)

381. Lee H-g, Zhu X, Perry G, Smith MA. The fallacy of amyloid and cognition in Alzheimer‘s disease (Letter). Drugs Aging 23:179, 2006.

382. Raina AK, Garrett MR, Previll LA, Obrenovich ME, Hartzler AW, Webber KM, Casadesus G, Lee H-g, Perry G, Zhu X, Smith MA. Oncogenic parallels in Alzheimer disease. Int J Neuroprotec Neuroregener 2:80-85, 2006.

383. Webber KM, Casadesus G, Zhu X, Obrenovich ME, Atwood CS, Perry G, Bowen RL, Smith MA. The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target. Curr Pharm Design 12:691-697, 2006.(12)

384. Casadesus G, Garrett M, Perry G, Smith MA. Comment: The serotonergic malady in Alzheimer disease: implications for patients and caregivers. Alzheimer Research Forum, 2006, http://www.alzforum.org/pap/annotation.asp?powID=48278.

385. Lee H-g, Perry G, Smith MA, Zhu X. Comment: Tau-amyloid interactions: a timely revival? Alzheimer Research Forum, 2006, http://www.alzforum.org/pap/annotation.asp?powID=52386.

386. Zhu X, Lee H-g, Moreira PI, Smith MA, Perry G. Commentary: Presenilin mutation: a deadly first hit in Alzheimer disease: a commentary on ―Aging sensitizes towards ROS formation and lipid peroxidation in PS1M146L transgenic mice.‖ Free Radic Biol Med 40:737-739, 2006.(3)

387. Lee H-g, Nunomura A, Perry G, Smith MA, Zhu X. Comment: Imagine imaging iron in Alzheimer disease. Alzheimer Research Forum, 2006, http://www.alzforum.org/pap/annotation.asp?powID=48256.

388. Lee H-g, Nunomura A, Perry G, Smith MA, Zhu X. Comment: Star-struck by amyloid. Alzheimer Research Forum, 2006, http://www.alzforum.org/pap/annotation.asp?powID=53355.

389. Lee H-g, Nunomura A, Perry G, Smith MA. Comment: Less amyloid-β equals more disease. Alzheimer Research Forum, 2006, http://www.alzforum.org/res/for/journal/detail.asp?LiveID=46#BFE81EC4-37BE-448B-9134-CE6D4C79FC1A.

George Perry

104

390. Castellani RJ, Lee H-g, Perry G, Smith MA. Antioxidant protection and neurodegenerative disease: the role of amyloid-β and tau. Am J Alzheimers Dis Other Dement 21:126-130, 2006.(7)

391. Nunomura A, Castellani RJ, Lee H-g, Moreira PI, Zhu X, Perry G, Smith MA. Neuropathology in Alzheimer‘s disease: awaking from a hundred-year-old dream. Sci Aging Knowl Environ 2006:8 pages, pp. pe10, 2006, doi:10.1126/sageke.2006.8.pe10, 2006.

392. Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, Perry G. Oxidative damage to RNA in neurodegenerative diseases. J Biomed Biotechnol 2006:6 pages, doi:10.1155/JBB/2006/82323, 2006.(42)

393. Casadesus G, Garrett MR, Webber KM, Hartzler AW, Atwood CS, Perry G, Bowen RL, Smith MA. The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer‘s disease. Drugs R D 7:187-193, 2006.(2)

394. Castellani RJ, Lee H-G, Zhu X, Nunomura A, Perry G, Smith MA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 111:503-509, 2006.(83)

395. Moreira PI, Zhu X, Lee H-G, Honda K, Smith MA, Perry G. The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. Mech Ageing Dev 127:501-506, 2006.(13)

396. Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G. Therapeutic options in Alzheimer‘s disease. Expert Rev Neurother 6:897-910, 2006.(6)

397. Lee H-g, Nunomura A, Perry G, Smith MA, Zhu X. Comment: Amyloid-β: the finger or the moon? Alzheimer Research Forum, 2006, http://www.alzforum.org/new/detail.asp?id=1395.

398. Dwyer BE, Stone ML, Zhu X, Perry G, Smith MA. Heme deficiency in Alzheimer‘s disease: a possible connection to porphyria. J Biomed Biotech 2006:5 pages, doi:10.1155/JBB/2006/24038, 2006.(5)

399. Lee HG, Ueda M, Zhu X, Perry G, Smith MA. Aberrant localization of phospho-Smad2 in the vulnerable neurons of Alzheimer disease. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 79-82.

400. Zhu X, Smith MA, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Perry G, Chen SG. LRRK2 in Lewy bodies of Parkinson disease and dementia with Lewy bodies. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 229-232.

401. Casadesus G, Webber KM, Atwood CS, Bowen RL, Perry G, Smith MA. Luteinizing hormone mediates Alzheimer-type changes in neurons. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 307-310.

402. Lee HG, Ueda M, Zhu X, Perry G, Smith MA. Failure of cytoplasmic-nuclear transport in Alzheimer disease. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 341-344.

403. Moreira PI, Siedlak SL, Santos MS, Oliveira CR, Fujioka H, Tabaton M, Nunomura A, Aliev G, Szweda LI, Zhu X, Smith MA, Perry G. Mitochondrial autophagocytosis in Alzheimer disease. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 373-376.

404. Lee HG, Smith MA, Richardson SL, Perry G, Petersen RB. Oxidative stress and prion protein mutations. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 377-380.

405. Previll LA, Crosby ME, Castellani RJ, Bowser R, Perry G, Smith MA, Zhu X. Increased expression of p130 in Alzheimer disease. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 381-384.

406. Nunomura A, Chiba S, Yamaguchi H, Smith MA, Perry G. Intraneuronal amyloid-β42 may silence oxidative stress in Alzheimer‘s disease. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 447-449.

407. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G. Lipoic acid and N-acetyl cysteine protect against oxidative stress in fibroblasts from Alzheimer disease patients. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 541-544.

408. Webber KM, Stocco DM, Casadesus G, Bowen RL, Atwood CS, Previll LA, Harris PLR, Zhu X, Perry G, Smith MA. Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. In: Alzheimer‘s Disease: New Advances, Iqbal K, Winblad B, Avila J, Eds, Medimond S.r.l., Bologna, Italy, 2006, pp 581-584.

409. Lee H-g, Zhu X, Takeda A, Perry G, Smith MA. Emerging evidence for the neuroprotective role of α-synuclein. Exp Neurol 200:1-7, 2006.(22)

George Perry

105

410. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65:631-641, 2006.(224)

411. Perry G, Avila J, Kinoshita J, Smith MA. Preface: Alzheimer‘s disease: a century of scientific and clinical research. In: Alzheimer‘s Disease: A Century of Scientific and Clinical Research, Perry G, Avila J, Kinoshita J, Smith MA, Eds, IOS Press, Amsterdam, The Netherlands. J Alzheimers Dis 9:1, 2006.(1)

412. Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, Smith MA. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9:147-153, 2006.(76)

413. Perry G. Solving the insoluble. In: Alzheimer‘s Disease: A Century of Scientific and Clinical Research, Perry G, Avila J, Kinoshita J, Smith MA, Eds, IOS Press, Amsterdam, The Netherlands. J Alzheimers Dis 9:301-304, 2006.

414. Smith MA, Perry G, Zhu X, Haoudi A. Editorial: Neurodegenerative diseases: mechanisms and therapies. J Biomed Biotechnol 2006:2 pages, doi:10.1155/JBB/2006/47539, 2006.(1)

415. Lee H-g, Perry G, Zhu X, Nunomura A, Smith MA. Commentary: Amyloid-β, BACE, and oxidative stress in Alzheimer‘s disease, a commentary on ―The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression.‖ Free Radic Biol Med 41:188-189, 2006.(10)

416. Forero DA, Casadesus G, Perry G, Arboleda H. Synaptic dysfunction and oxidative stress in Alzheimer‘s disease: emerging mechanisms. J Cell Mol Med 10:796-805, 2006.(44)

417. Casadesus G, Puig ER, Webber KM, Atwood CS, Escuer MC, Bowen RL, Perry G, Smith MA. Targeting gonadotropins: an alternative option for Alzheimer disease treatment. J Biomed Biotechnol 2006:8 pages, doi:10.1155/JBB/2006/39508, 2006.(7)

418. Lee H-g, Perry G, Smith MA, Zhu X. Comment: Antioxidant defenses – nitric oxide, amyloid-β and tau phosphorylation: a zero sum game. Alzheimer Research Forum, 2006, http://www.alzforum.org/pap/annotation.asp?powID=57357.

419. Lee H-g, Zhu X, Nunomura A, Perry G, Smith MA. Commentary: Amyloid-β vaccination: testing the amyloid hypothesis? Heads we win, tails you lose! Am J Pathol 169:738-739, 2006.(8)

420. Smith MA, Jagannathan Rao KS, Perry G. Foreword: Apoptotic mechanisms in neurodegenerative diseases. Curr Alzheimer Res 3:267, 2006.

421. Zhu X, Raina AK, Perry G, Smith MA. Apoptosis in Alzheimer disease: a mathematical improbability. Curr Alzheimer Res 3:393-396, 2006.(9)

422. Smith MA, Perry G. Commentary on ―Perspective on a pathogenesis and treatment of Alzheimer‘s disease.‖ Therapeutic strategies for Alzheimer‘s disease: the need for a new era of innovation. Alzheimers Dement 2:294-295, 2006.

423. Perry G, Knight R, Smith MA. Maladie d‘Alzheimer: les quarante dernieres années. Alzheimer Actualités, No. 189, pp 8-11, 2006.

424. Lam-Himlin D, Espey MG, Perry G, Smith MA, Castellani RJ. Malignant glioma progression and nitric oxide. Neurochem Int 49:764-768, 2006.(24)

425. Aliev G, Liu J, Xu K, Puchowicz M, Siedlak SL, Shenk JC, Smith MA, Gasimov E, Obrenovich ME, Fischbach K, Koistinaho J, LaManna JC, Ames BN, Perry G. ApoE4 in mice induces age-dependent brain hypoperfusion, neuronal, glial and microvascular damage, and cognitive impairment, which can be prevented by feeding acetyl-L-carnitine and R-lipoic acid. In: New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007, Hanin I, Windisch M, Poewe W, Fisher A, Eds, Medimond S.r.l., Bologna, Italy, 2007, pp 105-126.

426. Castellani RJ, Alexiev BA, Phillips D, Perry G, Smith MA. Microscopic investigations in neurodegenerative diseases. In: Modern Research and Educational Topics in Microscopy, Vol. 1, Méndez-Vilas A, Díaz J, Eds, Formatex, Badajoz, Spain, 2007, pp 171-182.

427. Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G. Oxidative damage is the earliest change of Alzheimer‘s disease: therapeutic opportunities. In: Research Progress in Alzheimer‘s Disease and Dementia, Vol. 1, Sun M-K, Ed, Nova Science Publishers, Inc., Hauppauge, New York, 2007, pp 301-317.

428. Evans TA, Zhu X, Lee H-g, Previll LA, Webber KM, Casadesus G, Perry G, Smith MA. Alzheimer‘s disease: a deregulated cell cycle disease. In: Research Progress in Alzheimer‘s Disease and Dementia, Vol. 2, Sun M-K, Ed, Nova Science Publishers, Inc., Hauppauge, New York, 2007, pp 109-122.

429. Bonda DJ, Webber KM, Siedlak SL, Perry G, Friedland RP, Smith MA. The pathology of Alzheimer disease elicits an in vivo immunological response. Am J Immunol 3:10-14, 2007.

George Perry

106

430. Liu G, Men P, Perry G, Smith MA. Nanoparticles for the treatment of Alzheimer's disease: theoretical rationale, present status and future perspectives. In: Nanotechnologies for the Life Sciences, Vol. 10, Kumar CSSR, Ed, WILEY-VCH Verlag GmbH & co.KGaA, Weinheim, Germany, 2007, pp 644-706.

431. Webber KM, Casadesus G, Atwood CS, Bowen RL, Perry G, Smith MA. Gonadotropins: a cohesive gender-based etiology of Alzheimer disease. Mol Cell Endocrinol 260-262:271-275, 2007.(13)

432. Castellani R, Lee H-g, Nunomura A, Perry G, Smith MA. Comment: Amyloid-β: a protective function. Alzheimer Research Forum, 2007, http://www.alzforum.org/com/pol/polldetail.asp?pollID=49.

433. Liu Q, Xie F, Rolston R, Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G. Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini-Rev Med Chem 7:171-180, 2007.(6)

434. Moreira PI, Nunomura A, Honda K, Aliev G, Casadesus G, Zhu X, Smith MA, Perry G. The key role of oxidative stress in Alzheimer‘s disease. In: Oxidative Stress and Neurodegenerative Disorders, Qureshi GA, Parvez SH, Eds, Elsevier B.V., Amsterdam, The Netherlands, 2007, pp 267-281.

435. Nunomura A, Perry G, Smith MA. Prospects for antioxidant therapy in mild cognitive impairment and Alzheimer's disease. In: Oxidative Stress and Neurodegenerative Disorders, Qureshi GA, Parvez SH, Eds, Elsevier B.V., Amsterdam, The Netherlands, 2007, pp 451-466.

436. Perry G, Smith MA. Editorial: Sir Martin Roth – a debt of gratitude. J Alzheimers Dis 11:1, 2007.

437. Castellani R, Lee H-g, Perry G, Smith MA, Zhu X. Comment: Amyloid: getting less toxic every day. Alzheimer Research Forum, 2007, http://www.alzforum.org/pap/annotation.asp?powID=62708.

438. Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G. Indices of metabolic dysfunction and oxidative stress. Neurochem Res 32:717-722, 2007.(13)

439. Zhu X, Lee H-g, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 1772:494-502, 2007.(58)

440. Castellani RJ, Zhu X, Lee H-g, Moreira PI, Perry G, Smith MA. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother 7:473-485, 2007.

441. Petersen RB, Nunomura A, Lee H-g, Casadesus G, Perry G, Smith MA, Zhu X. Signal transduction cascades associated with oxidative stress in Alzheimer‘s disease. J Alzheimers Dis 11:143-152, 2007.(54)

442. Zhu X, Avila J, Perry G, Smith MA. Treating the lesions, not the disease. Am J Pathol 170:1457-1459, 2007.(8)

443. Lee H-g, Nunomura A, Perry G, Smith MA. Comment: Less amyloid-β equals more disease. J Alzheimers Dis 11:402-403, 2007.

444. Lee H-g, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA. Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321:823-829, 2007.(39)

445. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PLR, Siedlak SL, Perry G. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 257:240-246, 2007.(100)

446. Reddy VP, Beyaz A, Perry G, Cooke MS, Sayre LM, Smith MA. The role of oxidative damage to nucleic acids in the pathogenesis of neurological disease. In: Oxidative Damage to Nucleic Acids, Evans MD, Cooke MS, Eds, Landes Bioscience and Springer Science+Business Media, Austin, Texas, Philadelphia, Pennsylvania, 2007, pp 123-140.

447. Castellani R, Lee H-g, Perry G, Smith MA, Zhu X. Comment: Amyloid spin doctors. Alzheimer Research Forum, 2007, http://www.alzforum.org/pap/annotation.asp?powID=66848.

448. Zhu X, Su B, Wang X, Smith MA, Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 64:2202-2210, 2007.(194)

449. Bryan K, Casadesus G, Perry G, Smith MA. Comment: Estrogen and Alzheimer disease: is it really all in the timing? Alzheimer Research Forum, 2007, http://www.alzforum.org/pap/annotation.asp?powID=69747.

450. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X. Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 32:1640-1645, 2007.(88)

451. Webber KM, Perry G, Smith MA, Casadesus G. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 5:177-183, 2007.

452. Castellani RJ, Lee H-g, Zhu X, Nunomura A, Perry G, Smith MA. Alzheimer‘s disease: pathology vs etiology. Int J Neuroprot Neuroregen 4:36-40, 2007.

453. Nunomura A, Moreira PI, Takeda A, Smith MA, Perry G. Oxidative RNA damage and neurodegeneration. Curr Med Chem 14:2968-2975, 2007.(48)

George Perry

107

454. Perry G, Zhu X, Lee H-g, Smith MA. Alzheimer disease, the oxidative hypothesis. 2007 Conference Proceedings of the 58th Annual Meeting of the American College of Veterinary Pathologists/42nd Annual Meeting of the American Society for Veterinary Clinical Pathology, pp 374-377, 2007.

455. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G. Increased autophagic degradation of mitochondria in Alzheimer disease. Autophagy 3:614-615, 2007.(59)

456. Castellani RJ, Perry G, Smith MA. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox Res 12:269-274, 2007.(7)

457. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Target 6:411-423, 2007.

458. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 7:300-303, 2007.

459. Wang X, Su B, Perry G, Smith MA, Zhu X. Insights into amyloid-β-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med 43:1569-1573, 2007.(55)

460. Aliev G, Cobb CJ, Pacheco G, Shenk JC, Moreira PI, Morales LA, Fischbach K, Gasimov E, Perry G. The role of oxidative stress and vasoactive substances in the pathophysiology of Alzheimer‘s disease. In: Biomarkers for Early Diagnosis of Alzheimer‘s Disease, Galimberti D, Scarpini E, Eds, Nova Science Publishers, Inc., Hauppauge, New York, 2008, pp 241-263.

461. Moreira PI, Smith MA, Zhu X, Nunomura A, Perry G. The potential application of antioxidant agents in Alzheimer disease therapeutics. In: Pharmacological Mechanisms in Alzheimer‘s Therapeutics, Cuello AC, Ed, Springer Press, New York, New York, 2008, pp 194-211.

462. Nunomura A, Moreira PI, Zhu X, Cash AD, Smith MA, Perry G. Role of oxidative insult and neuronal survival in Alzheimer‘s and Parkinson‘s diseases. In: Advances in Alzheimer‘s and Parkinson‘s Disease, Fisher A, Memo M, Stocchi F, Hanin I, Eds, Springer Press, New York, New York, 2008, pp 133-148.(1)

463. Zhu X, Perry G, Smith MA. Two hits and you‘re out? A novel mechanistic hypothesis of Alzheimer disease. In: Advances in Alzheimer‘s and Parkinson‘s Disease, Fisher A, Memo M, Stocchi F, Hanin I, Eds, Springer Press, New York, New York, 2008, pp 191-204.(4)

464. Zhu X, Casadesus G, Webber KM, Atwood CS, Bowen RL, Perry G, Smith MA. Parallels between neurodevelopment and neurodegeneration: a case study of Alzheimer‘s disease. In: Handbook of Neurochemistry and Molecular Neurobiology: Developmental and Aging Changes in the Nervous System, Lajtha A, Perez-Polo JR, Rossner S, Eds, Springer Science+Business Media, LLC, Philadelphia, Pennsylvania, 2008, pp 147-155.

465. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Tox 21:172-188, 2008.(91)

466. Perry G, Castellani RJ, Moreira PI, Lee H-g, Zhu X, Smith MA. Pathology's new role: defining disease process and protective responses. Int J Clin Exp Pathol 1:1-4, 2008.(3)

467. Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, Perry G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 7:3-10, 2008.(70)

468. Casadesus G, Rolston RK, Webber KM, Atwood CS, Bowen RL, Perry G, Smith MA. Menopause, estrogen, and gonadotropins in Alzheimer‘s disease. Adv Clin Chem 45:139-153, 2008.(8)

George Perry

108

469. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin L-S, Choi A, Chu CT, Chung J, Clarke PGH, Clark RSB, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, DiFiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA Jr, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen E-L, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao F-B, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He Y-W, Heidenreich K, Hill JA, Høyer-Hansen M, Hu X, Huang W-P, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JAKW, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan C-Y, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei H-Y, Lenardo MJ, Levine B, Lieberman A, Lim K-L, Lin F-C, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska I, Moore MN, Moreira PI, Moriyasu Y, Motyl T, Münz C, Murphy LO, Naqvi NI, Neufeld TP, Nishino I, Nixon RA, Noda T, Nürnberg B, Ogawa M, Oleinick NL, Olsen LJ, Ozpolat B, Paglin S, Palmer GE, Papassideri I, Parkes M, Perlmutter DH, Perry G, Piacentini M, Pinkas-Kramarski R, Prescott M, Proikas-Cezanne T, Raben N, Rami A, Reggiori F, Rohrer B, Rubinsztein DC, Ryan KM, Sadoshima J, Sakagami H, Sakai Y, Sandri M, Sasakawa C, Sass M, Schneider C, Seglen PO, Seleverstov O, Settleman J, Shacka JJ, Shapiro IM, Sibirny A, Silva-Zacarin ECM, Simon H-U, Simone C, Simonsen A, Smith MA, Spanel-Borowski K, Srinivas V, Steeves M, Stenmark H, Stromhaug PE, Subauste CS, Sugimoto S, Sulzer D, Suzuki T, Swanson MS, Tabas I, Takeshita F, Talbot NJ, Tallóczy Z, Tanaka K, Tanaka K, Tanida I, Taylor GS, Taylor JP, Terman A, Tettamanti G, Thompson CB, Thumm M, Tolkovsky AM, Tooze SA, Truant R, Tumanovska LV, Uchiyama Y, Ueno T, Uzcátegui NL, van der Klei I, Vaquero EC, Vellai T, Vogel MW, Wang H-G, Webster P, Wiley JW, Xi Z, Xiao G, Yahalom J, Yang J-M, Yap G, Yin X-M, Yoshimori T, Yu L, Yue Z, Yuzaki M, Zabirnyk O, Zheng X, Zhu X, Deter RL. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4:151-175, 2008.(1359)

470. Perry G, Nunomura A, Moreira PI, Castellani RJ, Lee H-g, Zhu X, Smith MA. Comment: Alzheimer in the wind. Alzheimer Research Forum, 2008, http://www.alzforum.org/res/for/journal/detail.asp?liveID=162

471. Castellani RJ, Zhu X, Lee H-G, Perry G, Smith MA, Casadesus G. Neurogenesis in human hippocampus: implications for Alzheimer disease pathogenesis. Neuroembryol Aging 4:175-182, 2008.

472. Joseph JA, Smith MA, Perry G, Shukitt-Hale B. Nutrients and food constituents in cognitive decline and neurodegenerative disease. In: Nutrition in the Prevention and Treatment of Disease, 2

nd edition, Coulston

AM, Boushey CJ, Eds, Elsevier, Inc., San Diego, California, 2008, pp 269-287.

473. Perry G, Zhu X, Babar AK, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Chen SG. Leucine-rich repeat kinase 2 colocalizes with α-synuclein in Parkinson‘s disease, but not tau-containing deposits in tauopathies. Neurodegener Dis 5:222-224, 2008.(15)

474. Evans TA, Siedlak SL, Lu L, Fu X, Wang Z, McGinnis WR, Fakhoury E, Castellani RJ, Hazen SL, Walsh WJ, Lewis AT, Salomon RG, Smith MA, Perry G, Zhu X. The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical-induced lipid oxidation. Chauhan A, Ed, Chauhan V, Perry G, Associate Eds. Am J Biotechnol Biochem 4:61-72, 2008.

475. Smith MA, Castellani RJ, Lee H-g, Nunomura A, Zhu X, Perry G. Comment: Amyloid-β: the beginning of the end and the end of the beginning. Alzheimer Research Forum, 2008, http://www.alzforum.org/new/detail.asp?id=1795#5540F949-E476-42E1-B8F9-252429E71853.

476. Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G. Nucleic acid oxidation in Alzheimer disease. Free Rad Biol Med 44:1493-1505, 2008.(89)

477. Shah RS, Lee H-G, Xiongwei Z [sic], Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer‘s disease. Biomed Pharmacother 62:199-207, 2008.(79)

478. Castellani RJ, Nunomura A, Rolston RK, Moreira PI, Takeda A, Perry G, Smith MA. Sublethal RNA oxidation as a mechanism for neurodegenerative disease. Int J Mol Sci 9:789-806, 2008.(27)

479. Smith MA, Nunomura A, Moreira P, Zhu X, Castellani RJ, Lee H-g, Perry G. Comment: Oxidative stress and amyloid-β: a stop sign, not a vicious cycle. Alzheimer Research Forum, 2008, http://www.alzforum.org/pap/annotation.asp?powID=76834#4CD74F2E-E73A-46DE-8E1F-FE0481252AB6.

George Perry

109

480. Smith MA, Castellani RJ, Moreira PI, Nunomura A, Lee H-g, Zhu X, Perry G. Comment: Amyloid in normal people: quelle surprise! Alzheimer Research Forum, 2008, http://www.alzforum.org/new/detail.asp?id=1805#B652AA0F-2E0B-4EE1-A7BD-BA26308B7C38.

481. Smith MA, Castellani RJ, Moreira PI, Nunomura A, Lee H-g, Zhu X, Perry G. Comment: No justification in moving from treatment to prevention. Alzheimer Research Forum, 2008, http://www.alzforum.org/pap/annotation.asp?powID=77114#56961F36-3ACE-4E59-9269-CB665B757D35.

482. Aliev G, Gasimov E, Obrenovich ME, Fischbach K, Shenk JC, Smith MA, Perry G. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer‘s disease. Vasc Health Risk Manag 4:721-730, 2008.

483. Castellani RJ, Lee H-g, Zhu X, Perry G, Smith MA. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67:523-531, 2008.(89)

484. Bryan K, Lee H-g, Perry G, Castellani RJ, Smith MA, Casadesus G. Nonestrogen-based hormonal therapies for Alzheimer‘s disease. Future Neurol 3:399-407, 2008.

485. Gonzalez-Cuyar LF, Morrison AL, Perry G, DeJong JJ, Smith MA, Castellani RJ. Cerebrotendinous xanthomatosis: a critical update. Future Neurol 3:491-501, 2008.

486. Smith MA, Zhu X, Lee H-g, Castellani RJ, Avila J, Tabaton M, Sayre LM, Perry G. Comment: Peroxidation in Alzheimer disease: time to put the ducks in a row. Alzheimer Research Forum, 2008, http://www.alzforum.org/pap/annotation.asp?powID=78667#7F7A6308-E9D1-4412-B140-4B6E20D68FF7.

487. Castellani RJ, Perry G, Zhu X, Lee H-g, Smith MA. Comment: 1911 to 2008: the dismal progress of knowledge in Alzheimer‘s disease research. Alzheimer Research Forum, 2008, http://www.alzforum.org/new/detail.asp?id=1871#01A37E03-AA6A-43B6-8776-282A73663C1D.

488. Castellani RJ, Perry G, Zhu X, Lee H-g, Smith MA. Comment: The next phase: prevention. Where do I sign up? Alzheimer Research Forum, 2008, http://www.alzforum.org/new/detail.asp?id=1879#7795CA3C-E27F-40F7-A0D5-C0FAB8E9E016.

489. Avila J, Perry G, Smith M. Preface: is tau aggregation toxic or protective? J Alzheimers Dis 14:363, 2008.

490. Castellani RJ, Nunomura A, Lee H-g, Perry G, Smith MA. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Disease 14:377-383, 2008.(38)

491. Aliev G, Shenk JC, Fischbach K, Perry G. Stem cell niches as clinical targets: the future of anti-ischemic therapy? Nat Clin Pract Cardiovasc Med 5:590-591, 2008.(5)

492. Marlatt MW, Lucassen PJ, Perry G, Smith MA, Zhu X. Alzheimer‘s disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 15:199-210, 2008.(37)

493. Nunomura A, Smith MA, Perry G. RNA oxidation in neurodegenerative diseases: sublethal damage as a mechanism for chronic degeneration. Yamanashi Med J 23:75-95, 2008.

494. Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G. Antioxidant therapy in Alzheimer‘s disease: theory and practice. Mini Rev Med Chem 8:1395-1406, 2008.(47)

495. Rolston RK, Perry G, Zhu X, Castellani RJ, Dwyer BE, Lee H-G, Petersen RB, Smith MA. Iron: a pathological mediator of Alzheimer disease? Agro Food Ind Hi-Tech 19:33-36, 2008.(1)

496. Perry G. Avances en la enfermedad de Alzheimer (Spanish). Ciencia Conocimiento Technología, Numero 83, p. 63-65, 2008.

497. Perry G, Aliev G, Moreira P, Siedlak SL, Smith MA, Cobb CJ, Ferrer D, José Yacaman M. En la enfermedad de Alzheimer: evidencia de aumento de cobre y hierro en el sistema: autofagosoma-lisosoma (Spanish). Biotechnologia Para La Salud, Numero 85, p. 32, 2008.

498. Castellani RJ, Lee H-G, Nunomura A, Zhu X, Perry G, Smith MA. Protein misfolding in Alzheimer‘s disease: pathogenic or protective? In: Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies, Smith HJ, Simons C, Sewell RDE, Eds, CRC Press, Taylor & Francis Group, Boca Raton, Florida, 2008, pp 327-335.(4)

499. Pallas M, Camins A, Smith MA, Perry G, Lee H-g, Casadesus G. From aging to Alzheimer‘s disease: unveiling ―the switch‖ with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 15:615-624, 2008.(76)

500. Su B, Wang X, Nunomura A, Moreira PI, Lee H-g, Perry G, Smith MA, Zhu X. Oxidative stress signaling in Alzheimer‘s Disease. Curr Alz Res 5:525-532, 2008.(89)

George Perry

110

501. Perry G, Zhu X, Nunomura A, Moreira P, Smith MA. Reactive oxygen: its sources and significance in Alzheimer disease. Slide World, 2008, http://www.slideworld.org/slideshow.aspx/Reactive-oxygen-its-sources-and-significance-in-A-305257.

502. Bryan KJ, Lee H-g, Perry G, Smith MA, Casadesus G. Transgenic mouse models of Alzheimer‘s disease: behavioral testing and considerations. In: Methods of Behavior Analysis in Neuroscience, 2

nd Edition,

Buccafusco JJ, Ed, Taylor & Francis Group, Boca Raton, Florida, 2009, pp 1-18.

503. Casadesus G, Bryan KJ, Perry G, Smith MA. Involvement of gonadotropins in cognitive function: implications for Alzheimer‘s disease. In: Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies, Hogervorst E, Henderson VW, Gibbs RB, Brinton RD, Eds, Cambridge University Press, Cambridge, United Kingdom, 2009, pp 251-258.

504. Gonzalez-Cuyar LF, Tavora F, Caminha I, Perry G, Smith MA, Castellani RJ. Cellular respiration and tumor suppressor genes. In: Cellular Respiration and Carcinogenesis, Apte SP, Sarangarajan R, Eds, Humana Press, Springer Science+Business Media, LLC, Totowa, New Jersey, 2009, pp 131-144.

505. Moreira PI, Nunomura A, Zhu X, Lee H-G, Aliev G, Smith MA, Perry G. Alzheimer disease: oxidative stress and compensatory responses. In: Oxidative Neural Injury, Veasey SC, Ed, Humana Press, Springer Science+Business Media, LLC, Totowa, New Jersey, 2009, pp 109-120.

506. Petersen RB, Nunomura A, Lee H-g, Casadesus G, Perry G, Smith MA, Zhu X. Oxidative stress associated signal transduction cascades in Alzheimer disease. In: Oxidative Neural Injury, Veasey SC, Ed, Humana Press, Springer Science+Business Media, LLC, Totowa, New Jersey, 2009, pp 121-136.

507. Moreira PI, Zhu X, Smith MA, Perry G. Alzheimer‘s disease: an overview. In: Encyclopedia of Neuroscience, Vol. 1, Squire LR, Ed, Elsevier Ltd, Amsterdam, The Netherlands, 2009, pp 259-263.

508. Reddy VP, Perry G, Smith MA. Brain composition: age-related changes. In: Encyclopedia of Neuroscience, Vol. 2, Squire LR, Ed, Elsevier Ltd, Amsterdam, The Netherlands, 2009, pp 313-316.

509. Reddy VP, Perry G, Smith MA. Brain composition: age-related changes. In: Handbook of the Neuroscience of Aging, Hof PR, Mobbs CV, Eds, Academic Press, Oxford, United Kingdom, 2009, pp 39-42.

510. Moreira PI, Zhu X, Smith MA, Perry G. Alzheimer‘s disease: an overview. In: Handbook of the Neuroscience of Aging, Hof PR, Mobbs CV, Eds, Academic Press, Oxford, United Kingdom, 2009, pp 389-393.

511. Moreno FJ, Santa-Maria I, Smith MA, Perry G, Avila J. Aging, oxidative stress, tau and Alzheimer disease. In: The Role of Oxidative Stress, Mitochondria Failure and Cellular Hypoperfusion in the Pathobiology of Alzheimer‘s Disease, Aliev G, Herrera AS, Bragin V, Leszek J, LaManna JC, Eds, Research Signpost, Kerala, India, 2009, pp 83-96.

512. Nunomura A, Takeda A, Moreira PI, Castellani RJ, Lee H-g, Zhu X, Smith MA, Perry G. Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer‘s disease. In: Current Hypotheses and Research Milestones in Alzheimer‘s Disease, Maccioni RB, Perry G, Eds, Springer Science+Business Media, LLC, Berlin, Heidelberg, 2009, pp 103-113.(1)

513. Ramiro-Puig E, Castell M, McShea A, Perry G, Smith MA, Casadesus G. Food antioxidants and Alzheimer‘s disease. In: Micronutrients and Brain Health, Packer L, Sies H, Eggersdorder M, Cadenas E, Eds, CRC Press, Taylor & Francis Group, Boca Raton, Florida, 2009, pp 41-49.(7)

514. Castellani RJ, Perry G, Smith MA. Is Alzheimer‘s disease a myth? When is disease a disease? Curr Alzheimer Res 6:82, 2009.

515. Saper CB, Maunsell JHR, Destexhe A, Richmond B, Campagnoni A, Sarter M, Fritschy J-M, Saper C, Bloom FE, Perry G, Smith MA, Maunsell J, Ascoli G, Eichenbaum H, Greenamyre JT, Krystal J, Zilles K, Zaborszky L, Byrne JH, Blumberg M, Lumsden A, Harris B, Sanes J, Wang R, Eatock RA, Gilman S, Frangou S, Sagvolden T, Ottersen OP, Lisberger S, Poznanski RR, Simons RF. The neuroscience peer review consortium. J Alzheimers Dis 16:445-447, 2009.(1)

516. Lee H-g, Casadesus G, Zhu X, Castellani RJ, McShea A, Perry G, Petersen RB, Bajic V, Smith MA. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer‘s disease. Neurochem Intern 54:84-88, 2009.(59)

517. Perry G, Zhu X, Moreira PI, Smith MA. Altered redox balance in disease: can we change the new equilibria? Ann Neurol 65:121-123, 2009.(8)

518. Castellani R, Lee H-P, Lee H-g, Nunomura A, Perry G, Smith MA, Zhu X. Comment: HSV, amyloid, and Alzheimer disease. Alzheimer Research Forum, 2009, http://www.alzforum.org/pap/annotation.asp?powID=83081#2F1BAC6A-17AA-45BF-AA6A-167F1D57F99C.

George Perry

111

519. Castellani RJ, Zhu X, Lee H-G, Smith MA, Perry G. Molecular pathogenesis of Alzheimer‘s disease: reductionist versus expansionist approaches. Intern J Mol Sci 10:1386-1406, 2009.(21)

520. Liu G, Zhu X, Dwyer B, Castellani RJ, Lee H-g, Perry G, Smith MA. Comment: Chelation and neurodegenerative diseases: nanoparticles as proof of concept. Alzheimer Research Forum, 2009, http://www.alzforum.org/pap/annotation.asp?powID=83081#2F1BAC6A-17AA-45BF-AA6A-167F1D57F99C

521. Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S. Leptin: a novel therapeutic strategy for Alzheimer‘s disease. J Alzheimers Dis 16:731-740, 2009.(65)

522. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer‘s disease. J Alzheimers Dis 16:763-774, 2009.(92)

523. Friedlich AL, Smith MA, Zhu X, Takeda A, Nunomura A, Moreira PI, Perry G. Oxidative stress in Parkinson‘s disease. Open Pathol J 3:38-42, 2009.

524. Obrenovich ME, Morales LA, Cobb CJ, Shenk JC, Méndez GM, Fischbach K, Smith MA, Qasimov EK, Perry G, Aliev G. Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. J Cell Mol Med 13:853-865, 2009.(4)

525. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer‘s disease. J Neurochem 109 (Suppl 1):153-159, 2009.(119)

526. Hong H, Perry G, Sörgel F, Gedela S, Akulapalli S. Editorial: Journal of Bioequivalence and Bioavailability. J Bioequiv Bioavailab 1:2 pages, doi:10.4172/jbb.1000001e, 2009.

527. Liu G, Men P, Perry G, Smith MA. Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer‘s disease. J Nanoneurosci 1:42-55, 2009.

528. Nunomura A, Hofer T, Moreira PI, Castellani RJ, Smith MA, Perry G. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol 118:151-166, 2009.(64)

529. Friedlich AL, Rolston RK, Zhu X, Marlatt MW, Castellani RJ, Nunomura A, Lee H-g, Casadesus G, Perry G, Smith MA. Treatment advances in Alzheimer‘s disease based on the oxidative stress model. F1000 Med Rep 1:5 pages, doi:10.3410/M1-54, 2009.

530. Marlatt MW, Moreira PI, Lee H-g, Casadesus G, Castellani RJ, Takeda A, Nunomura A, Zhu X, Perry G, Smith MA. Therapeutic opportunities in Alzheimer disease: current concepts. Front in Med Chem 4:767-788, 2009.

531. Casadesus G, Lee H-g, Moreira P, Perry G, Smith MA, Zhu X. Comment: Strengthening the links between amyloid-β, mitochondria and oxidative stress. Alzheimer Research Forum, 2009, http://www.alzforum.org/pap/readmore.asp?commentID=BB6953EE-AE19-462F-9E14-33C58FE61053.

532. Casadesus G, Lee H-g, Moreira P, Perry G, Smith MA, Zhu X. Comment: Uric acid: not just for gout anymore. Alzheimer Research Forum, 2009, http://www.alzforum.org/pap/annotation.asp?powID=91797#0F6DFA58-9498-46B3-A1AC-46940ED154C3.

533. Carvalho C, Correia SC, Santos RX, Cardoso S, Moreira PI, Clark TA, Zhu X, Smith MA, Perry G. Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. J Bioenerg Biomembr 41:433-440, 2009.(19)

534. Castellani RJ, Lee H-g, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA. Reexamining Alzheimer‘s disease: evidence for a protective role for amyloid-β protein precursor and amyloid-β. J Alzheimers Dis 18:447-452, 2009.(73)

535. Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR, Perry G, Smith MA, Zhu X, Moreira PI. Insulin is a two-edged knife on the brain. J Alzheimers Dis 18:483-507, 2009.(35)

536. Crain BJ, Terry RD, Perry G. Meritorious contributions to neuropathology. J Neuropathol Exp Neurol 68:1244-1246, 2009.

537. Lee H-P, Casadesus G, Zhu X, Lee H-g, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer‘s disease. Expert Rev Neurother 9:1615-1621, 2009.

538. Perry G, Moreira PI, Siedlak SL, Nunomura A, Zhu X, Smith MA. Natural oxidant balance in Parkinson disease. Arch Neurol 66:1445, 2009.

539. Liu G, Men P, Perry G, Smith MA. Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. In: Progress in Brain Research, Vol. 180, Sharma HS, Ed, Elsevier B.V., Amsterdam, The Netherlands, 2009, pp 97-108.(8)

George Perry

112

540. Cardoso S, Santos R, Correia S, Carvalho C, Zhu X, Lee H-G, Casadesus G, Smith MA, Perry G, Moreira PI. Insulin and insulin-sensitizing drugs in neurodegeneration: mitochondria as therapeutic targets. Pharmaceuticals 2:250-286, 2009.

541. Bonda DJ, Wang X, Gustaw-Rothenberg KA, Perry G, Smith MA, Zhu X. Mitochondrial drugs for Alzheimer disease. Pharmaceuticals 2:287-298, 2009.

542. Bonda DJ, Castellani RJ, Lee H-g, Tabaton M, Casadesus G, Perry G, Zhu X, Smith MA. Down syndrome and Alzheimer disease: a ―multi-hit‖ hypothesis based on multiple contributing factors resulting in pleotrophic consequences. In: Advances in Genetics Research, Vol. 2, Urbano KV, Ed, Nova Science Publishers, Inc., Hauppauge, New York, 2010, pp 87-97.

543. Evans TA, Perry G, Smith MA, Salomon RG, McGinnis WR, Sajdel-Sulkowska EM, Zhu X. Evidence for oxidative damage in the autistic brain. In: Autism: Oxidative Stress, Inflammation, and Immune Abnormalities, Chauhan A, Chauhan V, Brown WT, Eds, CRC Press/Taylor & Francis, Boca Raton, Florida, 2010, pp 35-46.

544. Friedlich AL, Tanzi RE, Perry G, Takeda A, Zhu X, Smith MA. Regulation of α-synuclein gene expression: implications for Parkinson‘s disease and other neurodegenerative disorders. In: Horizons in Neuroscience Research, Vol. 2, Costa A, Villalba E, Eds, Nova Science Publishers, Inc., Hauppauge, New York, 2010, pp 171-178.

545. Lee HP, Rolston RK, Zhu X, Marlatt MW, Castellani RJ, Nunomura A, Lee H-G, Casadesus G, Perry G, Smith MA. Targeting oxidative mechanisms in Alzheimer disease. In: RSC Drug Discovery Series No. 3: Emerging Drugs and Targets for Alzheimer‘s Disease, Vol. 2, Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies, Martinez A, Ed, Royal Society of Chemistry, Cambridge, United Kingdom, 2010, pp 97-107.

546. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. In: Free Radicals and Antioxidant Protocols, Methods in Molecular Biology 610, Uppu RM, Murthy SN, Pryor WA, Parinandi NL, Eds, Humana Press, Springer Science+Business Media, LLC, Totowa, New Jersey, 2010, pp 123-144.

547. Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA, Perry G. Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. In: Free Radicals and Antioxidant Protocols, Methods in Molecular Biology 610, Uppu RM, Murthy SN, Pryor WA, Parinandi NL, Eds, Humana Press, Springer Science+Business Media, LLC, Totowa, New Jersey, 2010, pp 419-434.

548. Perry G, Mondragón-Rodríguez S, Nunomura A, Zhu X, Moreira PI, Smith MA. Redox homeostasis in Alzheimer disease. In: Tόpicos de Actualizaciόn en Neurobiología: Biología Molecular del Desarrollo, Neurodegeneraciόn y Medicina Genόmica, Ortuńo-Sahagùn D, Beas-Zárate C, Armendáriz JS, Sánchez-Corona J, Pallás-Lliberìa M, Camins A, Eds, Universidad de Guadalajara, Jalisco, Mexico, 2010, pp 147-157.

549. Perry G. Living with aging: Alzheimer, the disease of our times. Slide World, 2010, http://www.slideworld.org/slideshow.aspx/Living-With-Aging-Alzheimer,-the-Disease-of-our-Times-ppt-2845969.

550. Rodrigues R, Bonda DJ, Perry G, Castellani RJ, Casadesus G, Lee H-g, Lee H-P, Wang X, Zhu X, Petersen RB, Smith MA. Oxidative stress and neurodegeneration: an inevitable consequence of aging? Implications for therapy. In: Brain Protection in Schizophrenia, Mood and Cognitive Disorders, Ritsner MS, Ed, Springer Science+Business Media B.V., Philadelphia, Pennsylvania, 2010, pp 305-323.

551. Rolston RK, Lee H-g, Castellani RJ, Bajic V, Perry G, Zhu X, Smith MA. Cell cycle related mechanisms in Alzheimer disease. In: Cell Cycle Regulators in Alzheimer‘s Disease, Padmanabhan J, Ed, Transworld Research Network, Kerala, India, 2010, pp 1-16.

552. Stone JG, Bryan K, Perry G, Smith MA, Casadesus G. Hormones in Alzheimer disease: treatment modalities and future directions. In: Metabolic Influences on Neurological Disorders, Doherty GH, Ed, Transworld Research Network, Kerala, India, 2010, pp 29-41.

553. Stone JG, Nunomura A, Hayashi T, Nakamura M, Dwyer B, Zhu X, Perry G, Smith MA. Iron-mediated neurotoxicity in Alzheimer disease: causes, consequences, and future therapeutic directions. In: Metals and Neurodegeneration, Huang S, Ed, Research Signpost, Kerala, India, 2010, pp 83-100.

554. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer‘s disease pathophysiology. Biochim Biophys Acta 1802:2-10, 2010.(94)

555. Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 1802:135-142, 2010.(29)

556. Moreira PI, Zhu X, Wang X, Lee H-g, Nunomura A, Petersen RB, Perry G, Smith MA. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 1802:212-220, 2010.(97)

George Perry

113

557. Tabaton M, Zhu X, Perry G, Smith MA, Giliberto L. Signaling effect of amyloid-β42 on the processing of AβPP. Exp Neurol 221:18-25, 2010.(20)

558. Smith MA, Greco S, Johnston JM, Ashford JW, Perry G, Casadesus G, Tezapsidis N. Comment: Leptin—a key pathogenic modulator in Alzheimer disease. Alzheimer Research Forum, 2010, http://www.alzforum.org/new/detail.asp?id=2316.

559. Gustaw-Rothenberg K, Lerner A, Bonda DJ, Lee H-g, Zhu X, Perry G, Smith MA. Biomarkers in Alzheimer‘s disease: past, present and future. Biomarkers Med 4:15-26, 2010.(33)

560. Perry G. Foreword. US Neurol 5:8, 2010.

561. Tabaton M, Perry G, Zhu X, Lee H-g, Casadesus G, Smith MA. Memantine: ―Hypothesis Testing‖ not ―Disease Modifying‖ in Alzheimer‘s disease. Am J Pathol 176:540-541, 2010.

562. Lee H-g, Zhu X, Wang X, Castellani RJ, Perry G, Smith MA. Comment: Cancer, Alzheimer disease, and cardiovascular disease: associations and disassociations—clues to etiology? Alzheimer Research Forum, 2010, http://www.alzforum.org/pap/readmore.asp?commentID=1FACEA9A-1E87-4D7A-8D15-BF3637170AF9.

563. Bonda DJ, Lee H-P, Lee H-g, Friedlich AL, Perry G, Zhu X, Smith MA. Novel therapeutics for Alzheimer‘s disease: an update. Curr Opinion Drug Disc Devel 13:235-246, 2010.(24)

564. Bonda DJ, Wang X, Perry G, Smith MA, Zhu X. Mitochondrial dynamics in Alzheimer‘s disease: opportunities for future treatment strategies. Drugs Aging 27:181-192, 2010.(26)

565. Lee H-p, Zhu X, Liu G, Chen SG, Perry G, Smith MA, Lee H-g. Divalent metal transporter, iron, and Parkinson‘s disease: a pathological relationship. Cell Res 20:397-399, 2010.

566. Perry G, Smith MA. Obituary: William R. Markesbery, M.D.: a tribute. J Alzheimers Dis 20:1, 2010.

567. Perry G, Zhu X, Castellani RJ, Phelix C, Moreira P, Casadesus G, Lee H-g, Smith MA. Comment: Evolution of the cholesterol story. Alzheimer Research Forum, 2010, http://www.alzforum.org/pap/readmore.asp?commentID=0335687F-45B5-477E-A063-F4F324BEB88E.

568. Avila J, Perry G, Martínez-Martín P. Prospects on the origin of Alzheimer‘s disease. J Alzheimers Dis 20:669-672, 2010.

569. Mondragón-Rodríguez S, Basurto-Islas G, Lee H-g, Perry G, Zhu X, Castellani RJ, Smith MA. Causes versus effects: the increasing complexities of Alzheimer‘s disease pathogenesis. Expert Rev Neurother 10:683-691, 2010.(17)

570. Sheng B, Lee H-g, Perry G, Smith MA, Zhu X. Comment: Evading apoptosis in Alzheimer disease. Alzheimer Research Forum, 2010, http://www.alzforum.org/pap/annotation.asp?powID=101126#B7DEEDB9-1D3F-4FFA-B328-5C794941D1C9.

571. Perry G. Advancements in Alzheimer‘s research. 2010 Healthcare Professional Conference, Alzheimer‘s Association, San Antonio, Texas, 2010.

572. Zhu X, Beal MF, Wang X, Perry G, Smith MA. Mitochondria and neurodegenerative diseases. J Alzheimers Dis 20:S253, 2010.

573. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, Zhu X. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer‘s disease. J Alzheimers Dis 20:S401-S412, 2010.(45)

574. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Mitochondria: the missing link between preconditioning and neuroprotection. J Alzheimers Dis 20:S475-S485, 2010.(19)

575. Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X. Abnormal mitochondrial dynamics—a novel therapeutic target for Alzheimer‘s disease? Mol Neurobiol 41:87-96, 2010.(1)

576. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, Zhu X. Alzheimer‘s disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol 3:570-581, 2010.(42)

577. Castellani RJ, Moreira P, Aliev G, Shenk JC, Siedlak SL, Harris PLR, Sayre LM, Szweda PA, Szweda LI, Zhu X, Smith MA, Perry G. Hydroxynonenal-generated crosslinking fluorophore and mitochondria-derived lipoic acid accumulation in Alzheimer disease reveal a dichotomy of protein turnover. Micros Microanal 16 (Suppl 2):1014-1015, 2010.

578. Smith MA, Zhu X, Lee H, Castellani RJ, Perry G. The importance of histochemical detection of oxidative damage in tissue. Micros Microanal 16 (Suppl 2):1016, 2010.

579. Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee H-g, Perry G. Antioxidant approaches for the treatment of Alzheimer‘s disease. Expert Rev Neurother 10:1201-1208, 2010.(53)

George Perry

114

580. Moreira PI, Santos RX, Zhu X, Lee H-g, Smith MA, Casadesus G, Perry G. Autophagy in Alzheimer‘s disease. Expert Rev Neurother 10:1209-1218, 2010.

581. Perry G. Oxidative stress and its role in the pathogenesis of Alzheimer disease. The Science Advisory Board: Member Spotlights, 2010, http://scienceboard.net/community/memberSpotlight.asp?spotid=175.

582. Correia SC, Carvalho C, Cardoso S, Santos RX, Santos MS, Oliveira CR, Perry G, Zhu X, Smith MA, Moreira PI. Mitochondrial preconditioning: a potential neuroprotective strategy. Front Aging Neurosci 2:13 pages, doi:10.3389/fnagi.2010.00138, 2010.(13)

583. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacol 59:290-294, 2010.(140)

584. Clark TA, Lee HP, Rolston RK, Zhu X, Marlatt MW, Castellani RJ, Nunomura A, Casadesus G, Smith MA, Lee H-g, Perry G. Oxidative stress and its implications for future treatments and management of Alzheimer disease. Int J Biomed Sci 6:225-227, 2010.

585. Perry G, Castellani RJ, Smith MA. Comment: Failure of the amyloid-β-based therapeutics: is amyloid the culprit or the savior? Alzheimer Research Forum, 2010, http://www.alzforum.org/new/detail.asp?id=2536#2C4A6E0A-3412-4DEE-B971-1767E988A2E5.

586. Perry G, Zhu X, Nunomura A, Moreira PI, Castellani RJ, Smith MA. Comment: Amyloid-β protein precursor at the center of iron and redox homeostasis: the amyloid reparative cascade hypothesis. Alzheimer Research Forum, 2010, http://www.alzforum.org/new/detail.asp?id=2562#431B0B61-1699-45F9-AD33-AAE34AA3C08A.

587. Dwyer BE, Zacharski LR, Balestra DJ, Lerner AJ, Perry G, Zhu X, Smith MA. Potential role of iron in a Mediterranean-style diet. Arch Neurol 67:1286, 2010.(1)

588. de Mendonça A, Perry G. Obituary: Edgar da Cruz e Silva 1958-2010. J Alzheimers Dis 21:1037, 2010.

589. Perry G. Eulogy for Mark Smith. J Alzheimers Dis, 2010, http://www.j-alz.com/marksmith.html. Alzheimer Research Forum, 2010, http://www.alzforum.org/new/detail.asp?id=2647#294503B4-514D-4007-BB26-261F264C2609.

590. Ashford JW, Black SE, Frisoni G, Perry G. Preface. In: Handbook of Imaging the Alzheimer Brain, Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M, Eds, Perry G, Smith MA, Series Eds, IOS Press, Amsterdam, The Netherlands, 2011, pp vii-viii.

591. Carvalho C, Correia SC, Santos RX, Cardoso S, Moreira PI, Zhu X, Smith MA, Perry G. Association of mitochondrial signaling in Alzheimer‘s disease and hypoxia. In: Molecular Aspects of Neurodegeneration and Neuroprotection, Farooqui AA, Farooqui T, Eds, Bentham Science Publishers Ltd., Sharjah, United Arab Emirates, 2011, pp 50-61.

592. Castellani RJ, Marlatt MW, Nunomura A, Moreira PI, Lee H-G, Casadesus G, Zhu X, Perry G, Smith MA. Thinking outside the box in Alzheimer disease treatment. In: Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing, Gad SC, Ed, John Wiley and Sons, Inc., Hoboken, New Jersey, 2011, pp 929-941.

593. Castellani RJ, Zhu X, Lee H-g, Petersen R, Perry G. Obituary: Mark A. Smith. Soc Neurosci, 2011, http://www.sfn.org/index.aspx?pagename=memberObituaries_MarkSmith&print=on.

594. Chang J, Pallas M, Zhu X, Kim H-J, Camins A, Lee H-g, Perry G, Smith MA, Casadesus G. Unveiling ―the switch‖ from aging to Alzheimer‘s disease with the senescence-accelerated mouse model (SAMP8). In: Handbook of Animal Models in Alzheimer‘s Disease, Vol. 1, Casadesus G, Ed, Perry G, Smith MA, Series Eds, IOS Press, Amsterdam, The Netherlands, 2011, pp 39-48.

595. Chang J, Siedlak S, Moreira P, Nunomura A, Castellani RJ, Smith MA, Zhu X, Perry G, Casadesus G. Oxidative stress in Alzheimer‘s disease: a critical appraisal of the causes and the consequences. In: Studies on Experimental Models, Basu S, Wiklund L, Eds, Springer Science+Business Media, LLC, Philadelphia, Pennsylvania, 2011, pp 211-220.

596. Mondragón-Rodríguez S, García-Sierra F, Casadesus G, Lee H-g, Petersen RB, Perry G, Zhu X, Smith MA. Oxidative stress and Alzheimer disease: mechanisms and therapeutic opportunities. In: Neurochemical Mechanisms in Disease, Blass JP, Ed, Springer Science+Business Media, LLC, Philadelphia, Pennsylvania, 2011, pp 607-631.

597. Perry G. Launch of ‗Atlas Journal of Medical and Biological Sciences.‘ Atlas J of Med Biol Sci 1:1, doi:10.5147/ajmbs.2011.0042, 2011.

George Perry

115

598. Perry G, Mondragόn-Rodríguez S, Nunomura A, Zhu X, Moreira PI, Smith MA. Oxidative stress and balance in neurodegenerative diseases. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2

nd Edition, Dickson DW, Weller RO, Eds, Blackwell Publishing Ltd., Oxford, United Kingdom,

2011, pp 10-12.

599. Perry G, Zhu X. Obituary: Mark Anthony Smith (1965-2010): visionary, Alzheimer researcher, and editor-in-chief of the Journal of Alzheimer‘s Disease. J Alzheimers Dis 24:1-2, 2011.

600. Zhu X, Lee H-g, Castellani RJ, Petersen RB, Perry G. Obituary: Mark A. Smith: international neurochemist perfection. Int Soc Neurochem, 2011, http://www.neurochemistry.org/LinkClick.aspx?fileticket=fNA5_lhLtjA%3d&tabid=37.

601. Stone JG, Casadesus G, Gustaw-Rothenberg K, Siedlak SL, Wang X, Zhu X, Perry G, Castellani RJ, Smith MA. Frontiers in Alzheimer‘s disease therapeutics. Ther Adv Chronic Dis 2:9-23, 2011.

602. Perry G. Editorial. Ann Rev Res Biol 1:i-ii, 2011.

603. Bonda DJ, Lee H-g, Blair JA, Zhu X, Perry G, Smith MA. Role of metal dyshomeostasis in Alzheimer‘s disease. Metallomics 3:267-270, 2011.(89)

604. Gustaw Rothenberg K, Siedlak SL, Lee H-g, Zhu X, Perry G, Smith MA. Neurodegenerative processes in Alzheimer‘s disease: an overview of pathogenesis with strategic biomarker potential. Future Neurol 6:173-185, 2011.

605. Perry G. Rubens Pamies. Funeral Service Program, 2011.

606. Perry G, Smith MA, Casadesus G, Lee H-g, Moreira PI, Castellani RJ, Zhu X. Using biology to untie the Gordian Knot of Alzheimer‘s disease. J Alzheimers Dis 23 (Suppl 1):S31-S32, 2011.

607. Perry G. Alzheimer‘s disease: beyond the amyloid hypothesis, 2011, http://www.tuttocongressi.it/website/contenutiriservati/viewContent.aspx?idc=1247&id=344176&type=N&tab=0&w=900&h=520.

608. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: the culprit in sporadic Alzheimer‘s disease? Ageing Res Rev 10:264-273, 2011.(58)

609. Zhu X, Castellani RJ, Perry G. Obituary: Mark Anthony Smith 1965-2010: clinical investigator. Clinical Trial Magnifier 4:78, 2011.

610. Zhu X, Castellani RJ, Lee H-G, Petersen RB, Nunomura A, Tabaton M, Perry G. Obituary: The concept of redox balance in Alzheimer‘s disease: Mark Anthony Smith 1965-2010. Redox Report 16:47-48, 2011.

611. Britton GB, Smith MA, Perry G, Sambamurti K, Jagannatha Rao KS. Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets. J Alzheimers Dis 24 (Suppl 2):1-2, 2011.

612. Perry G. Journal of Parkinson‘s disease – birth of JAD‘s new sister. J Alzheimers Dis 25:1, 2011.

613. Castellani RJ, Zhu X, Perry G. Obituary: Mark A. Smith, PhD: renegade scientist and visionary. J Neuropath Exp Neurol 70:495-497, 2011.

614. Perry G. George Perry on the role of oxidative stress in Alzheimer‘s disease. Special Topic of Alzheimer‘s Disease Interview, 2011, http://sciencewatch.com/ana/st/alz2/11monSTAlz2Perr/.

615. Castellani R, Perry G, Lee H-g, Zhu X. Obituary: Mark A. Smith: scholar and innovator. Eur J Histochem 55:1, 2011.

616. Wang X, Smith MA, Perry G, Zhu X. Mitochondrial fragmentation mediates MPP+ toxicity in neurons:

implications for Parkinson‘s disease. Microsc Microanal 17 (Suppl 2):196-197, 2011.

617. Perry G, Wang X, Smith MA, Zhu X. Mitochondrial abnormalities in Alzheimer disease. Micros Microanal 17 (Suppl 2):200-201, 2011.

618. Zhu X, Castellani RJ, Lee H-g, Perry G. Obituary: The origin of oxidative stress in neurodegenerative disease: Mark Anthony Smith 1965-2010. Free Rad Biol Med 51:248-249, 2011.

619. Castellani RJ, Zhu X, Nunomura A, Perry G. Obituary: In memoriam: Mark A. Smith, PhD: neuroscientist and visionary. Neuropathology 31:458-459, 2011.

620. Liu Q, Xie F, Alvarado-Diaz A, Smith MA, Moreira PI, Zhu X, Perry G. Neurofilamentopathy in neurodegenerative diseases. Open Neurol J 5:58-62, 2011.

621. Bonda DJ, Castellani RJ, Zhu X, Nunomura A, Lee H-g, Perry G, Smith MA. A novel perspective on tau in Alzheimer‘s disease. Curr Alzheimer Res 8:639-642, 2011.(15)

622. Castellani RJ, Zhu X, Perry G. Foreword: Alzheimer‘s disease therapy: a moving target. Therapy 8:457-458, 2011.

George Perry

116

623. Castellani RJ, Lee H-g, Petersen RB, Zhu X, Perry G. Pathological phenotype in familial neurodegenerative disease: implications for families and therapeutic constructs. Therapy 8:475-479, 2011.

624. Castellani RJ, Rolston RK, Zhu X, Petersen RB, Perry G. Obituary: In memoriam: Mark A. Smith, PhD. Disease-A-Month 57:524-526, 2011.

625. Perry G, Castellani RJ, Ziats NP, Petersen RB, Lee H-g, Zhu X. Obituary: Mark A. Smith: impresario of Alzheimer. Alzheimer Dis Assoc Disord 25:369-370, 2011.

626. Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack CR Jr, Sabri O, Adamson MM, Coburn KL, Olichney J, Schuff N, Spielman D, Edland SD, Black S, Rosen A, Kennedy D, Weiner M, Perry G. Imaging the Alzheimer Brain. J Alzheimers Dis 26:1-27, 2011.(8)

627. Bonda DJ, Smith MA, Perry G, Lee H-g, Wang X, Zhu X. The mitochondrial dynamics of Alzheimer‘s disease and Parkinson‘s disease offer important opportunities for therapeutic intervention. Curr Pharm Design 17:3374-3380, 2011.(3)

628. Correia SC, Cardoso S, Santos RX, Carvalho C, Santos MS, Perry G, Smith MA, Moreira PI. New insights into the mechanisms of mitochondrial preconditioning-triggered neuroprotection. Curr Pharm Design 17:3381-3389, 2011.(13)

629. Castellani RJ, Petersen RB, Lee H-g, Zhu X, Perry G. Obituary: Mark A. Smith: the scientist, the man. Int J Exp Pathol 92:297-298, 2011.

630. Ziats NP, Petersen RB, Lee H-g, Castellani RJ, Perry G, Zhu X. Obituary: Mark A. Smith, 1965-2010: consummate student of pathogenesis. Int J Clin Exp Pathol 4:731-732, 2011.

631. Li X, Ng S-K, Wang JTL, Aidong Z, Akutsu T, Aung Z, Bajic V, Chen J, Chen P, Chua H, Cui J, Dai Y, Gao X, Han X, Hansen D, Hsu W-L, Huang J, Isokpehi R, Li D, Li H, Jurisica I, Kihara D, Krishnaswamy S, Kwoh CK, Mamitsuka H, Parida L, Perry G, Ragan MA, Rabadan R, Ruan J, Sarkar IN, Singh AK, Srinivasan N, Syed Z, Tseng VS, Valencia A, Yan H, Yu PS, Zeng E, Zhang X, Zvelebil M. Preface. Proceedings - 11

th

IEEE International Conference on Data Mining, ICDM, pp i-iii, 2011.

632. Phelix CF, LeBaron RG, Roberson DJ, Villanueva RE, Villareal G, Rahimi OB, Siedlak S, Zhu X, Perry G. In vivo and in silico evidence: hippocampal cholesterol metabolism decreases with aging and increases with Alzheimers disease: Modeling brain aging and disease. 2011 11

th IEEE International Conference on Data

Mining Workshops, pp 1064-1070, 2011.

633. Bonda DJ, Castellani RJ, Lee H-g, Tabaton M, Casadesus G, Perry G, Zhu X, Smith MA. Down syndrome and Alzheimer disease: a ―multi-hit‖ hypothesis based on multiple contributing factors resulting in pleotrophic consequences. In: Alzheimer‘s Disease Research Compendium, Sun M-K, Ed, Nova Science Publishers, Inc., Hauppauge, New York, 2012, pp 183-193.

634. Liu G, Men P, Perry G, Smith MA. Nanoparticle-iron chelator conjugates as multifunctional disease-modifying drugs for prevention and treatment of Alzheimer‘s disease. In: Nanomedicine and the Nervous System, Martin CR, Preedy VR, Hunter RJ, Eds, CRC Press, Boca Raton, Florida, 2012, pp 347-366.

635. Mondragón-Rodríguez S, Perry G. Zhu X, Moreira PI, Williams S. Glycogen synthase kinase 3: a point of integration in Alzheimer‘s disease and a therapeutic target? Int J Alzheimers Dis 2012:4 pages, doi:10.1155/2012/276803, 2012.

636. Mondragón-Rodríguez S, Perry G, Zhu X, Boehm J. Amyloid beta and tau proteins as therapeutic targets for Alzheimer‘s disease treatment: rethinking the current strategy. Int J Alzheimers Dis 2012:7 pages, doi:10.1155/2012/630182, 2012.

637. Morelli L, Perry G, Tagliavini F. The contribution of the Amyloid hypothesis to the understanding of Alzheimer‘s disease: a critical overview. Int J Alzheimers Dis 2012:2 pages, doi:10.1155/2012/709613, 2012.

638. Reed-Cossairt A, Zhu X, Lee H-G, Reed C, Perry G, Petersen RB. Alzheimer‘s disease and vascular deficiency: lessons from imaging studies and Down syndrome. Curr Gerontol Geriatr Res 2012:5 pages, doi:10.1155/2012/929734, 2012.

639. Zhu X, Lee H-g, Perry G. Mark Anthony Smith (August 15, 1965 - December 19, 2010): an inspiration for Alzheimer‘s disease. In: Neurodegenerative Diseases, Ahmad SI, Ed, Lands [sic] Bioscience and Springer Science+Business, Austin, Texas, Philadelphia, Pennsylvania, 2012, pp xxxi-xxxii.

640. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Mitochondrial importance in Alzheimer‘s, Huntington‘s and Parkinson‘s diseases. In: Neurodegenerative Diseases, Ahmad SI, Ed, Landes Bioscience and Springer Science+Business Media, Austin, Texas, Philadelphia, Pennsylvania, 2012, pp 205-221.

641. Perry G. A new era for medicinal chemistry. Mini Rev in Med Chem 12:1, 2012.

George Perry

117

642. Perry G, Phelix CF, Nunomura A, Colom LV, Castellani RJ, Petersen RB, Lee H-g, Zhu X. Untangling the vascular web from Alzheimer disease and oxidative stress. Can J Neurol Sci 39:4, 2012.(2)

643. Perry G. Journal of Huntington‘s Disease – the family gets bigger. J Alzheimers Dis 30:735, 2012.

644. Santos RX, Correia SC, Zhu X, Lee H-G, Petersen RB, Nunomura A, Smith MA, Perry G, Moreira PI. Nuclear and mitochondrial DNA oxidation in Alzheimer‘s disease. Free Rad Res 46:565-576, 2012.(19)

645. Bonda DJ, Lui G, Men P, Perry G, Smith MA, Zhu X. Nanoparticle delivery of transition-metal chelators to the brain: oxidative stress will never see it coming! CNS Neurol Disord Drug Targets 11:81-85, 2012.(6)

646. Zhu X, Castellani RJ, Ziats NP, Petersen RB, Lee H-g, Perry G. Obituary: Mark A. Smith: neurocytochemistry innovator. J Neurochem 120:1139-1140, 2012.

647. Perry G, Perry EA, Zhu X, Castellani R. A Pleotrophic age for Alzheimer and Parkinson disease. J Alzheimers Dis Parkinsonism 2:1, 2012.

648. Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 38:133-138, 2012.(27)

649. Klionsky DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8:445-544, 2012.(1169)

650. Williams WM, Castellani RJ, Weinberg A, Perry G, Smith MA. Do β-defensins and other antimicrobial peptides play a role in neuroimmune function and neurodegeneration? The Scientific World Journal 2012:11 pages, doi:10.1100/2012/905785, 2012.(7)

651. Liu G, Men P, Zhu X, Perry G. Iron chelation and nanoparticle target delivery in the development of new multifunctional disease-modifying drugs for Alzheimer‘s disease. Ther Deliv 3:571-574, 2012.

652. Rodrigues R, Smith MA, Wang X, Perry G, Lee H-g, Zhu X, Petersen RB. Molecular neuropathogenesis of Alzheimer‘s disease: an interaction model stressing the central role of oxidative stress. Future Neurol 7:287-305, 2012.

653. Perry G, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Casadesus G, Zhu X, Wang X. LRRK2 directly interacts with DLP1 to regulate mitochondrial dynamics and function. Micros Microanal 18 (Suppl 2):196-197, 2012.(68)

654. Casadesus G, Castellani R, Colom L, Lee H-g, Moreira P, Nunomura A, Perry G, Peterson [sic] RB, Wang X, Zhu X. Comment: Failure of antioxidants to treat Alzheimer disease: toward a homeostatic view of chronic

disease. Alzheimer Research Forum, 2012, http://alzforum.org/pap/annotation.asp?powID=129767.

655. Bonda DJ, Smith MA, Perry G, Lee H-g, Wang X, Zhu X. R-α-lipoic acid as a potent agent of mitochondrial protection in Alzheimer‘s disease. In: Mitochondrial Signaling in Health and Disease, Orrenius S, Packer L, Cadenas E, Eds, CRC Press, Taylor & Francis Group, Boca Raton, Florida, 2012, pp 455-467.

656. Castellani RJ, Zhu X, Nunomura A, Perry G. Obituary: In memoriam: Mark A. Smith, PhD: neuroscientist and visionary. UH Neurological Institute J 5:4-5, 2012.

657. Perry G, Wang X, Zhu X. Comment: A critical role of mitochondrial dynamics in the pathogenesis of AD.

Alzheimer Research Forum, 2012, http://alzforum.org/pap/annota tion.asp?powID=136427.

658. Perry G, Choudhary MI, López Rodríguez ML, Kalasz H, Bernard M, Barlocco D, Zacharie B, Kenneth S, Hwu JR. Special issue in honor of the 70

th birthday of Dr. Atta-ur-Rahman, FRS. Mini Rev Med Chem 12:i,

2012.

659. Perry EA, Castellani R, Moreira P, Perry G. A new age in metabolism. Metabolomics 2:1 page, doi:10.4172/2153-0769.1000e118, 2012.

660. Lee H-g, Perry G, Zhu X. Mark Smith: pioneer of Alzheimer disease research. Neurotox Res 22:181, 2012.

661. Nunomura A, Moreira PI, Castellani RJ, Lee H-g, Zhu X, Smith MA, Perry G. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res 22:231-248, 2012.(38)

662. Perry G, Zhu X, Lee H-g, Petersen RB, Castellani RJ. Mark Anthony Smith: enthusiasm for tackling the intractable. Coord Chem Rev 256:2127-2128, 2012.

663. Miklossy J, Donta S, Mueller K, Nolte O, Perry G. Editorial: Chronic or late Lyme neuroborreliosis: present and future. Open Neurol J 6 (Suppl 1-M1):78, 2012.

664. Joseph JA, Casadesus G, Smith MA, Perry G, Shukitt-Hale B. Nutrients and food constituents in cognitive decline and neurodegenerative disease. In: Nutrition in the Prevention and Treatment of Disease, 3

rd Edition,

Coulston AM, Boushey CJ, Ferruzzi M, Eds, Elsevier Inc., San Diego, California, 2012, pp 373-390.

George Perry

118

665. Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer‘s disease: the flat line of progress. Arch Med Res 43:694-698, 2012.(32)

666. Perry EA, Castellani RJ, Perry G. Pharmaceutical regulation: crossroad of opportunity as the distinction between food and drugs blurs. Pharmaceut Reg Affairs 1:1 page, doi:10.4172/2167-7689.1000e117, 2012.

667. Candeias E, Duarte AI, Carvalho C, Correia SC, Cardoso S, Santos RX, Plácido AI, Perry G, Moreira PI. The impairment of insulin signaling in Alzheimer‘s disease. IUBMB Life 64:951-957, 2012.(12)

668. Castellani KC, Perry EA, Perry G, Castellani RJ. Treating Alzheimer disease: is diet and exercise more effective than small molecule therapy? J Membra Sci Technol 3:1 page, doi:10.4172/2155-9589.1000e111, 2012.

669. Perry EA, Perry G, Castellani RJ, Moreira PI. Failure of A β removal to improve Alzheimer‘s dementia opens the door to new thinking. J Alzheimers Dis Parkinsonism 2:1 page, doi:10.4172/2161-0460.1000e126, 2012.

670. Castellani RJ, Li B-X, Farshori A, Perry G. Oxidative Stress and Alzheimer‘s Disease. In: Studies on Alzheimer Disease, Praticò D, Mecocci P, Eds, Springer Science+Business Media, New York, New York, 2013, pp 9-13.

671. Perry G. Excommunicating scientific discourse from the imprimatur of authority. WebMedCentral plus, 2013, http://www.webmedcentralplus.com/chief_foreword.

672. Alonso AD, Gong C-X, Perry G, Avila J. Obituary: Inge Grundke-Iqbal: a legacy of tau in the etiology of Alzheimer disease (1937-2012). J Alzheimers Dis 33:1-2, 2013.(1)

673. Colom LV, Perry G, Kuljiš RO. Tackling the elusive challenges relevant to conquering the 100-plus year old problem of Alzheimer‘s disease. Curr Alzheimer Res 10:108-116, 2013.(2)

674. Perry G. Foreword: the largest unmet market: chronic diseases of aging. Mini Rev Med Chem 13:1, 2013.

675. Perry G, Zhu X, Smith MA, Sorensen A, Avila J. Preface: Alzheimer‘s disease: advances for a new century. J Alzheimers Dis 33:S1, 2013.(27)

676. Zhu X, Perry G, Smith MA, Wang X. Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer‘s disease. J Alzheimers Dis 33:S253-S262, 2013.

677. Perry G. Alzheimer disease: where do we go from here? Meetings of the Minds State Plan Conference, 2013.

678. Perry G. Oceanography: not just the oceans. Oceanography 1:1 page, doi:10.4172/ocn.1000e102, 2013.

679. Perry G, Rodrigues R, Castellani RJ. Book Review: Are Alzheimer‘s disease and aging evolutionary? The origin of everything, Kelley DB, Woodhollow Press, Newbury, OH, 2013 (Book Review). J Alzheimers Dis 35:637, 2013.

680. Shammas R, Perry EA, Perry G. Cloning‘s promise. Clon Transgen 2:1 page, doi:10.4172/2168-9849.1000109, 2013.

681. Garcίa-Escudero V, Martίn-Maestro P, Perry G, Avila J. Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxid Med Cell Longev 2013:13 pages, http://dx.doi.org/10.1155/2013/162152, 2013.(1)

682. Santos RX, Correia SC, Zhu X, Smith MA, Moreira PI, Castellani RJ, Nunomura A, Perry G. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer‘s disease. Antioxid Redox Signal 18:2444-2457, 2013.(21)

683. Mondragón-Rodríguez S, Perry G, Zhu X, Moreira PI, Acevedo-Aquino MC, Williams S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer‘s disease. Oxid Med Cell Longev 2013:6 pages, doi:10.1155/2013/940603, 2013.

684. Sabbagh MN, Perry G, Hunsaker JC III, Schreurs B. Obituary: Larry Sparks: innovator and iconoclast. J Alzheimers Dis 37:1, 2013.

685. Correia SC, Perry G, Castellani R, Moreira PI. Is exercise-in-a-bottle likely to proffer new insights into Alzheimer‘s disease? J Neurochem 127:4-6, 2013.(1)

686. Perry G. Oxidative, metabolic, and fibril stress in Alzheimer disease. From Neurodegeneration to Brain Health, 2013, http://www.brainhealth2013.com/program.html.

687. Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer‘s and other neurodegenerative diseases. Transl Psychiatry 3:9 pages, doi:10.1038/tp.2013.97, 2013.

688. Castellani RJ, Peclovits A, Perry G. Neuropathology of Alzheimer‘s disease. In: Pathobiology of Human Disease, McManus LM, Mitchell RN, Eds, Elsevier, Oxford, United Kingdom, 2014, pp 2014-2020.

George Perry

119

689. Castellani RJ, Perry G. Pathogenesis of Alzheimer‘s disease. In: Handbook of Neurotoxicity, Kostrzewa RM, Ed, Springer Science+Business Media, New York, New York, 2014, pp 2327-2337.

690. Johnston JM, Perry G, Ashford JW, Tezapsidis N. Leptin in Alzheimer‘s disease and other cognitive disorders and association with underlying lipid abnormalities. In: Leptin: Biosynthesis, Functions, and Clinical Significance, Blum EL, Ed, Nova Science Publishers, Inc., Hauppauge, New York, 2014, pp 1-16.

691. Perry G. Preface. In: Recent Advances in Medicinal Chemistry, Vol. 1, Rahman A, Choudhary MI, Perry G, Eds, Bentham Science Publisher, Sharjah, United Arab Emirates, 2014, p iii.

692. Perry G. Looking at Alzheimer‘s disease from a different angle. Future Neurol 9:19-22, 2014.

693. Brinkley WR, Perry G. Obituary: Lester (Skip) Binder (1949-2013): In the beginning was tau. J Alzheimers Dis 40:S5, 2014.

694. Rosen AC, Ashford JW, Perry G. Ethics review as a catalyst for progress. J Alzheimers Dis 40:233-235, 2014.

695. Perry G. AFAExpertChat with Dr. George Perry, 2014, http://storify.com/alzfdn/afaexpertchat-with-dr-george-perry.

696. Perry EA, Castellani RJ, Perry G. A new outlook for Alzheimer‘s disease. Atlas J Med Bio Sci 1:21-22, 2014. doi: 10.5147/ajmbs.2014.0200

697. Bonda DJ, Wang X, Lee H-G, Smith MA, Perry G, Zhu X. Neuronal failure in Alzheimer‘s disease: a view through the oxidative stress looking-glass. Neurosci Bull 30:243-252, 2014.(11)

698. Perry G, Castellani R. Preface: plaques and tangles: birthmarks of the aging soul. Biochem Pharmacol 88:423-425, 2014.(1)

699. Castellani RJ, Perry G. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. Biochem Pharmacol 88:671-676, 2014.(17)

700. Perry EA, Castellani RJ, Perry G. An epidemiological approach to the study of Alzheimer‘s disease. Int J Clin Thera Diagn 2(2):1, 2014.

701. Perry G. In praise of pathologists: a commencement address delivered at the University of Maryland in Baltimore, pathologists‘ assistants graduate program. Atlas J Med Biol Sci 1:23-25, 2014. Doi:10.5147/ajmbs.2014.0201

702. Wang X, Wang W, Li L, Perry G, Lee H-g, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer‘s disease. Biochim Biophys Acta, 1842:1240-1247, 2014.(45)

703. Rodrigues R, Petersen RB, Perry G. Parallels between major depressive disorder and Alzheimer‘s disease: role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol 34:925-949, 2014.

704. Habibi L, Perry G, Mahmoudi M. Global warming and neurodegenerative disorders: speculations on their linkage BioImpacts 4:167-170, 2014.

705. Castellani RJ, Zhu X, Perry G, Moreira PI. Alzheimer‘s disease: an overview. In: Reference Module in Biomedical Research, Caplan M, Ed, Elsevier Publishing, Amsterdam. doi: 10.1016/B978-0-12-801238-3.04491-3, 2015.

706. Castellani RJ Moreira PI, Zhu X, Perry G. Alzheimer disease: pathology and pathogenesis. In: Reference Module in Biomedical Research, Holmes DJ, Ed., Elsevier Limited, Oxford, United Kingdom. doi: 10.1016/B978-0-12-801238-3.00160-4, 2014.

707. Forero DA, Vélez-van-Meerbeke A, Deshpande SN, Nicolini H, Perry G. Neuropsychiatric genetics in developing countries: current challenges, World J Psychiatry 4:69-71, 2014.

708. Correia SC, Moreira PI, Perry G. Autophagy in Alzheimer‘s disease: a cleaning service out-of-order? In: Current Topics in Neurotoxicity 9: Toxicity and Autophagy in Neurodegenerative Disorders, Fuentes JM, Ed, Springer International Publishing Switzerland, 2015, pp. 123-142. (24)

709. Perry G. Meet the editorial board. Curr Protein Peptide Sci 16:181, 2015. 710. Perry G. Editorial: Two hundred treasured issues! J Alzheimer Dis 44:725, 2015.

711. Atta-ur Rahman, Choudhary MI, Perry G. Overview. Mini Rev Med Chem 15:2-3, 2015.

712. Luna-Muñoz J, Perry G, Guevara J. Obituary: Raúl Mena: 1953-2014. J Alzheimer Dis 45:325-327, 2015.

713. Rodrigues R, Perry G, Petersen R. Basis and argument into the work ―parallels on depression and Alzheimer‘s disease and different genomic vulnerability leading to therapeutic utilities‖. Int J Neurol Neurother 2:1, 2015.

George Perry

120

714. Petersen RB, Lissemore FM, Appleby B, Aggarwal N, Boyatzis R, Casadesus G, Cummings J, Jack A, Perry G, Safar J, Sajatovic M, Surewicz W, Wang Y, Whitehouse P, Lerner A. From neurodegeneration to brain health: an integrated approach J Alzheimer‘s Dis 46:271-283, 2015.

715. Bajic V, Stanojevic B, Zivkovic L, Cabarkapa A, Perry G, Arendt T, Spremo-Potparevic B. Cyclin dependent Kinase 11, neuroinflammation and Alzheimer‘s disease: a review. J Clin Cell Immunol 6:2, 2015. doi:10.172/2155-9899.1000305

716. Rodrigues R, Ahmad F, Perry G, Petersen RB. Synergy between depression and Alzheimer‘s disease: a spectrum model of genomic vulnerability with therapeutic implications. Integrative Mol Med 2:139-141, 2015.

717. Perry G. Editorial. J Systems Integrative Neurosci 1:1, 2015.

718. Avila J, Perry G, Strange BA, Hernandez F. Alternative neural circuitry that might be impaired in the development of Alzheimer disease. Frontiers in Neuroscience 9:1-5, 2015. doi: 10.3389/fnins.2015.00145

719. Castellani RJ, Perry G, Iverson GL. Chronic effects of mild neurotrauma: putting the cart before the horse? J Neuropathol Exp Neurol 74:493-499, 2015.(1)

720. Perry G. Meet our editorial board member. Mini Rev Med Chem 15:719, 2015.

721. Castellani RJ, Perry G. We should have better results in the Alzheimer‘s battle. The Wall Street Journal, Tuesday, June 16, 2015, Page A14. http://www.wsj.com/articles/we-should-have-better-results-in-the-alzheimers-battle-1434399633?KEYWORDS=Alzheimer

722. Perry G. Introducing the JAD Editor‘s Blog. J Alzheimer Dis, 2015. http://j-alz.com/editors-blog/posts/introducing-jad-editors-blog

723. Jiang Z, Wang W, Perry G, Zhu X, Wang X. Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Trans Neurodeg 4:14, 2015. doi: 10.1186/s40035-015-0037-x.

724. Perry EA, Perry G.Cellular Pathology of Alzheimer disease. Cell Dev Biol 4:e134. http://dx.doi.org/10.4172/2168-9296.1000e134, 2015.

725. Perry G. Lifelong Mentorship, 2015. http://www.slideshare.net/GeorgePerry3/lifelong-mentorship-loma-linda-university.

726. Perry G, Dixson M. Understanding Impact Factors, 2015. http://www.slideshare.net/GeorgePerry3/research-impact-factors

727. Perry, van der Holst R. Journal of Alzheimer‘s Disease 2015 Editorial Board Meeting, 2015. http://www.slideshare.net/GeorgePerry3/journal-of-alzheimers-disease-2015.

728. Perry G. Alzheimer‘s Disease: The Hispanic Challenge. Slide Share, 2016. http://www.slideshare.net/GeorgePerry3/alzheimer-disease-the-hispanic-challenge

729. Perry G, Sorensen A. Brain Health Retreat, Case Wester Reserve University, 2015. http://www.slideshare.net/GeorgePerry3/brain-health-retreat-case-western-reserve-university.

730. Perry G. Medical Education In the Wired Age, 2015. http://www.slideshare.net/GeorgePerry3/medical-education-in-the-wired-age.

731. Perry G. Alzheimer Disease: The Hispanic Challenge, Fuerza Contra Alzheimer 2015. http://www.slideshare.net/GeorgePerry3/fuerza-contra-alzheimer-november-2015?related=1

732. Mohorovic L, Lavezza AM, Stifter S, Perry G, Malatestinic D, Micovic V, Materljan E. Ferric iron brain deposition as the cause, source and originator of chronic neurodegenerative diseases. Environmental Analytical Chem 2: http://dx.doi.org/10.4172/2380-2391.1000169, 2015.

733. Nunomura A, Tamaoki T, Motohashi N, Lee H-g, Zhu X, Perry G. Oxidative Stress and Neuropsychiatric Disorders in the Life Spectrum . In :Reactive Oxygen Species in Biology and Human Health: a Comprehensive Treatise, Ahmad S, Ed, CRC Press, 2016, pp. 157-163.

734. Perry G. Alzheimer ‗disease-in-a-dish‘ and development of novel therapeutics. RegenMed SA, Session III—Clinical Progress & Applications, 2016. http://www.slideshare.net/GeorgePerry3/alzheimer-diseaseinadish-and-development-of-novel-therapeutics?qid=2063b9ba-fa9f-417c-a62d-0a32d3521762&v=&b=&from_search=2

735. Moreira P, Zhu X, Smith MA, Perry G. Mitochondria in Alzheimer disease. Mitochondrion (in preparation).

736. Perry G. Memoirs of a senior scientist. Cell Mol Life Sci (in preparation).

737. Carvalho C, Correia SC, Perry G, Castellani RJ, Moreira PI. Cerebrovascular and mitochondrial abnormalities in Alzheimer‘s disease: a brief overview. J Neural Trans 123:107-111, 2016.

George Perry

121

738. Singh S, Castellani RJ, Perry G. Oxidative stress and Alzheimer‘s disease. In: Inflammation, Aging and Oxidative Stress, Bondy SC, Campbell A, eds., Springer (in press).

739. Perry G. Meet Our Associate Editor. Current Alzheimer Research 13:1311, 2016

740. Perry G. Preface. In: Biomarkers in Alzeimer‘s Disease, Elsevier Publishing, Amsterdam, p. vii, 2016

741. Kontush A, Perry G. Antioxidant properties of amyloid β. (in preparation).

742. Perry G. Editorial: Promise from the sea. Marine Drugs 14:178, 2016.

743. Perry G. Editorial Article. Therapeutic Delivery (in prepration).

744. Singh SK, Srikrishna S, Castellani RJ, Perry G. Antioxidants in the prevention and treatment of Alzheimer‘s disease. In: Nutritional Antioxidant Therapies: treatments and perspectives, Part 3: Nutritional antioxidants in health and disease. (in print), 2016.

745. Perry G. Neuroinflammation in Alzheimer disease: the therapeutic potential of polyphenolic nutraceuticals (in preparation).

746. Castellani RJ, Correia SC, Moreira PI, Perry G. Tackling Alzheimer‘s disease by targeting oxidative stress and mitochondria. In: Developing Therapeutics for Alzheimer‘s Disease: Progress and Challenges, Wolfe M, Ed., Elsevier Publishing, Amsterdam, pp. 477-502, 2016.

747. Gang L, Perry G. Nanoscience applied to Alzheimer disease. Int J Biomed Nanosci Nanotech (in preparation).

748. Itzhaki RS, Lathe R, Balin B, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, Del Tredici K, Field H, Fulop T, Grassi C, Griffin WST, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lövheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, StrandbergT , Tabet N, Taylor-Robinson SD, Whittum-Hudson

JA. Microbes and Alzheimer‘s disease. J

Alzheimer‘s Dis 51:979-984, 2016.

749. Perry G. Finding Portuguese Identity. In: Untamed Dreams: Faces of America, Dinis FH, Rodrigues JdC, Eds, pp.333-338, 2016.

750. Mondragón-Rodríguez S, Perry G, Peña-Ortega F, Williams S. Tau, amyloid beta and deep brain stimulation: aiming to restore cognitive deficit in Alzheimer‘s disease. Current Alz Res 14:40-46, 2016.

751. Hofer T, Perry G. Nucleic acid oxidative damage in Alzheimer‘s disease—explained by the hepcidin-ferroportin neuronal iron overload hypothesis? J Trace Elements Med Biol,38:1-9, 2016.

752. Forero DA, Wonkam A, Wang W, Laissue P, López-Correa C, Fernández-López JC, Mugasimangalam R, Perry G. Current needs for human and medical genomics research infrastructure in low and middle income countries. J Med Genet 53:438-440, 2016.

753. Castellani RJ, Perry G, Keane D, Iverson GL. Is chronic traumatic encephalopathy inexorably progressive? (submitted)

754. Mondragón-Rodriguez S, Perry G, Peña-Ortega F. The tau protein (in preparation).

755. Pistollato F, Ohayon EL, Lam A, Langley GR, Novak TJ, Pamies D, Perry G, Trushina E, Williams RSB, Roher AE, Hartung T, Harnad S, Barnard N, Morris MC, Lai M-C, Merkley R, Chandrasekera PC. Alzheimer disease research in the 21

st century: past and current failures, new perspectives and funding priorities.

Oncotarget, 7:38999-39016, 2016.

756. Plascencia-Villa G, Yacamán MJ, Perry G. Metals and mitochondria in neurodegeneration. In: Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics, White A, Aschner M, Costa L, Bush A, Eds, pp. 283-311, 2017

757. Correia SC, Perry G, Moreira PI. Chapter 13: Unravelling the role of mitochondria in Alzheimer‘s disease – toward assembling the puzzle! In: Vascular Disease, Alzheimer‘s Disease, and Mild Cognitive Impairment; Advancing an Integrated Approach, Libon DJ, Swenson R, Lamar M, Heilman KM,Eds, 2015. (in preparation)

758. Singh S, Castellani RJ, Perry G. Overview of Alzheimer‘s disease and some therapeutic approaches targeting Aβ by using several synthetic and herbal compounds. Oxidative Med Cellular Longevity 2016:22 pages. http://dx.doi.org/10.1155/2016/7361613, 2016.

759. Nunomura A, Perry G. RNA oxidation (in preparation)

760. Perry G. Mass Spectra for revealing disease-associated pathways. Mass Spectrometry and Purification Techniques 2:1, 2016.

761. Correia SC, Perry G, Moreira PI. Mitochondrial traffic jams in Alzheimer‘s disease – pinpointing the roadblocks. BBA – Mol Basis of Dis 1862:1909-1917, 2016.

George Perry

122

762. Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3

rd edition). Erratum: Autophagy 12:1-222, 2016.

763. Reddy VP, Perry G, Smith MA. Brain composition: age-related changes In: Reference Module in Neurosciences (submitted)

764. Skrobot OA, O‘Brien J, Black S, Chen C, DeCarli C, Erkinjuntti T, Ford GA, Kalaria RN, Pantoni L, Pasquier F, Roman GC, Wallin A, Sachdev P, Skoog I, VICCCS group, Ben-Shlomo Y, Passmore AP, Love S, Kehoe PG, Taragano FE, Kril J, Cavalieri M, Jellinger KA, Kovacs GG, Engelborghs S, Lafosse C, Bertolucci PH, Brucki S, Caramelli P, de Toledo Ferraz Alves TC, Bocti C, Fulop T, Hogan DB, Hsiung GR, Kirk A, Leach L, Robillard A, Sahlas DJ, Guo Q, Tian J, Hokkanen L, Jokinen H, Benisty S, Deramecourt V, Hauw J, Lenoir H, Tsatali M, Tsolaki M, Sundar U, Coen RF, Korczyn AD, Altieri M, Baldereschi M, Caltagirone C, Caravaglios G, Di Carlo A, DI Piero V, Gainotti G, Galluzzi S, Logroscino G, Mecocci P, Moretti DV, Padovani A, Fukui T, Ihara M, Mizuno T, Kim SY, Akinyemi R, Baiyewu O, Ogunniyi A, Szczudlik A, Bastos-Leite AJ, Firmino H, Massano J, Verdelho A, Kruglov LS, Ikram MK, Kandiah N, Arana E, Barroso-Ribal J, Calatayud T, Cruz-Jentoft AJ, López-Pousa S, Martinez-Lage P, Mataro M, Börjesson-Hanson A, Englund E, Laukka EJ, Qiu C, Viitanen M, Biessels GJ, de Leeuw FE, den Heijer T, Exalto LG, Kappelle LJ, Prins ND, Richard E, Schmand B, van den Berg E, van der Flier WM, Bilgic B, Allan LM, Archer J, Attems J, Bayer A, Blackburn D, Brayne C, Bullock R, Connelly PJ, Farrant A, Fish M, Harkness K, Ince PG, Langhorne P, Mann J, Matthews FE, Mayer P, Pendlebury ST, Perneczky R, Peters R, Smithard D, Stephan BC, Swartz JE, Todd S, Werring DJ, Wijayasiri SN, Wilcock G, Zamboni G, Au R, Borson S, Bozoki A, Browndyke JN, Corrada MM, Crane PK, Diniz BS, Etcher L, Fillit H, Greenberg SM, Grinberg LT, Hurt SW, Lamar M, Mielke M, Ott BR, Perry G, Powers WJ, Ramos-Estebanez C, Reed B, Roberts RO, Romero JR, Saykin AJ, Seshadri S, Silbert L, Stern Y, Zarow C.The Vascular Impairment of Cognition Classification Consensus Study (VICCCS). Alzheimer‘s and Dementia (in press)

765. Hajipour MJ, Rezaee F, Morteza M, Perry G. New therapeutic targets in Alzheimer disease: are we on the right track? (submitted)

766. Perry G. Session with George Perry, 14 July 2016. Quora.com, 2016. https://www.quora.com/session/George-Perry-5/1

767. Perry G, Semião F. Message from the publisher. Portuguese American Yearbook 2nd

Edition, 2016, pp. 5-6, The National Organization of Portuguese-Americans, 2016.

768. Perry G. Meet our editorial board member: Dr. George Perry. Current Aging Science 9:159, 2016.

769. Perry G. Editorial article: Prof George Perry: Perspectives on Alzheimer‘s disease research – Part 1, Key role for oxidative stress. SelectScience, 2016. http://www.selectscience.net/editorial-articles/prof-george-perry-perspectives-on-alzheimers-disease-research--part-1/?artID=39817

770. Perry G. Editorial article: Prof George Perry: Perspectives on Alzheimer‘s disease research – Part 2, Are amyloid plaques the best therapeutic targer? SelectScience, 2016. http://www.selectscience.net/editorial-articles/prof-george-perry-perspectives-on-alzheimers-disease-research--part-2/?artID=39829

771. Nunomura A, Zhu X, Perry G. Modulation of Parkinson‘s disease associated protein rescues Alzheimer‘s degeneration. J Alz Dis (in press).

772. Perry G. Networking Tools. Sixteenth Portuguese American Postgraduate Society Forum, Memorial Sloan-Kettering Cancer Center, New York, NY, 2016.

773. Perry G. Editorial. Biological System: Open Access 5:1, 2016..

774. Perry G. Editor‘s Note. Management of neuro degenerative diseases of elderly adults. J Alzheimer‘s Dis Parkinsonism 6:3, 2016.

775. Khalsa D, Perry G. Four pillars of Alzheimer‘s disease. Cerebrum (in preparation).

776. Bajic V, Bajic V, Zivkovic L, Arendt T, Perry G, Spremo-Potparavic B. Late phase cell cycle proteins in Alzheimer‘s Disease: a possible target for therapy?. (in preparation).

777. Perry G. Meet our Co-Editor. Mini-Reviews Med Chem 17:319, 2017.

778. Nunomura A, Perry G. Consequences of RNA oxidation on protein synthesis rate and fidelity. Biochem Society Transactions (in preparation)

779. Singh S, Perry G. Oxidative stress in Alzheimer disease (in preparation)

780. Perry G. Editor statement. Int J Clin Therapeutics Diagnosis (in press)

781. Perry G. Meet our Editor-in-Chief. Letters Drug Design Disc 14:251, 2017.

782. Perry G. Message from chairman of MPHBS. Intl Congress Med, Pub Health, Bio Sci 2016

George Perry

123

783. Shea TB, Remington R, Perry G. Nutritional supplements and dementia. Clinical Nutrition (accepted), doi: 10.16/j/clnu.2016.12.032, 2017.

784. Velez-Pardo C, Perry G, Jimenez-Del-Rio M. Will Alzheimer‘s disease be cured by 2016? (in preparation)

785. Perry G. Foreword. In: Environmental Causes for Alzheimer‘s Disease and Prevention Measures. (submitted)/

Abstracts:

1. Perry G, Epel D. Calcium control of a cyanide insensitive respiration in Arbacia punctulata eggs, and its relation to echinochrome. Biol Bull 149:441, 1975.(5)

2. Perry G. Echinochrome oxidation in Arbacia punctulata embryos. Biol Bull 151:423, 1976.(5)

3. Perry G, Epel D. Calcium stimulation of a lipoxygenase activity accounts for the respiratory burst at fertilization of the sea urchin egg. J Cell Biol 75:40, 1977.(8)

4. Byrd W, Perry G, Weidner E. Role of the egg cortex and actin in fertilization of the sea urchin egg. J Cell Biol 75:267, 1977.(8)

5. Perry G. Studies on calcium-stimulated oxidations in the sea urchin egg. Diss Abst Int 40:5115B, 1980.

6. Epel D, Perry G, Cheung WY, Wallace R. Targets for calcium in egg activation at fertilization: NAD kinase-calmodulin and lipoxygenase. Eur J Cell Biol 22:452, 1980.

7. Perry G, Brinkley BR, Bryan J. Microtubule-calmodulin interactions. J Cell Biol 87:253, 1980.(5)

8. Perry G, Wible L, Brinkley BR. Microtubules in dystrophic chicken cells in vitro. J Cell Biol 91:337, 1981.

9. Anderson DC, Brinkley BR, Perry G, Smith CW. Abnormal mobility of neonatal (N) PMNs: Relationship to impaired orientation and polymerization of microtubules (MT). Pediatr Res 16:219A, 1982.(1)

10. Perry G, Gambetti P. Mice immunized with isolated paired helical filaments of Alzheimer's disease produce antibodies to normal axons. J Neuropathol Exp Neurol 42:342, 1983.(1)

11. Perry G, Gambetti P. Paired helical filament fractions of Alzheimer's disease contain insoluble neurofilament antigens. J Cell Biol 97:242a, 1983.(2)

12. Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P. Staining of Alzheimer's PHF with silver and antibodies: An EM study. Trans Am Soc Neurochem 15:102, 1984.

13. Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P. Ultrastructural localization of cytoskeletal markers on Alzheimer's paired helical filaments. J Neuropathol Exp Neurol 43:346, 1984.(7)

14. Wisniewski HM, Skinner M, Merz G, Gambetti P, (Perry G), Iqbal K, Selkoe D. Pathogenesis of neurofibrillary tangles and neuritic and amyloid plaques in senile dementia of Alzheimer type. XIII Internat Congr Gerontol, New York, p. 397, 1985.

15. Galloway PG, Perry G, Gambetti P. Hirano body filaments contain actin and tropomyosin. Soc Neurosci Abstr 11:952, 1985.(3)

16. Perry G, Stewart D, Gambetti P. Ultrastructural immunocytochemical localization of cytoskeletal markers within the Pick body. J Cell Biol 101:18a, 1985.(1)

17. Gambetti P, Autilio-Gambetti L, Perry G. Neuronal cytoskeleton in Alzheimer disease and other pathologic conditions of the nervous system. XIth Meet Soc Suisse Neuropathol, 1986, p. 14.

18. Galloway P, Perry G, Gambetti P. An immunocytochemical study of Hirano and Lewy bodies. 10th Annual Graduate Res Symp, p. 2, 1986.

19. Galloway P, Perry G, Gambetti P. A study of actin binding proteins in Hirano bodies. J Neuropathol Exp Neurol 45:335, 1986.(1)

20. Perry G, Stewart D, Autilio-Gambetti L, Gambetti P. Pick body straight filaments contain neurofilament and microtubule elements. J Neuropathol Exp Neurol 45:377, 1986.(1)

21. Galloway P, Perry G, Grundke-Iqbal I, Autilio-Gambetti L, Gambetti P. Lewy bodies share epitopes with neurofilaments, tubulin and neurofibrillary tangles. Xth Internat Congr Neuropathol, p. 298, 1986.(4)

22. Perry G, Autilio-Gambetti L, Gambetti P. Neurofilament and microtubule elements are present in pick body straight filaments. Xth Internat Congr Neuropathol, 1986, p. 298.(2)

23. Galloway P, Perry G, Gambetti P. A study of neuronal cytoskeletal involvement in Hirano body formation. J Cell Biol 103:263a, 1986.

George Perry

124

24. Perry G, Galloway P, Autilio-Gambetti L, Gambetti P. Alteration in the neuronal cytoskeleton in Alzheimer, Pick and Parkinson diseases. J Cell Biol 103:418a, 1986.

25. Perry G, Autilio-Gambetti L, Gambetti P. Neurofilament antibodies are elicited by Alzheimer paired helical filament fractions. J Cell Biol 103:564a, 1986.(2)

26. Gambetti P, Chau V, Mulvihill P, Manetto V, Weiss M, Autilio-Gambetti L, Perry G. A new protein in Alzheimer disease: Ubiquitin. Italian Study Group on Brain Aging Internat Symp on New Trends in Aging Res. p. 55, 1987.

27. Chau V, Perry G, Friedman R, Shaw G. Ineffective turnover of abnormal proteins in Alzheimer's disease. Fed Proc 46:2146, 1987.(1)

28. Onorato M, Gambetti P, Kosik K, Perry G. Electron microscopic localization of tau in Alzheimer NFT and PHF. J Neuropathol Exp Neurol 46:334, 1987.

29. Perry G, Manetto V, Autilio-Gambetti L, Gambetti P. Straight filaments of Alzheimer neurofibrillary tangles. J Neuropathol Exp Neurol 46:334, 1987.

30. Galloway P, Grundke-Iqbal I, Autilio-Gambetti L, Gambetti P, Perry G. Neuronal cytoskeletal involvement in Lewy body formation. J Neuropathol Exp Neurol 46:374, 1987.(4)

31. Manetto V, Gambetti P, Perry G, Autilio-Gambetti L. Two neurofilament probes react with Alzheimer paired helical filaments and not with tau proteins. J Neuropathol Exp Neurol 46:376, 1987.

32. Koo H, Ghetti B, Perry G, Gambetti P. Abnormal phosphorylation of neurofilaments following administration of antimitotic drugs. J Neuropathol Exp Neurol 46:379, 1987.

33. Miller CA, Rudnicka M, Perry G, Hinton D, Kozlowski M. Alzheimer's disease: Topographical distribution of a neuronal antigen. Second World Congress Neurosci (IBRO) S439, 1987.

34. Miller CA, Rudnicka M, Perry G, Hinton D, Kozlowski M. Alzheimer's disease: Topographical distribution of a neuronal antigen. Neuroscience 22:S439, 1987.

35. Matsumoto Y, Perry G, Aikawa M. Role of calmodulin in Plasmodium falciparum: Implications for erythrocyte invasion by the merozoite. Third Internatl Conf on Malaria and Babesiosis p. 33, 1987.

36. Onorato M, Connolly J, Kosik K, Perry G. Altered neurites of Alzheimer disease contain a distinct subset of filaments sharing epitopes with tau. J Cell Biol 105:203a, 1987.(8)

37. Perry G, Mulvihill P, Manetto V, Fried V, Smith H, Grundke-Iqbal I, Iqbal K, Autilio-Gambetti L, Gambetti P. Ubiquitin epitopes in Alzheimer paired helical filaments: A study with monoclonal antibodies to ubiquitin and paired helical filaments. J Cell Biol 105:203a, 1987.(7)

38. Manetto V, Gambetti P, Tabaton M, Mulvihill P, Fried V, Smith H, Autilio-Gambetti L, Perry G. Ubiquitin conjugates: A new component of abnormal cytoskeletal derived filaments in degenerative diseases. J Cell Biol 105:208a, 1987.

39. Galloway P, Grundke-Iqbal I, Autilio-Gambetti L, Gambetti P, Perry G. Lewy bodies of idiopathic Parkinson's disease contain cytoskeletal components. J Cell Biol 105:269a, 1987.(1)

40. Tabaton M, Manetto V, Fried V, Perry G. Epitopes of neurofibrillary tangle (NFT) are influenced by the neuronal type in Alzheimer disease (AD) and progressive supranuclear palsy (PSP). J Cell Biol 105:316a, 1987.(3)

41. Manetto V, Gambetti P, Tabaton M, Mulvihill P, Fried V, Smith H, Autilio-Gambetti L, Perry G. Ubiquitin conjugates: A new component of abnormal neuronal filaments in neurodegenerative diseases. Soc Neurosci Abstr 13:820, 1987.(2)

42. Tabaton M, Manetto V, Autilio-Gambetti L, Gambetti P, Fried V, Perry G. Neurofibrillary tangles (NFT) of progressive supranuclear palsy (PSP) and Alzheimer disease (AD): Influence of neuronal cell location on antigenic properties. Soc Neurosci Abstr 13:1151, 1987.(2)

43. Perry G, Mulvihill P, Manetto V, Fried V, Smith H, Grundke-Iqbal I, Iqbal K, Autilio-Gambetti L, Gambetti P. Ubiquitin in Alzheimer paired helical filaments: A study with monoclonal antibodies. Soc Neurosci Abstr 13:1152, 1987.(2)

44. Morandi A, Fried V, Smith H, Perry G, Gambetti P. Ubiquitin response in cultured nervous tissue after heat shock and aluminum intoxication. Soc Neurosci Abstr 13:1327, 1987.

45. Matsumoto Y, Perry G, Aikawa M. Role of calmodulin in Plasmodium falciparum: Implications for erythrocyte invasion by the merozoite. 36th Annual Meeting, Amer Soc Tropical Med Hygiene. p. 223, 1987.

George Perry

125

46. Manetto V, Tabaton M, Perry G. Immunoelectronmicroscopic localization of ubiquitin in the abnormal cytoskeleton-derived filaments found in degenerative diseases. Great Lakes Electron Microscopy Conference. p. 30, 1987.

47. Onorato M, Perry G. Altered neurites of Alzheimer disease contain distinct 13 nm filaments sharing epitopes with tau: An immunoelectronmicroscopic study. Great Lakes Electron Microscopy Conference. p. 37, 1987.

48. Galloway P, Perry G. Immunoelectronmicroscopic localization of cytoskeletal epitopes in Hirano bodies. Great Lakes Electron Microscopy Conference. p. 50, 1987.

49. Kawahara H, Perry G, Gambetti P, Manetto V, Ohta M, Marceau N, Cadrin M, French SW. Ubiquitination in stressed hepatocytes in vivo and in vitro. Hepatology 8:1398, 1988.

50. Morandi A, Fried V, Smith H, Welch W, Perry G, Autilio-Gambetti L, Gambetti P. Ubiquitin and other stress proteins in cultured nervous tissue after heat shock and aluminum intoxication. J Neuropathol Exp Neurol 47:331, 1988.(6)

51. Kovacs D, Morandi A, Groger R, Golde TE, Younkin L, Tykocinski M, Perry G, Autilio-Gambetti L, Gambetti P. Analysis of mRNA content for the β-amyloid precursor protein in fibroblasts from aged, Alzheimer and Down donors. J Neuropathol Exp Neurol 47:332, 1988.

52. Tabaton M, Morandi A, Masters C, Beyreuther K, Perry G, Gambetti P, Autilio-Gambetti L. Immunoreactivity of fibroblasts from Alzheimer, Down and control cases with an antiserum to amyloid (A4) synthetic peptide. J Neuropathol Exp Neurol 47:336, 1988.(5)

53. Perry G, Cras P, Rudnicka M, Mulvihill P, Tabaton M, Bizzi A, Autilio-Gambetti L, Gambetti P, Miller C, Van Heuverswyn H, Soler Federsppiel BS, Martin JJ, Gheuens J. Ultrastructural localization and characterization of an Alzheimer paired helical filament antigen. J Neuropathol Exp Neurol 47:336, 1988.

54. Manetto V, Perry G, Abdul-Karim F, Tabaton M, Autilio-Gambetti L, Gambetti P. Ubiquitin: Selective presence in neuronal and non-neuronal inclusions. J Neuropathol Exp Neurol 47:336, 1988.(3)

55. Rudnicka M, Perry G, Miller CA. Selective vulnerability of a subpopulation of cortical neurons in Pick's disease. J Neuropathol Exp Neurol 47:342, 1988.

56. Galloway PG, Likavec MJ, Perry G. Leu-7 positivity of ethylnitrosourea rat brain microtumors. J Neuropathol Exp Neurol 47:350, 1988.

57. Tabaton M, Manetto V, Perry G, Davies P, Gambetti P. Study of an antigen present in the early stages of neurofibrillary tangle formation. Ital J Neurol Sci 9:185-186, 1988.

58. Manetto V, Tabaton M, Perry G, Autilio-Gambetti L, Gambetti P. Site of ubiquitin in the central nervous system. Ital J Neurol Sci 9:186, 1988.

59. Lew EO, Rozdilsky B, Munoz DG, Perry G. A new type of neuronal inclusion in human pathology. Can J Neurol Sci 15:173-174, 1988.(3)

60. Manetto V, Perry G, Abdul-Karim F, Tabaton M, Autilio-Gambetti L, Gambetti P. Ubiquitin: selective presence in neuronal and non-neuronal inclusions. Clin Neuropathol 7:186, 1988.

61. Tabaton M, Mandybur TI, Perry G, Gambetti P. Diffuse abnormal cortical neurites without amyloid deposition in subacute sclerosing panencephalitis with neurofibrillary tangles formation. Clin Neuropathol 7:214, 1988.

62. Perry G, Manetto V, Mulvihill P, Onorato M, Tabaton M, Autilio-Gambetti L, Gambetti P. Cell biology of neurons in Alzheimer and other degenerative diseases. Alzheimer Dis Assoc Disord 2:195, 1988.

63. Morandi A, Welch W, Perry G, Autilio-Gambetti L, Gambetti P. Different stress conditions in cultured nervous tissue: Response of heat-shock proteins and ubiquitin system. Alzheimer Dis Assoc Disord 2:199 1988.

64. Iqbal K, Saitoh T, Khatoon S, Kosik KS, Perry G, Miller DL. Brain protein pathology in Alzheimer disease. Neurobiol Aging 9:418, 1988.

65. Kovacs D, Morandi A, Tabaton M, Perry G, Master C, Robakis N, Hauer C, Groger R, Tykocinski M, Gambetti P, Autilio-Gambetti P. Amyloid precursor in cultured human cells. Alzheimer Dis Assoc Disord 2:402, 1988.

66. Perry G, Lipphardt S, Mulvihill P, Kancherla M, Autilio-Gambetti L, Gambetti P, Sharma S, Maggiora L, Cornette J, Lobl T, Greenberg B. Amyloid precursor protein: Immunolocalization surrounding senile plaque core. Alzheimer Dis Assoc Disord 2:411, 1988.

67. Gambetti P, Welch W, Perry G, Autilio-Gambetti L, Morandi A. Concomitant presence of ubiquitin and tau protein in experimental neuronal inclusions. Soc Neurosci Abstr 14:897, 1988.

68. Galloway PG, Likavec MJ, Perry G. Tropomyosin isoform expression in normal and neoplastic astrocytes. Soc Neurosci Abstr 14:1057, 1988.

George Perry

126

69. Morandi A, Welch W, Perry G, Autilio-Gambetti L, Gambetti P. Heat shock proteins and ubiquitin in cultured nervous tissue. Soc Neurosci Abstr 14:1087, 1988.

70. Tabaton M, Perry G, Davies P, Gambetti P. Alzheimer disease: The monoclonal antibody Alz 50 revealed the fine structure of the diffuse neuropil abnormalities. Neurosci Lett (Suppl) 33:S188, 1988.

71. Mulvihill P, Lipphardt S, Mijares M, Kancherla M, Perry G. Localization and isolation of the amyloid precursor protein of Alzheimer disease using anti-peptide antibodies. J Cell Biol 107:724a, 1988.

72. Perry G, Siedlak S, Mulvihill P, Kawai M, Mijares M, Gambetti P, Lowery D, Sharma S, Maggiora L, Cornet J, Greenberg B. Immunolocalization of the β-amyloid precursor protein in brain tissue. American Health Assistance Foundation Alzheimer's Disease Res Conf 14, 1989.

73. Cadrin M, Perry G, Ohta M, Kawahara H, Marceau N, French SW. Ubiquitin: A common phenomenon in cytokeratin aggregates: An in vivo and in vitro study. FASEB J 3:A324, 1989.(4)

74. Chou SM, Kawai M, Sunohara N, Perry G. Ubiquitination in "core fibers" induced by local tetanus in rat soleus. Neurology (Suppl 1) 39:129-130, 1989.(2)

75. Harik SI, Whitney P, Perry G, Kalaria RN, Andersson L, Lundahl P. Tissue distribution and cellular localization of the glucose transporter by immunocytochemistry. Neurology (Suppl 1) 39:371, 1989.(2)

76. Manetto V, Cammarata S, Mancardi GL, Perry G, Autilio-Gambetti L, Tabaton M. Immunocytochemical differences of intra- and extracellular neurofibrillary tangles. J Neuropathol Exp Neurol 48:337, 1989.

77. Tabaton M, Mandybur TI, Perry G, Autilio-Gambetti L, Gambetti P. The widespread alteration of neurites in Alzheimer disease may be unrelated to amyloid deposition. J Neuropathol Exp Neurol 48:340, 1989.

78. Osofsky LR, Morandi A, Wicker N, Perry G, Autilio-Gambetti L, Gambetti P. Experimental induction of neuronal inclusions. J Neuropathol Exp Neurol 48:342, 1989.

79. Perry G, Johnson AB, Mulvihill P, Siedlak S, Galloway P, Tabaton M, Gambetti P. Alzheimer disease paired helical filament fractions contain insoluble tubulin. J Neuropathol Exp Neurol 48:354, 1989.(3)

80. Perry G, Johnson AB, Mulvihill P, Siedlak S, Tabaton M, Galloway P, Gambetti P. Detection of insoluble tubulin in Alzheimer disease paired helical filament fractions. Alzheimer Dis Assoc Disord 3 (Suppl 1):29, 1989.

81. Gambetti P, Autilio-Gambetti L, Perry G, Tabaton M, Manetto V, Morandi A. Neuronal cytoskeletal proteins in Alzheimer's disease. Aging of the Brain and Dementia: Ten Years Later, p. 18, 1989.

82. Tabaton M, Cammarata S, Manetto V, Gambetti P, Perry G, Mancardi GL. Extracellular neurofibrillary tangles lack ubiquitin and neurofilament epitopes. Ital J Neurol Sci 10:239-240, 1989.

83. Kawai M, Harik SI, Kalaria RN, Perry G. Spatial relationship of amyloid plaques and capillaries in Alzheimer disease. Soc Neurosci Abstr 15:647, 1989.(1)

84. Harik SI, Kalaria RN, Perry G. Distribution of the hexose transporter in the eye. Soc Neurosci Abstr 15:820, 1989.

A* Cadrin M, Kawahara H, Ohta M, Perry G, Marceau N, French SW. Ubiquitin is associated with cytokeratin in

hepatic Mallory bodies. Hepatology 10:612, 1989.(4)

85. Perry G, Siedlak S, Mulvihill P, Kawai M, Mijares M, Gambetti P, Lowery D, Sharma S, Maggiora L, Cornet J, Greenberg B. Immunolocalization of the β-amyloid precursor protein in brain tissue. Neurobiol Aging 11:83, 1990.

86. Bennett L, Galloway PG, Perry G. The solubility of the Hirano body in Alzheimer's disease. J Elec Microscopy Tech 14:375, 1990.

87. Kawai M, Greenberg G, Perry G. Cellular elements involved in amyloid deposition in congophilic angiopathy. Neurology (Suppl 1) 40:372, 1990.(2)

88. Ko L, Sheu KFR, Perry G, Blass JP. -protein precursor in cerebrovasculature of Alzheimer's disease. Trans Am Soc Neurochem 21:112, 1990.(1)

89. Murphy G, Forno LS, Perry G, Eng LF. How useful is anti-ubiquitin immunocytochemistry for identification of Lewy bodies in the amygdala-parahippocampal region. J Neuropathol Exp Neurol 49:279, 1990.(1)

* Added in 2001

George Perry

127

90. Perry G, Siedlak S, Kawai M, Cras P, Mulvihill P, Cordell B, Marian Scardina J, Gambetti P. Neurofibrillary tangles, neuropil threads and senile plaques all contain abundant binding sites for basic fibroblast growth factor (b-FGF). J Neuropathol Exp Neurol 49:318, 1990.(4)

91. Tabaton M, Cammarata S, Gambetti P, Autilio-Gambetti L, Perry G, Mancardi G. Dorsal root ganglia in alcoholic rats: Tau and ubiquitin immunoreactivity. J Neuropathol Exp Neurol 49:319, 1990.

92. Kawai M, Cras P, Siedlak S, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Shelton E, Gambetti P, Perry G. Role of vascular smooth muscle cells in amyloid deposition in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 49:331, 1990.(3)

93. Cammarata S, Perry G, Mancardi G, Autilio-Gambetti L, Gambetti P, Tabaton M. Is ubiquitin an early marker of neuritic degeneration secondary to amyloid deposition in both Alzheimer and Creutzfeldt-Jakob diseases? J Neuropathol Exp Neurol 49:333, 1990.

94. Cras P, Kawai M, Siedlak S, Galloway P, Lowery D, Altman RA, Greenberg B, Perry G. Cellular elements involved in amyloid deposition in the senile plaque. J Neuropathol Exp Neurol 49:334, 1990.(1)

95. Perry G, Siedlak S, Mulvihill P, Kawai M, Cras P, Cordell B, Marian Scardina J, Ledbetter S, Greenberg B, Gambetti P. Neurofibrillary tangles contain heparan sulfate proteoglycans. Neurobiol Aging 11:269, 1990.(4)

96. Cras P, Kawai M, Siedlak S, Lowery D, Altman RA, Greenberg B, Perry G. Amyloid precursor protein immunoreactive neurites may be involved in amyloid deposition in the senile plaque. Neurobiol Aging 11:310, 1990.

97. Miyata S, Perry G, Monnier VM. Pyrraline, an advanced glycosylation endproduct, in basement membrane

and plasma: Probing with monoclonal A. Diabetes (Suppl 1) 39: 30a, 1990.(5)

98. Cammarata S, Mancardi GL, Perry G, Tabaton M. Tau and ubiquitin immunoreactivity in dorsal root ganglia from alcoholic rats. Ital J Neurol Sci 2:210, 1990.

99. Kawai M, Cras P, Siedlak S, Perry G. Amyloid plaque size in Alzheimer's disease is strongly correlated with capillary association. Ann Neurol 28:228, 1990.

100. Cras P, Kawai M, Siedlak S, Mulvihill P, Perry G, Lowery D, Altman RA, Greenberg B, Dystrophic neurites in Alzheimer's disease may accumulate amyloid precursor protein prior to developing cytoskeletal abnormalities. Ann Neurol 28:229, 1990.

101. Perry G, Siedlak S, Richey P, Mulvihill P, Kawai M, Cras P, Ledbetter S, Gambetti P. Neurofibrillary tangles contain a heparan sulfate proteoglycan core protein. First Annual All-Ohio Alzheimer's Disease Symposium p. 22, 1990.

102. Galloway PG, Perry G, Siedlak S. Basic fibroblast growth factor binding sites are selectively involved in neuronal degenerative diseases. First Annual All-Ohio Alzheimer's Disease Symposium p. 44, 1990.

103. Cras P, Kawai M, Siedlak S, Mulvihill PL, Greenberg B, Perry G. Amyloid precursor protein immunoreactive neurites may be involved in amyloid deposition in the senile plaque. First Annual All- Ohio Alzheimer's Disease Symposium. p. 68, 1990.

104. Kawai M, Cras P, Siedlak S, Perry G. The smaller the amyloid plaques are, the less frequently are they associated with capillaries. First Annual All-Ohio Alzheimer's Disease Symposium p. 69, 1990.

105. Galloway PG, Perry G, Kalaria RN. Immunolocalization of amyloid P component in the neurofibrillary pathology of Alzheimer and other neurodegenerative diseases. Soc Neurosci Abstr 16:15, 1990.

106. Lowery DE, Gonzalez-DeWhitt PA, Altman RA, Cras P, Perry G, Greenberg BD. Expression, purification, and characterization of the Alzheimer's amyloid precursor produced by baculovirus. Soc Neurosci Abstr 16:16, 1990.

107. Mattson MP, Perry G, Engle MG. Actions of calcium on the cytoskeleton and tau in cultured human cerebral cortical neurons. Soc Neurosci Abstr 16:945, 1990.(1)

108. Perry G, Mulvihill P, Richey P, Siedlak SL. Solubilization and analysis of the neurofibrillary pathology (NFP) of Alzheimer disease. J Neuropathol Exp Neurol 50:301, 1991.

109. Siedlak SL, Cras P, Kawai M, Vande Weghe J, Greenberg B, Perry G. A distinct type of senile plaque: β-amyloid protein immunoreactive extracellular neurofibrillary tangles associated with dystrophic neurites and glial cells. J Neuropathol Exp Neurol 50:314, 1991.(2)

110. Cras P, Kawai M, Siedlak SL, Richey P, Perry G. Extracellular neurofibrillary tangles are associated with microglia in Alzheimer disease. J Neuropathol Exp Neurol 50:316, 1991.

111. Kawai M, Cras P, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Gambetti P, Perry G. Subcellular localization of β-amyloid precursor protein of Alzheimer's disease. J Neuropathol Exp Neurol 50:338, 1991.

George Perry

128

112. Cras P, Perry G, Kawai M, Tabaton M, Martin J-J. Neurofibrillary pathology and amyloid deposits in normal aging and in Alzheimer disease. 5th Intern Symp Neurobiol, p. 5, 1991.

113. Cras P, Kawai M, Stanik M, Richey PL, Younkin SG, Perry G. Several mechanisms cause neuronal loss in the subiculum in Alzheimer disease and aging. Soc Neurosci Abstr 17:756, 1991.

114. Perry G, Mulvihill P, Siedlak SL, Richey P. Quantitative solubilization and analysis of detergent-insoluble paired helical filaments (PHF) of Alzheimer disease (AD). Soc Neurosci Abstr 17:1069, 1991.

115. Sisodia SS, Koo EH, Hoffman PN, Koliatsos VE, Perry G, Price DL. Fate of amyloid precursor protein in the nervous system. Soc Neurosci Abstr 17:1104, 1991.(6)

116. Ali SM, Gonzalez-DeWhitt PA, Siedlak SL, Altman RA, Polites HG, Perry G, Greenberg BD. A partial transgenic mouse model for Alzheimer's disease. International Business Communications USA: Transgenic Disease Models, p. 130, 1992.

117. Perry G, Siedlak SL. Mapping of paired helical filament proteins at molecular resolution. J Neuropathol Exp Neurol 51:318, 1992.(1)

118. Villanova M, Lubke U, Mercken M, Vandermeeren M, Ceuterick C, Martin JJ, Perry G, Cras P. Rimmed vacuoles of oculopharyngeal muscular dystrophy (OPMD) and inclusion body myositis (IBM) contain amyloid precursor protein. Acta Neurol Belg 92:305, 1992.

119. Harik SI, Hall AK, Perry G. Ontogeny of Glut-1 glucose transporter in the rat central nervous system (CNS). Neurol 42:407, 1992.(1)

120. Perry G. Transformation of cytoskeletal and extracellular matrix proteins in Alzheimer disease. 5th Intern Cong Cell Biol p. 437, 1992.

121. Perry G, Kawai M, Kalaria R, Tabaton M, Cras P. Transformation of neurofibrillary tangles. Neurobiol Aging 13:S37, 1992.

122. Villanova M, Lubke U, Mercken M, Vandermeeren M, Martin J-J, Perry G, Cras P. Rimmed vacuoles in oculopharyngeal muscular dystrophy contain amyloid precursor protein. Neurobiol Aging 13:S42, 1992.

123. Sisodia SS, Koliatsos VE, Lo A, Hoffman P, Koo EH, Perry G, Price DL. Processing of the β-amyloid precursor protein (APP). Neurobiol Aging 13:S82, 1992.

124. Kalaria RN, Kroon SN, Perry G. Serum proteins and the blood-brain barrier in the pathogenesis of Alzheimer's disease. Neurobiol Aging 13:S86-S87, 1992.(2)

125. Greenberg BD, Ali SM, Siedlak S, Kuentzel S, Gonzalez-DeWhitt PA, Altman RA, Polites HG, Glendening JM, Raub TJ, Perry G. Transgenic mouse studies of Alzheimer amyloid precursor (AAP) proteins and derivatives. Neurobiol Aging 13:S101, 1992.

126. Kalaria RN, Kroon SN, Perry G. Acetylcholinesterase and its association with the heparan sulphate glycosaminoglycans in cortical amyloid deposits of Alzheimer disease. 8th Intern Cholinergic Symp. Cholinergic neurotransmission: function and dysfunction, p. 83, 1992.

127. Perry G. Transformation of cytoskeletal and extracellular matrix molecules in Alzheimer disease. 3rd Ann All Ohio Alzheimer's Disease Symp, pp. 47-48, 1992.

128. Harik SI, Hall AK, Perry G. Development of the glut-1 glucose transporter in the rat central nervous system. 2nd Craigie Conf on Brain Capillaries, p. 31, 1992.

129. DeWitt DA, Silver J, Canning DR, Perry G. Chondroitin sulfate proteoglycan surrounds the senile plaques of Alzheimer's disease. 16th Annual Graduate Student Res Symp, p. 9, 1992.

130. Greenberg BD, Ali SM, Siedlak S, Gonzalez-DeWhitt PA, Kuentzel S, Altman RA, Polites HG, Glendening JM, Lowery DE, Cras P, Raub TJ, Perry G. Transgenic mouse studies of Alzheimer amyloid precursor (AAP) proteins and derivatives. Soc Neurosci Abstr 18:1465, 1992.

131. Marks N, Berg MJ, Tanzi R, Perry G, Nixon R. Potential animal and cellular models of Alzheimer's. Winter Conf Brain Res 26:16, 1993.

132. Maggio JE, Mantyh PW, Perry G, Schenk D. β-amyloid peptides: deposition, aggregation, neurotoxicity, biological effects. Winter Conf Brain Res 26:34, 1993.

133. Ben-Meir A, Bardenstein DS, Lee P, Friedland R, Mulvihill P, Perry G. Tau protein, ubiquitin and amyloid precursor protein in the eyes of patients with Alzheimer disease (AD). Invest Ophthalmol Vis Sci 34:997, 1993.

134. Perry G. Interaction of cytoskeletal and extracellular matrix protein may promote amyloid deposition in Alzheimer disease. African J Neurosci 1:8, 1993.

George Perry

129

135. Perry G. Cytoskeleton, extracellular matrix and conformational change in the amyloid deposition of Alzheimer disease. FASEB J 7:A635, 1993.

136. Tabaton M, Cammarata S, Perry G, Autilio-Gambetti L, Gambetti P. Ubiquitin reactive neurites in cerebral cortex of Huntington's chorea: do they correlate with dementia? J Neuropathol Exp Neurol 52:280, 1993.

137. DeWitt DA, Silver J, Canning DR, Perry G. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. J Neuropathol Exp Neurol 52:300, 1993.

138. Velasco ME, Schmidt CJ, Perry G. Striated linear neurites: a subpopulation of cortical neuropil threads in aging and Alzheimer disease. J Neuropathol Exp Neurol 52:303, 1993.

139. Smith MA, Kalaria RN, Jacobowitz DM, Perry G. 1-chymotrypsin and 1-trypsin immunolocalize with neurofibrillary tangles and senile plaques of Alzheimer disease. J Neuropathol Exp Neurol 52:303, 1993.

140. Richey PL, Smith MA, Miller CA, Nawrot M, Perry G. Aldehyde-modification of the neurofilament component of neurofibrillary tangles in Alzheimer disease. J Neuropathol Exp Neurol 52:304, 1993.

141. Kalaria RN, Kroon SN, Perry G. Cerebellar /A4 deposits and acute phase proteins in Alzheimer's disease. J Neuropathol Exp Neurol 52:306, 1993.

142. Tresser N, Perry G, Richey P, Gambetti P, LeBlanc A. Amyloid precursor protein expression and localization in rat cerebral cortex cultures. J Neuropathol Exp Neurol 52:307, 1993.

143. Perry G, Mulvihill P, Richey PL, Siedlak S, Kalaria R. Interaction of with amyloid β deposits. J Neuropathol Exp Neurol 52:334, 1993.(3)

144. Perry G. Application of immunochemical and histochemical methods to the study of Alzheimer disease. Histology Soc Ohio Ann Conf, p. 1, 1993.

145. Greenberg BD, Ali SM, Gonzalez-DeWhitt PA, Altman RA, Siedlak S, Kuentzel SL, Raub TJ, Perry G. Transgenic mouse studies of Alzheimer amyloid precursor (APP). VIIth Intern Symp Amyloidosis, p. 99, 1993.

146. Smith MA, Jacobowitz DM, Kalaria RN, Perry G. Alzheimer disease shows increased cortical levels of 1-

chymotrypsin and 1-trypsin. VIIth Intern Symp Amyloidosis, p. 109, 1993.

147. DeWitt DA, Silver J, Canning DR, Perry G. Different forms of chondroitin sulfate proteoglycan surround amyloid deposits of Alzheimer's disease. VIIth Intern Symp Amyloidosis, p. 112, 1993.

148. Smith MA, Richey PL, Miller CA, Nawrot M, Perry G. Carbonyl-crosslinking of NFT proteins: a mechanism of amyloidogenesis in Alzheimer disease? VIIth Intern Symp Amyloidosis, p. 117, 1993.

149. Perry G, Mulvihill P, Richey PL, Siedlak S, Kalaria R. Is Alzheimer disease a synergistic amyloidosis? interaction with amyloid β deposits. VIIth Intern Symp Amyloidosis, p. 118, 1993.

150. Smith MA, Richey PL, Taneda S, Monnier VM, Perry G. Immunocytochemical evidence for oxidative glycation-mediated cross-linking in Alzheimer disease. Second Intern Symp Reactive Oxygen Species, p. II.17, 1993.

151. Holash JA, Harik SI, Perry G, Stewart PA. Astrocyte-like cells in testis. Soc Neurosci Abstr 19:691, 1993.(1)

152. Greenberg BD, Schwartz D, Savage M, Pinsker L, Howland D, Ali SM, Gonzalez-DeWhitt PA, Altman RA, Siedlak S, Perry G, Scott R. Yet more transgenic mouse studies of Alzheimer amyloid precursor (APP). Soc Neurosci Abstr 19:1035, 1993.

153. DeWitt DA, Richey P, Silver J, Perry G. Chondroitin sulfate proteoglycans are a common component of inclusions in neurodegenerative diseases. Soc Neurosci Abstr 19:1471, 1993.(1)

154. Canning DR, McKeon RJ, DeWitt DA, Perry G, Wujek JR, Frederickson RCA, Silver J. Blocking of axon outgrowth by reactive gliosis induced with β-amyloid peptides. Soc Neurosci Abstr 19:1738, 1993.(1)

155. Ben-Meir A, Bardenstein DS, Friedland R, Perry G. Antibody to tau protein appears to identify cone photoreceptors in the retina. J Am Geriatr Soc 41:SA40, 1993.

156. Ben-Meir A, Bardenstein DS, Friedland R, Perry G. Antibody to tau protein appears to identify cone photoreceptors in the retina. Irwin H. Lepow Student Research Day, p. 8, 1994.

157. Perry G. Is a Lewy body always a Lewy body? Behav Neurol 7:27, 1994.(7)

158. Smith MA, Richey PL, Kutty RK, Chader GJ, Wiggert B, Petersen RB, Perry G. Heme oxygenase-1 in Alzheimer disease pathology. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 22, 1994.

159. Ben-Meir A, Bardenstein DS, Friedland R, Richey P, Harik S, Perry G. Immunocytochemical (ICC) localization of glucose transporter (GLUT-1) in the human eye. Invest Ophthalmol Vis Sci 35:1787, 1994.(1)

George Perry

130

160. Bardenstein DS, Ben-Meir A, Richey P, Friedland R, Perry G. Immunocytochemical (ICC) localization of glucose transporter (GLUT-1) in retinoblastoma. Invest Ophthalmol Vis Sci 35:2085, 1994.(1)

161. Praprotnik D, Richey PL, Perry G. Cytoskeletal transformations in dystrophic neurites of senile plaques. Neurobiol Aging 15:S23, 1994.(2)

162. Shimohama S, Matsushima H, Fujimoto S, Tsuji T, Taniguchi T, Takenawa T, Perry G, Richey P, Whitehouse PJ, Kimura J. Abnormalities of phospholipase C-delta in Alzheimer's disease. Neurobiol Aging 15:S38, 1994.

163. Kalaria RN, Pax AB, Perry G, Premkumar DRD. Mechanisms of cerebral amyloid angiopathy (CAA) in Alzheimer's disease: soluble Aβ protein in brain vessels. Neurobiol Aging 15:S51-S52, 1994.

164. Perry G, Siedlak S, Mulvihill P, Richey PL, Praprotnik D, Ghiso J, Frangione B, Kalaria R, Smith MA. β

protein precursor interaction with . Neurobiol Aging 15:S78, 1994.(2)

165. Smith MA, Mulvihill P, Taneda S, Richey PL, Siedlak SL, Sayre LM, Monnier VM, Perry G. Post-translational protein modification and crosslinking in Alzheimer disease. Neurobiol Aging 15:S78-S79, 1994.

166. Smith MA, Mulvihill P, Richey PL, Siedlak SL, Taneda S, Sayre LM, Monnier VM, Perry G. Advanced glycosylation end products (AGEs), protein crosslinking and insolubility in Alzheimer disease. Brain Pathol 4:551, 1994.

167. Perry G, Siedlak S, Mulvihill P, Richey PL, Smith MA, Praprotnik D, Kalaria R, Ghiso J, Frangione B, Bugiani

O, Tagliavini F. interaction with protein precursor. Brain Pathol 4:555, 1994.

168. DeWitt DA, Canning DR, Richey PL, Silver J, Perry G. Chondroitin sulfate proteoglycans, gliosis, and axonal loss in the senile plaques of Alzheimer disease. 18th Annual Graduate Student Res Symp, p. 5, 1994.

169. Castellani RJ, Smith MA, Richey PL, Perry G, Gambetti P. Evidence for oxidative stress in ballooned neurons. Mod Pathol 8:135A, 1995.

170. Smith MA, Richey PL, Praprotnik D, Mulvihill P, Sayre LM, Perry G. Oxidative posttranslational modifications in Alzheimer disease. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 51, 1995.

171. Perry G, Richey PL, Mulvihill P, Praprotnik D, Sayre LM, Smith MA. Evidence for oxidative protein modifications in Alzheimer disease. Second Soc of Neurosci of Africa Intern Conference, p. 189, 1995.

172. Smith MA, Richey PL, Kutty RK, Chader GJ, Wiggert B, Petersen RB, Perry G. Heme oxygenase-1 in Alzheimer disease pathology. Mol Chem Neuropathol 24:286, 1995.

173. Tabaton M, Masturzo P, Angelini G, Hansen LA, Saitoh T, Petersen R, Perry G, Gambetti P, Bertolini S. Apolipoprotein E4 allele frequency is not increased in progressive supranuclear palsy. Neurology 45:A470, 1995.(37)

174. DeWitt DA, Silver J, Doller C, Siedlak SL, Smith MA, Perry G. An in vitro model to demonstrate interactions of neurons, astrocytes, and microglia with Alzheimer senile plaque cores. J Neuropathol Exp Neurol 54:411, 1995.

175. Smith MA, Richey PL, Praprotnik D, Mulvihill P, Sayre LM, Perry G. Carbonyl-related modification of neurofilaments in Alzheimer disease. J Neuropathol Exp Neurol 54:434, 1995.

176. Perry G, Siedlak SL, Richey PL, Mulvihill P, Praprotnik D, Kalaria RN, Smith MA. Molecular characterization

of the /βPP interaction: the pathogenic pathway? J Neuropathol Exp Neurol 54:435, 1995.

177. Richey P, Castellani R, Smith M, Gambetti P, Perry G. Evidence for oxidative stress in Pick‘s disease and corticobasal degeneration. J Neuropathol Exp Neurol 54:459, 1995.

178. Smith MA, Premkumar DRD, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN. Induction of heme oxygenase-1 mRNA in neocortex in Alzheimer disease. Neurodegenerative Disease ‗95: Molecular and Cellular Mechanisms and Therapeutic Advances, p. 80, 1995.

179. Giaccone G, Pedrotti B, Migheli A, Perez J, Racagni G, Smith MA, Perry G, De Gioia L, Slevaggini C, Salmona M, Ghiso J, Frangione B, Islam K, Bugiani O, Tagliavini F. βPP and tau interaction: a possible link between amyloid and tangle formation in Alzheimer disease. Alzheimer‘s Research (Suppl 1):41, 1995.

180. Smith MA, Perry G. Involvement of oxidative protein modifications in Alzheimer disease. Free Radicals in Brain Physiology and Disorders, p. 22, 1995.

181. DeWitt DA, Perry G, Doller C, Siedlak SL, Silver J. Interactions of glial cells with Alzheimer senile plaque cores in vitro. Soc Neurosci Abstr 21:1499, 1995.

182. Smith MA, Richey PL, Mulvihill P, Sayre LM, Perry G. Oxidative stress, posttranslational protein modifications and Alzheimer disease. Soc Neurosci Abstr 21:1499, 1995.(1)

George Perry

131

183. Perry G, Siedlak SL, Richey PL, Mulvihill P, Praprotnik D, Kalaria RN, Smith MA. /βPP interaction: the pathogenic pathway of Alzheimer disease? Soc Neurosci Abstr 21:1499, 1995.

184. Premkumar DRD, Smith MA, Kutty RK, Wiggert B, Perry G, Kalaria RN. Induction of heme oxygenase-1 mRNA in cerebral vessels and neocortex in Alzheimer‘s disease. Soc Neurosci Abstr 21:2004, 1995.

185. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer‘s disease. Intern Symp on Oxidative Stress, Apoptosis, and Brain Damage, p. 45, 1995.

186. Smith MA, Perry G. Application of microscopy in the study of oxidative damage in neurodegenerative diseases such as Alzheimer disease. Great Lakes Microscopy Affiliates Conf, p. 21, 1995.

187. DeWitt DA, Perry G, Doller C, Siedlak SL, Silver J. Phagocytosis and break-down of Alzheimer senile plaque cores by microglia is inhibited by astrocytes. The Spectrum of Research on Aging and the Aged, p. 11, 1995.

188. DeWitt DA, Perry G, Doller C, Siedlak SL, Silver J, Smith MA. Astrocytes, but not neurons, show an in vitro increase in oxidative stress in response to Alzheimer senile plaque cores. The Spectrum of Research on Aging and the Aged, p. 12, 1995.

189. DeWitt DA, Perry G, Doller C, Silver J. Astrocyte inhibition of microglial phagocytosis may be responsible for

persistence of A in senile plaques of Alzheimer‘s disease. 19th Annual Graduate Student Res Symp, p. 2, 1995.

190. Castellani RJ, Smith MA, Monnier VM, Richey PL, Gambetti P, Perry G. Advanced glycation end products and oxidative stress markers immunolocalize to Lewy bodies in Parkinson disease and diffuse Lewy body disease. Lab Invest 74:139A, 1996.(1)

191. Smith MA, Perry G. The study of oxidative damage in neurodegenerative diseases such as Alzheimer disease: the use of microscopy. Microsc Res Tech 33:527, 1996.

192. Sauer S, Bardenstein DS, Friedland R, Perry G. Immunohistochemical detection of increased facilitative glucose transporter-1 expression in corneal endothelial stress. Invest Ophthalmol Vis Sci 37:S86, 1996.

193. Smith MA, Siedlak SL, Mulvihill P, Richey PL, Perry G. Interaction of with -protein precursor as a pathogenic mechanism in Alzheimer disease. J Neurochem 66 (Suppl 1):S27, 1996.

194. Smith MA, Mulvihill P, Richey PL, Siedlak SL, Sayre LM, Perry G. 2,4-dinitrophenylhydrazine, a marker of oxidative modifications, specifically labels the neurofibrillary alterations of Alzheimer disease. J Neurochem 66 (Suppl 1):S96, 1996.

195. Smith MA, Siedlak SL, Richey PL, Mulvihill P, Kalaria RN, Perry G. Protein-protein interactions, including the

interaction of with -protein precursor, as a pathogenic mechanism in Alzheimer disease. Acta Neurol Belg 96:73, 1996.

196. Smith MA, Richey PL, Mulvihill P, Sayre LM, Perry G. Molecular dissection of the neurofilament protein component of the neurofibrillary pathology in Alzheimer disease reveals distincts posttranslational carbonyl-related modifications. Acta Neurol Belg 96:73, 1996.

197. Omar R, Smith M, Perry G, Pappolla M. Immunohistochemical evidence of oxidative stress in Parkinson‘s disease (PD). J Neuropathol Exp Neurol 55:634, 1996.(1)

198. Smith MA, McCann CE, Siedlak SL, Perry G. Muscle cell degeneration of the posterior cerebral artery in Alzheimer disease. J Neuropathol Exp Neurol 55:649, 1996.

199. Perry G, Smith MA, Praprotnik D, Velasco M. Segmental accumulation of abnormal filaments in neuronal processes of Alzheimer disease. J Neuropathol Exp Neurol 55:651, 1996.

200. Smith MA, Sayre LM, Perry G. Protein oxidation and glycation in neurodegenerative diseases. Oxidative Stress and Redox Regulation: Cellular Signaling, Aids, Cancer and Other Diseases, p. 110, 1996.

201. Perry G. What exactly is a Lewy body? Mov Disord 11 (Suppl 1): 19, 1996.(1)

202. Velasco M, Smith MA, Siedlak SL, Praprotnik D, Perry G. Accumulation of segmental abnormal filaments in neuronal processes of Alzheimer disease. Neurobiol Aging 17:S129, 1996.

203. Smith MA, Sayre LM, Anderson V, Richey PL, Siedlak SL, Beal MF, Kowall N, Perry G. A specific marker of oxidative protein modifications, 2,4-dinitrophenylhydrazine, labels the neurofibrillary pathology of Alzheimer disease. Neurobiol Aging 17:S201, 1996.

204. Zelasko DA, Perry G, Richey PL, Siedlak SL, Salomon RG, Sayre LM, Smith MA. Evidence for oxidative stress and lipid peroxidation in Alzheimer‘s and Parkinson‘s diseases: a common pathogenic mechanism? 2nd Annual CWRU Summer Program in Undergraduate Research (SPUR), pp. 13-14, 1996.

205. Smith MA, Dal Canto M, Richey PL, Perry G. The transgenic SOD-1 mouse model of ALS: selective oxidative stress in motor neurons. Soc Neurosci Abstr 22:712, 1996.

George Perry

132

206. Richey PL, Perry G, Cashman NR, Smith MA. Oxidative stress in a motor neuron cell line: a model of amyotrophic lateral sclerosis. Soc Neurosci Abstr 22:2141, 1996.

207. Ströhlein A, Bierhaus A, Luther T, Langer S, Peterson I, Perry G, Kasper M, Müller M. Detection of tissue factor synthesis in the neurons of Alzheimer‘s disease. Ann Hematol 74 (Suppl 2 ):A114, 1997.

208. Smith MA, Siedlak SL, Harris PLR, Perry G. Early contribution of oxidative stress in the pathogenesis of Alzheimer disease. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 8, 1997.

209. Perry G, Zelasko DA, Salomon R, Sayre LM, Smith MA. Lipoperoxidative protein modification are associated with neuronal degeneration in Alzheimer and Parkinson disease. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 62, 1997.

210. Rickner K, Dawson E, Sauer S, Perry G, Bardenstein DS. Induction and preservation of GLUT-1 in optisol preserved corneas. Invest Ophthalmol Vis Sci 38:S1040, 1997.

211. Sayre LM, Zelasko DA, Harris PLR, Salomon RG, Perry G, Smith MA. 4-Hydroxynonenal-derived lipid peroxidation end products are increased in Alzheimer disease. J Neuropathol Exp Neurol 56:574, 1997.

212. Perry G, Harris PLR, Sayre LM, Beckman JS, Smith MA. Evidence for widespread peroxynitrite-mediated damage in Alzheimer disease. J Neuropathol Exp Neurol 56:575, 1997.

213. Castellani RJ, Perry G, Harris PLR, Monnier VM, Cohen ML, Salomon RG, Sayre LM, Smith MA. Advanced glycation and lipid modification of Rosenthal fibers in Alexander‘s disease. J Neuropathol Exp Neurol 56:595, 1997.

214. Smith MA, Harris PLR, Sayre LM, Perry G. Redox-active iron is associated with the pathological lesions in Alzheimer disease. J Neuropathol Exp Neurol 56:608, 1997.

215. Perry G, Sayre LM, Smith MA. Macromolecular oxidative damage in neurodegenerative diseases. Progress in Alzheimer‘s and Parkinson‘s Diseases. Fourth International Conference, p. 22, 1997.

216. Smith MA, Perry G. The role of oxidative stress in the pathological sequelae of Alzheimer disease. Free Radicals, Oxidative Stress and Antioxidants. Pathological and Physiological Significance, p. 71, 1997.

217. Friedland RP, Lerner AJ, Smith AL, Huang YT, Siedlak SL, Perry G. Latent infection with cytomegalovirus in Alzheimer‘s disease (AD): serum antibody and immunocytochemical studies. Soc Neurosci Abstr 23:563, 1997.

218. Smith MA, Harris PLR, Sayre LM, Perry G. In situ generation of oxidizing species by neurofibrillary tangles and senile plaques in Alzheimer disease. Soc Neurosci Abstr 23:2219, 1997.

219. Perry G, Zelasko DA, Sayre LM, Smith MA. Axonal cytoskeletal proteins: physiological and pathological targets for oxidative stress. Soc Neurosci Abstr 23:2221, 1997.

220. Perry G. Daño macromolecular por oxidación en enfermedad de Alzheimer. Conferencia Nacional Alzheimer, p. 36, 1997.

221. Perry G, Zelasko DA, Sayre LM, Smith MA. Physiological and pathological targets for oxidative stress: axonal cytoskeletal proteins. Neurobiol Aging 18:678, 1997.

222. Smith MA, Harris PLR, Sayre LM, Perry G. Neurofibrillary tangles and senile plaques in Alzheimer‘s disease: a potent in situ source for the generation of reactive oxygen species. Neurobiol Aging 18:682, 1997.

223. Smith MA, Perry G. Oxidative stress is central to the pathogenesis of Alzheimer‘s disease. Neurobiol Aging 18:686-687, 1997.

224. Wade R, Hirai K, Perry G, Smith MA. 8-Hydroxy-deoxyguanosine is increased in mitochondria of susceptible neurons in Alzheimer disease: an in situ analysis. 4th Internet World Congress on Biomedical Sciences ‘97, PA0036, 1997.

225. Perry G, Hirai K, Sayre LM, Smith MA. Oxidative damage precedes the formation of cytopathological lesions in Alzheimer disease. Oxygen Club of California 1998 World Congress, p. 41, 1998.

226. Smith MA, Perry G. Is oxidative stress the mediator of neurodegeneration in Alzheimer disease? Neurodegenerative Disorders: Common Molecular Mechanisms, p. 44, 1998.

227. Smith MA, Perry G. Oxidative damage: the earliest cytopathological alteration in Alzheimer disease. J Neurochem 70 (Suppl 1):S78, 1998.(1)

228. Wade R, Hirai K, Perry G, Smith MA. An increase in 8-hydroxy-deoxyguanosine adducts in mitochondria, but not nuclei, in susceptible neurons in Alzheimer disease: an in situ analysis. The First Regional Meeting on Medical Sciences: The Roles of Free Radicals in Health and Disease, p. 16, 1998.

229. Perry G, Wataya T, Nunomura A, Szweda L, Sayre LM, Smith MA. Neurofilament heavy subunit (NFH) is a specific target of oxidative damage in the axon. J Neuropathol Exp Neurol 57:492, 1998.(1)

George Perry

133

230. Hirai K, Smith MA, Wade R, Perry G. Vulnerable neurons in Alzheimer disease accumulate mitochondrial DNA with the common 5kb deletion. J Neuropathol Exp Neurol 57:511, 1998.(11)

231. Wade R, Hirai K, Perry G, Smith MA. Accumulation of 8-hydroxy-guanosine in neuronal cytoplasm indicates mitochondrial damage and radical production are early features of Alzheimer disease. J Neuropathol Exp Neurol 57:511, 1998.(3)

232. Castellani RJ, Perry G, Harris PLR, Smith MA. Iron regulatory proteins in Alzheimer disease. J Neuropathol Exp Neurol 57:511, 1998.

233. Hirai K, Smith MA, Wade R, Perry G. Neuronal RNA oxidation and mitochondrial proliferation denote profound metabolic abnormalities in Alzheimer disease. Neurobiol Aging 19 (Suppl 4S):S4-S5, 1998.(4)

234. Guevara J, Espinosa B, Vázquez L, Luna J, Zenteno E, Perry G, Mena R. O-glycosylation and 9-O-acetyl-sialylation, abnormal glycoslyation of amyloid-β and tau deposits in Alzheimer‘s disease. Neurobiol Aging 19 (Suppl 4S):S48, 1998.

235. Sayre LM, Smith MA, Salomon RG, Szweda LI, Perry G. Advanced lipoperoxidation end products (ALEs) in Alzheimer disease. Neurobiol Aging 19 (Suppl 4S):S70, 1998.

236. Smith JD, Sikes J, Perry G, Smith MA. ApoE: isoform specific antioxidant activity. Neurobiol Aging 19 (Suppl 4S):S222, 1998.(1)

237. Smith MA, Sayre LM, Harris PLR, Perry G. Alzheimer disease pathology contains iron and supports redox cycling. Neurobiol Aging 19 (Suppl 4S):S264, 1998.(1)

238. Omar R, Bozner P, Chyan Y-J, Hsiao K, Perry G, Smith M, Ghiso J, Pappolla M. Oxidative stress in Alzheimer‘s disease: a transgenic mouse model. Neurobiol Aging 19 (Suppl 4S):S290-S291, 1998.

239. Castillo GM, Nochlin D, Wight TN, Perry G, DeWitt D, Snow AD. Characterization of proteoglycans present in human Alzheimer‘s disease brain and in isolated amyloid plaque cores. Neurobiol Aging 19 (Suppl 4S):S297, 1998.

240. Sayre LM, Xu G, Salomon RG, Smith MA, Perry G. Mechanisms of oxidative stress protein damage in neurodegenerative disease. 216th National American Chemical Society Meeting, Abstr TOXI 95, 1998.

241. Bozner P, Chyan Y-J, Omar RA, Hsiao K, Perry G, Smith MA, Pappolla M. Evidence of oxidative stress and in vivo neurotoxicity of beta amyloid in a transgenic mouse model of Alzheimer‘s disease. Soc Neurosci Abstr 24:729, 1998.

242. Pappolla MA, Chyan Y-J, Bozner P, Martin B, Frangione B, Hsiao K, Omar RA, Perry G, Smith MA, Ghiso J. NADPH cytochrome P450 reductase mediates oxidative stress induced by the amyloid β protein. Soc Neurosci Abstr 24:1751, 1998.(1)

243. Perry G, Nunomura A, Hirai K, Petersen RB, Smith MA. Is Alzheimer disease a metabolic disorder? Molecular and Genomic Effects of Tissue Oxygen Deprivation in Sleep Apnea, p. 6, 1998.

244. Perry G, Nunomura A, Hirai K, Smith MA. Neuronal mitochondrial proliferation and RNA oxidation denote profound metabolic abnormalities in Alzheimer‘s disease. Clin Neurosci 51:23-24, 1998.

245. Perry G, Hirai K, Wade R, Smith MA. Nucleic acid oxidation and proliferation in Alzheimer disease: indices of metabolic abnormalities? Alzheimer‘s Disease: The Therapeutic Era, Paris, France, November 5-6, 1998.

246. Perry G, Hirai K, Nunomura A, Petersen RB, Smith MA. Neuronal mitochondrial proliferation in Alzheimer disease: evidence for a fundamental metabolic abnormality. Mitochondria: Genetics, Health, and Disease, p. 18, 1998.

247. Smith MA, Aliev G, Nunomura A, Perry G. Mitochondria abnormalities and metabolic dysfunction in Alzheimer disease. Oxygen Club of California 1999 World Congress, p. 82, 1999.

248. Smith MA, Sayre LM, Perry G. Role of iron in neurodegenerative diseases and aging. J Neurochem 72 (Suppl):S5, 1999.

249. Clapp KL, Smith MA, Perry G, Duffy LK. Melatonin exhibits both antioxidant and pro-oxidant properties in a mouse brain slice model of ischemia. J Neurochem 72 (Suppl):S29, 1999.

250. Nunomura A, Perry G, Smith MA. Neuronal nucleic acid oxidation in Alzheimer‘s disease and Down‘s syndrome: possible role of amyloid β as a radical scavenger. NY Acad Sci Conf: Oxidative/Energy Metabolism in Neurodegenerative Disorders, p. 28, 1999.

251. Aliev G, Smith MA, Vinters H, Johnson AB, Nunomura A, Perry G. Mitochondria abnormalities mark vulnerable neurons in Alzheimer disease. J Neuropathol Exp Neurol 58:511, 1999.(16)

252. Nunomura A, Perry G, Smith MA. Oxidation of nucleic acids in neurons precedes amyloid β deposition in Down syndrome. J Neuropathol Exp Neurol 58:511, 1999.(2)

George Perry

134

253. Russell RL, Smith MA, Raina AK, Nunomura A, Perry G. Alzheimer disease is marked by a major shift in redox balance. J Neuropathol Exp Neurol 58:512, 1999.

254. Raina AK, Perry G, Smith MA. Genetic evidence for oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 58:531, 1999.

255. Pappolla MA, Chyan Y-J, Bozner P, Poeggeler B, Frangione B, Hsiao K, Omar RA, Perry G, Smith MA, Ghiso J. Induction of NAPH cytochrome P450 reductase by amyloid β protein: friend or foe of neurons? J Neuropathol Exp Neurol 58:531, 1999.

256. Zhang J, Perry G, Robertson D, Olson SJ, Graham DG, Montine TJ. Oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons of patients with Parkinson‘s disease. J Neuropathol Exp Neurol 58:555, 1999.

257. Castellani R, Siedlak S, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 58:555, 1999.

258. Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G. Prospects for noninvasive imaging of brain amyloid in Alzheimer‘s disease. Alzheimer‘s Reports 2 (Suppl 1):S27, 1999.(16)

259. Smith MA, Sayre LM, Nunomura A, Perry G. Protein and lipid oxidation in Alzheimer‘s disease. Clin Chem Lab Med 37 (Special Suppl):S97, 1999.

260. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic and mitotic sources of oxidative stress in Alzheimer disease. Antioxidants: Strategies for Interventions in Aging and Age-Related Diseases, p. 16, 1999.

261. Perry G, Nunomura A, Takeda A, Russell RL, Aliev G, Raina AK, Smith MA. Looking for death in all the wrong places: apoptosis in Alzheimer disease. Int Soc Neurochem, Symposium on Neuronal Apoptosis, p. 31, 1999.

262. Zhu X, Raina AK, Takeda A, Perry G, Smith MA. Dysfunctional regulation of the p38 pathway in Alzheimer disease (AD): a compensation to oxidative stress. Soc Neurosci Abstr 25:546, 1999.

263. Tabaton M, Garibaldi S, Norese R, Angelini G, Marinelli L, Valentini S, Menini S, Traverso N, Zaccheo D, Siedlak S, Perry G, Smith M, Odetti P. Lipoperoxidation is selectively involved in progressive supranuclear palsy. Soc Neurosci Abstr 25:325, 1999.

264. Snow AD, Ngo C, Cummings JA, Wight TN, Lara S, Perry G, DeWitt D, Castillo GM. Perlecan and highly sulfated glycosaminoglycans induce spontaneous formation of Alzheimer‘s amyloid plaques in vitro. Soc Neurosci Abstr 25:1806, 1999.

265. Shi J, Perry G, Aliev G, Smith MA, Friedland RP. Basic fibroblast growth factor and serum amyloid P component binding to amyloid deposits in a transgenic animal model overexpressing β-amyloid: evidence for integrity of the blood-brain barrier. Soc Neurosci Abstr 25:1860, 1999.

266. Smith MA, Sayre LM, Perry G. Methods to detect oxidative stress and oxidative damage. Free Radicals, Nitric Oxide and Antioxidants in Health and Disease, pp 33-34, 1999.

267. Smith MA, Perry G. Role of oxidative stress in Alzheimer disease. Free Radicals, Nitric Oxide and Antioxidants in Health and Disease, pp 35-36, 1999.

268. Perry G, Aliev G, Nunomura A, Smith MA. Mitochondria abnormalities and metabolic dysfunction in Alzheimer disease. 6th Meeting of the Portuguese Society for Neuroscience, p. 33, 1999.

269. Nunomura A, Chiba S, Smith MA, Perry G. Immunocytochemical studies on RNA oxidation in Alzheimer‘s disease brain (Japanese). Dementia Japan 13:150, 1999.

270. Smith MA, Hirai K, Nunomura A, Perry G. Mitochondrial abnormalities in Alzheimer disease. Fourth European Meeting on Mitochondrial Pathology, p. 203, 1999.(1)

271. Smith MA, Nunomura A, Raina AK, Perry G. Oxidative stress, antioxidants and Alzheimer disease. In Quest of Dementia Drugs: 14th International Symposium, p. 30, 1999.

272. Perry G, Raina AK, Zhu X, Takeda A, Smith MA. Unexpected cell cycle events are a feature of Alzheimer disease and related to oxidative stress. American College of Neuropsycopharmacology, p. 52, 1999.

273. Smith MA, Perry G. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? 4th International NILS Workshop for Longevity Sciences, pp 32-33, 1999.

274. Perry G, Aliev G, Nunomura A, Smith MA. Metabolic dysfunction is the source of oxidative damage in Alzheimer disease. 4th International Symposium on Medicinal Chemistry of Neurodegenerative Disease, p. 61, 2000.

George Perry

135

275. Clapp-Lilly KL, Smith MA, Perry G, Duffy LK. The effects of melatonin on oxidative stress in a brain slice model of stroke and Alzheimer‘s disease. J Neurochem 74 (Suppl): S17A, 2000.

276. Zhu X, Raina AK, Rottkamp CA, Boux H, Siedlak SL, Takeda A, Perry G, Smith MA. Activation of mitogen-activated kinase pathways links tau phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease. 23rd Graduate Student Symposium, p. 56, 2000.

277. Smith MA, Nunomura A, Raina AK, Zhu X, Rottkamp CA, Perry G. Metabolic and mitotic mediators of Alzheimer disease. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 55, 2000.

278. Perry G, Takeda A, Smith MA, Avilá J, Nunomura A, Siedlak SL, Sayre LM. In Alzheimer disease, heme oxygenase is coincident with Alz50, an epitope of τ induced by 4-hydroxy-2-nonenal modification. J Neuropathol Exp Neurol 59:448, 2000.

279. Zhang J, Montine TJ, Smith MA, Siedlak SL, Perry G. The 'mitochondrial common deletion' in Parkinson‘s disease and related movement disorders. J Neuropathol Exp Neurol 59:460, 2000.

280. Snow AD, Cummings JA, Choi PY, Ngo C, Wight TN, Perry G, DeWitt D, Castillo GM. Alzheimer‘s plaques re-created in a test tube: further insights into the mechanism of amyloid plaque formation. Neurobiol Aging 21 (Suppl 1S):S52-S53, 2000.

281. Cuajungco MP, Atwood CS, Huang X, Lynch T, Cherny RA, Perry G, Bush AI. Competitive regulation of Aβ redox activity by copper and zinc: parallels in the pathogenetic mechanisms of Alzheimer‘s disease and familial amyotrophic lateral sclerosis. Neurobiol Aging 21 (Suppl 1S):S62, 2000.

282. Perry G, Smith MA, Siedlak SL, Tabaton M, Ghanbari K, Ghanbari H. Increased oxidative stress involving olfactory neurons in Alzheimer disease. Neurobiol Aging 21 (Suppl 1S):S89, 2000.

283. Atwood CS, Moir RD, Jones WD, Huang X, Perry G, Tanzi RE, Roher AE, Bush AI. Human amyloid-derived Aβ contains tyrosine cross-linked oligomers. Neurobiol Aging 21 (Suppl 1S):S199, 2000.(3)

284. Perry G, Hirai K, Aliev G, Nunomura A, Siedlak SL, Smith MA. Mitochondrial abnormalities in Alzheimer disease. Neurobiol Aging 21 (Suppl 1S):S213, 2000.

285. Zhu X, Raina AK, Rottkamp CA, Boux H, Siedlak SL, Takeda A, Perry G, Smith MA. Activation of p38 kinase links τ phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease. Neurobiol Aging 21 (Suppl 1S):S267, 2000.

286. Nunomura A, Chiba S, Lippa CF, Smith MA, Perry G. Neuronal RNA oxidation in familial and sporadic Alzheimer‘s disease, Down‘s syndrome, and in the aging process of non-demented patients. Neuropathology 20:A3, 2000.

287. Smith MA, Zhu X, Nunomura A, Raina AK, Rottkamp CA, Takeda A, Perry G. Metabolic, metallic and mitotic sources of oxidative stress in Alzheimer disease. The 3rd ILSONG International Symposium on Aging and Neurodegenerative Diseases, pp 23-28, 2000.

288. Takeda A, Perry G, Abraham NG, Dwyer BE, Kutty RK, Laitinen JT, Nunomura A, Petersen RB, Smith MA. Heme oxygenase: a pivotal player in the pathogenesis of Alzheimer disease. Acta Haematol 103 (Suppl 1):79, 2000.

289. Zhu X, Raina AK, Rottkamp CA, Perry G, Smith MA. Activation of mitogen-activated kinase pathways links tau phosphorylation and cell cycle abnormalities in Alzheimer disease. 3rd International Symposium on Anti-Oxidants & Free Radicals in Health & Disease, p. 20, 2000.

290. Combs M, Perry G, Smith M. Oxidative stress and nucleotide excision repair in Alzheimer disease. CWRU Summer Program in Undergraduate Research (SPUR), pp 4-5, 2000.

291. Nunomura A, Chiba S, Smith MA, Perry G. Oxidative damage and amyloid β deposition in Alzheimer disease with reference to apolipoprotein E4 (Japanese). Dementia Japan 14:232, 2000.(3)

292. Smith MA, Nunomura A, Sayre LM, Rottkamp CA, Zhu X, Raina AK, Hirai K, Friedland RP, Shi J, Aliev G, Wataya T, Scimohama S [sic], Atwood CS, Perry G. Fundamental role of oxidative stress and stressor in Alzheimer disease. Dementia Japan 14:232, 2000.

293. Perry G, Hirai K, Nunomura A, Aliev G, Siedlak SL, Smith MA. Oxidative stress and mitochondrial abnormalities in Alzheimer disease. Brain Pathol 10:725, 2000.

294. Numomura A [sic], Chiba S, Lippa C, Smith M, Perry G. Increasing amyloid Aβ 42 deposition is associated with decreasing neuronal RNA oxidation in Down‘s syndrome and familial Alzheimer‘s disease. Brain Pathol 10:783, 2000.(6)

295. Smith MA, Raina AK, Nunomura A, Hochman A, Takeda A, Perry G. Apoptosis in Alzheimer disease: fact or fiction. Brain Pathol 10:797, 2000.(6)

George Perry

136

296. Perry G, Aliev G, Nunomura A, Smith MA. The source of oxidative damage in Alzheimer disease. First International Conference: Metals and Brain, p. 37, 2000.

297. Perry G, Atwood CS, Sayre LM, Nunomura A, Aliev G, Hirai K, Smith MA. Redox active metals play a key role in modulating neuronal oxidative balance. First International Conference: Metals and Brain, p. 137, 2000.

298. Perry G, Nunomura A, Friedlich AL, Boswell MV, Brazdil L, Jones PK, Rottkamp CA, Zhu X, Raina AK, Hirai K, Friedland RP, Shi J, Aliev G, Cash A, Russell RL, Wataya T, Shimohama S, Atwood CS, Smith MA. Factors controlling oxidative damage in Alzheimer disease: metals and mitochondria. Society of Free Radical Research International 2000, p. 57, 2000.

299. Shi J, Perry G, Berridge MS, Aliev G, Smith MA, LaManna JC, Friedland RP. Labeling of cerebral amyloid β deposits in vivo using nasally administrated basic fibroblast growth factor. Soc Neurosci Abstr 26:294, 2000.(19)

300. Zhu X, Raina AK, Rottkamp CA, Siedlak SL, Takeda A, Boux H, Perry G, Smith MA. Activation of mitogen-activated kinase pathways links tau phosphorylation, oxidative stress and cell cycle-related events in Alzheimer‘s disease. Soc Neurosci Abstr 26:540, 2000.

301. Perry G, Raina AK, Rottkamp CA, Zhu X, Aprelikova O, Smith MA. Is Alzheimer disease an oncogenic event? Soc Neurosci Abstr 26:541, 2000.

302. Atwood CS, Moir RD, Jones WD, Huang X, Smith MA, Perry G, Tanzi RE, Roher AE, Bush AI. Neurotoxic Aβ oligomers derived from Alzheimer amyloid are cross-linked at tyrosine. Soc Neurosci Abstr 26:799, 2000.

303. Aliev G, Shi J, Perry G, Lamb B-T, LaManna JC, Friedland RP. Neuronal mitochondrial abnormalities in yeast artificial chromosome transgenic mice overexpressing amyloid precursor protein. Soc Neurosci Abstr 26:804, 2000.(1)

304. Rottkamp CA, Perry G, Atwood CS, Petersen RB, Smith MA. Toxicity of amyloid-β1-42 is mediated by transition metals. Soc Neurosci Abstr 26:1830, 2000.

305. Smith MA, Nunomura A, Raina AK, Zhu X, Rottkamp CA, Perry G. Metabolic and mitotic mediators of Alzheimer disease. J Alzheimers Dis 2:186-187, 2000.

306. Perry G, Atwood CS, Sayre LM, Nunomura A, Aliev G, Hirai K, Smith MA. Redox active metals play a key role in modulating neuronal oxidative balance. J Alzheimers Dis 2:329, 2000.

307. Perry G, Aliev G, Nunomura A, Smith MA. The source of oxidative damage in Alzheimer disease. J Alzheimers Dis 2:336-337, 2000.

308. Zhou F, Zhu X, Smith MA, Castellani RJ, Stimmelmayr R, Perry G, Drew KL. Hibernation, a model of neuroprotection. Advances in Gene Technology: Cell Death and Aging 12:108, 2001.

309. Zhu X, Nunomura A, Takeda A, Raina AK, Rottkamp CA, Castellani RJ, Perry G, Smith MA. Alzheimer disease: regenerative and degenerative aspects. The 2nd Experimental Neurosciences Meeting: Regeneration, Plasticity and Neural Repair, p. 9, 2001.

310. Smith MA, Raina AK, Nunomura A, Hochman A, Shimohama S, Takeda A, Perry G. Apoptosis in Alzheimer‘s disease: an abortive event. 5th International Conference on Progress in Alzheimer‘s and Parkinson‘s Disease, p. 12, 2001.

311. Perry G, Hirai K, Nunomura A, Aliev G, Siedlak SL, Smith MA. Abnormalities in oxidative metabolism in Alzheimer‘s disease. J Neurochem 78 (Suppl 1):103, 2001.

312. Castellani RJ, Nunomura

A, Fujioka H, Smith MA, Perry G. Redox-active transition metals are associated with

RNA in Alzheimer disease. J Neuropathol Exp Neurol 60:504, 2001.

313. Smith MA, Zhu X, Sun Z, Perry G. Activation of c-Jun in Alzheimer disease. J Neuropathol Exp Neurol 60:546, 2001.(4)

314. Smith MA, Petot G, Nunomura A, Takeda A, Hirai K, Atwood CS, Friedland RP, Perry G. The role of oxidative stress and dietary modulation in Alzheimer‘s disease. Diet and Optimum Health, p. 34, 2001.

315. Nunomura A, Chiba S, Kosaka K, Castellani RJ, Smith MA, Perry G. Oxidative damage to neuronal RNA in the cerebral cortex of dementia with Lewy bodies. Neuropathology 21 (Suppl):A22, 2001.

316. Raina AK, Hochman A, Nunomura A, Shimohama S, Takeda A, Perry G, Smith MA. Abortive apoptotic signaling in Alzheimer disease: a last gasp or a survival mechanism? Gerontology 47 (Suppl 1):378, 2001.

317. Nunomura A, Chiba S, Kosaka K, Castellani RJ, Smith MA, Perry G. Widespread oxidative damage to neuronal RNA in dementia with Lewy bodies. 4th International Neurodegeneration in Alzheimer‘s Disease, Parkinson‘s Disease and Related Disorders, pp 21-22, 2001.

George Perry

137

318. Zhu X, Castellani RJ, Atwood CS, Perry G, Smith MA. Abnormalities of mitogen-activated protein kinase pathways in Alzheimer disease. Inaugural Alaskan Summer Neuroscience Conference, pp 12-13, 2001.

319. Hoang H, Zhu X, Harris P, Perry G, Smith M. Death by proteolysis: cathepsin C and Alzheimer‘s disease. CWRU Summer Program in Undergraduate Research (SPUR), p. 7, 2001.

320. Smith MA, Atwood CS, Sayre LM, Nunomura A, Aliev G, Hirai K, Perry G. Metal-catalyzed redox chemistry underlies oxidative damage in Alzheimer disease. Workshop on Copper and Prion Disease, p. 20, 2001.

321. Perry G, Smith MA, Kubat Z, Tabaton M, Wolozin B, Ghanbari K, Ghanbari H. Increased oxidative stress involving olfactory epithelium in Alzheimer disease. J Neuropathol Exp Neurol 60:504, 2001.

322. Duffy LK, Clapp-Lilly KL, Smith MA, Perry G, Zhu X, Drew KL, et al. Melatonin exhibits both antioxidant and pro-oxidant properties in a mouse brain slice model of ischemia using NMDA. 2001 Arctic Science Odyssey: Exploring New Technologies and Methodologies for Arctic Science Management, 52nd Arctic Science Conference, p. 71, 2001.

323. Perry G, Castellani RJ, Atwood CS, Taddeo MA, Nunomura A, Smith MA. Nucleic acids are the site of bound redox-active transition metals in Alzheimer disease. International Symposium on Ageing and Dementia, p. 26, 2001.

324. Smith MA, Zhu X, Nunomura A, Takeda A, Hirai K, Perry G. Causes and consequences of oxidative stress in aging and Alzheimer disease. Brain Aging: Identifying Accelerators and Brakes, p. 40, 2001.

325. Clapp-Lilly KL, Duffy LK, Smith MA, Perry G, Zhu X, Drew KL, et al. Melatonin exhibits both antioxidant and pro-oxidant properties in a mouse brain slice model of ischemia using NMDA. Brain Aging: Identifying Accelerators and Brakes, p. 113, 2001.

326. Bowen RL, Atwood C, Perry G, Smith M. Alzheimer‘s disease - - - dying for sex? Brain Aging: Identifying Accelerators and Brakes, p. 119, 2001.

327. Perry G, Castellani RJ, Harris PLR, Siedlak SL, Taddeo MA, Nunomura A, Fujioka H, Smith MA. Redox-active transition metals are associated with RNA in Alzheimer disease. Second International Workshop on Iron and Copper Homeostasis, p. 9, 2001.

328. Zhu X, Rottkamp CA, Kubat Z, Raina AK, Siedlak SL, Leuven FV, Atwood CS, Perry G, Smith MA. Amyloid-β toxicity is metal-mediated and acts through the activation of the JNK/SAPK pathway in Alzheimer disease. Soc Neurosci Abstr 27: Program No. 322.7, 2001.(1)

329. Atwood CS, Zeng H, Kato Y, Chen SG, Smith MA, Perry G. -Synuclein derived from Parkinson‘s disease brain is tyrosine crosslinked. Soc Neurosci Abstr 27: Program No. 545.14, 2001.

330. Gasimov EK, Perry G, Aliev G. The eefect [sic] of experimental edema on the permeability of microvessels of the sciatic nerve. Soc Neurosci Abstr 27: Program No. 561.6, 2001.

331. Ghanbari HA, Smith MA, Kubat Z, Tabaton M, Wolozin B, Ghanbari K, Perry G. Olfactory epithelium shows increased oxidative stress in Alzheimer disease. Soc Neurosci Abstr 27: Program No. 651.10, 2001.

332. Aliev G, Perry G, Lamb BT, Seyidova D, Neal ML, Zimina TV, Siedlak SL, LaManna JC, Smith MA, Friedland RP. Aged YAC AβPP transgenic mice develop atherosclerotic lesions and mitochondrial DNA deletions in brain microvessels without exogenous cholesterol supplementation. Soc Neurosci Abstr 27: Program No. 752.12, 2001.(5)

333. Zhu X, Rottkamp CA, Zvez K [sic], Atwood CS, Perry G, Smith MA. Metal-mediated amyloid-beta toxicity acts through the activation of JNK/SAPK pathway in Alzheimer disease. Free Radic Biol Med 31 (Suppl 1):S65, 2001.(8)

334. Perry G, Castellani RJ, Harris PLR, Siedlak SL, Taddeo MA, Nunomura A, Fujioka H, Smith MA. Redox-active transition metals are associated with non-base paired DNA and RNA in Azheimer [sic] disease. J Alzheimers Dis 4:47, 2002.

335. Zhu X, Ogawa O, Atwood CS, Perry G, Smith MA. Signaling oxidative stress in Alzheimer‘s disease. Oxygen Club of California 2002 World Congress, p. 73, 2002.

336. Zhu X, Wang Y, Ogawa O, Lee H-g, Raina AK, Fujioka H, Boux H, Shimohama S, Atwood CS, Perry G, Smith MA. Bcl-w mediates neuroprotection in Alzheimer disease. FASEB J 16:A963, 2002.(1)

337. Aliev G, Perry G, Seyidova D, Lamb BT, Neal ML, Siedlak SL, Smith MA, LaManna J, Friedland RP. Aged YAC AβPP transgenic mice develop atherosclerotic lesions and mitochondrial DNA deletions in brain microvessels. Third World Congress on Vascular Factors in Alzheimer‘s Disease, p. 102, 2002.

George Perry

138

338. Takata K, Kitamura Y, Kakimura J, Shibagaki K, Perry G, Shimohama S, Taniguchi T. A possible neuroprotective effects of heme oxygenase-1 in the brain. Third World Congress on Vascular Factors in Alzheimer‘s Disease, p. 123, 2002.

339. Bowen RL, Atwood C, Perry G, Smith MA. Alzheimer‘s disease – dying for sex? Neurodegenerative Disorders: Common Molecular Mechanisms, p. 60, 2002.

340. Atwood C, Perry G, Kubat Z, Harris P, Bowen R, Smith MA. Luteinizing hormone is a potent neuronal mitogen: implications for the pathogenesis of Alzheimer‘s disease. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 61, 2002.

341. Zhu X, Ogawa O, Atwood CS, Perry G, Smith MA. Mitogen activated protein kinase pathways in Alzheimer disease: the ―two hit‖ hypothesis. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 66, 2002.

342. Perry G, Castellani RJ, Harris PLR, Siedlak SL, Taddeo MA, Nunomura A, Fujioka H, Smith MA. Non-base paired DNA and RNA: a novel source of oxidative radicals in Alzheimer‘s disease. Neurodegenerative Disorders: Common Molecular Mechanisms, p. 68, 2002.

343. Perry G, Liu Q, Wataya T, Shimohama S, Nunomura A, Siedlak SL, Sayre LL [sic], Smith MA. Neurofilament proteins are major targets of oxidative damage in the nervous system. J Neuropathol Exp Neurol 61:456, 2002.(2)

344. Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced DNA damage. 25th Graduate Student Symposium, p. 17, 2002.

345. Liu Q, Smith MA, Siedlak SL, Harris PLR, Sayre LM, Perry G. Phosphorylation-dependent regulation of neurofilament protein oxidation in Alzheimer disease. 25th Graduate Student Symposium, p. 25, 2002.

346. Taddeo MA, Smith MA, Harris PLR, Siedlak SL, Perry G. Nucleic acids as sites of metal-catalyzed redox activity. 25th Graduate Student Symposium, p. 49, 2002.

347. Nunomura A, Chiba S, Kosaka K, Castellani RJ, Smith MA, Perry G. Neuronal RNA oxidation in dementia with Lewy bodies. Neuropathology 22:A25, 2002.

348. Zhu X, Wang Y, Ogawa O, Lee H-g, Raina AK, Fujioka H, Shimohama S, Atwood CS, Petersen RB, Perry G, Smith MA. Bcl-w plays a key neuroprotective role in Alzheimer‘s disease. J Neurochem 81 (Suppl 1):76, 2002.

349. Zhu X, Ogawa O, Atwood CS, Perry G, Smith MA. Signaling oxidative stress in Alzheimer disease. 31st Annual Meeting of the American Aging Association, p. 12, 2002.

350. Ghanbari H, Ghanbari K, Kubat Z, Castellani RJ, Smith MA, Perry G, Tabaton M. Increased oxidative stress involving olfactory neurons in Alzheimer disease. Neurobiol Aging 23 (Suppl 1):S18, 2002.

351. Vitali A, Borghi R, Piccini A, Giliberto L, Siedlak S, Perry G, Smith MA, Tabaton M, Zaccheo D, Ghetti B. Soluble amyloid β-protein is increased in frontotemporal dementia associated with tau gene mutations. Neurobiol Aging 23 (Suppl 1):S193, 2002.

352. Shi J, Kuniyoshi S, Friedland R, Perry G, Berridge M, Aliev G, Smith M, LaManna J. In vivo labeling of cerebral amyloid-β deposits using intranasal bFGF and SAP in a transgenic mouse model. Neurobiol Aging 23 (Suppl 1):S276, 2002.

353. Lee H-g, Ogawa O, Zhu X, Castellani RJ, Perry G, Smith MA, Ghanbari H. The expression of metabotropic glutamate receptors predicts neuronal vulnerability in Alzheimer‘s disease. Neurobiol Aging 23 (Suppl 1):S372, 2002.

354. Rottkamp C, Zhu X, Kubat Z, Raina A, Siedlak S, Atwood C, Perry G, Smith M, Van Leuven F. Metal-mediated amyloid-β toxicity recruits the JNK/SAPK pathway in Alzheimer‘s disease. Neurobiol Aging 23 (Suppl 1):S398, 2002.

355. Aliev G, Perry G, Seyidova D, Siedlak SL, Smith MA, Lamb BT, Neal ML, LaManna JC, Friedland RP. The role of mitochondria failure in the development of AD-like pathology in an aged transgenic mouse model of AD. Neurobiol Aging 23 (Suppl 1):S415, 2002.(4)

356. Perry G, Zhu X, Atwood CS, Smith MA, Nunomura A. Oxidative abnormalities as a window to Alzheimer‘s disease. Neurobiol Aging 23 (Suppl 1):S427, 2002.

357. Liu Q, Smith MA, Siedlak SL, Harris PLR, Sayre LM, Perry G, Wataya T, Shimohama S, Nunomura A. Phosphorylation-dependent regulation of neurofilament protein oxidation. Neurobiol Aging 23 (Suppl 1):S511-S512, 2002.

George Perry

139

358. Taddeo MA, Harris PLR, Siedlak SL, Smith MA, Perry G. Nucleic acids as sites of metal-catalyzed redox activity. Neurobiol Aging 23 (Suppl 1):S515, 2002.

359. Zhu X, Wang Y, Ogawa O, Lee H-g, Raina AK, Fujioka H, Atwood CS, Petersen RB, Perry G, Smith MA, Boux H, Shimohama S. Bcl-w plays a neuroprotective role in Alzheimer‘s disease. Neurobiol Aging 23 (Suppl 1):S516-S517, 2002.

360. Atwood C, Perry G, Kubat Z, Harris P, Smith M, Bowen R. Luteinizing hormone is a potent neuronal mitogen: implications for the pathogenesis of Alzheimer‘s disease. Neurobiol Aging 23 (Suppl 1):S528, 2002.(1)

361. Bowen RL, Smith MA, Kubat Z, Harris P, Perry G, Atwood C. Increased gonadotropin production secondary to age-related loss of reproductive function as a risk factor for Alzheimer‘s disease. Neurobiol Aging 23 (Suppl 1):S531, 2002.

362. Smith MA, Perry G. Phosphorylation regulation of HNE-adduction to proteins: relevance to neurodegenerative disease. First International Meeting of the HNE-Club, p. 30, 2002.

363. Smith MA, Zhu X, Nunomura A, Takeda A, Hirai K, Perry G. Oxidative stress in Alzheimer disease: causes and consequences. Free Radic Biol Med 33 (Suppl 1):S115, 2002.

364. Zhu X, Ogawa O, Drew K, Lee H-g, Perry G, Smith MA. Downstream consequences of oxidative stress in Alzheimer disease. 2nd Alaskan Summer Neuroscience Conference, p. 20, 2002.

365. Nunomura A, Chiba S, Kosaka K, Castellani R, Smith M, Perry G. Intraneuronal amyloid-beta and alpha-synuclein in dementia with Lewy bodies. 12th World Congress of Psychiatry 2:273, 2002.

366. Perry G, Zhu X, Aliev G, Avila J, Atwood CS, Nunomura A, Smith MA. Oxidative stress, a mediator of Alzheimer disease. International Conference on Cell and Molecular Biology of Alzheimer's Disease, p. 5, 2002.

367. Perry G, Taddeo MA, Atwood CS, Smith MA. Metal-catalyzed redox activity in neurodegenerative disease. Second International Conference: Metals and Brain, p. 7, 2002.

368. Smith MA, Zhu X, Ogawa O, Nunomura A, Takeda A, Hirai K, Perry G. Causes and consequences of oxidative stress in Alzheimer‘s disease. 2nd International Symposium on Mechanisms of Cell Death in Neurodegenerative Diseases: New Therapeutics for the Future, p. 2, 2002.

369. Atwood CS, Perry G, Kubat Z, Harris PL, Bowen RL, Smith MA. Neurotropic actions of gonadotropins: implications for the pathogenesis of Alzheimer‘s disease. 3rd Neurobiology of Aging Conference, pp 69-70, 2002.

370. Koudinov AR, Koudinova NV, Kontush A, Smith MA, Perry G. Amyloid dogma, synaptic function, and Alzheimer‘s disease. 3rd Neurobiology of Aging Conference, p. 80, 2002.

371. Koudinov AR, Koudinova NV, Perry G, Smith MA. Alzheimer‘s disease and amyloid beta protein: dogma is bad for science. Soc Neurosci Abstr, Program No. 21.11, 2002.

372. Bishop GM, Smith MA, Perry G, Atwood CS. Expression of oxidative stress markers after injection of Aβ into mouse hippocampus and cerebral cortex. Soc Neurosci Abstr, Program No. 193.18, 2002.

373. Shi J, Seyidova D, Perry G, Lamb B, Neal M, Siedlak S, Smith MA, LaManna J, Friedland RP, Aliev G. Neuronal mitochondria abnormalities in a transgenic mouse model overexpressing amyloid beta. Soc Neurosci Abstr, Program No. 295.2, 2002.(4)

374. Seyidova D, Perry G, Lamb BT, Neal ML, Siedlak SL, Smith MA, LaManna JC, Head E, Cotman CW, Aliev G. The role of mitochondrial DNA deletions in the development of Alzheimer‘s-like pathology in an aged transgenic mouse model of AD. Soc Neurosci Abstr, Program No. 621.1, 2002.

375. Raina AK, Rottkamp CA, Obrenovich ME, Cash A, Sayre L, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. Soc Neurosci Abstr, Program No. 723.6, 2002.

376. Aliev G, Seyidova D, Lamb BT, Neal ML, Siedlak SL, Smith MA, LaManna JC, Head E, Perry G, Cotman CW. The role of mitochondrial DNA deletions in the development of Alzheimer‘s-like pathology in an aged transgenic mouse model of AD. Soc Neurosci Abstr, Program No. 778.6, 2002.

377. Lee H, Ogawa O, Zhu X, Castellani RJ, Ghanbari H, Petersen RB, Perry G, Smith MA. Aberrant expression of metabotropic glutamate receptor 2 (mGluR2) in the vulnerable neurons in Alzheimer‘s disease. Soc Neurosci Abstr, Program No. 785.16, 2002.

378. Aliev G, Seyidova D, Lamb BT, Smith MA, Perry G. Atherosclerotic lesions and mitochondrial DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. 6th International Conference on Stroke and 3rd Conference of the Mediterranean Stroke Society, pp 3-4, 2003.

George Perry

140

379. Liu T, Perry G, Bishop G, Chan H, Smith M, Atwood C, Verdile G, Martins RN. Differentiation associated changes in tau modulate amyloid-β-induced toxicity of primary neurons. Research ShowCASE 2003, p. 40, 2003.

380. Lee H-g, Ogawa O, Zhu X, O‘Neill MJ, Ghanbari H, Petersen RB, Perry G, Smith MA. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons in Alzheimer disease. Research ShowCASE 2003, p. 70, 2003.

381. Raina A, Zhu X, Cash A, Sayre L, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. Research ShowCASE 2003, p. 70, 2003.

382. Webber K, Zhu X, Mentlein R, Perry G, Smith MA. Pleiotrophin and Alzheimer disease: a driving force? Research ShowCASE 2003, p. 71, 2003.

383. Wung JK, Perry G, Kowalski A, Harris PLR, Bishop GM, Smith MA, Denhardt DT, Atwood CS. Pro-inflammatory osteopontin is elevated in pyramidal neurons of the Alzheimer‘s disease brain. Research ShowCASE 2003, p. 71, 2003.

384. Zhu X, Rottkamp CA, Kubat Z, Raina AK, Siedlak SL, Atwood CS, Perry G, Smith MA. A mechanistic study on amyloid-beta-induced JNK activation. Research ShowCASE 2003, p. 72, 2003.

385. Ogawa O, Zhu X, Lee H, Raina A, Obrenovich ME, Bowser R, Ghanbari HA, Castellani RJ, Perry G, Smith MA. Ectopic localization of phosphorylated histone H3: a mitotic catastrophe? J Neuropathol Exp Neurol 62:546, 2003.

386. Zhu X, Ogawa O, Perry G, Smith MA. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer disease. J Neuropathol Exp Neurol 62:551, 2003.

387. Raina AK, Sayre L, Zhu X, Cash A, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. J Neuropathol Exp Neurol 62:551, 2003.(1)

388. Lee H-g, Ogawa O, Zhu X, O‘Neill MJ, Ghanbari H, Castellani RJ, Perry G, Smith MA. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer disease. J Neuropathol Exp Neurol 62:551, 2003.

389. Smith MA, Perry G, Zhu X. Amyotrophic lateral sclerosis: a novel hypothesis involving a gained loss of function in the JNK/SAPK pathway. J Neuropathol Exp Neurol 62:556, 2003.

390. Perry G, Cash AD, Aliev G, Siedlak SL, Raina AK, Nunomura A, Vinters HV, Johnson AB, Castellani RJ, Smith MA. Microtubule reduction found in Alzheimer disease and aging is independent of tau abormalities [sic]. J Neuropathol Exp Neurol 62:582, 2003.

391. Zhu X, Raina AK, Atwood CS, Perry G, Smith MA. A mechanistic study on amyloid-β-induced JNK/SAPK activation. J Neurochem 87 (Suppl 1):16, 2003.

392. Lee H-g, Ogawa O, Zhu X, O‘Neill MJ, Ghanbari H, Castellani RJ, Perry G, Smith MA. Aberrant expression of metabotropic glutamate receptor 2. 2003 Biomedical Graduate Student Symposium, p. 44, 2003.

393. Liu Q, Smith MA, Sayre LM, Perry G. Neurofilament protein oxidation in Alzheimer disease. 2003 Biomedical Graduate Student Symposium, p. 46, 2003.

394. Raina AK, Zhu X, Cash A, Sayre L, Ogawa O, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. 2003 Biomedical Graduate Student Symposium, p. 56, 2003.

395. Perry G, Siedlak SL, Harris PLR, Atwood CS, Smith MA. Nucleic acid metal-directed reactive oxygen production in Alzheimer disease. Oxidative Stress in Aging and Neurodegenerative Diseases: From Biology to Therapy, p. 16, 2003.

396. Zhu X, Ogawa O, Perry G, Smith MA. MAPK pathways and oxidative signaling in Alzheimer disease. Oxidative Stress in Aging and Neurodegenerative Diseases: From Biology to Therapy, p. 19, 2003.

397. Avila J, Perez M, Lucas JJ, Gomez-Ramos A, Diaz-Nido J, Lim F, Perry G, Smith M, Hernandez F. Tau phosphorylation and tau pathology. 6th International Conference on Alzheimer‘s and Parkinson‘s Diseases, p. 42, 2003.

398. Perry G, Siedlak SL, Harris PLR, Zhu X, Atwood CS, Smith MA. Mechanism of metal dependent reactive oxygen production in Alzheimer disease. 6th International Conference on Alzheimer‘s and Parkinson‘s Diseases, p. 124, 2003.

399. Smith MA, Castellani RJ, Atwood CS, Perry G, Zhu X. Oxidative stress and Alzheimer disease: the ―two hit‖ hypothesis. 6th International Conference on Alzheimer‘s and Parkinson‘s Diseases, p. 124, 2003.

400. Zhu X, Perry G, Smith MA. Causes and consequences of oxidative stress in Alzheimer disease. Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects and Clinical Perspectives, p. 42, 2003.

George Perry

141

401. Zhu X, Perry G, Smith MA. Antioxidants as a therapeutic for Alzheimer disease: a critical assessment. Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects and Clinical Perspectives, p. 43, 2003.

402. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Smith MA, Perry G. Increased neuronal RNA oxidation in familial Alzheimer disease. Neuropathology 23:A53, 2003.

403. Smith MA, Casadesus G, Joseph JA, Perry G. Do amyloid-β and tau serve antioxidant functions in the aging and Alzheimer brain? 32nd Annual Meeting of the American Aging Association, p. 2, 2003.

404. Perry G, Seyidova D, Lamb BT, Smith MA, Aliev G. Are mitochondrial [sic] the central targets for the development of Alzheimer disease and AD-like pathology in aged transgenic mice? Mitochondria 2003, p. 27, 2003.

405. Whitaker CD, Scharre DW, Beversdorf DQ, Pavlicova M, Chaudhury AR, Dashner RA, Smith MA, Perry G, Chakeres DW, Schmalbrock P. Hahn, CPMG, and combined analysis of T2 relaxation in the Alzheimer‘s hippocampus using a mixed effects model. Proc Intl Soc Mag Reson Med 11:2064, 2003.(1)

406. Aliev G, Smith MA, Perry G. Vascular hypoperfusion, mitochondria failure and oxidative stress in Alzheimer disease. First Congress of the International Society for Vascular Behavioral and Cognitive Disorders (VAS-COG), p. 21, 2003.

407. Aliev G, Smith MA, Perry G. Atherosclerotic lesions and mitochondrial DNA deletions in brain microcirculatory systems as a central target for the development of Alzheimer pathology. 7th Congress of the European Federation of Neurological Societies, p. 883, 2003.

408. Drew K, Ma Y, Rivera P, Toien O, Perry G, LaManna J, Smith MA, Zhu X. Arousal from hibernation: a natural model of tolerance to reperfusion. Defenses Against Brain Hypoxia: Molecule to Organism, p. 9, 2003.

409. Nunomura A, Chiba S, Smith MA, Perry G. Oxidative damage to neuronal RNA shows age-dependent increases in human brain. XVth International Congress of Neuropathology, p. S101, 2003.

410. Perry G, Honda K, Smith M. Nucleic acid metal directed reactive oxygen production in Alzheimer disease. Acta Biochim Pol 50 (Suppl 1):119-120, 2003.

411. Smith MA, Zhu X, Casadesus G, Aliev G, Ogawa O, Nunomura A, Takeda A, Joseph JA, Petersen RB, Perry G. Alzheimer disease: causes, consequences, and surprises. Biogerontology 4 (Suppl 1):88-89, 2003.

412. Perry G, Siedlak SL, de la Torre [sic], Aliev G, Smith MA. Vascular and metabolic abnormalities in Alzheimer disease. 3rd International Congress on Vascular Dementia, p. 31, 2003.

413. Bishop GM, Smith MA, LaManna JC, Perry G, Atwood CS. Hypoxia induces the redistribution of redox metal ions in vivo: a potential prooxidant source during ischemic-reperfusion injury? Soc Neurosci Abstr, Program No. 346.3, 2003.

414. Liu Q, Smith MA, Siedlak SL, Harris PLR, Maccioni RB, Sayre LM, Perry G. Phosphorylation and sequence dependency of neurofilament protein oxidation in Alzheimer disease. Soc Neurosci Abstr, Program No. 628.14, 2003.(1)

415. Kang S, Brown DR, Whiteman M, Li R, Pan T, Perry G, Wisniewski T, Sy M, Wong B. Prion protein ubiquitination in scrapie infection. Soc Neurosci Abstr, Program No. 632.13, 2003.

416. Liu JN, Head E, Seyidova D, Smith MA, Cotman CW, Perry G, Aliev G, Ames BN. Age-associated neurodegeneration and mitochondrial decay: effects of mitochondrial metabolites acetyl-L-carnitine and R-lipoic acid in old rats. Soc Neurosci Abstr, Program No. 874.10, 2003.

417. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS. Amyloid-β-induced toxicity of primary neurons is dependent upon differentiation associated increases in tau and cyclin-dependent kinase 5. Soc Neurosci Abstr, Program No. 876.13, 2003.

418. Raina AK, Zhu X, Sayre L, Cash A, Perry G, Smith MA. Acetylation - - a novel stabilizing posttranslational mechanism in Alzheimer‘s disease. Soc Neurosci Abstr, Program No. 877.8, 2003.

419. Casadesus G, Ogawa O, Bowen RL, Atwood CS, Perry G, Smith MA. Modulation of hippocampal plasticity and cognition in the SwAPP transgenic mouse by the gonadotropin-releasing hormone agonist luprolide [sic] acetate: involvement of lutenizing [sic] hormone in the pathogenesis and treatment of AD. Soc Neurosci Abstr, Program No. 945.8, 2003.(3)

420. Aliev G, Obrenovich ME, Smith MA, Perry G, Burnstock G. Atherosclerotic lesions are selectively associated with increased immunoreactivity for inducible nitric oxide synthase (NOS2) and endothelin-1 (ET-1) in thoracic aortic intimal cells. Eighth International Conference on Endothelin, p. 61, 2003.

George Perry

142

421. Aliev G, Obrenovich ME, Smith MA, Perry G, Burnstock G. Increased expression of NOS and ET-1 immunoreactivity in malignant but not benign tumor is associated with depression of constitutive NOS immunoreactivity in vessel endothelium. Eighth International Conference on Endothelin, p. 100, 2003.

422. Zhu X, Ogawa O, Perry G, Smith MA. JKK1 is activated in Alzheimer‘s disease. J Neurochem 85 (Suppl 1):43, 2003.

423. Wong BS, Whiteman M, Sassoon J, Kang SC, Li R, Pan T, Smith MA, Perry G, Brown DR, Wisniewski T, Sy MS. Prion protein ubiquitination and proteasomal dysfunction in scrapie infection. J Neurochem 87 (Suppl 1):92, 2003.

424. Aliev G, Smith MA, Perry G. Hypoperfusion, mitochondria failure, oxidative stress and Alzheimer disease. 11th International Symposium: New Frontiers of Neurochemistry and Neurophysics on Diagnosis and Treatment of Neurological Diseases, pp 3-5, 2003.

425. Zhu X, Chao M, Perry G, Smith MA. RAF-1 is activated in Alzheimer disease. 3rd Annual Meeting of the International College of Geriatric Psychoneuropharmacology, p. 63, 2003.

426. Aliev G, Perry G, Liub [sic] J, Obrenovich ME, Smith MA, Ames BN, de la Torre JC. The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in Alzheimer disease. Restor Neurol Neurosci 21:263-264, 2003.

427. Smith MA, Lee H-g, Honda K, Zhu X, Perry G. Does pathology tell us anything about disease: lessons from Alzheimer‘s disease. J Neurochem 88 (Suppl 1):6, 2004.

428. Wong BS, Kang SC, Brown DR, Whiteman M, Li R, Pan T, Perry G, Wisniewski T, Sy MS. Prion protein ubiquitination in scrapie infection. J Neurochem 88 (Suppl 1):55, 2004.

429. Perry G. The role of neuronal death in chronic neurodegenerative diseases. Reminyl Neuroprotection Symposium, p. 13, 2004.

430. Casadesus G, Webber KM, Ogawa O, Bowen RL, Perry G, Smith MA. Involvement of lutenizing [sic] hormone in the pathogenesis and treatment of Alzheimer disease. Research ShowCASE 2004, p. 275, 2004.

431. Liu Q, Smith MA, Siedlak SL, Harris PLR, Zhu X, Maccioni RB, Sayre LM, Perry G. Phosphorylation and sequence dependency of neurofilament protein oxidation in Alzheimer disease. Research ShowCASE 2004, p. 275, 2004.

432. Zhu X, Chao M, Perry G, Smith MA. Distribution, levels and activation of Raf-1 in Alzheimer disease. Research ShowCASE 2004, p. 276, 2004.

433. Lee H-g, Zhu X, O‘Neill MJ, Perry G, Smith M. Differential expression of metabotrophic glutamate receptors (mGluRs) in Alzheimer disease. Research ShowCASE 2004, p. 277, 2004.

434. Honda K, Smith MA, Siedlak SL, Harris PL, Sayre LM, Liu Q, Perry G. Ribosomal RNA oxidation by redox-active iron in Alzheimer‘s brain. Research ShowCASE 2004, p. 277, 2004.

435. Raina A, Zhu X, Cash A, Sayre L, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. Research ShowCASE 2004, p. 278, 2004.

436. Webber KM, Zhu X, Mentlein R, Perry G, Smith M. Pleiotrophin and Alzheimer disease: a driving force? Research ShowCASE 2004, p. 280, 2004.

437. Lee H-g, Zhu X, O‘Neill MJ, Perry G, Smith MA. Altered expression of group I and group II metabotrophic glutamate receptors in the hippocampus of patients with Alzheimer disease. 27th Annual Biomedical Graduate Student Symposium, pp 31-32, 2004.

438. Raina AK, Zhu X, Cash A, Sayre L, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. 27th Annual Biomedical Graduate Student Symposium, p. 39, 2004.

439. Webber KM, Casadesus G, Ogawa O, Bowen RL, Atwood CS, Pappolla MA, Perry G, Smith MA. Improvement of hippocampal function and decreased amyloid burden in the aged SwAPP transgenic mouse after treatment with the gonadotropin-releasing hormone agonist leuprolide acetate. Is luteinizing hormone involved in the pathogenesis of AD? 27th Annual Biomedical Graduate Student Symposium, pp 50-51, 2004.

440. Casadesus G, Webber KM, Bowen RL, Atwood CS, Pappolla MA, Castellani RJ, Raina AK, Perry G, Smith MA. Differential regulation of hippocampal function and plasticity by luteinizing hormone during normal aging and Alzheimer disease. J Neuropathol Exp Neurol 63:521, 2004.(1)

441. Webber KM, Casadesus G, Ogawa O, Bowen RL, Atwood CS, Pappolla MA, Perry G, Smith MA. Improved hippocampal function in aged SwAPP mice after pharmacological reduction of luteinizing hormone release with leuprolide acetate. J Neuropathol Exp Neurol 63:521, 2004.

George Perry

143

442. Honda K, Smith MA, Nunomura A, Harris PL, Siedlak SL, Perry G. Redox-active iron oxidizes ribosomal RNA in Alzheimer brain. J Neuropathol Exp Neurol 63:522, 2004.

443. Lee H, Zhu X, O‘Neill MJ, Perry G, Smith MA. Altered expression of group I and group II metabotrophic glutamate receptors in the hippocampus of patients with Alzheimer disease. J Neuropathol Exp Neurol 63:522, 2004.

444. Liu Q, Smith MA, Siedlak SL, Harris PL, Maccioni RB, Sayre LM, Perry G. Phosphorylation modulated oxidative modification of neurofilament protein. J Neuropathol Exp Neurol 63:523, 2004.

445. Castellani RJ, Fortino AE, Common R, Perry G, Ghetti B, Smith MA. Calcofluor stains amyloid-beta deposits. J Neuropathol Exp Neurol 63:524, 2004.(1)

446. Perry G, Honda K, Liu Q, Aliev G, Siedlak SL, Harris PLR, Zhu X, Smith MA. Stress and homeostatic regulation of oxidative damage in neurodegenerative disease. Free Radic Biol Med 36 (Suppl 1): S9, 2004.

447. Cash AD, Aliev G, Siedlak SL, Raina AK, Nunomura A, Vinters HV, Johnson AB, Castellani RJ, Smith MA, Perry G. Microtubule diminution in Alzheimer disease and aging is independent of abnormalities in tau. 2004 Irwin H. Lepow Student Research Day, p. 20, 2004.

448. Nunomura A, Chiba S, Smith MA, Perry G. Oxidative stress and cell cycle dysregulation in vulnerable neurons of Alzheimer disease. Neuropathology 24:A10, 2004.

449. Aliev G, Seyidova D, Smith MA, Perry G, de la Torre JC. Vascular hypoperfusion and mitochondria abnormality induce oxidative stress that appeared to be a key factor for the development of Alzheimer disease. Cardiovasc Pathol 13:26-27, 2004.

450. Raina AK, Zhu X, Cash AD, Sayre LM, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. 33rd Annual Meeting of the American Aging Association, p. 41, 2004.(1)

451. Zhu X, Rottkamp CA, Kubat Z, Raina AK, Siedlak SL, Perry G, Smith MA. A mechanistic study on amyloid-beta-induced JNK activation. 33rd Annual Meeting of the American Aging Association, p. 41, 2004.

452. Lee H-G, Zhu X, O‘Neill MJ, Perry G, Smith MA. Differential expression of metabotrophic glutamate receptors (mGluRs) in Alzheimer disease. 33rd Annual Meeting of the American Aging Association, pp 41-42, 2004.

453. Zhu X, McShea A, Harris PL, Raina AK, Castellani RJ, Funk JO, Shah S, Atwood CS, Bowen R, Bowser R, Morelli L, Perry G, Smith MA. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1 associated regulator of cyclin B, in Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S40, 2004.

454. Aliev G, Siedlak SL, Smith MA, Aliyev A, Rzayev N, de la Torre JC, Perry G. Vascular and metabolic failure in Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S61, 2004.

455. Smith MA, Raina AK, Perry G, Zhu X. Alzheimer disease: the two hit hypothesis. Neurobiol Aging 25 (Suppl 2):S68, 2004.

456. Zhu X, Lee H-G, Perry G, Smith MA. The critical role of the ERK pathway in the pathogenesis of Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S172, 2004.(1)

457. Strocchi P, Smith MA, Perry G, Tabaton M, Dozza B. Glycogen synthase kinase-3β activity is regulated by products of lipid peroxidation: relevance to Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S177, 2004.

458. Casadesus G, Webber KM, Ogawa O, Bowen RL, Atwood CS, Perry G, Smith MA. Modulation of cognition and amyloid load in the aged SwAβPP transgenic mouse by luprolide [sic] acetate, a GnRH agonist: targeting luteinizing hormone as a novel treatment for AD. Neurobiol Aging 25 (Suppl 2):S203, 2004.

459. Friedland RP, Shi J, Smith MA, Perry G, Sparks DL. Cholesterol feeding enhances cerebral amyloid beta pathology in beagles. Neurobiol Aging 25 (Suppl 2):S224, 2004.(1)

460. Raina AK, Zhu X, Adam C [sic], Sayre L, Perry G, Smith MA. Acetylation: a novel posttranslational modification in Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S417, 2004.

461. Liu Q, Smith MA, Siedlak SL, Harris PL, Maccioni RB, Sayre LM, Perry G. Phosphorylation dependent control of oxidative modification in Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S432, 2004.

462. Lee H-g, Zhu X, O‘Neill MJ, Perry G, Smith MA. Differential expression of metabotrophic glutamate receptors (mGluRs) in Alzheimer disease. Neurobiol Aging 25 (Suppl 2):S442, 2004.

463. Vidal R, Ghetti B, Delisle MB, Rascol O, Perry G, Smith MA. Oxidative damage in ferritin-induced neurodegeneration. Neurobiol Aging 25 (Suppl 2):S224, 2004.

464. Honda K, Smith MA, Nunomura A, Harris PL, Siedlak SL, Perry G. Redox-active iron oxidizes ribosomal RNA in neurons vulnerable to Alzheimer‘s disease. Neurobiol Aging 25 (Suppl 2):S546, 2004.

George Perry

144

465. Zhu X, Lee H-g, Perry G, Smith MA. The ERK pathway plays a critical role in the pathogenesis of Alzheimer disease. J Histochem Cytochem 52 (Suppl 1):S23, 2004.

466. Perry G, Honda K, Liu Q, Moreira PI, Aliev G, Siedlak SL, Harris PL, Zhu X, Smith MA. Homeostatic regulation of chronic oxidative insult in neurodegenerative diseases. J Neurochem 90 (Suppl 1):108, 2004.

467. Perry G, Harris PLR, Aliev G, Sayre LM, Liu Q, Honda K, Smith MA. Oxidative stress and neurodegeneration. 8th International Symposium on the Maillard Reaction, p. 37, 2004.

468. Aliev G, Obrenovich ME, Smith MA, de la Torre JC, Perry G. Hypoperfusion, mitochondria failure, oxidative stress and Alzheimer disease. J Alzheimers Dis 6:548-549, 2004.

469. Liu Q, Smith MA, Siedlak SL, Harris PLR, Honda K, Moreira PI, Maccioni RB, Sayre LM, Perry G. Phosphorylation regulated protein oxidation in Alzheimer disease. Soc Neurosci Abstr, Program No. 556.16, 2004.

470. Yang Y, Zhang D, Anantharam V, Kanthasamy A, Siedlak SL, Perry G, Kanthasamy AG. Oxidative stress sensitive PKCδ is highly expressed in nigral dopaminergic neurons: relevance to selective dopaminergic degeneration in Parkinson‘s disease. Soc Neurosci Abstr, Program No. 1014.16, 2004.

471. Seyidova D, Siedlak SL, Obrenovich ME, Head E, Cotman CW, Liu JN, Ames BN, Smith MA, Perry G, de la Torre JC, Aliev G. The mitochondria DNA deletion, increased in aged dog brain, can be diminished following administration of supplemental antioxidants and mitochondrial cofactors. Soc Neurosci Abstr, Program No. 1017.9, 2004.

472. Perry G, Aliev G, Zhu X, Smith MA. Oxidative stress in Alzheimer disease: consequence or initiator of pathogenesis. Korea Conference on Innovative Science and Technology [KCIST-2004], p. 38a, 2004.

473. Honda K, Smith MA, Nunomura A, Harris PLR, Siedlak SL, Perry G. Redox-active iron oxidizes ribosomal RNA in Alzheimer brain. Third International Workshop on Iron and Copper Homeostasis, p. 18, 2004.

474. Perry G, Avila J, Nunomura A, Smith MA. Cellular responses to oxidative stress in Alzheimer disease. Second Workshop on Comparative Aspects of Oxidative Stress in Biological Systems, p. P9, 2005.

475. Bowen RL, Smith MA, Perry G, Atwood CS. Leuprolide acetate for the treatment [sic] Alzheimer‘s disease from bench to bedside: background and interim data from a phase II clinical trial. 7th International Conference AD/PD 2005, p. 53, 2005.

476. Perry G, Cash AD, Nunomura A, Smith MA. The role of oxidative insult and neuronal survival in chronic neurodegenerative diseases. 7th International Conference AD/PD 2005, p. 151, 2005.

477. Smith MA, Perry G, Zhu X. Mitotic and oxidative mechanisms in Alzheimer disease: the two hit hypothesis. 7th International Conference AD/PD 2005, p. 151, 2005.

478. Garrett MR, Lee H-g, Perry G, Smith MA. A novel approach for the diagnosis of Alzheimer disease. 2005 Irwin H. Lepow Medical Student Research Day, p. 31, 2005.

479. Aliev G, Smith MA, Perry G. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. J Neurol Sci 229-230:354-355, 2005.

480. Perry G, Siedlak SL, de la Torre [sic], Aliev G, Smith MA. Vascular and metabolic abnormalities in Alzheimer disease. J Neurol Sci 229-230:375, 2005.

481. Zhu X, Smith MA, Perry G, Wang Y, LaManna JC, Drew KL. The MAPKs are differentially modulated in AGS during hibernation. Research ShowCASE 2005, p. 171, 2005.

482. Lee H-g, Zhu X, Perry G, Smith MA. Entropic disregulation [sic] of tau phosphorylation pathways in Alzheimer disease. Research ShowCASE 2005, p. 172, 2005.

483. Ueda M, Lee H-g, Zhu X, Perry G, Smith MA. Uncoupling of the TGF-β pathway in Alzheimer disease. Research ShowCASE 2005, p. 177, 2005.

484. Webber K, Smith MA, Lee H-g, Harris P, Moreira P, Perry G, Zhu X. MSK1: convergence of the ERK and p38 pathways in Alzheimer disease. Research ShowCASE 2005, p. 178, 2005.

485. Marlatt M, Perry G, Smith M, Zhu X. Chronic oxidative stress increases tau phosphorylation: a pathogenic mechanism in Alzheimer disease. Research ShowCASE 2005, p. 516, 2005.

486. Mei M, Siedlak S, Perry G, Smith M, Zhu X. Alterations in phosphorylation and localization of CREB in Alzheimer‘s disease. Research ShowCASE 2005, p. 517, 2005.

487. Garrett M, Lee H-g, Perry G, Smith MA. Alzheimer disease: approaching diagnosis. Research ShowCASE 2005, p. 518, 2005.

George Perry

145

488. Perry G, Caplan AI. CASE Aging Training Program in Molecular and Cellular Aging. Research ShowCASE 2005, p. 570, 2005.

489. Casadesus G, Webber KM, Atwood CS, Zhu X, Perry G, Bowen RL, Smith MA. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. International Conference on Gonadotropins and Receptors, p. 49, 2005.

490. Perry G, Moreira PI, Zhu X, Smith MA. Oxidative stress in a sea of amyloid. International Symposium on Aging and Neurodegeneration, p. 14, 2005.

491. Honda K, Smith MA, Nunomura A, Harris PLR, Siedlak SL, Perry G. Oxidative stress in Alzheimer disease: an early regulated event. 2nd European Ipsen Symposium. Alzheimer Disease: From Repair to Prevention, p. 35, 2005.

492. Sparks L, Petanceska S, Schreurs BG, Rockefeller B, Sharma A, DeRosa S, Perry G, Smith M, Shi J, Friedland R. Copper may influence the clearance of Alzheimer-like amyloid β (Aβ) from the brain. J Nutr Health Aging 9:136, 2005.

493. Lee H-g, Ueda M, Zhu X, Perry G, Smith MA. Ectopic localization of active Smad2 in the vulnerable neurons in Alzheimer disease. J Neurochem 94 (Suppl 1):26, 2005.

494. Nunomura A, Chiba S, Smith MA, Perry G. Intraneuronal accumulation of amyloid β and oxidative RNA damage in Alzheimer disease. Neuropathology 25:A43, 2005.

495. Casadesus G, Webber KM, Atwood CS, Zhu X, Perry G, Bowen RL, Smith MA. The role of gonadotropin hormones in the development of Alzheimer disease. Gonadal and Nongonadal Actions of LH/hCG, p. 28, 2005.

496. Perry G, Nunomura A, Harris PLR, Siedlak SL, Smith MA, Salomon RB. Is autism a disease of oxidative stress? Oxidative Stress in Autism Symposium, p. 15, 2005.(4)

497. Aliev G, Perry G, Liu J, Smith MA, Chen SG, Ames BN, de la Torre JC. The primary pathogenetic role of vascular [sic] contains vasoactive substances, hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. Alzheimers Dement 1 (Suppl 1):S31, 2005.

498. Zhu X, Nunomura A, Takeda A, Lee H-g, Casadesus G, Perry G, Smith MA. Oxidative imbalance in Alzheimer disease. Free Radic Res 39 (Suppl 1):S31, 2005.

499. Jordan JV, Previll L, Webber K, Perry G, Smith M. Role of the breast cancer gene BRCA-1 in cell cycle dysfunction of Alzheimer disease. Cleveland High School Student Scientific Enrichment & Opportunity Program Student Research Poster Presentations, p. 20, 2005.

500. Short L, Previll L, Perry G, Smith MA, Zhu X. Activation of c-Jun in Alzheimer‘s disease. Cleveland High School Student Scientific Enrichment & Opportunity Program Student Research Poster Presentations, p. 26, 2005.

501. Smith MA, Nunomura A, Takeda A, Lee H-g, Webber KM, Casadesus G, Perry G, Zhu X. A two-hit hypothesis for the pathogenesis of Alzheimer‘s disease. Oxygen Club of California Annual Meeting, p. 57, 2005.

502. Aliev G, Perry G, Smith MA, Chen SG, de la Torre JC, Burnstock G. The role of nitric oxide and ET-1 in the pathobiology of cardiovascular diseases, tumors and neurodegeneration. Ninth International Conference on Endothelins, p. 39, 2005.

503. Aliev G, Perry G, Chen SG, Smith MA, de la Torre JC. Vasoactive substances, hypoperfusion, mitochondria failure and oxidative stress in aging and AD. Fourth International Congress on Vascular Dementia, p. 5, 2005.

504. Honda K, Smith MA, Aliev G, Moreira PI, Nunomura A, Harris PLR, Siedlak SL, Perry G. The role of oxidative insult and neuronal survival in chronic neurodegenerative disease. Fourth International Congress on Vascular Dementia, p. 6, 2005.

505. Nunomura A, Chiba S, Smith MA, Perry G. Intraneuronal amyloid-β accumulation in Alzheimer disease: a compensatory response to oxidative stress? Fourth International Congress on Vascular Dementia, p. 20, 2005.

506. Smith MA, Perry G. Maillard chemistry in Alzheimer disease. 15th Japan Maillard Meeting, p. 15, 2005.

507. Lee H, Ueda M, Zhu X, Cai DX, Perry G, Smith MA. Uncoupling of the TGFβ pathway in Alzheimer disease. Soc Neurosci Abstr, Program No. 82.11, 2005.

508. Dwyer BE, Takeda A, Zhu X, Perry G, Smith MA. Ferric cycle activity and Alzheimer‘s disease. Soc Neurosci Abstr, Program No. 903.14, 2005.

George Perry

146

509. Perry G, Nunomura A, Takeda A, Lee H-g, Casadesus G, Smith MA, Zhu X. Cellular oxy-pathology in Alzheimer disease. III International Symposium: The Biology of Brain & Mind Disorders, p. 12, 2005.

510. Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreiara [sic] PI, Miller FP, Nunomura A, Shimohama S, Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. Philip Morris External Research Program Symposium: Advances in Biomarkers and Screening Models for Tobacco Related Disease, p. 4, 2005.

511. Nunomura A, Chiba S, Smith MA, Perry G. Neuronal RNA oxidation in very mild Alzheimer disease. Neuropathology 26:A10, 2006.

512. Moreira PI, Honda K, Santos MS, Oliveira CR, Smith MA, Zhu X, Nunomura A, Perry G. Oxidative stress in Alzheimer disease: role of antioxidants. 4th International Congress on the Improvement of the Quality of Life on Dementia, Epilepsy, MS and Peripheral Neuropathies, p. 34, 2006.

513. Lee H-g, Ueda M, Zhu X, Perry G, Smith MA. Failure of cytoplasmic-nuclear transport in Alzheimer disease. Research ShowCASE 2006, p. 493, 2006.

514. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G. Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. Research ShowCASE 2006, p. 494, 2006.

515. Petersen R, Smith MA, Richardson SL, Perry G, Lee H-g. Oxidative stress and prion protein mutations. Research ShowCASE 2006, p. 495, 2006.

516. Previll L, Crosby M, Zhu X, Bowser R, Perry G, Smith MA. P130, a regulator of the G1 phase of the cell cycle, in Alzheimer disease: evidence of a stuttered cell cycle. Research ShowCASE 2006, p. 496, 2006.

517. Su B, Smith MA, Perry G, Zhu X. Chronic oxidative stress causes differential effects on tau phosphorylation at different sites. Research ShowCASE 2006, p. 498, 2006.

518. Ueda M, Lee H-g, Zhu X, Perry G, Smith MA. Aberrant expression of phospho-Smad2 in the vulnerable neurons of Alzheimer‘s disease. Research ShowCASE 2006, p. 499, 2006.

519. Webber KM, Casadesus G, Previll L, Zhu X, Perry G, Stocco DM, Smith MA. Evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. Research ShowCASE 2006, p. 500, 2006.

520. Babar A, Siedlak S, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG, Zhu X. Detection of LRRK2 in Lewy bodies of Parkinson‘s disease and dementia with Lewy bodies. SOURCE Undergraduate Symposium & Poster Session, p. 14, 2006.

521. Choi R, Siedlak S, Previll L, Webber K, Zhu X, Perry G, Smith MA. The role of forkhead transcription factors in Alzheimer‘s disease. SOURCE Undergraduate Symposium & Poster Session, p. 19, 2006.

522. Thakur A, Siedlak SL, Perry G, Smith MA, Zhu X. JNK pathway abnormalities are prominent in the pathology of Alzheimer‘s disease. SOURCE Undergraduate Symposium & Poster Session, p. 56, 2006.

523. Webber KM, Casadesus G, Previll L, Zhu X, Bowen R, Atwood C, Perry G, Stocco DM, Smith MA. Evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. 29th Annual Biomedical Graduate Student Symposium, p. 50, 2006.

524. Smith MA, Perry G, Lee H-g, Nunomura A, Zhu X. Therapeutic targets in Alzheimer disease: signal transduction mechanisms. AGE 28:19-20, 2006.

525. Moreira PI, Siedlak SL, Santos MS, Oliveira CR, Fujioka H, Tabaton M, Nunomura A, Aliev G, Szweda LI, Zhu X, Smith MA, Perry G. Mitochondrial autophagocytosis in Alzheimer disease. Alzheimers Dement 2 (Suppl 1):S79, 2006.

526. Webber KM, Casadesus G, Previll LA, Zhu X, Gregory C, Bowen R, Atwood CS, Perry G, Stocco DM, Smith MA. Evidence of gonadotropin-induced steroidogenesis in Alzheimer‘s disease. Alzheimers Dement 2 (Suppl 1):S206, 2006.

527. Lee H-G, Ueda M, Zhu X, Perry G, Smith MA. Failure of cytoplasmic-nuclear transport in Alzheimer‘s disease. Alzheimers Dement 2 (Suppl 1):S211-S212, 2006.

528. Lee H-G, Ueda M, Zhu X, Perry G, Smith MA. Ectopic localization of phospho-Smad2 in the vulnerable neurons of Alzheimer‘s disease. Alzheimers Dement 2 (Suppl 1):S220, 2006.

529. Smith MA, Previll LA, Crosby ME, Zhu X, Bowser R, Perry G. P130, a regulator of the G1 phase of the cell cycle, in Alzheimer disease: evidence of a stuttered cell cycle. Alzheimers Dement 2 (Suppl 1):S443, 2006.

530. Casadesus G, Webber KM, Atwood CS, Bowen RL, Perry G, Smith MA. Luteinizing hormone mediates Alzheimer-type changes in neurons. Alzheimers Dement 2 (Suppl 1):S462, 2006.

George Perry

147

531. Nunomura A, Chiba S, Yamaguchi H, Smith MA, Perry G. Intraneuronal amyloid-β42 may silence oxidative stress in Alzheimer‘s disease. Alzheimers Dement 2 (Suppl 1):S484, 2006.

532. Lee H-G, Smith MA, Richardson SL, Perry G, Petersen RB. Oxidative stress and prion protein mutations. Alzheimers Dement 2 (Suppl 1):S485, 2006.

533. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G. Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. Alzheimers Dement 2 (Suppl 1):S486, 2006.

534. Smith MA, Zhu X, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Perry G, Chen SG. LRRK2 in Lewy bodies of Parkinson‘s disease and dementia with Lewy bodies. Alzheimers Dement 2 (Suppl 1):S564, 2006.

535. James SL, Previll LA, Webber K, Siedlak SL, Zhu X, Perry G, Smith MA. Abberant expression of phospho-retinoblastoma in Alzheimer disease. CASE Summer Program in Undergraduate Research (SPUR), pp 28-29, 2006.

536. Lee HG, Zhu XW, Perry G, Smith M. Amyloid-β toxicity in Alzheimer disease: the null versus the alternate hypotheses. J Neurochem 98 (Suppl 1):12, 2006.(91)

537. Lee HG, Smith MA, Richardson SL, Perry G, Petersen RB. Oxidative stress and prion protein mutations. J Neurochem 98 (Suppl 1):27, 2006.

538. Perry G. Evidence for a role of luteinizing hormone in Alzheimer disease. XVI International Congress of Neuropathology, p. 38, 2006.

539. Nunomura A, Chiba S, Smith MA, Perry G. Neuronal RNA oxidation in preclinical and very mild Alzheimer disease. 6th Annual Meeting of the International College of Geriatric Psychoneuropharmacology, p. 121, 2006.

540. Dwyer BE, Stone ML, Gorman N, Sinclair PR, Zhu X, Smith MA, Perry G. Measurement of cerebral heme. Soc Neurosci Abstr, Program No. 79.13, 2006.

541. Goldrick M, Gonzales J, Lee H, Smith MS [sic], Perry G, Castellani R, Prediger EA. miRNA expression profiling of Alzheimer‘s diseased cells. Soc Neurosci Abstr, Program No. 169.10, 2006.

542. Su B, Wang X, Drew K, Smith MA, Perry G, Zhu X. Physiological regulation of tau phosphorylation during hibernation-the role of o-GlcNAcylation. Soc Neurosci Abstr, Program No. 468.23, 2006.

543. Ramiro E, Casadesús G, Izquierdo-Pulido M, Castell M, Lee YH [sic], Zhu X, Perry G, Smith MA. Neuroprotective effect of cocoa flavonoids in vitro. 10th Karlsruhe Nutrition Congress, p. 49, 2006.

544. Casadesus G, Webber KM, Perry G, Smith MA. Role of gonadotropins in cognition: relevance to aging and Alzheimer disease. Hormones, Cognitive Function and Dementia, p. 51, 2007.

545. Tarkowsky S, Casadesus G, Webber KM, Gregory CW, Bowen RL, Atwood CS, Perry G, Smith MA. Alzheimer‘s disease pathology mediated by gonadotropins. 2007 Irwin H. Lepow Medical Student Research Day, Presentation #79, 2007.

546. Dwyer BE, Stone ML, Gorman N, Sinclair PR, Perry G, Smith MA, Zhu X. Cerebral heme-a is increased in Alzheimer‘s disease. 21

st Annual Neuroscience Day at Dartmouth, p. 8, 2007.

547. Liu Q, Ju W-K, Crowston JG, Xie F, Perry G, Smith MA, Lindsey JD, Weinreb RN. Early onset of oxidative stress in pressure induced retinal ganglion cell damage in glaucoma models. 8

th Scientific Meeting of the

Association for Ocular Pharmacology and Therapeutics, p. 119, 2007.

548. Castellani RJ, Lee H-g, Zhu X, Nunomura A, Perry G, Smith MA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Third International Congress of the Society for the Study of Neuroprotection and Neuroplasticity, p. 26, 2007.

549. Smith MA, Perry G, Lee H-g, Nunomura A, Zhu X. Pathogenic mechanisms in Alzheimer disease: interplay between oxidative stress and mitotic dysfunction. Third International Congress of the Society for the Study of Neuroprotection and Neuroplasticity, p. 55, 2007.

550. Aliev G, Puchowicz M, Xu K, Shenk J, Smith MA, Siedlak SL, Obrenovich ME, De La Tore JC [sic], Friedland RP, Perry G, La Manna JC. Apoe [sic] deficiency induces age-dependent brain hypoperfusion and neuronal-glial and microvascular damage in mice. Neurodeg Dis 4 (Suppl 1):182, 2007.

551. Zhu X, Baber A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Chen SG, Perry G. LRRK2 is a component of Lewy bodies. Neurodeg Dis 4 (Suppl 1):186, 2007.

552. Nunomura A, Lee HG, Casadesus G, Petersen RB, Richardson SL, Chiba S, Yamaguchi H, Perry G, Smith MA. Neuronal cell cycle re-entry induces intraneuronal Aβ accumulation in CaMKII-MYC mice. Neuropathology 27:205, 2007.

George Perry

148

553. Perry G, Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA. Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. FASEB J 21:A73, 2007.

554. Perry G, Moreira PI, Siedlak SL, Santos MS, Oliveira CR, Fujioka H, Tabaton M, Nunomura A, Aliev G, Szweda LI, Smith MA. Mitochondrial autophagocytosis in Alzheimer disease. FASEB J 21:A73, 2007.

555. Perry G, Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA. Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. J Neuropathol Exp Neurol 66:434, 2007.

556. Tarkowsky S, Casadesus G, Webber KM, Perry G, Smith MA. Gonadotropin mediated changes in neuronal oxidative stress, signaling, and death: Alzheimer‘s disease implications. Research ShowCASE 2007, p. 321, 2007.

557. Su B, Wang X, Drew K, Perry G, Smith MA, Zhu X. Physiological regulation of tau phosphorylation during hibernation. Research ShowCASE 2007, p. 352, 2007.

558. Lee H-g, Casadesus G, Richardson SL, Perry G, Petersen RB, Smith MA. Neurodegenerative phenotypes induced by the expression of MYC in the brain. Research ShowCASE 2007, p. 356, 2007.

559. Wang X, Su B, Perry G, Smith MA, Zhu X. Role of DLP1 in mitochondrial abnormalities in AD. Research ShowCASE 2007, p. 357, 2007.

560. Evans T, Delacourte A, Raina AK, Zhu X, Perry G, Smith MA. BRCA-1 may attenuate neurodegenerative changes in Alzheimer disease. Research ShowCASE 2007, p. 358, 2007.

561. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X. c-Jun phosphorylation in Alzheimer disease. Research ShowCASE 2007, p. 359, 2007.

562. Mondragon-Rodriguez S, Salas-Benito JS, Mena R, Binder LI, Perry G, Smith MA, Garcia-Sierra F. Phosphorylation and cleavage of tau protein follows the appearance of P70 S6 kinase. Research ShowCASE 2007, p. 360, 2007.

563. Perry G, Mondragon-Rodriguez S, Mena R, Binder LI, Smith MA, Garcia-Sierra F. Tau processing in Pick disease parallels Alzheimer disease. Research ShowCASE 2007, p. 361, 2007.

564. Thakur A, James SL, Siedlak SL, Raina AK, Bonda D, Perry G, Smith MA, Zhu X. Ectopic localization of phospho-retinoblastoma in Alzheimer disease. SOURCE Symposium & Poster Session, p. 74, 2007.

565. Smith MA, Castellani R, Napoli S, Perry G, Guttmann C, De Girolami U, Bakshi R. Gray matter iron deposition in patients with multiple sclerosis: a histochemical study. 59th Annual Meeting of the American Academy of Neurology, P03.033, 2007.(1)

566. Perry G, Moreira PI, Siedlak SL, Santos MS, Oliveira CR, Fujioka H, Tabaton M, Nunomura A, Aliev G, Szweda LI, Smith MA. Mitochondrial autophagocytosis in Alzheimer disease. J Neuropathol Exp Neurol 66:434, 2007.

567. Liu Q, Ju W-K, Crowston JG, Xie F, Perry G, Smith MA, Lindsey JD, Weinreb RN. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage in glaucoma models. The Association for Research in Vision and Ophthalmology 2007 Annual Meeting, Program No. 4942, 2007.

568. Nunomura A, Lee H-g, Casadesus G, Petersen RB, Richardson SL, Chiba S, Yamaguchi H, Perry G, Smith MA. Neuronal cell cycle re-entry induces intraneuronal Aβ accumulation in CaMKII-MYC mice (Japanese). Neuropathology 27 (Suppl):166, 2007.

569. Lee H-g, Casadesus G, Richardson SL, McShea A, Perry G, Petersen RB, Smith MA. The development of novel cellular and transgenic models of neuronal cell cycle re-entry: relevance to Alzheimer disease. 36

th

Annual Meeting of the American Aging Association, pp 63-64, 2007.

570. Perry G, Moreira PI, Harris PLR, Zhu X, Nunomura A, Smith MA. Is oxidative stress the initiator of Alzheimer disease? 6th Dutch Endo-Neuro-Psycho Meeting, p. 57, 2007.

571. Sarda G, Siedlak SL, Perry G, Smith MA, Sayre LM. Oxidative stress pathology in older people shows similarities to pathology of patients with Alzheimer‘s disease. 2007 CWRU Summer Program in Undergraduate Research (SPUR), p. 34, 2007.

572. Aliev G, Perry G, Shenk JC, Puchowicz M, Xu K, Siedlak SL, Obrenovich ME, Smith MA, Friedland RP, Chen SG, Ames BN, Liu J, De La Tore JC [sic], LaManna JC, Koistinaho J. The primary pathogenetic role of vascular hypoperfusion, and oxidative stress in Alzheimer disease. Atherosclerosis Supplements 8:105, 2007.(2)

George Perry

149

573. Rao AS, Siedlak SL, Phelix CF, Perry G, Smith MA, Zhu X. Upregulation of SREBP-2 contributes to defects in cholesterol homeostasis in the brain of patients with Alzheimer‘s disease. 2007 CWRU Summer Program in Undergraduate Research (SPUR), pp 31-32, 2007.

574. Skidmore SC, Lee H-g, Zhu X, Smith MA, Perry G, Sayre LM. Neuroblastoma cells: implications for Alzheimer‘s disease. 2007 CWRU Summer Program in Undergraduate Research (SPUR), pp 36-37, 2007.

575. Stone JG, Rolston RK, Ueda M, Lee H-g, Richardson S, Siedlak S, Perry G, Smith M. Prostate-specific antigen: evidence for the expression of a novel protein in the brain. 2007 CWRU Summer Program in Undergraduate Research (SPUR), p. 38, 2007.

576. Aliev G, Shenk JC, de la Torre JC, Puchowicz M, Xu K, Smith MA, Siedlak SL, Obrenovich ME, LaManna JC, Ames BN, Koistinaho J, Perry G. ApoE deficiency induces brain hypoperfusion, which can be diminished by feeding acetyl-L-carnitine and R-lipoic acid. Third Congress of the International Society for Vascular and Cognitive Disorders (VAS-COG), p. 68, 2007.

577. Zhu X, Su B, Wang Y, Mondragon-Rodriguez S, Cash A, Avila J, Perry G, Smith MA. Increased tubulin acetylation in Alzheimer disease. J Neurochem 102 (Suppl 1):75, 2007.(1)

578. Liu Q, Ju W-K, Crowston JG, Xie F, Perry G, Smith MA, Lindsey JD, Weinreb RN. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage in glaucoma models. 4

th Annual

Residents, Fellows and Alumni Meeting of the Shiley Eye Center, p. 29, 2007.

579. Nunomura A, Lee H-G, Casadesus G, Petersen RB, Richardson SL, Yamaguchi H, Chiba S, Perry G, Smith MA. Cell cycle re-entry induces intraneuronal amyloid-β accumulation in CaMKII-MYC mice: pathogenic implication for the mitotic abnormality in Alzheimer‘s disease. International Psychogeriatrics 19 (Suppl 1):154-155, 2007.

580. Su B, Wang X, Smith M, Perry G, Zhu X. Chronic oxidative stress induces increased tau phosphorylation in M17 cells. Soc Neurosci Abstr, Program No. 367.18, 2007.

581. Zhu X, Evans TA, Siedlak SL, Lu L, McGinnis W, Castellani RJ, Salomon RG, Smith MA, Perry G. The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical-induced lipid oxidation. Soc Neurosci Abstr, Program No. 594.16, 2007.

582. Wang X, Su B, Petersen RB, Smith MA, Perry G, Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer disease. Soc Neurosci Abstr, Program No. 888.21, 2007.

583. Perry G, Ames BN, Aliev G. Is oxidative stress an initiator of mitochondrial failure and vascular hypoperfusion during aging and Alzheimer disease? Present and future. Fifth International Congress on Vascular Dementia, p. 76, 2007.

584. Aliev G, Shenk JC, Liu J, Puchowicz M, Xu K, Smith MA, Siedlak SL, Obrenovich ME, Ames BN, de la Torre JC, Koistinaho J, LaManna JC, Perry G. Preventative effect of mitochondrial antioxidants in ApoE deficiency mouse model of brain hypoperfusion. Fifth International Congress on Vascular Dementia, p. 78, 2007.

585. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Perry G. Autophagocytosis of mitochondria is prominent in Alzheimer disease. Fifth International Congress on Vascular Dementia, p. 89, 2007.

586. Evans TA, Siedlak SL, Lu L, Fu X, Wang Z, McGinnis WR, Fakhoury E, Castellani RJ, Hazen SL, Walsh WJ, Lewis AT, Salomon RG, Smith MA, Zhu X, Perry G. The autistic phenotype exhibits a remarkable localized modification of brain proteins by products of free radical-induced lipid oxidation. 24

th International

Neurotoxicology Conference: Environmental Etiologies of Neurological Disorders, pp 22-23, 2007.

587. Perry G, Nunomura A, Moreira PI, Harris PLR, Zhu X, Smith MA. Oxidative stress as an initiator of Alzheimer‘s Disease. 2007 International Conference ―Current Hypotheses on Alzheimer‘s Disease‖, p. 13, 2007.

588. Perry G, Moreira PI, Nunomura A, Harris PLR, Zhu X, Smith MA, Aliev G. Abnormalities in protein, RNA and metal trafficking underlie oxidative damage in Alzheimer‘s Disease. 2007 International Conference ―Current Hypotheses on Alzheimer‘s Disease‖, p. 32, 2007.

589. Casadesus G, Lee H-g, Zhu X, Smith MA, Perry G. The role of cell cycle-related mechanisms in Alzheimer‘s disease. Philip Morris External Research Program Symposium: Regulatory Circuitry, p. 6, 2007.

590. Perry G, Honda K, Nunomura A, Moreira PI, Zhu X, Smith MA, Aliev G. Mechanism of mitochondrial dependent metal-catalyzed oxidative stress in Alzheimer‘s disease. Philip Morris External Research Program Symposium: Regulatory Circuitry, p. 17, 2007.

George Perry

150

591. Zhu S-H, Lee H-G, Casadesus G, Richardson S, Perry G, Peterson [sic] RB, Smith M. Neuronal cell cycle reactivation in the pathogenesis of Alzheimer‘s disease. 2008 Irwin H. Lepow Medical Student Research Day, Presentation #99, 2008.

592. Wang X, Su B, Smith MA, Perry G, Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer disease. Mitochondria Minisymposium 2008: Mitochondria and their Proteomics, p. 38, 2008.

593. Dwyer BE, Smith MA, Richardson S, Perry G, Zhu X. Heme metabolism in Alzheimer‘s disease. 21st Winter

Conference on Brain Research, p. 115, 2008.

594. Aliev G, Liu J, Xu K, Puchowicz M, Siedlak SL, Shenk JC, Smith MA, Gasimov E, Obrenovich ME, Fischbach K, Zatta A, Galbaiati E, LaManna JC, Ames BN, Perry G. Age-dependent cholesterol increases in ApoE4 mice induces brain hypoperfusion and cognitive impairment which can be diminished by Alcar+R-LA treatment. 2

nd International Conference on Hypertension, Lipids, Diabetes and Stroke Prevention, 2008,

http://www.kenes.com/strokeprevention2008/program/session1.asp?SessionId=PS1&SSessionDate=3/7/2008.

595. Smith MA, Casadesus G, Richardson SL, Perry G, Petersen RB, Lee HG. Neurodegeneration induced by neuronal cell cycle re-entry in CaMKII-MYC transgenic mice. J Neurochem 104 (Suppl 1):76, 2008.

596. Smith MA, Wang X, Su B, Perry G, Zhu X. Abnormalities in mitochondrial fission and fusion in Alzheimer disease fibroblasts and neurons. J Neurochem 104 (Suppl 1):22, 2008.

597. Zhu X, Wang X, Su B, Perry G, Smith MA. Abnormal mitochondrial dynamics in Alzheimer disease. FASEB J 22:167.1, 2008.

598. Aliev G, Shenk JC, Fischbach K, Perry G, Ames BN. The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. FASEB J 22:167.3, 2008.

599. Smith MA, Casadesus G, Richardson SL, Perry G, Petersen RB, Lee H-g. Neurodegenerative phenotypes induced by MYC-driven neuronal cell cycle re-entry: relevance to Alzheimer disease. FASEB J 22:167.6, 2008.

600. Smith MA, Gustaw K, Garrett MR, Siedlak SL, Zhu X, Friedland RP, Lee H-g, Perry G. Antibody-antigen dissociation: a novel diagnostic tool in Alzheimer disease. J Neuropathol Exp Neurol 67:494, 2008.

601. Bryan K, Harris PL, Perry G, Zhu X, Smith MA, Casadesus G. Expression of CD74 is increased in neurofibrillary tangles of Alzheimer‘s brains. Research ShowCASE 2008, p. 323, 2008.

602. Lee H-g, Zhu X, Richardson SL, Perry G, Smith MA. Failure in the control of cell cycle causes neurodegeneration. Research ShowCASE 2008, p. 326, 2008.

603. Siedlak S, Myung N-H, Perry G, Smith MA, Lee H-g. Evidence of DNA damage in Alzheimer disease: phosphorylation of the histone H2AX in astrocytes. Research ShowCASE 2008, p. 330, 2008.

604. Su B, Wang X, Smith MA, Perry G, Zhu X. Chronic oxidative stress induces increased tau phosphorylation in M17 cells. Research ShowCASE 2008, p. 332, 2008.

605. Wang X, Su B, Perry G, Smith MA, Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer disease. Research ShowCASE 2008, p. 335, 2008.

606. Zhu X, Su B, Wang X, Perry G, Smith MA. Increased tubulin acetylation in Alzheimer disease. Research ShowCASE 2008, p. 337, 2008.

607. Aliev G, Liu J, Puchowicz M, Xu K, Siedlak SL, Obrenovich ME, Shenk JC, Smith MA, Gasimov E, LaManna JC, Ames BN, Perry G. Does the oxidative stress and cerebral atherosclerosis initiate brain hypoperfusion and the development of Alzheimer disease? Atherosclerosis Supplements 9:154, 2008.

608. Zhu X, Wang X, Su B, Perry G, Smith MA. Abnormal mitochondrial dynamics in Alzheimer disease. J Neuropathol Exp Neurol 67:492, 2008.

609. Aliev G, Shenk JC, Fischbach K, Perry G, Ames BN. The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. J Neuropathol Exp Neurol 67:493, 2008.

610. Smith MA, Casadesus G, Richardson SL, Perry G, Petersen RB, Lee H-g. Neurodegenerative phenotypes induced by MYC-driven neuronal cell cycle re-entry: relevance to Alzheimer disease. J Neuropathol Exp Neurol 67:493, 2008.

611. Smith MA, Gustaw K, Garrett MR, Siedlak SL, Zhu X, Friedland RP, Lee H-g, Perry G. Antibody-antigen dissociation: a novel diagnostic tool in Alzheimer disease. J Neuropathol Exp Neurol 67:494, 2008.

George Perry

151

612. Zhu XW, Wang XL, Su B, Perry G, Smith MA. Impaired balance of mitochondrial fission and fusion in Alzheimer‘s disease. 8

th International Meeting for Brain Energy Metabolism – ―Neurodegeneration and

Regeneration‖, p. 21, 2008.

613. Smith MA, Garrett MR, Lee H-g, Siedlak SL, Zhu X, Perry G, Friedland RP, Gustaw K. A novel approach to diagnosis: antigen-antibody disassociation in Alzheimer‘s disease. Alzheimers Dement 4 (Suppl 2):T321, 2008.

614. Lee H-g, Zhu X, Richardson SL, Perry G, Smith MA. Failure in the control of cell cycle causes neurodegeneration. Alzheimers Dement 4 (Suppl 2):T614, 2008.

615. Wang X, Su B, Smith MA, Perry G, Zhu X. Impaired balance of mitochondrial fission and fusion in susceptible neurons of Alzheimer disease. Alzheimers Dement 4 (Suppl 2):T645, 2008.

616. Zhu X, Wang X, Su B, Fujioka H, Wang Y, Perry G, Smith MA. Overexpression of amyloid precursor protein causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Alzheimers Dement 4 (Suppl 2):T719, 2008.

617. Perry G, Cash AD, Harris PL, Siedlak SL, Smith MA, Zhu X. Peroxidative nitrotyrosine formation in Alzheimer‘s disease. Alzheimers Dement 4 (Suppl 2):T720, 2008.

618. Aliev G, Shenk JC, Fischbach K, Cobb CJ, Pacheco GJ, Gasimov E, Perry G. Cerebral hypoperfusion-induced oxidative stress and mitochondrial failure as initiators of aging and Alzheimer‘s disease pathology. Alzheimers Dement 4 (Suppl 2):T721, 2008

619. Moreira PI, Santos MS, Siedlak SL, Harris P, Smith MA, Aliev G, Perry G, Oliveira CR. Mitochondrial dysfunction in Alzheimer‘s disease. Alzheimers Dement 4 (Suppl 2):T725, 2008.

620. Perry G, Zhu X, Wang X, Su B, Moreira PI, Smith MA. Mitochondrial fission and fusion in Alzheimer disease fibroblats [sic] and neurons. XVI

th National Congress of Biochemistry, p. 34, 2008.

621. Castellani RJ, Zhu X, Lee H, Perry G, Smith MA. Pathological lesions as a host response to oxidative stress in Alzheimer‘s disease. 2

nd World Congress on Controversies in Neurology, pp A10-A11, 2008.

622. Aliev G, Moreira P, Siedlak SL, Smith MA, Cobb CJ, Ferrer D, Jose Yacaman M, Perry G. Evidence of increased copper and iron but not zinc in Alzheimer‘s disease: energy dispersive x-ray spectroscopy (EDS) elemental microanalysis. 13

th International Meeting on Trace Elements in Man and Animals (TEMA), p. 53,

2008.

623. Aliev G, Morales LA, Obrenovich MA, Fischbach K, Gasimov E, Perry G. The primary pathogenetic role of oxidative stress induced mitochondria failure and cerebral hypoperfusion in aging and Alzheimer disease: a lesson from the past 100 years. 2

nd WFSBP Asia-Pacific Congress and 30

th Annual Meeting of JSBP, S-

08.04, 2008.

624. Perry G, Wang X, Su B, Moreira PI, Smith MA, Zhu X. Mitochondrial transport, fission-fusion and autophagy in Alzheimer disease. VI Fórum Internacional de Investigadores Portugueses, p. 97, 2008.

625. Smith MA, Wang XC, Su B, Perry G, Zhu X. Metabolic, metalic [sic] and mitotic sources of oxidative stress in Alzheimer disease. J Neurochem 108 (Suppl 1):68-69, 2009.

626. Wang X, Su B, Perry G, Smith M, Zhu X. Impaired regulation of mitochondria dynamics in Alzheimer disease. J Neurochem 108 (Suppl 1):71, 2009.

627. Smith MA, Siedlak SL, Evans TA, Salomon RG, Perry G, Zhu X. Oxidative damage in the autistic brain: therapeutic considerations. J Neurochem 108 (Suppl 1):93, 2009.

628. Castellani RJ, Lee H-G, Zhu X, Perry G, Smith MA. Neuropathology is neuroprotection in degenerative diseases. Second Joint Congress of the Global College of Neuroprotection and Neuroregeneration and Society for the Study of Neuroprotection and Neuroplasticity, p. 50, 2009.

629. Smith MA, Wang X, Su B, Castellani RJ, Nunomura A, Lee H-g, Perry G, Zhu X. The causes and consequences of oxidative stress in Alzheimer disease: therapeutic implications. Second Joint Congress of the Global College of Neuroprotection and Neuroregeneration and Society for the Study of Neuroprotection and Neuroplasticity, p. 113, 2009.

630. Perry G, Wang X, Su B, Moreira P, Smith M, Zhu X. Mitochondrial dynamics in Alzheimer disease fibroblasts and neurons. Neurodegener Dis 6 (Suppl 1):180, 2009.

631. Wang X, Su B, Perry G, Smith M, Zhu X. Abnormal mitochondrial dynamics in Alzheimer‘s disease. Neurodegener Dis 6 (Suppl 1):1979, 2009.

632. Dwyer BE, Zacharski LR, Balestra DJ, Perry G, Smith MA, Zhu X. Getting the iron out: phlebotomy for Alzheimer‘s disease? 23

rd Annual Neuroscience Day at Dartmouth, p. 15, 2009.(13)

George Perry

152

633. Stone J, Rolston RK, Ueda M, Lee HG, Richardson SL, Castellani RJ, Perry G, Smith MA. Evidence for the novel expression of human kallikrein-related peptidase 3, prostatespecific [sic] antigen, in the brain. 23

rd

National Conference on Undergraduate Research, p. 1019, 2009.

634. Smith MA, Wang X, Su B, Castellani RJ, Nunomura A, Lee H-g, Perry G, Zhu X. Oxidative stress and protein modifications: cause or consequence in neurodegeneration? Mechanisms and Consequences of Free Radical-Mediated Oxidative Protein Modifications, FEBS Advanced Lecture Course, p. 32, 2009.

635. Smith MA, Sayre LM, Moreira PI, Zhu X, Nunomura A, Perry G. Histochemical detection of protein-associated oxidative damage in tissues and cells. Mechanisms and Consequences of Free Radical-Mediated Oxidative Protein Modifications, FEBS Advanced Lecture Course, p. 38, 2009.

636. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi T. Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid. The 6

th International Human Peroxidase Meeting, p. 55, 2009.

637. Lee H-g, Richardson S, Zhu X, Castellani R, Smith M, Perry G, Petersen R. Pathogenic mutations in the prion protein increase susceptibility to oxidative stress in neuronal cells. J Neuropathol Exp Neurol 68:553, 2009.(1)

638. Nugent S, Harris P, Zhu X, Chen S, Lee H-G, Perry G, Oettgen P, Smith M, Castellani R. CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson‘s disease. J Neuropathol Exp Neurol 68:556-557, 2009.

639. Zhu X, Wang X, Su B, Fujioka H, Wang Y, Perry G, Smith M. Overproduction of amyloid-beta causes abnormal mitochondrial dynamics. J Neuropathol Exp Neurol 68:561, 2009.

640. Smith M, Gustaw-Rothenberg K, Siedlak S, Lee H-g, Castellani R, Zhu X, Perry G, Petersen R, Friedland R, Lerner A. Newly diagnosed Alzheimer‘s disease patients show increased dissociated Aβ antibody levels. J Neuropathol Exp Neurol 68:569, 2009.

641. Shenk J, Castellani R, Moreira P, Aliev G, Siedlak S, Harris P, Sayre L, Szweda P, Szweda L, Smith M, Perry G. Hydroxynonenal-generated crosslinking fluorophores accumulation in Alzheimer disease reveals a dichotomy of protein turnover. J Neuropathol Exp Neurol 68:571, 2009.

642. Lee H-g, Casadesus G, Richardson S, Perry G, Petersen R, Smith M. Overexpression of MYC in post-mitotic neurons induces cell cycle re-entry and neurodegeneration. J Neuropathol Exp Neurol 68:572, 2009.

643. Wang X, Castellani R, Perry G, Siedlak S, Stone J, Smith M, Zhu X. Oxidative and mitochondrial changes in Fragile X and related disorders. J Neuropathol Exp Neurol 68:575-576, 2009.

644. Perry G. Recovering lost memories: aging and Alzheimer‘s disease therapeutics. Alamo Sigma Xi Science Café, 2009, http://www.sigmaxi.org/chapters/web/index.php?chapter_id=171&page_id=432.

645. Shenk JC, Castellani RJ, Moreira P, Aliev G, Siedlak SL, Harris PLR, Sayre L, Szweda PA, Smith MA, Perry G. Hydroxynonenal generated crosslinking fluorophores accumulate in Alzheimer‘s disease. Alzheimers Dement 5 (Suppl):315, 2009.

646. Gustaw-Rothenberg K, Siedlak SL, Lee H-g, Castellani RJ, Zhu X, Perry G, Petersen RB, Friedland RP, Lerner AJ, Smith MA. Dissociated Aβ antibody level in newly diagnosed Alzheimer‘s disease: a population-based study. Alzheimers Dement 5 (Suppl):363, 2009.

647. Clark TA, Gupta Y, Siedlak SL, Harris PLR, Coller JM, Smith MA, Perry G. Role of stress granules in oxidative stress protection and pathogenesis of Alzheimer‘s disease. The Texas Brain and Spine Institute 2009 Annual Neuroscience Symposium on Alzheimer‘s Disease, p. 1, 2009.

648. Clark TA, Gupta Y, Siedlak SL, Harris PLR, Coller JM, Smith MA, Perry G. Role of stress granules in oxidative stress protection and pathogenesis of Alzheimer‘s disease. UTSA College of Sciences Research Conference 2009, p. 24, 2009.

649. Smith MA, Perry G, Lee HG, Nunomura A, Zhu X, Casadesus G. Pleuripotent treatments for pleuripotent mechanisms in Alzheimer disease: lessons from nature. J Neurochem 110 (Suppl 2):89, 2009.

650. Lee HG, Zhu X, Richardson SL, Perry G, Smith MA. Neuronal cell cycle re-entry causes neurodegeneration in animal models. J Neurochem 110 (Suppl 2):157, 2009.

651. Perry G, Wang X, Su B, Moreira PI, Smith MA, Zhu X. Mitochondria in the balance ofAlzheimer [sic] disease. 6

th International Symposium: ―Advances in Alzheimer‘s Disease‖, p. 5, 2009.

652. Clark TA, Gupta Y, Siedlak SL, Harris PLR, Coller JM, Smith MA, Perry G. Role of stress granules in oxidative stress protection and pathogenesis of Alzheimer‘s disease. UTSA College of Sciences MBRS-RISE & MARC-U*STAR Symposium 2009, p. 15, 2009.

George Perry

153

653. Dwyer BE, Smith MA, Richardson SL, Perry G, Zhu X. Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer‘s disease. 6

th International Congress on Heme

Oxygenase: Heme Oxygenases in Biology & Medicine, p. 31, 2009.(4)

654. Clark T, Gupta Y, Siedlak S, Harris P, Coller J, Smith M, Perry G. Role of stress granules in oxidative stress protection and pathogenesis of Alzheimer‘s disease. 2009 SACNAS National Conference, p. 248, 2009.

655. Lee H-g, Zhu X, Richardson SL, Perry G, Smith MA. Failure in the control of cell cycle causes neurodegeneration. The Case Comprehensive Cancer Center ―Signaling in Cancer Symposium,‖ p. 15, 2009.

656. Perry G, Wang X, Su B, Moreira PI, Smith MA, Zhu X. Mitochondria in the balance of Alzheimer disease. Psicogeriatría 1:254-255, 2009.

657. Smith MA, Lee H-g, Wang X, Sharma HS, Perry G, Zhu X, Castellani RJ. The multiple, yet convergent, pathways involved in the pathogenesis of Alzheimer disease. 7

th Annual Global Conference on

Neuroprotection and Neuroregeneration, p. 57, 2010.

658. Perry G. Alzheimer as the disease of our times. 4th UTSA Architecture, Business, Engineering, and Science

Students‘ Conference, 2010, http://ace.utsa.edu/abes2010/Geroge%20Perry%20%20Poster_w_Abstract.pdf.

659. Smith M, Gupta Y, Siedlak S, Harris P, Coller J, Perry G, Zhu X. Phosphorylated ribosomal protein S6 is greatly increased in Alzheimer disease. J Neuropathol Exp Neurol 69:523, 2010.

660. Gustaw-Rothenberg K, Lerner A, Siedlak S, Zhu X, Perry G, Smith M. Oxidative stress parameters in newly diagnosed Alzheimer‘s disease patients: a population-based study. J Neuropathol Exp Neurol 69:525, 2010.

661. Stone J, Bonda D, Lee H-g, Richardson S, Perry G, Casadesus G, Smith M. Association of leptin receptor with neurofibrillary tangles of Alzheimer disease. J Neuropathol Exp Neurol 69:531, 2010.

662. Smith MA, Wang X, Lee H-g, Perry G, Zhu X, Casadesus G. Factors driving the pathogenesis of Alzheimer‘s disease. 39

th Annual Meeting of the American Aging Association, p. 30, 2010.

663. Shenk JC, Smith MA, Castellani RJ, Moreira P, Aliev G, Siedlak SL, Harris PLR, Sayre L, Szweda PA, Szweda LI, Perry G. Lipid peroxidation markers are associated with granulovacuolar degeneration but not lipofuscin formation. Alzheimers Dement 6 (Suppl):S230, 2010.

664. Bamburg JR, Bernstein BW, Davis RC, Goldsbury C, Maloney MT, Marsden IT, Minamide LS, Pak CW, Perry G, Podlisny MB, Selkoe DJ, Shaw AE, Siedlak SL, Whiteman IT. ADF/cofilin-actin rods and synaptic loss in Alzheimer‘s disease. Alzheimers Dement 6 (Suppl):S378, 2010.

665. Lee H-G, Lee H-P, Kudo W, Zhu X, Perry G, Smith MA. Disturbance in AMP-activated protein kinase (AMPK) signaling pathway in Alzheimer‘s disease. Alzheimers Dement 6 (Suppl):S406, 2010.

666. Gustaw-Rothenberg KA, Lerner A, Perry G, Siedlak SL, Zhu X, Smith MA. MDA and GSH levels in newly diagnosed Alzheimer‘s disease patients: a population-based study. Alzheimers Dement 6 (Suppl):S510-S511, 2010.

667. Gustaw-Rothenberg KA, Siedlak SL, Perry G, Lerner A, Smith MA. Total antioxidant status in newly diagnosed Alzheimer‘s patients: population based study. Alzheimers Dement 6 (Suppl):S512, 2010.

668. Zhu X, Wang X, Su B, Protter A, Perry G, Smith MA. Latrepirdine (Dimebon™) modulate mitochondrial dynamics in AD cell models. Alzheimers Dement 6 (Suppl):S588, 2010.

669. Perry G, Wang X, Su B, Moreira PI, Smith MA, Zhu X. Mitochondria fusion/fission in the balance of alzheimer [sic] disease. Brain Pathol 20 (Suppl 1):2, 2010.

670. Clark TA, Castellani RJ, Moreira P, Aliev G, Shenk JC, Siedlak SL, Harris PLR, Sayre LM, Szweda PA, Szweda LI, Zhu X, Smith MA, Perry G. Intraneuronal accumulation of hydroxynonenal-generated lipid peroxidation protein crosslinks in Alzheimer disease. Society Advancement Chicanos and Native Americans National Conference Abstracts, p. 181, 2010.

671. Castellani RJ, Lee H-g, Zhu X, Nunomura A, Perry G, Smith MA. Alzheimer disease neuropathology is pathognomonic but not pathogenic. 4

th World Congress on Controversies in Neurology (CONy), 2010,

http://comtecmed.com/cony/2010/Uploads/assets/smith%20formatted.pdf.

672. Castellani RJ, Zhu X, Perry G, Smith MA. Environmental factors in Parkinson‘s disease. 4th World Congress

on Controversies in Neurology (CONy), 2010, http://comtecmed.com/cony/2010/Uploads/assets/parkinson_castellani.pdf.

673. Blair JA, Siedlak SL, Lee H-g, Salomon RG, Zagorski MG, Nunomura A, Perry G, Castellani RJ, Smith MA. Intracellular amyloid-β is a consistent feature of hippocampal neurons and unrelated to age or Alzheimer disease. Microscopy Society of Northeastern Ohio Fall Meeting, p. 2, 2010.

George Perry

154

674. Dwyer BE, Bean JR, Perry G, Zhu X, Smith MA. Cerebral heme homeostasis in a mouse model of Alzheimer disease. Soc Neurosci, Program No. 247.11, 2010.

675. Smith MA, Liu G, Men P, Zhu X, Castellani RJ, Perry G. Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer‘s disease. Soc Neurosci Abstr, Program No. 428.1, 2010.

676. Smith MA, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Castellani RJ. The pathology of Alzheimer disease: pathogenic or pathognomonic? Pathological Society: Understanding Disease, p. S.5, 2011.

677. zhu x [sic], Wang X, Su B, Gao Y, Castellani RJ, Perry G, Smith MA. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium (MPP

+) toxicity in neurons. FASEB J 25:441.7, 2011.

678. Blair JA, Siedlak SL, Lee H-g, Salomon RG, Zagorski MG, Nunomura A, Perry G, Castellani RJ, Smith MA. Colorimetric detection of 4-hydroxynonenal adduction to neurofilament protein KSP repeats. Intersections: SOURCE Symposium and Poster Session, p. 101, 2011.

679. Rothenberg K, Perry G, Siedlak SL, Smith MA. Oxidative stress parameters in Alzheimer‘s disease: potential biomarkers of the neurodegenerative process. 164

th Annual Meeting of the American Psychiatric Association,

pp 38-39, 2011.

680. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Smith MA, Perry G. Neuronal RNA oxidation in age-related neurodegenerative disorders. BIT‘s 2

nd Annual World Congress of NeuroTalk-2011,

p. 173, 2011.

681. Gobstein H, Abraham L, Ekland-Olson S, Perry G. It takes a university for science teacher preparation: a discussion among an education chair, a science dean, and a provost. 2011 PhysTEC Program, p. 5, 2011.

682. Perry G, Wang X, Smith MA, Zhu X. Mitochondrial homeostasis at the center of oxidative stress. Conferencia Internacional Sobre: Nuevos Descubrimientos en el Cerebro, pp 26-28, 2011.

683. Zhu X, Perry G. Mark A. Smith: homeostatic bal ance [sic] in aging and Alzheimer disease. 40th Annual

Meeting of the American Aging Association, pp 50-51, 2011.

684. Zhu X, Su B, Gao Y, Castellani R, Perry G, Smith M, Wang X. Mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implication for Parkinson disease (PD). J Neuropathol Exp Neurol 6:504-505, 2011.

685. Phelix C, Siedlak S, Zhu X, Perry G. In vivo and in silico evidence: hippocampal cholesterol metabolism decreases with aging and increases with Alzheimer disease. J Neuropathol Exp Neurol 70:517, 2011.

686. Correia S, Perry G, Zhu X, Smith M, Moreira P. Decline in mitochondrial bioenergetics underlies central insulin resistance in streptozocin-induced model of sporadic Alzheimer‘s disease. Alzheimers Dement 7 (Suppl 1):S562, 2011.

687. Correia S, Casadesus G, LaManna J, Perry G, Zhu X, Smith M, Moreira P. Neuroprotective effects of hypoxic preconditioning on streptozotocin-induced animal model of sporadic Alzheimer‘s disease. Alzheimers Dement 7 (Suppl 1):S609, 2011.

688. Perry G, Wang X, Smith MA, Zhu X. Oxidative and mitochondrial abnormalities in Alzheimer disease. Global Alzheimer‘s Research Summit, p. 13, 2011, http://www.nature.com/natureconferences/alz11/alz11speakerabstracts.pdf.

689. Duran Gonzalez J, Perez-Cardova MG, Pacheco-Otalora LF, Perry G, Colom LV. Amyloid Î2 [sic] reduces

expression of antioxidant repair enzymes. University of Texas at San Antonio College of Sciences Research Conference 2011, p. 73, 2011.

690. Perez Cordova MG, Colom LV, Hernandez S, Garcia IM, Perry G. Intraseptal injections of oligomeric AÎ2 [sic]

1-42 increase oxidative stress in septal neurons. University of Texas at San Antonio College of Sciences Research Conference 2011, p. 79, 2011.

691. Nunomura A, Yasuda K, Tamaoki T, Zhu X, Perry G. Neuronal RNA oxidation in aging, preclinical Alzheimer disease, and mild cognitive impairment. Dementia Japan 25:425, 2011.

692. Perry G, Siedlak S, Zhu X, Phelix C. Hippocampal cholesterol metabolism decreases with aging and increases with Alzheimer‘s disease. Soc Neurosci Abstr, Program No 143.01, 2011.

693. Zhu X, Su B, Fujioka H, Perry G, Wang X. LRRK2 is involved in the regulation of mitochondrial dynamics. Soc Neurosci Abstr, Program No. 423.04, 2011.

694. Phelix CF, Schafer R, Perry G, Zhu X. Transcriptome to reactome: biosimulation of oxidation and apoptosis in Alzheimer‘s disease. Soc Neurosci Abstr, Program No. 877.14, 2011.

George Perry

155

695. Perry G, Phelix C, Zhu X, Fujioka H. Apolipoprotein E4/4 inhibits intraerythrocyte growth of Plasmodium falciparum, malaria, parasites in vitro. 2011 STCEID Symposium, p. 19, 2011.

696. Stone JG, Bonda DJ, Richardson S, Siedlak S, Perry G, Markesbery WR, Casadesus G, Smith MA, Zhu X, Lee H-g. Evidence for hippocampal leptin resistance in Alzheimer disease. American College of Physicians, 2012 Hawaii Chapter Scientific Meeting, p. 18, 2012.

697. Zhu X, Shen [sic] B, Lee H-g, Casadesus G, Perry G, Wang X. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer‘s disease. J Neuropathol Exp Neurol 71:550, 2012.(111)

698. Perry G, Yan M, Fujioka H, Liu J, Wilson-Delfosse A, Chen S, Casadesus G, Zhu X, Wang X. Parkinson-related LRRK2 mutations result in impaired mitochondrial dynamics and function via direct interaction with DLP1. J Neuropathol Exp Neurol 71:581, 2012.

699. Zhu X, Perry G, Yan M, Fujioka H, Liu J, Wilson-Delfosse A, Chen S, Casadesus G, Wang X. Impaired mitochondrial dynamics and function result from LRRK2 mutations. 41

st Annual Meeting of the American

Aging Association, pp 49-50, 2012.

700. Phelix C, Rahimi O, Colom L, Perry G, Ginsberg S. Transcriptome-to-reactome biosimulation: basal forebrain cholinergic neuron neurotrophin signaling. Alzheimers Dement 8 (Suppl):P467-P468, 2012.

701. Rahimi O, Phelix C, Perry G. Transcriptome-to-reactome biosimulation: oxidative pathways to apoptotic cell death. Alzheimers Dement 8 (Suppl):P478-P479, 2012.

702. Phelix C, Villareal G, Perez-Cordova M, Hernandez S, Perry G, Colom L. Reanimating basal forebrain cholinergic neurons in electrophysiology biosimulations using COPASI software. Alzheimers Dement 8 (Suppl):P593-P594, 2012.

703. Duran J, Perez-Cordova M, Pacheco-Otalora L, Perry G, Colom L. Beta-amyloid reduces the expression of antioxidant repair genes. Alzheimers Dement 8 (Suppl):P670, 2012.

704. Perry G, Wang X, Moreira P, Smith MA, Nunomura A, Zhu X. Oxidative STRESS and mitochondrial abnormalities in Alzheimer disease. 1

st International Symposium on Prion Chemical Biology and Enabling

Technologies: Towards a Cure for Alzheimer‘s Disease, p. 1, 2012.

705. Whitehouse P, George D, Perry G. New diagnostic guidelines for Alzheimer‘s disease do patients benefit? ? 27

th International Conference of Alzheimer‘s Disease International, p. 212, 2012.

706. Perry G. Oxidative, cell cycle and mitochondrial abnormalities in Alzheimer disease. Alzheimer‘s Centers of Excellence, p. 3, 2012, http://centeronaging.med.miami.edu/documents/Alzheimer20122.pdf.

707. Perry EA, Castellani RJ, Moreira PI, Siedlak SL, Harris PLR, Sayre LM, Szweda PA, Szweda LI, Zhu X, Smith MA, Perry G. Lipid peroxidation creates intramolecular crosslinking of neurofilaments. 2012 Collaborative Basic and Translational Research in the Sciences, p. 39, 2012.

708. Perry E, Perry G. Lipid peroxidation creates intramolecular crosslinking of neurofilaments. SACNAS National Conference, p. 184, 2012.

709. Fujioka H, Phelix C, Perry EA, Zhu X, Perry G. Apolipoprotein E 4/4 serum inhibits growth of Plasmodium falciparum. 13

th RCMI International Symposium on Health Disparities, p. 73, 2012.

710. Perry G, Yan MH, Chen SG, Fujioka H, Wilson-Delfosse A, Liu J, Casadesus G, Zhu X, Wang X. LRRK2 mutations result in impaired mitochondrial dynamics. 13

th RCMI International Symposium on Health

Disparities, p. 134, 2012.

711. Phelix CF, Perry G. Oxidative stress and apoptosis in progression of Alzheimer‘s disease. 13th RCMI

International Symposium on Health Disparities, p. 134, 2012.

712. Ochoa CF, Zhu X, Perry G, Barea-Rodriguez EJ. The effects of methylene blue on long-term potentiation and protein conformation in the rat hippocampus. 13

th RCMI International Symposium on Health Disparities, p.

136, 2012.

713. Perry EA, Castellani RJ, Moreira PI, Siedlak SL, Harris PLR, Sayre LM, Szweda PA, Szweda LI, Zhu X, Smith MA, Perry G. Lipid peroxidation creates intramolecular crosslinking of neurofilaments. 13

th RCMI

International Symposium on Health Disparities, p. 140, 2012.

714. Perry G, Coskuner O, Aloglu AK, Cavazos J, Dunn A, Wise-Scira O, Xu L. Structures of intrinsically disordered fibrillogenic proteins. 13

th RCMI International Symposium on Health Disparities, p. 141, 2012.

715. Perry EA, LeBaron RG, Perry G, Phelix CF. An in silico study of transforming growth factor-β1 induced collagen-I expression in human periodontal ligament. Texas Academy of Science, p. 54, 2013.

716. Fukioka [sic] H, Zhu X, Phelix C, Perry E, Perry G. Apolipoprotein E 4/4 serum inhibits growth of malaria in culture. Texas Academy of Science, pp 60-61, 2013.

George Perry

156

717. Perry EA, Perry G, Castellani RJ, Moreira PI. Hydroxynonenal intramolecular crosslinking of neurofilaments. Texas Academy of Science, p. 92, 2013.

718. Phelix CF, Perry G, Schafer RK. Oxidative stress and apoptosis in the progression of Alzheimer‘s disease in the hippocampal CA1 region. Texas Academy of Science, pp 93-94, 2013.

719. Perry G, Wang X, Moreira P, Castellani RJ, Smith MA, Nunomura A, Zhu X. Is Alzheimer‘s disease a metabolic disorder? 1er Encuentro internacional Avance en la Investigación y Terapéutica de la Enfermedad de Alzheimer, pp 11-12, 2013.

720. Fujioka H, Phelix C, Perry E, Zhu X, Perry G. Apolipoprotein E4 inhibits growth of plasmodium in culture. J Neuropathol Exp Neurol 72:580, 2013.

721. Castellani R, Mehta R, Klochko C, Perry G, DeJong J. Chronic traumatic encephalopathy-like focal tauopathy after single traumatic events. J Neuropathol Exp Neurol 72:582, 2013.

722. Perry E, Castellani R, Moreira P, Perry G. Lipid peroxidation mediated intromolecular [sic] crosslinking of neurofilaments. J Neuropathol Exp Neurol 72:582, 2013.

723. Phelix C, Perry G, Schafer R. Apoptosis and oxidative stress in the progression of Alzheimer‘s disease. J Neuropathol Exp Neurol 72:582, 2013.

724. Phelix C, LeBaron R, Roberson D, Villareal G, Perry G. Flux and metabolite pathway mapping in the aging and Alzheimer‘s disease hippocampus. Alzheimers Dement 9 (Suppl):P346-P347, 2013.

725. Wang X, Zhu X, Perry G, Wang W, Casadesus G, Lee H-G. Presenilin mutations impair mitochondrial dynamics in neurons. Alzheimers Dement 9 (Suppl):P349-P350, 2013.

726. Bonda D, Stone J, Richardson S, Siedlak S, Perry G, Casadesus G, Smith M, Zhu X, Lee H-g. Neuronal leptin resistance in Alzheimer‘s disease. Alzheimers Dement 9 (Suppl):P574-P575, 2013.

727. Mohorovic L, Perry G, Lavezzi AM, Stifter S, Malatestinic D, Micovic V, Materljan E, Haller H, Petrovic O. Methemoglobin catabolism and Alzheimer‘s disease. Alzheimers Dement 9 (Suppl):P861, 2013.

728. Perry G. Portuguese-American educational attainment and scholarly identity. Exploring the Portuguese Diaspora in Interdisciplinary and Comparative Perspectives: An International Conference, p. 69, 2013.

729. Perry G. Mitochondria at the origin of oxidative stress in Alzheimer‘s disease. International Conference on Psychology, Autism and Alzheimer's Disease, J Alzheimers Dis Parkinsonism 3:68, 2013.

730. Perry G. Testing the two-hit hypothesis of Alzheimer‘s disease: cell cycle re-entry. International Conference on Psychology, Autism and Alzheimer's Disease, J Alzheimers Dis Parkinsonism 3:73, 2013.

731. Morris J, Phelix C, Perry G. Transcriptome-To-ReactomeTM

biosimulation: basal forebrain cholinergic neuron neurotrophin signaling. 2013 SACNAS National Conference, p. 60, 2013.

732. Perry E, Phelix C, Perry G. Zhu X, Fujioka H. Apolipoprotein E 4/4 serum inhibits growth of Plasmodium falciparum. 2013 SACNAS National Conference, pp 125-126, 2013.

733. Centeno G Jr, Perry G, Phelix C. Sphingolipid pathway maps from metabolic biosimulations reveal increases in progressive stages of Alzheimer‘s disease. 2013 SACNAS National Conference, p. 374, 2013.

734. Centeno GA, Perry G, Phelix CF. Sphingolipid pathway maps from metabolic biosimulations reveal increases in progressive stages of Alzheimer‘s disease. Collaborative Basic and Translational Research in the Sciences at the University of Texas at San Antonio College of Sciences, p. 51, 2013.

735. Smith K, Kelley A, Perry G, Glickman R, Renthal R, Bach SBH. Imaging mass spectrometry at UTSA. Collaborative Basic and Translational Research in the Sciences at the University of Texas at San Antonio College of Sciences, p. 75, 2013.

736. Morris J, Perry G, Phelix CF. Transcriptome-To-ReactomeTM

biosimulation: basal forebrain cholinergic neuron neurotrophin signaling. Collaborative Basic and Translational Research in the Sciences at the University of Texas at San Antonio College of Sciences, p. 97, 2013.

737. Shammas R, Nunomura A, Perry G. Nucleic acid oxidation is correlated with mitochondrial abnormalities in aging but not Alzheimer disease. Collaborative Basic and Translational Research in the Sciences at the University of Texas at San Antonio College of Sciences, p. 100, 2013.

738. Phelix CF, Perry G. Therapeutic efficacy for mitochondrial pyruvate carrier inhibitors as treatment of Alzheimer‘s disease: biomarkers from biosimulations. Collaborative Basic and Translational Research in the Sciences at the University of Texas at San Antonio College of Sciences, p. 103, 2013.

739. Perry G, Zhu X, Castellani R. Amyloidosis in a templated universe. From Neurodegeneration to Brain Health: An Integrated Approach, 2013.

George Perry

157

740. Perry G, Zhu X, Castellani R. Predator-prey in a templated universe. Cantoblanco Workshop on Tau, p. 26, 2013.

741. Nunomura A, Tamaoki T, Motohashi N, Zhu X, Perry G. Oxidative damage to RNA in aging and neurodegenerative disorders. 11

th International Conference onEnvironment [sic] Mutagens, p. 95, 2013.

742. Nunomura A, Tamaoki T, Motohashi N, Zhu X, Perry G. Oxidative RNA damage in diverse neuropsychiatric disorders. 8

th Brain Research Conference [RNA Metabolism in Neurological Disease], p. 72, 2013.

743. Fawver JN, Ghiwot Y, Koola C, Rodriguez-Rivera J, Dineley KT, Shankar S, Jhamandas JH, Perry G, Murray IV. Islet amyloid polypeptide (IAPP) association with Alzheimer‘s disease pathology and diagnosis. Soc Neurosci Conf, 2013, http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=3236&sKey=5e9734a3-a116-47b6-9978-567fbe5ea720&cKey=225b4c3d-05ae-49f9-8c2e-cb30ea3683d5.

744. Farias GA, Guzman L, Perry G, Maccioni RB. Multilevel evaluation of an Andean shilajit based compound. The Journal of Nutrition, Health & Aging 17:850. 2013.

745. Perry G. Testing the two-hit hypothesis of Alzheimer disease: cell cycle re-entry. International Summit on Clinical Pharmacy & Dispensing, Clinic Pharmacol Biopharmaceut 2:27, 2013.

746. Perry G, Wang X, Moreira P, Castellani RJ, Smith MA, Nunomura A, Zhu X. Mitochondrial abnormalities at the origin of oxidative stress in Alzheimer‘s disease. International Summit on Clinical Pharmacy & Dispensing, Clinic Pharmacol Biopharmaceut 2:32, 2013.

747. Perry G, Wang X, Moreira P, Castellani RJ, Nunomura A, Zhu X. Mitochondria at the origin of oxidative stress. J Neuroimmune Pharmacol 9 (Suppl 1):S18-S19, 2014.

748. Fujioka H, Phelix C, Friedland R, Zhu X, Perry EA, Castellani RJ, Perry G. Apolipoprotein E 4/4 serum inhibits growth of Plasmodium falciparumi at the intraerythrocyte stage: Seventh Health Disparities Conference, p. 39, 2014.

749. Smith K, Kelley A, Castellani RJ, Perry G, Bach SBH. Probing Alzheimer‘s disease using imaging mass spectrometry. 247th American Chemical Society National Meeting and Exposition, No. 369, 2014.

750. Perry G, Shammas R, Castellani RJ, Zhu X, Wang X, Lee H-g, Nunomura A. Oxidative damage is correlated with mitophagy in aging but not Alzheimer disease. 43

rd Annual Meeting of the American Aging Association, p

43, 2014.

751. Perry G, Shammas R, Zhu X, Wang X, Lee H-g, Castellani R, Nunomura A. Oxidative damage is correlated with mitochondrial abnormalities in aging but not Alzheimer disease. J Neuropath Exp Neurol 73:628, 2014.

752. Kelley AR, Davidson MA, Martinez AJ, Perry G, Castellani RJ, Glickman R, Bach SBH. Platinum-based drug binding to tissue – an in-vivo look. UTSA College of Sciences Research Conference 2014, p. 71, 2014.

753. Phelix CF, Villareal G, LeBaron RG, Roberson DJ, Perry G. Racial and ethnic differences in response to drugs: transcriptome-to-metabolome

TM biosimulation of pioglitazone effects in subcutaneous adipose tissue in

silico. Minority Health and Health Disparities Grantees‘ Conference, p. 6, 2014.

754. Arulanandam BP, Rodriguez AR, Plascencia-Villa G,Witt CM, Yu J-J, José-Yacamán M, Chambers JP, Perry G, Guentzel MN. Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Minority Health and Health Disparities Grantees‘ Conference, p. 59, 2014.

755. Perry G, Perry EA, Moreira PI, Correia S, Castellani RJ, Wang X, Lee H-g, Zhu X. Oxidative damage is correlated with mitochondrial autophagy. Minority Health and Health Disparities Grantees‘ Conference, p. 74, 2014.

756. Bellinger FP, Moreira PI, Rueli RHLH, Uyehara-Lock JH, Berry MJ, Perry G. Selenate and reduction of neurofibrillary tangle formation: role of selenoproteins. Minority Health & Health Disparities Grantees‘ Conference, p. 77, 2014.

757. Castellani RJ, White K, Klochko C, DeJong JL, Perry G. Chronic traumatic encephalopathy: myth versus reality. Minority Health and Health Disparities Grantees‘ Conference, p. 153, 2014.

758. Kelley AR, Smith K, Perry G, Castellani RJ, Bach SBH. Probing Alzheimer‘s disease using imaging mass spectrometry. Minority Health and Health Disparities Grantees‘ Conference, p. 230, 2014.

759. Legesse T, Peclovitz A, White K, Zielke HR, Shetty A, Perry G, Castellani R. Gene expression differences in asymptomatic, middle aged ApoE4 homozygotes. Modern Pathol 28 (Suppl 2): pp.431A-432A, 2015.

760. Legesse T, Peclovitz A, White K, Zielke HR, Shetty A, Perry G, Castellani RJ. Gene expression differences in asymptomatic, middle aged ApoE4 homozygotes, Lab Invest 95 (Suppl 1): pp.431A-432A, 2015

George Perry

158

761. Kelley AR, Perry G, Castellani RJ, Bach SBH. Molecular Mapping of Alzheimer‘s disease – imaging mass spectrometry. Texas Academy of Science pp. 41-42, 2015.

762. Perry G, Perry EA, Moreira PI, Correia S, Castellani RJ, Wang X, Lee H-g, Zhu X. Oxidative damage is correlated with mitochondrial autophagy. Texas Academy of Science pp. 104-105, 2015.

763. Correia SC, Zhu X, Perry G, Moreira PI. Altered mitochondrial transport in Alzheimer‘s disease-HUMMR as a traffic cop! XIV Meeting of the Portuguese Society for Neurosciences, p. 558, 2015..

764. Perry G, Perry EA, Moreira PI, Correia S, Castellani RJ, Wang X, Lee H-g, Zhu. Oxidative damage is correlated with mitochondrial autophagy. FASEB J 29 (1):613.1, 2015

765. Correia SC, Pinho TS, Zhu X, Perry G, Moreira PI. Loss of HUMMR participates on mitochondrial traffic jams in Alzheimer‘s disease. Neurodegen, p.129, 2015

766. Perry G, Kelley AR, Bach S, Castellani RJ. Molecular mapping of Alzheimer‘s disease: imaging mass spectrometry. 2015 Alzheimer‘s Association International Conference, 2015.

767. Perry G, Perry EA, Moreira PI, Correia SS [sic], Castellani RJ, Wang X, Lee H-g, Zhu X. Oxidative damage is correlated with mitochondrial autophagy. 2015 Alzheimer‘s Association International Conference, 2015. www.alz.org/aaic/portal/overview.asp.

768. Phelix CF, Perry G, McHardy SF. Molecular docking analysis of mitochondrial pyruvate carrier (MPC) 1 & 2 with pyruvate and inhibitors: thiazolidinediones currently in clinical trials to delay mild cognitive impairment and Alzheimer‘s disease, Alzheimer‘s International Conference, 2015. http://www.alz.org/aaic/portal/overview.asp.

769. Phelix CF, McHardy SF, Perry G. Novel drug target for treating Alzheimer‘s disease: mitochondrial pyruvate carrier. SURF 2015, p.154-155, 2015

770. Grow D, Chaudhari S, Lee H-g, Perry G, Navara C. Characterization of neurons from induced pluripotent stem cells derived from patients with Alzheimer‘s disease. Third Annual San Antonio Postdoctoral Research Forum, p. 42, 2015.

771. Kelley AR, Colley M, Yan F, Perry G, Bach SBH. An Investigation into Cu(II)-Aβ Binding via MALDI MS. COS Research Conference 2015, p. 32, 2015.

772. Hammack CD, Schafer RK, McHardy SF, Phelix CF, Perry G. Novel Drug Target Identification and Testing for Treatment of Alzheimer‘s Disease, in silico: Pioglitazone and Oxidative Stress in Early Stage Interventions. COS Research Conference 2015, p. 77, 2015.

773. Phelix CF, McHardy SF, Perry G. Novel in silico precision medicine for Alzheimer‘s disease: from SNP to targeted therapy. COS Research Conference 2015, p.81, 2015.

774. Plascencia-Villa G, Ponce A, Collingwoo d J, José-Yacamán M, Perry G. Purification and advanced imaging of amyloid plaque cores from Alzheimer disease. COS Research Conference 2015, p. 81, 2015.

775. Grow DA, Gomez JA, Chaudhari S, Lee H-G, Paladini CA, Perry G, Navara CS. Characterization of neurons from induced pluripotent stem cells derived from humans with Alzheimer‘s disease. COS Research Conference 2015, p.100, 2015.

776. Ahmad F, Perry G. Brain health: Phelix CF, conceptualizing Alzheimer‘s disease pathology and shaping future treatment with neuroethical considerations. 2015 International Neuroethics Society Meeting (submitted).

777. Phelix CF, Perry G. Biosimulation of neurotrophin signaling pathways in schizophrenia. Soc Neurosci, 2015.

778. Perry G, Perry EA, Moreira PI, Correia S, Castellani RJ, Wang X, Lee H-g, Zhu X. Oxidative damage is correlated with mitochondrial autophagy. SAIB, 51 Annual Meeting Argentine Society for Biochemistry and Molecular Biology, p. 20, 2015.

779. Correia SC, Pinho T, Zhu X, Perry G, Moreira PI. Hummr acts as a ―roadblock‖ for mitochondrial transport in Alzheimer‘s disease. II International Health Congress Gaia-Porto (II CISGP), p. 86, 2015.

780. Perry G. Alzheimer‘s: a disease of mitochondria? International Conference on Recent Advances in Biosciences and Applications of Engineering in Production of Biopharmaceuticals & 9

th Convention of

Association of Biotechnology and Pharmacy, Special Satellite Meeting on ―Molecular Neurochemical Networking Complexes in Alzheimer‘s disease‖, 2015.

781. Castellani RJ, Perry G. Chronic traumatic encephalopathy: is a role for biomarkers premature? BABE – 2014 (submitted).

782. Kelley A, Perry G, Castellani R, Bach S. Molecular mapping of Alzheimer‘s disease – imaging mass spectrometry. American Society for Mass Spectroscopy (in press)

George Perry

159

783. Phelix CF, Villareal G, Perry G. CX3CR1 and DAP12-TREM1&2 signaling in MS- vs-AD: Biosimulation of proteomics differences and effects of a novel orally active CX3CR1 blocker (AZD8797) Texas Academy of Science Annual Meeting (in press).

784. Hammack CD, Perry G, Phelix CF. In silico investigation of oxidative damage in the pathophysiological progression of late onset alzheimer‘s disease. NCUR, 2016. https://ncurdb.cur.org/ncur2016/search/Display_NCUR.aspx?id=96493

785. Perry G, Kelley A, Bach, SBH. An investigation into Aβ/metal binding via MALDI MS. Texas Academy of Science, p. 27, 2016.

786. Plascencia-Villa G, Ponce A, Collingwood JF, José-Yacamán M, Perry G. Purification and advanced imaging of amyloid plaque cores from Alzheimer disease. Texas Academy of Science p. 27, 2016.

787. Perry G. Castellani R. Beyond the horizon in dementia. 10th World Congress on Controversies in Neurology,

http://comtecmed.com/cony/2016/Uploads/Editor/Perry.pdf, 2016.

788. Kelley A, Perry G, Bach S. An investigation into Aβ/metal binding via MALDI TOF MS. ASMS 2016 (submitted).

789. Plascencia Villa G, Perry G. Structural arrangement and aggregation of amyloid-beta peptides triggered by metal cations. University of Texas at San Antonio COS Research Conference, p. 77, 2016.

790. Herrera L, Stephens DE, D‘Ávila A, George KG, Arman H, Zhang Y, Perry G, Lleonart R, Larionov O, Fernandez PL. Patrones estructurales involucrados en la actividad antileishmanie de bi y tricíclicos n-heterociclos. APANAC INDICASAT AIP 2016 http://indicasat-times.org.pa/l-herrera-1%2c2%2c.html

791. Perry G. Integrative medicine strategies for the prevention of Alzheimer‘s disease: from research. International Congress on Integrative Medicine and Health, 2016. http://icimh.org/agenda

792. Phelix CF, Villareal G, Perry G. CX3CR1 and DAP12-TREM1&2 signaling in MS-vs-AD: biosimulations of proteomics differences and effects of a novel orally active CX3CR1 blocker (AZD8797). SALSI Neuroscience Symposium, p.24, 2016.

793. Kelley AR, Colley ME, Bach SBH, Perry G. The role of metal salts in the analysis of Amyloid-beta via matrix-assisted laser desorption/ionization mass spectrometry. SALSI Neuroscience Symposium, p.26, 2016.

794. Manassero G, Guglielmotto M, Borghi R, Perry G, Odetti P, Arancio O, Tamagno E, Tabaton M. Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Journal of Alzheimer‘s Dis 52:S77, 2016.

795. Perry G, Castellani R. Beyond the horizon in dementia. Clinical Neurosciences and Mental Health 3(Suppl 1):L9, 2016.

796. Plascencia-Villa, Ponce A, Collingwood JR, Arellano MJ, Jose-Yacaman M, Perry G. Acvanced imaging and holography of Amyloid plaque cores from Alzheimer‘s disease. SALSI Neuroscience Symposium, p.30, 2016.

797. Perry G. Oxidative damage is correlated with mitochondrial autophagy. WAC 2016, World Automation Congress p. 11, 2016.

798. Perry G. Suppressing gonadotropin signaling preserves cognition function in Alzheimer‘s disease. 21st IAGG

World Congress of Gerontology and Geriatrics, (submitted).

799. Hammack C, Phelix CF, Perry G. The oxidative regulating effects of Thiazolidinedione intervention on the CISD1 protein, mitoNEET, in late onset Alzheimer‘s disease. SALSI Neuroscience Symposium, p. 17, 2016.

800. Colley ME, Kelley AR, Bach SBH, Perry G. A top-down method for the identification of ɑ-Synuclein by matrix assisted laser desorption ionization mass spectrometry. SALSI Neuroscience Symposium, p. 25, 2016.

801. Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Himenez, Zhu X, Rogers JT, Betancourt I, Jose-Yacaman M, Perry G. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer‘s disease. XXV International Materials Research Congress, http://www.mrs-mexico.org.mx/imrc2016/app_abstractsbook-authors-abstract.php?name=Perry,George, 2016.

802. Phelix CF, Villareal G, Lee AY, Perry G. Texas FreshAIR Neuroscience, 2016.

803. Phelix CF, Villareal G, Perry G. CX3CR1 and DAP12-TREM1&2 signaling in MS-vs-AD: biosimulations of proteomics differences and effects of a novel orally active CX3CR1 blocker (AZD8797). PISA 2016 (accepted).

804. Mohorovic L, Pavelic K, Simovic-Medica J, Jonjic N, Stifter S, Micovic V, Lavezzi AM, Perry G, Labinac-Peteh L. Ferric-iron accumulation in the brain: novel modes for prevention and therapy for neurodegenerative disease. (submitted)

George Perry

160

805. Plascencia-Villa G, Jose-Yacaman, M, Perry G. Metallo-biology of amyloid-beta plaque cores from Alzheimer‘s disease. PISA 2016 (accepted).

806. Perry G. Role of metal salts in the analysis of amyloid-beta and ɑ-synuclein via matrix-assisted laser desorption/ionization mass spectrometry. Southwest Regional Meeting ACS (submitted).

807. Kelley AR, Colley M, Perry G, Bach SBH. Role of metal salts in the analysis of amyloid-beta and ɑ-synuclein via matrix-assisted laser. University of Texas at San Antonio COS Research Conference, p.30, 2016.

808. Hammack CD, Phelix CF, Perry G. Low dose Thiazolidinedione intervention attenuates oxidative damage in late-onset Alzheimer‘s disease by targeting the CISDI protein, mitoNEET. University of Texas at San Antonio COS Research Conference, pp.74-75, 2016.

809. Kelley AR, Perry G, Bach SB. Analysis of Cu(II)-mediated dityrosine cross-linking of amyloid-beta in-vitro and in-vivo by MALDI MS. American Chemical Society Annual Meeting (submitted).

810. Plascencia-Villa G, Perry G. Characterization of amyloid-beta peptide aggregation induced by copper ions. Texas Academy of Science Annual Meeting (in press).

811. Phelix CF, Renthal RD, Chen LY, McHardy SF, Perry G. Mitochondrial Pyruvate carrier: homology modeling, docking, and dynamic simulation to integrate non-synonymous SNPs into individualized patient metabolic biosimulations. 2017 SURF (submitted).